"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,ES,U8,ES 1074859 U8,142-204-297-153-431,2011-09-19,2011,ES 201100468 U,2011-05-19,ES 201100468 U,2011-05-19,PULSERA DE IDENTIFICACION PARA PACIENTES EN HOSPITALES,,JORGE URTIAGA BAONZA SOLUTIONS S L,URTIAGA BAONZA JORGE;;GONZALEZ MARTINEZ DOLORES,,https://lens.org/142-204-297-153-431,Unknown,no,0,0,3,3,0,,A44C5/00,,0,0,,,,EXPIRED
2,ES,Y,ES 1074859 Y,034-115-914-839-149,2011-09-19,2011,ES 201100468 U,2011-05-19,ES 201100468 U,2011-05-19,PULSERA DE IDENTIFICACION PARA PACIENTES EN HOSPITALES,,JORGE URTIAGA BAONZA SOLUTIONS S L,URTIAGA BAONZA JORGE;;GONZALEZ MARTINEZ DOLORES,,https://lens.org/034-115-914-839-149,Limited Patent,no,0,0,3,3,0,,A44C5/00,,0,0,,,,EXPIRED
3,US,A1,US 2018/0110972 A1,102-138-628-012-69X,2018-04-26,2018,US 201715790149 A,2017-10-23,US 201715790149 A;;US 201662410898 P,2016-10-21,SYSTEMS AND METHODS FOR INTRACRANIAL DEVICE IMPLANTATION,"The present disclosure relates generally to implanting intracranial devices (e.g., electrodes, catheters, biopsy probes, etc.) independently (not in parallel) into a patient's brain. A single entry point can be opened in a patient's head. At least two intracranial devices can be inserted through the entry point. The at least two intracranial devices can be implanted to at least two different locations in the patient's brain through the same entry point.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE;;GALE JOHN T,THE CLEVELAND CLINIC FOUNDATION (2018-07-05),https://lens.org/102-138-628-012-69X,Patent Application,yes,8,0,1,1,0,A61N1/0534;;A61N1/0534;;A61B5/0031;;A61B5/0031;;A61B5/0059;;A61B5/0059;;A61B5/031;;A61B5/031;;A61B5/6851;;A61B5/6851;;A61B5/6864;;A61B5/6864;;A61B5/7275;;A61B5/7275;;A61N1/0539;;A61N1/0539,A61N1/05;;A61B5/03,,0,0,,,,DISCONTINUED
4,US,B2,US 11523768 B2,170-663-989-873-841,2022-12-13,2022,US 201716348766 A,2017-11-10,US 201716348766 A;;US 201662421037 P;;US 2017/0061122 W,2016-11-11,Identifying the epileptogenic zone from nonseizure recordings using network fragility theory,"A method of identifying an epileptogenic zone of a subjects brain includes: receiving a plurality N of physiological brain signals that extend over a duration, each of the plurality N of physiological brain signals acquired from the subjects brain; calculating within a time window a state transition matrix based on at least a portion of each of the plurality N of physiological brain signals, wherein the state transition matrix is a linear time invariant model of a network of N nodes corresponding to the plurality N of physiological brain signals; calculating a minimum norm of a perturbation on the state transition matrix that causes the network to transition from a stable state to an unstable state; and assigning a fragility metric to each of the plurality N of physiological brain signals based on the minimum norm of the perturbation for that physiological brain signal.",UNIV JOHNS HOPKINS;;CLEVELAND CLINIC FOUND,SARMA SRIDEVI;;LI ADAM;;GONZALEZ-MARTINEZ JORGE,THE JOHNS HOPKINS UNIVERISTY (2017-05-10);;THE CLEVELAND CLINIC FOUNDATION (2017-05-09),https://lens.org/170-663-989-873-841,Granted Patent,yes,9,0,7,7,0,A61B5/4094;;A61B5/7253;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7253;;A61B5/00;;A61B5/369;;A61B5/316,A61B5/00;;A61B5/316;;A61B5/369;;A61B5/372,,92,88,008-316-241-629-291;;026-778-271-783-221;;079-453-102-750-274;;059-112-058-794-243;;092-228-802-073-075;;009-801-313-950-996;;093-854-242-913-770;;003-444-933-287-055;;006-467-594-942-932;;014-083-522-407-938;;023-402-648-789-574;;159-580-234-554-402;;014-587-424-113-222;;032-781-454-635-461;;077-495-197-373-223;;005-887-611-043-504;;106-641-197-556-794;;052-526-284-006-861;;109-444-308-496-672;;005-749-668-128-706;;018-494-938-818-10X;;029-452-596-138-078;;004-595-345-572-751;;044-239-465-597-638;;049-755-052-302-013;;069-054-483-732-799;;107-846-610-200-405;;023-915-720-639-372;;009-489-023-634-262;;026-296-603-566-644;;112-501-000-133-791;;012-461-413-765-966;;014-220-313-033-616;;035-743-258-200-462;;059-840-038-063-983;;124-859-787-328-593;;129-207-679-767-466;;099-807-956-808-573;;019-673-311-889-959;;161-426-145-232-678;;125-639-662-728-27X;;019-140-792-022-421;;014-364-651-093-147;;086-207-058-922-023;;060-302-513-135-374;;025-010-058-319-003;;049-257-557-121-144;;072-473-197-281-063;;052-358-930-856-714;;002-711-639-395-642;;041-751-607-791-641;;016-073-550-989-051;;007-138-563-896-434;;033-338-848-479-430;;063-683-371-883-350;;065-667-311-936-839;;017-565-428-437-883;;042-024-181-132-969;;014-146-617-362-184;;013-260-287-536-622;;148-487-473-438-489;;120-656-671-113-288;;085-539-614-981-281;;007-713-998-909-714;;090-248-907-029-746;;042-535-346-107-249;;106-489-538-932-53X;;070-966-782-586-370;;009-978-572-218-867;;014-889-878-009-343;;007-242-405-238-903;;058-438-741-549-035;;024-487-569-774-958;;014-711-025-896-958;;031-249-796-318-856;;009-444-954-183-608;;070-222-286-171-596;;059-058-137-492-150;;091-178-802-379-016;;076-077-635-305-370;;009-957-002-177-378;;032-799-973-708-269;;073-718-147-874-820;;111-798-729-083-622;;001-035-244-566-198;;132-097-806-900-674;;141-582-718-958-804;;087-644-885-664-760,10.1016/s1042-3680(18)30444-3;;7670323;;18759613;;10.3171/foc/2008/25/9/e12;;766135;;10.1016/0013-4694(69)90016-9;;4182026;;4182027;;10.1016/s1388-2457(01)00591-0;;11514258;;10714408;;10.1111/j.1528-1157.2000.tb00166.x;;10.1111/epi.13084;;26216617;;10.1016/j.ncl.2009.06.001;;pmc2827183;;19853220;;10.1111/j.1528-1167.2006.00440.x;;16499772;;10.1016/j.eplepsyres.2013.04.011;;23726290;;9579928;;10.1111/j.1528-1157.1997.tb01224.x;;10.1111/j.1528-1167.2012.03633.x;;22905787;;10.1073/pnas.1401752111;;pmc4267355;;25404339;;10.1111/epi.12222;;23899122;;22687387;;10.1016/j.yebeh.2012.04.135;;10.3389/fnins.2015.00058;;25784851;;pmc4347430;;10.1212/wnl.40.11.1670;;2122275;;22367987;;pmc3296971;;10.1002/ana.22621;;16205108;;10.1159/000088656;;25296546;;10.1007/s00381-014-2499-z;;10.1111/j.1528-1167.2012.03672.x;;23016576;;10.1111/j.1528-1167.2010.02648.x;;20561026;;10.1159/000366001;;25359500;;pmc4268349;;10.1002/ana.20872;;16802302;;pmc4107736;;10.1093/brain/awu133;;24919973;;10.1111/j.1528-1167.2010.02619.x;;20618410;;10.1111/j.1528-1167.2010.02618.x;;20618409;;10.1056/nejmra1004418;;21899452;;10660394;;10.1056/nejm200002033420503;;10.1111/epi.13106;;26249524;;17012067;;15215219;;10.1093/brain/awh221;;10.1212/wnl.0b013e3182302056;;21917777;;10.1097/01.wco.0000218233.60217.84;;16538091;;17012070;;20067507;;pmc3410521;;10.1111/j.1528-1167.2009.02481.x;;25058705;;10.1162/neco_a_00644;;10.3182/20140824-6-za-1003.00313;;18164485;;10.1016/j.nurt.2007.10.069;;pmc5084128;;17698787;;10.1212/01.wnl.0000267427.91987.21;;24618797;;10.1227/neu.0000000000000343;;pmc4151501;;10.1016/j.eplepsyres.2014.01.009;;24518890;;10.1007/s00127-012-0622-6;;23143217;;10.1227/neu.0000000000000453;;24887288;;24405074;;10.3171/2013.11.jns13635;;25296543;;10.1007/s00381-014-2497-1;;24448180;;10.1227/neu.0000000000000286;;10.1227/neu.0000000000000787;;26181929;;10.1227/01.neu.0000255438.13871.fa;;17460523;;10.1097/wco.0000000000000176;;25692411;;11781412;;10.1212/wnl.58.1.97;;10.1177/0883073894009002091;;7806787;;10576223;;10.1097/00004691-199909000-00002;;16801667;;10.1212/01.wnl.0000219810.71010.9b;;19914135;;10.1016/s1474-4422(09)70304-7;;10.1016/s0090-3019(00)00324-4;;11165607;;10.1016/j.eplepsyres.2015.04.009;;26220373;;10.1227/neu.0b013e318235183d;;21904264;;16538092;;10.1097/01.wco.0000218234.67840.cb;;10.3174/ajnr.a4362;;pmc7964876;;26113069;;10.1227/01.neu.0000489861.93311.a5;;27399570;;2505493;;10.1007/978-3-7091-9029-6_2;;10.1016/0920-1211(95)00090-9;;8964275;;10.1016/j.clinph.2007.09.117;;18035590;;10.1016/s1042-3680(02)80009-2;;11754319;;11522572;;10.1093/brain/124.9.1683;;11440459;;10.1097/00006123-200107000-00007;;10.1227/00006123-200107000-00007;;10.1227/01.neu.0000429839.76460.b7;;23615090;;10.3171/2014.7.jns132306;;25148007;;10.1016/j.neuroimage.2013.06.018;;23774395;;26086908;;10.1227/neu.0000000000000732;;7008525;;10.1007/978-3-7091-8592-6_5;;1543087;;pmc3500670;;10.1002/ana.22535;;22162063;;23732793;;10.1007/s00381-013-2169-6;;10.1227/neu.0b013e318285b4ae;;23313979;;10.1016/j.eplepsyres.2009.06.007;;19619985;;26280814;;10.1016/j.yebeh.2015.07.022;;11516732;;10.1016/s1388-2457(01)00547-8;;10.1227/01.neu.0000467119.69709.ae;;10.1055/s-2008-1052406;;3374766;;10.1016/0013-4694(74)90031-5;;4136279;;1006011;;5971290;;10.1016/s0370-4475(79)80004-0;;523735;;10.1016/s0370-4475(82)80007-5;;7048445;;5320688;;4975234,"International Search Report from corresponding International Application No. PCT/US2017/061122, dated Jan. 25, 2018.;;Written Opinion from corresponding International Application No. PCT/US2017/061122, dated Jan. 25, 2018.;;Adelson et al., “Chronic invasive monitoring for identifying seizure foci in children”, Neurosurgery clinics of North America. 1995;6(3):491-504.;;Anderson et al., “Implantation of a responsive neurostimulator device in patients with refractory epilepsy”, Neurosurg Focus. (2008) 25:E12.;;Bancaud et al., “[Neurophysiopathological hypothesis on startle epilepsy in man]”, Revue neurologique. 1975;131(8):559-571.;;Bancaud et al., “Activation by Megimide in the topographic diagnosis of focal cortical epilepsies (clinical EEG and SEEG study)”, Electroencephalography and clinical neurophysiology. 1969;26(6):640.;;Bartolomei et al., “Neural networks involving the medial temporal structures in temporal lobe epilepsy”, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2001;112(9):1746-1760.;;Begley et al., “The cost of epilepsy in the United States: an estimate from population-based clinical and survey data”, Epilepsia (2000) 41: 342-351.;;Begley et al., “The direct cost of epilepsy in the United States: A systematic review of estimates”, Epilepsia. 2015;56(9):1376-1387.;;Berg “Identification of Pharmacoresistant Epilepsy”, Neurol Clin 27 (2009) 1003-1013.;;Berg et al., “Defining intractability: comparisons among published definitions,” Epilepsia. 2006;47(2):431-436.;;Bonini et al., “Epileptogenic networks in seizures arising from motor systems”, Epilepsy research. 2013;106(1-2):92-102.;;Brodie et al., “Commission on European Affairs: appropriate standards of epilepsy care across Europe”, ILEA. Epilepsia. 1997;38(11):1245-1250.;;Bulacio et al., “Long-term seizure outcome after resective surgery in patients evaluated with intracranial electrodes”, Epilepsia. 2012;53(10):1722-1730.;;SAMUEL P. BURNS, SABATO SANTANIELLO, ROBERT B. YAFFE, CHRISTOPHE C. JOUNY, NATHAN E. CRONE, GREGORY K. BERGEY, WILLIAM S. ANDERSON: ""Network dynamics of the brain and influence of the epileptic seizure onset zone"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 49, 9 December 2014 (2014-12-09), pages E5321 - E5330, XP055358609, ISSN: 0027-8424, DOI: 10.1073/pnas.1401752111;;Cardinale et al., “Stereo-electroencephalography safety and effectiveness: Some more reasons in favor of epilepsy surgery”, Epilepsia. 2013;54(8):1505-1506.;;Curry et al. “MR-guided stereotactic laser ablation of epileptogenic foci in children”, Epilepsy & behavior: E&B. 2012;24(4):408-414.;;DANIEL EHRENS, DULUXAN SRITHARAN, SRIDEVI V. SARMA: ""Closed-loop control of a fragile network: application to seizure-like dynamics of an epilepsy model"", FRONTIERS IN NEUROSCIENCE, vol. 9, XP055693678, DOI: 10.3389/fnins.2015.00058;;Engel et al., “Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG”, Neurology. 1990;40(11):1670-1677.;;Fisher “Therapeutic devices for epilepsy”, Annals of neurology. 2012;71(2):157-168.;;Fountas et al., “Implantation of a closed loop stimulation in the management of medically refractory focal epilepsy: a technical note”, Stereotact Funct Neurosurg.(2005) 83:153-58.;;Gonzalez-Martinez et al., “Stereoelectroencephalography in children with cortical dysplasia: technique and results. Child's nervous system”, ChNS : official journal of the International Society for Pediatric Neurosurgery. 2014;30(11):1853-1857.;;Gonzalez-Martinez et al., “Stereoelectroencephalography in the “difficult to localize” refractory focal epilepsy: early experience from a North American epilepsy center”, Epilepsia. 2013;54(2):323-330.;;Gumnit et al., “Guidelines for Essential Services, Personnel, and Facilities in Specialized Epilepsy Centers”, (2010) 2010 NAEC Guidelines for Specialized Epilepsy Centers. Retrieved from http://naec-epilepsy.orxispec care/documents/NAEC-FinalGuidelineswithruralcenterrevision.pdf.;;Hawasli et al., “Laser ablation as treatment strategy for medically refractory dominant insular epilepsy: therapeutic and functional considerations”, Stereotactic and functional neurosurgery. 2014;92(6):397-404.;;Hermann et al., “Cognitive prognosis in chronic temporal lobe epilepsy”, Annals of neurology. 2006;60(1):80-87.;;Jirsa et al., “On the nature of seizure dynamics. Brain : a journal of neurology”, 2014;137(Pt 8):2210-2230.;;Jiruska et al., “Effects of direct brain stimulation depend on seizure dynamics”, (2010) Epilepsia 51: S93-S97.;;Jobst et al., “Brain stimulation for the treatment of epilepsy”, Epilepsia (2010) 51: S88-S92.;;Kwan et al., “Drug-resistant epilepsy”, N Engl J Med. 2011; 365(10): 919.;;Kwan et al., “Early identification of refractory epilepsy”, N Engl J Med. Feb. 3, 2000;342(5): 314-9.;;Lewis et al., “MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional epilepsy”, Epilepsia. 2015.;;Lüderset al., “The epileptogenic zone: general principles. Epileptic Disord”, Aug. 2006;8 Suppl 2:S1-9. Erratum in: Epileptic Disord. Jun. 2008;10(2):191.;;McIntosh et al., “Temporal lobectomy: long-term seizure outcome, late recurrence and risks for seizure recurrence”, Brain. Sep. 2004;127(Pt 9):2018-30. Epub Jun. 23, 2004.;;Morell et al., “Long term safety and efficacy of the RNSTM system in adults with medically intractable partial onset seizures”, (2008) Proc. American Epilepsy Society Annual Meeting. Abstract No. 8536. www.aesnet.org.;;Morrell “On behalf of the RNS System in Epilepsy Study Group. Responsive Cortical stimulation for the treatment of medically intractable partial epilepsy”. Neurology (2011) vol. 77, pp. 1295-1304.;;Morrell M. (2006) Brain stimulation for epilepsy: Can scheduled or responsive neurostimulation stop seizures? Curr Opinion Neural. 19:164-168.;;Najm et al., “Definition of the epileptogenic zone in a patient with non-lesional temporal lobe epilepsy arising from the dominant hemisphere”, Epileptic disorders : international epilepsy journal with videotape. 2006;8 Suppl 2:S27-35.;;Ngugi et al., “Estimation of the burden of active and life-time epilepsy: a meta-analytic approach”, Epilepsia. (2010) vol. 51, No. 5, pp. 883-890.;;Sritharan et al., “Fragility in Dynamic Networks: Application to Neural Networks in the Epileptic Cortex”, Neural Computation, Oct. 1, 2014, vol. 26, No. 10, pp. 2294-2327.;;Sritharan et al., “Fragility in Networks: Application to the Epileptic Brain”, IFAC The 2012 IFAC Workshop on Automatic Control in Offshore Oil and Gas Production, Jan. 1, 2014, vol. 47, No. 3, pp. 7505-7510.;;Sun et al., “Responsive Cortical Stim-ulation for the Treatment of Epilepsy”, Neurotherapeutics. Jan. 2008;5:68-74.;;Widdess-Walsh et al., “Subdural electrode analysis in focal cortical dysplasia: predictors of surgical outcome”, Neurology. 2007;69(7):660-667.;;Willie et al., “Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy”, Neurosurgery. (2014) vol. 74, No. 6, pp. 569-584; discussion 584-565.;;Esquenazi et al., “Stereotactic laser ablation of epileptogenic periventricular nodular heterotopia”, Epilepsy Research, (2014), vol. 108, No. 3, pp. 547-554.;;Ferro et al., “Stability of latent classes in group-based trajectory modeling of depressive symptoms in mothers of children with epilepsy: an internal validation study using a bootstrapping procedure”, Social psychiatry and psychiatric epidemiology, (2013), vol. 48, No. 7, pp. 1077-1086.;;Gonzalez-Martinez et al., “Stereoelectroencephalography in children and adolescents with difficult-to-localize refractory focal epilepsy”, Neurosurgery, (2014), vol. 75, No. 3, pp. 258-268; discussion 267-258.;;Gonzalez-Martinez et al., “Stereotactic placement of depth electrodes in medically intractable epilepsy”, Journal of Neurosurgery, (2014), vol. 120, No. 3, pp. 639-644.;;Gonzalez-Martinez et al., “Indications and selection criteria for invasive monitoring in children with cortical dysplasia”, Child's Nervous System, (2014), vol. 30, No. 11, pp. 1823-1829.;;Gonzalez-Martinez et al., “Robot-assisted stereotactic laser ablation in medically intractable epilepsy: operative technique”, Neurosurgery, (2014), vol. 10, Suppl 2, pp. 167-172; discussion 172-163.;;Gonzalez-Martinez, “Convergence of Stereotactic Surgery and Epilepsy: The Stereoelectroencephalography Method”, Neurosurgery, (2015), vol. 62, Suppl 1, pp. 117-122.;;Gonzalez-Martinez et al., “Long-term seizure outcome in reoperation after failure of epilepsy surgery”, Neurosurgery, (2007), vol. 60, No. 5, pp. 873-880; discussion 873-880.;;Gross et al., “Less is more: novel less-invasive surgical techniques for mesial temporal lobe epilepsy that minimize cognitive impairment”, Current Opinion in Neurology, (2015), vol. 28, No. 2, pp. 182-191.;;Hamer et al., “Complications of invasive video-EEG monitoring with subdural grid electrodes”, Neurology, (2002), vol. 58, No. 1, pp. 97-103.;;Jayakar et al., “Subdural monitoring in the evaluation of children for epilepsy surgery”, Journal of Child Neurology, (1994), vol. 9, Suppl 2, pp. 61-66.;;Jayakar, “Invasive EEG monitoring in children: when, where, and what?”, Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society, (1999), vol. 16, No. 5, pp. 408-418.;;Jeha et al., “Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy”, Neurology, (Jun. 27, 2006), vol. 66, No. 12, pp. 1938-1940.;;Kwan et al., “Definition of refractory epilepsy: defining the indefinable?”, The Lancet. Neurology, (2010), vol. 9, No. 1, pp. 27-29.;;Lee et al., “Complications and results of subdural grid electrode implantation in epilepsy surgery”, Surgical Neurology, (2000), vol. 54, No. 5, pp. 346-351.;;Lega et al., “Cortico-cortical evoked potentials for sites of early versus late seizure spread in stereoelectroencephalography”, Epilepsy Research, (2015), vol. 115, pp. 17-29.;;Lopez-Gonzalez et al., “Epilepsy surgery of the temporal lobe in pediatric population: a retrospective analysis”, Neurosurgery, (2012), vol. 70, No. 3, pp. 684-692.;;Luders et al., “Epilepsy surgery in patients with malformations of cortical development”, Current Opinion in Neurology, (2006), vol. 19, No. 2, pp. 169-174.;;Medvid et al., “Current Applications of MRI-Guided Laser Interstitial Thermal Therapy in the Treatment of Brain Neoplasms and Epilepsy: A Radiologic and Neurosurgical Overview”, AJNR. American Journal of Neuroradioiogy, Medvid, (Nov. 2015), pp. 1998-2006.;;Mullin et al., “Is Stereotacticelectroencephalography Safe? A Systematic Review and Meta-Analysis of Stereo-electroencephalography-Related Complications”, Neurosurgery, (Aug. 2016), vol. 63, No. 1, p. 211.;;Munari et al., “Stereotactic investigations in frontal lobe epilepsies”, Acta neurochirurgica. Supplementum, (1989) vol. 46, pp. 9-12.;;Murray et al., “Cost of refractory epilepsy in adults in the USA”, Epilepsy Research, (1996), vol. 23, No. 2, pp. 139-148.;;Nair et al., “Chronic subdural electrodes in the management of epilepsy”, Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology, (2008), vol. 119, No. 1, pp. 11-28.;;Najm et al., “The use of subdural grids in the management of focal malformations due to abnormal cortical development”, Neurosurgery Clinics of North America, (2002), vol. 13, No. 1, pp. 87-92, viii-ix.;;Rosenow et al., “Presurgical evaluation of epilepsy”, Brain : A Journal of Neurology, (2001), vol. 124, Pt 9, pp. 1683-1700.;;Rydenhag et al., “Complications of Epilepsy Surgery after 654 Procedures in Sweden, Sep. 1990-1995: A Multicenter Study Based on the Swedish National Epilepsy Surgery Register”, Neurosurgery, (2001), vol. 49, No. 1, pp. 51-56; discussion 56-57.;;See et al., “Surgical Outcomes in Patients With Extratemporal Epilepsy and Subtle or Normal Magnetic Resonance Imaging Findings”, Neurosurgery, (Jul. 2013), vol. 73, No. 1, pp. 68-77; discussion 76-7.;;Serletis et al., “The stereotactic approach for mapping epileptic networks: a prospective study of 200 patients”, Journal of Neurosurgery, (2014), vol. 121, No. 5, pp. 1239-1246.;;Spiegler et al., “Systematic approximations of neural fields through networks of neural masses in the virtual brain”, NeuroImage, (2013), vol. 83, pp. 704-725.;;Sun et al., “Tissue Ablation Dynamics During Magnetic Resonance-Guided, Laser-Induced Thermal Therapy”, Neurosurgery, (2015), vol. 77, No. 1, pp. 51-58; discussion 58.;;Talairach et al., “Application of stereotactic concepts to the surgery of epilepsy”, Acta Neurochirurgica. Supplementum, (1980), vol. 30, pp. 35-54.;;Talairach et al., “Stereotaxic exploration in frontal epilepsy”, Advances in Neurology, (1992), vol. 57, pp. 651-688.;;Thornton et al., “Epileptic Networks in Focal Cortical Dysplasia Revealed Using Electroencephalography—Functional Magnetic Resonance Imaging”, Annals of Neurology, (2011), vol. 70, No. 5, pp. 822-837.;;Tovar-Spinoza et al.,“The Use of MRI-Guided Laser-Induced Thermal Ablation for Epilepsy”, Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery, (2013), vol. 29, No. 11, pp. 2089-2094.;;Vadera et al., “Stereoelectroencephalography Following Subdural Grid Placement for Difficult to Localize Epilepsy”, Neurosurgery, (2013), vol. 72, No. 5, pp. 723-729; discussion 729.;;Vaugier et al., “Neural Networks Underlying Hyperkinetic Seizures of “temporal lobe” Origin”, Epilepsy Research, . (2009), vol. 86, Nos. 2-3, pp. 200-208.;;Waseem et ai., “Laser Ablation Therapy: An alternative Treatment for Medically Resistant Mesial Temporal Lobe Epilepsy After Age 50”, Epilepsy & Behavior: E&B, (2015), vol. 51, pp. 152-157.;;Wendling et al., “Interpretation of interdependencies in Epileptic Signals Using a Macroscopic Physiological Model of the EEG”, Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology, (2001), Vo. 112, No. 7, pp. 1201-1218.;;Willie et al., “Role of Repeat Ablation to Treat Seizure Recurrence Following Stereotactic Laser Amygdalohippocampotomy”, Neurosurgery, (2015), vol. 62, Suppl 1, pp. 233-234.;;Wyllie et al., “Subdural Electrodes in the Evaluation for Epilepsy Surgery in Children and Adults”, Neuropediatrics, (1988), vol. 19, No. 2, pp. 80-86.;;NeuroPace. RNS System Clinical Summary. (2013) Retrieved from http://www.neuropace.com/productJpdfs/RNS-300M Clinical Summary EN.pdf.;;Bancaud et al., “Generalized epileptic seizures elicited by electrical stimulation of the frontal lobe in man”, Electroencephalography and clinical neurophysiology, (1974), vol. 37, pp. 275-282.;;Bancaud et al., “Behavioral manifestations induced by electric stimulation of the anterior cingulate gyrus in man]”, Revue Neurologique, (Oct. 1976), vol. 132, No. 10, pp. 705-744. Abstract Only.;;Bancaud et al., “d'Ammon's horn and amygdaline nucleus: clinical and electric effects of their stimulation in man”, Revue Neurologique, (1966), vol. 115, No. 3, pp. 329-352. (Partial English translation of original French article).;;Munari et al., “Role of the amygdala in the occurence of oro-alimentary signs of during epileptic seizures in man (author's transl)”, Revue d'electroencephalographie et de neurophysioiogie clinique, (1979), vol. 9, No. 3, pp. 236-240. (Partial English translation of original French article).;;Munari et al., “Cerebral concentrations of anticonvulsants in patients with epilepsy of tumoral origin (author's transl)”, Revue d'electroencephalographie et de neurophysioiogie clinique, (1982), vol. 12, No. 1, pp. 38-43. (Partial English translation of original French article).;;Talairach et al., “Amygdalo-hippocampal partial destruction by yttrium-90 in the treatment of certain epilepsies of rhinencephalic manifestation”, Neuro-Chirurgie, (1965), vol. 11, No. 3, pp. 233-240. (Full English translation of original French article).;;Bancaud et al., “Activation by Megimide in the topographic diagnosis of focal cortical epilepsies”, (Clinical study, EEG and SEEG)]. French Language Electroencephalography Society, Revue Neurologique, (1968), vol. 119, No. 3, pp. 320-325. (Translation of article introduction from original French).",ACTIVE
5,WO,A1,WO 2018/089806 A1,188-185-784-686-41X,2018-05-17,2018,US 2017/0061122 W,2017-11-10,US 201662421037 P,2016-11-11,IDENTIFYING THE EPILEPTOGENIC ZONE FROM NONSEIZURE RECORDINGS USING NETWORK FRAGILITY THEORY,"A method of identifying an epileptogenic zone of a subjects brain includes: receiving a plurality N of physiological brain signals that extend over a duration, each of the plurality N of physiological brain signals acquired from the subjects brain; calculating within a time window a state transition matrix based on at least a portion of each of the plurality N of physiological brain signals, wherein the state transition matrix is a linear time invariant model of a network of N nodes corresponding to the plurality N of physiological brain signals; calculating a minimum norm of a perturbation on the state transition matrix that causes the network to transition from a stable state to an unstable state; and assigning a fragility metric to each of the plurality N of physiological brain signals based on the minimum norm of the perturbation for that physiological brain signal.",UNIV JOHNS HOPKINS;;CLEVELAND CLINIC FOUND,SARMA SRIDEVI;;LI ADAM;;GONZALEZ-MARTINEZ JORGE,,https://lens.org/188-185-784-686-41X,Patent Application,yes,5,2,7,7,0,A61B5/4094;;A61B5/7253;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7253;;A61B5/00;;A61B5/369;;A61B5/316,A61B5/00,,5,3,014-587-424-113-222;;129-207-679-767-466;;070-966-782-586-370,10.1073/pnas.1401752111;;pmc4267355;;25404339;;25058705;;10.1162/neco_a_00644;;10.1227/01.neu.0000429839.76460.b7;;23615090,"SAMUEL P. BURNS ET AL.: ""Network dynamics of the brain and influence of the epileptic seizure onset zone"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 49, 2014, pages E5321 - E5330, XP055358609, DOI: 10.1073/pnas.1401752111;;DULUXAN SRITHARAN ET AL.: ""Fragility in Dynamic Networks: Application to Neural Networks in the Epileptic Cortex"", NEURAL COMPUTATION, vol. 26, no. 10, 2014, pages 2294 - 2327, XP055693682, DOI: 10.1162/NECO_a_00644;;DULUXAN SRITHARAN ET AL.: ""Fragilty in Networks: Application to the Epileptic Brain"", IF AC PROCEEDINGS, vol. 47, 2014, pages 7505 - 7510, XP055693715, DOI: 10.3182/20140824-6-ZA-1003.00313;;SJ, JEHI LEVADERA SBULACIO JNAJM IBINGAMAN W: ""Surgical Outcomes in Patients With Extratemporal Epilepsy and Subtle or Normal Magnetic Resonance Imaging Findings"", NEUROSURGERY, vol. 73, no. 1, July 2013 (2013-07-01), pages 68 - 7,76-7;;See also references of EP 3525667A4",PENDING
6,EP,A1,EP 3525667 A1,008-772-557-586-629,2019-08-21,2019,EP 17869134 A,2017-11-10,US 201662421037 P;;US 2017/0061122 W,2016-11-11,IDENTIFYING THE EPILEPTOGENIC ZONE FROM NONSEIZURE RECORDINGS USING NETWORK FRAGILITY THEORY,,UNIV JOHNS HOPKINS;;CLEVELAND CLINIC FOUND,SARMA SRIDEVI;;LI ADAM;;GONZALEZ-MARTINEZ JORGE,,https://lens.org/008-772-557-586-629,Patent Application,yes,0,0,7,7,0,A61B5/4094;;A61B5/7253;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7253;;A61B5/00;;A61B5/369;;A61B5/316,A61B5/00,,0,0,,,,PENDING
7,US,A1,US 2019/0290185 A1,193-733-972-908-302,2019-09-26,2019,US 201716348766 A,2017-11-10,US 201716348766 A;;US 201662421037 P;;US 2017/0061122 W,2016-11-11,IDENTIFYING THE EPILEPTOGENIC ZONE FROM NONSEIZURE RECORDINGS USING NETWORK FRAGILITY THEORY,"A method of identifying an epileptogenic zone of a subjects brain includes: receiving a plurality N of physiological brain signals that extend over a duration, each of the plurality N of physiological brain signals acquired from the subjects brain; calculating within a time window a state transition matrix based on at least a portion of each of the plurality N of physiological brain signals, wherein the state transition matrix is a linear time invariant model of a network of N nodes corresponding to the plurality N of physiological brain signals; calculating a minimum norm of a perturbation on the state transition matrix that causes the network to transition from a stable state to an unstable state; and assigning a fragility metric to each of the plurality N of physiological brain signals based on the minimum norm of the perturbation for that physiological brain signal.",UNIV JOHNS HOPKINS;;CLEVELAND CLINIC FOUND,SARMA SRIDEVI;;LI ADAM;;GONZALEZ-MARTINEZ JORGE,THE JOHNS HOPKINS UNIVERISTY (2017-05-10);;THE CLEVELAND CLINIC FOUNDATION (2017-05-09),https://lens.org/193-733-972-908-302,Patent Application,yes,0,2,7,7,0,A61B5/4094;;A61B5/7253;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7253;;A61B5/00;;A61B5/369;;A61B5/316,A61B5/00;;A61B5/0476,,0,0,,,,ACTIVE
8,ES,A1,ES 2566203 A1,096-930-954-524-993,2016-04-11,2016,ES 201531440 A,2015-10-07,ES 201531440 A,2015-10-07,"Call management system (Machine-translation by Google Translate, not legally binding)","Call management system that has terminals (1e, 1r) of mobile telephony and a server (2). The server (2) is connected to the terminals (1, 1e, 1r) on a mobile telephone network. The server (2) has devices (21, 22, 23, 24) to detect a state that can be free/busy/out of service of the terminals (1, 1e, 1r) and to keep the users of the terminals informed. (1, 1e, 1r) of the operating state in which the terminals are located. (Machine-translation by Google Translate, not legally binding)",UNIV CARTAGENA POLITECNICA,MARTINEZ GONZALEZ ANTONIO MANUEL;;MENDOZA SAUCEDO JORGE,,https://lens.org/096-930-954-524-993,Patent Application,no,5,0,2,2,0,H04W8/22;;H04W4/20,H04W8/22;;H04W4/20,,1,0,,,3GPP TS 24.141 3rd generation Partnership Project;Technical Specification Group Core Network and Terminals;Presence service using the IP Multimedia (IM) Core Network (CN) subsystem; Stage 3(Release 7) [en línea] septiembre 2012 [recuperado el 30-03-2016] Recuperado de internet: < http://www.3gpp.org/ftp/Specs/archive/24_series/24.141/24141-740.zip >,ACTIVE
9,DE,A1,DE 102018130771 A1,123-769-572-689-230,2020-06-04,2020,DE 102018130771 A,2018-12-04,DE 102018130771 A,2018-12-04,Eingangsteil für einen Drehschwingungsdämpfer,"Eingangsteil (100) für einen Drehschwingungsdämpfer, das Eingangsteil (100) aufweisend ein Eingangsflanschteil (102) und einen Zahnkranz (104), das Eingangsflanschteil (102) aufweisend eine erste Axialanlagefläche für den Zahnkranz (104) und der Zahnkranz (104) aufweisend eine zweite Axialanlagefläche (504) für das Eingangsflanschteil (102), bei dem zwischen der ersten Axialanlagefläche und der zweiten Axialanlagefläche eine radial wirksame Formschlussverbindung wirksam ist, um ein Aufweiten des Zahnkranzes (104) zu verhindern, um das Eingangsteil (100) baulich und/oder funktional zu verbessern.",SCHAEFFLER TECHNOLOGIES AG,GONZALEZ NAGANO JAVIER TAKESHI;;MARTINEZ TORRES JORGE,,https://lens.org/123-769-572-689-230,Patent Application,no,1,0,1,1,0,F16F15/131;;F16F15/13142,F16F15/30,,0,0,,,,DISCONTINUED
10,WO,A1,WO 2022/125727 A1,003-533-898-221-02X,2022-06-16,2022,US 2021/0062523 W,2021-12-09,US 202063123417 P,2020-12-09,LOCATING AN EPILEPTOGENIC ZONE FOR SURGICAL PLANNING,"A machine-implemented method, computing device, and at least one non-transitory computer-readable medium are provided. A dynamical network model is parameterized by state transition matrices based on monitored interictal brain data. A node influence-to network score for each respective node is calculated indicating how influential the respective node is. An influenced-by score is calculated for the each respective node indicating an amount by which the respective node is influenced by the nodes. A score is calculated for the each respective node based on a sink index, a source influence index, and a sink connectivity index. Nodes that are in the epileptogenic zone are determined based on the calculated score for each of the nodes. An indication of the nodes in the epileptogenic zone is provided.",UNIV JOHNS HOPKINS,SARMA SRIDEVI;;GUNNARSDOTTIR KRISTIN;;GONZALEZ-MARTINEZ JORGE,,https://lens.org/003-533-898-221-02X,Patent Application,yes,3,0,4,4,0,G06N20/00;;A61B5/4094;;A61B5/7267;;G16H20/40;;G16H50/20;;A61B5/015;;A61B5/4094;;A61B5/7267,G06N3/10;;A61B5/24,,0,0,,,,PENDING
11,EP,A4,EP 3525667 A4,013-855-270-758-176,2020-06-24,2020,EP 17869134 A,2017-11-10,US 201662421037 P;;US 2017/0061122 W,2016-11-11,IDENTIFYING THE EPILEPTOGENIC ZONE FROM NONSEIZURE RECORDINGS USING NETWORK FRAGILITY THEORY,,UNIV JOHNS HOPKINS;;CLEVELAND CLINIC FOUND,SARMA SRIDEVI;;LI ADAM;;GONZALEZ-MARTINEZ JORGE,,https://lens.org/013-855-270-758-176,Search Report,no,0,0,7,7,0,A61B5/4094;;A61B5/7253;;A61B5/316;;A61B5/369;;A61B5/4094;;A61B5/7253;;A61B5/00;;A61B5/369;;A61B5/316,A61B5/00;;A61B5/04;;A61B5/0476,,5,4,014-587-424-113-222;;129-207-679-767-466;;099-807-956-808-573;;005-887-611-043-504,10.1073/pnas.1401752111;;pmc4267355;;25404339;;25058705;;10.1162/neco_a_00644;;10.3182/20140824-6-za-1003.00313;;10.3389/fnins.2015.00058;;25784851;;pmc4347430,"SAMUEL P. BURNS ET AL: ""Network dynamics of the brain and influence of the epileptic seizure onset zone"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 49, 17 November 2014 (2014-11-17), pages E5321 - E5330, XP055358609, ISSN: 0027-8424, DOI: 10.1073/pnas.1401752111;;DULUXAN SRITHARAN ET AL: ""Fragility in Dynamic Networks: Application to Neural Networks in the Epileptic Cortex"", NEURAL COMPUTATION., vol. 26, no. 10, 1 October 2014 (2014-10-01), US, pages 2294 - 2327, XP055693682, ISSN: 0899-7667, DOI: 10.1162/NECO_a_00644;;DULUXAN SRITHARAN ET AL: ""Fragility in Networks: Application to the Epileptic Brain"", IFAC THE 2012 IFAC WORKSHOP ON AUTOMATIC CONTROL IN OFFSHORE OIL AND GAS PRODUCTION, vol. 47, no. 3, 1 January 2014 (2014-01-01), Red Hook, NY, pages 7505 - 7510, XP055693715, ISSN: 1474-6670, ISBN: 978-1-123-47890-7, DOI: 10.3182/20140824-6-ZA-1003.00313;;DANIEL EHRENS ET AL: ""Closed-loop control of a fragile network: application to seizure-like dynamics of an epilepsy model"", FRONTIERS IN NEUROSCIENCE, vol. 9, 3 March 2015 (2015-03-03), XP055693678, DOI: 10.3389/fnins.2015.00058;;See also references of WO 2018089806A1",PENDING
12,ES,B1,ES 2566203 B1,141-124-459-046-414,2016-12-30,2016,ES 201531440 A,2015-10-07,ES 201531440 A,2015-10-07,Sistema de gestión de llamadas,,UNIV CARTAGENA POLITECNICA,MARTINEZ GONZALEZ ANTONIO MANUEL;;MENDOZA SAUCEDO JORGE,,https://lens.org/141-124-459-046-414,Granted Patent,no,0,0,2,2,0,H04W8/22;;H04W4/20,H04W8/22;;H04W4/20,,0,0,,,,ACTIVE
13,WO,A3,WO 2003/072186 A3,074-278-618-512-798,2004-03-25,2004,US 0302860 W,2003-01-31,US 35369702 P,2002-02-01,NEUROSTIMULATION FOR AFFECTING SLEEP DISORDERS,"A method of affecting a sleep disorder in a subject having the sleep disorder and a method of affecting a normal awakeness-sleep cycle in a subject having an abnormal awakeness-sleep cycle, said methods comprising: a) identifying at least one nucleus in a brain of the subject, said nucleus being a nucleus of the sleep circuitry of the brain; and b) stimulating the at least one identified nucleus so as to modulate the nucleus, thereby affecting the sleep disorder.",CLEVELAND CLINIC FOUNDATION;;REZAI ALI;;GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI,REZAI ALI;;GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI,,https://lens.org/074-278-618-512-798,Search Report,yes,2,0,5,86,0,A61N1/36082;;A61N1/36082;;A61N1/0529;;A61N1/0529,A61N/;;A61N1/05;;A61N1/18;;A61N1/36,,0,0,,,,PENDING
14,US,A1,US 2017/0117916 A1,048-991-737-001-799,2017-04-27,2017,US 201615299615 A,2016-10-21,US 201615299615 A;;US 201562245449 P;;US 201662337938 P,2015-10-23,SYSTEMS AND METHODS FOR AUTOMATED ELECTRICAL ELEMENT ADDRESSING,"The present disclosure relates generally to automating the task of assignment of labels to identify electrical elements (e.g., electrode contacts, electrodes including a plurality of electrode contacts, and/or non-addressable electrical elements, like wires). A system that can automate the task of assignment of labels can include an electrical element, a microelectronic circuit associated with the electrical element, and an acquisition system. The microelectronic circuit can transmit a sequence comprising a label corresponding to the electrical element. The acquisition system can assign the label corresponding to the electrical element to a recording channel after decoding the sequence.",CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;NAJM IMAD,THE CLEVELAND CLINIC FOUNDATION (2016-11-02),https://lens.org/048-991-737-001-799,Patent Application,yes,0,0,6,6,0,G06K19/06;;G06K17/0022;;G09F3/205;;H03M7/30;;A61B5/4362;;A61B5/0002;;G06K19/06;;G06K17/0022;;G09F3/205;;A61B5/282,H03M7/30,,0,0,,,,ACTIVE
15,EP,A1,EP 3365840 A1,022-388-284-443-884,2018-08-29,2018,EP 16798305 A,2016-10-21,US 201562245449 P;;US 201662337938 P;;US 2016/0058038 W,2015-10-23,SYSTEMS AND METHODS FOR AUTOMATED ELECTRICAL ELEMENT ADDRESSING,,CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;NAJM IMAD,,https://lens.org/022-388-284-443-884,Patent Application,yes,0,0,6,6,0,G06K19/06;;G06K17/0022;;G09F3/205;;H03M7/30;;A61B5/4362;;A61B5/0002;;G06K19/06;;G06K17/0022;;G09F3/205;;A61B5/282,G06K19/06,,0,0,,,,ACTIVE
16,US,A1,US 2005/0177192 A1,023-161-966-230-122,2005-08-11,2005,US 50282003 A,2003-01-31,US 50282003 A;;US 35369702 P;;US 0302860 W,2002-02-01,Neurostimulation for affecting sleep disorders,"A method of affecting a sleep disorder in a subject having the sleep disorder and a method of affecting a normal awakeness-sleep cycle in a subject having an abnormal awakeness-sleep cycle, said methods comprising: a) identifying at least one nucleus in a brain of the subject, said nucleus being a nucleus of the sleep circuitry of the brain; and b) stimulating the at least one identified nucleus so as to modulate the nucleus, thereby affecting the sleep disorder.",REZAI ALI;;GONZALEZ-MARTINEZ JORGE A.;;SHARAN ASHWINI,REZAI ALI;;GONZALEZ-MARTINEZ JORGE A;;SHARAN ASHWINI,CLEVELAND CLINIC FOUNDATION THE (2005-03-07),https://lens.org/023-161-966-230-122,Patent Application,yes,14,97,5,86,0,A61N1/36082;;A61N1/36082;;A61N1/0529;;A61N1/0529,A61N/;;A61N1/05;;A61N1/18;;A61N1/36,607/3,0,0,,,,EXPIRED
17,WO,A1,WO 2017/070425 A1,056-671-890-221-63X,2017-04-27,2017,US 2016/0058038 W,2016-10-21,US 201562245449 P;;US 201662337938 P,2015-10-23,SYSTEMS AND METHODS FOR AUTOMATED ELECTRICAL ELEMENT ADDRESSING,"The present disclosure relates generally to automating the task of assignment of labels to identify electrical elements (e.g., electrode contacts, electrodes including a plurality of electrode contacts, and/or non-addressable electrical elements, like wires). A system that can automate the task of assignment of labels can include an electrical element, a microelectronic circuit associated with the electrical element, and an acquisition system. The microelectronic circuit can transmit a sequence comprising a label corresponding to the electrical element. The acquisition system can assign the label corresponding to the electrical element to a recording channel after decoding the sequence.",CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;NAJM IMAD,,https://lens.org/056-671-890-221-63X,Patent Application,yes,4,0,6,6,0,G06K19/06;;G06K17/0022;;G09F3/205;;H03M7/30;;A61B5/4362;;A61B5/0002;;G06K19/06;;G06K17/0022;;G09F3/205;;A61B5/282,G06K19/06,,0,0,,,,PENDING
18,US,A1,US 2018/0235704 A1,067-360-844-534-599,2018-08-23,2018,US 201815901310 A,2018-02-21,US 201815901310 A;;US 201762461396 P,2017-02-21,CONFIGURING A STEREO-ELECTROENCEPHALOGRAPHY PROCEDURE,"Systems and methods for configuring a stereo-electroencephalography to target specific brain regions that are part of large scale neural networks responsible for neurological disorders are described. A hypothesis related to a large scale neural network responsible for a neurological disorder within patient's brain can be received. Coordinates for implantation of at least two depth electrodes in the patient's brain can be determined based on the hypothesis. Electrodes to be implanted can be selected for each of the coordinates. The electrodes can be designed and used to target these specific brain regions, including an insula electrode, a parietal-frontal electrode, a hippocampo electrode, and a perisylvian electrode. A visualization that includes the coordinates and the selected electrodes can be displayed, so that a surgeon can implant the selected electrodes into the patient's brain according to the coordinates to test the hypothesis.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;NAJM IMAD;;WANG ZHONG,THE CLEVELAND CLINIC FOUNDATION (2018-02-22),https://lens.org/067-360-844-534-599,Patent Application,yes,4,1,1,1,0,A61B34/10;;A61B34/10;;A61B5/16;;A61B5/291;;A61B5/369;;A61B5/369;;A61B5/4094;;A61B5/6868;;A61B5/6868;;A61B90/37;;A61B2034/107;;A61B2034/107;;A61B2560/063;;A61B2562/0209,A61B34/10;;A61B5/00;;A61B5/0478;;A61B5/16;;A61B90/00,,0,0,,,,DISCONTINUED
19,EP,B1,EP 3365840 B1,064-170-581-399-703,2019-09-25,2019,EP 16798305 A,2016-10-21,US 201562245449 P;;US 201662337938 P;;US 2016/0058038 W,2015-10-23,SYSTEMS AND METHODS FOR AUTOMATED ELECTRICAL ELEMENT ADDRESSING,,CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;NAJM IMAD,,https://lens.org/064-170-581-399-703,Granted Patent,yes,4,0,6,6,0,G06K19/06;;G06K17/0022;;G09F3/205;;H03M7/30;;A61B5/4362;;A61B5/0002;;G06K19/06;;G06K17/0022;;G09F3/205;;A61B5/282,G06K19/06,,0,0,,,,ACTIVE
20,US,B2,US 10456212 B2,187-568-294-294-562,2019-10-29,2019,US 201615142730 A,2016-04-29,US 201615142730 A;;US 201562154279 P;;US 201562209558 P,2015-04-29,"Systems and methods for safe, precise stereotactic implantation","The present disclosure relates generally to precise stereotactic implantation of an instrument (e.g., a recording electrode, a stimulating electrode, a biopsy instrument, a catheter, a delivery device, and the like) into a target area in a patient's brain. As such, one aspect of the present disclosure can relate to a stereotactic device that can be used to accomplish the precise implantation of the instrument. The stereotactic device can include a body to secure the stereotactic device to the patient's head. In some instances, the body can have a u-shape. The stereotactic device can also include a guide attached between sides of the body to move an instrument holder into place above a target area. The guide can be locked in position to lock the instrument holder in the place to facilitate injection of the instrument into the target area.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;GALE JOHN;;SHAWAN ANTHONY,THE CLEVELAND CLINIC FOUNDATION (2017-08-03),https://lens.org/187-568-294-294-562,Granted Patent,yes,12,3,4,4,0,A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61N1/0526;;A61N1/0526,A61B17/00;;A61B90/11;;A61B90/14;;A61N1/05,,11,10,067-595-971-781-433;;011-689-490-485-92X;;048-247-895-523-60X;;060-302-513-135-374;;018-494-938-818-10X;;005-749-668-128-706;;025-010-058-319-003;;086-207-058-922-023;;009-978-572-218-867;;058-157-787-009-64X,24205027;;pmc3813548;;10.1371/journal.pone.0077916;;24650680;;10.1016/j.jocn.2013.12.014;;10.1136/jnnp-2013-305604;;23926279;;24405074;;10.3171/2013.11.jns13635;;10.1111/j.1528-1167.2012.03672.x;;23016576;;25296546;;10.1007/s00381-014-2499-z;;25296543;;10.1007/s00381-014-2497-1;;10.1227/neu.0000000000000453;;24887288;;10.3171/2014.7.jns132306;;25148007;;24908209;;10.1016/j.clineuro.2014.04.002,"Antony, Arun R., et al. “Functional connectivity estimated from intracranial EEG predicts surgical outcome in intractable temporal lobe epilepsy.” PloS one 8.10 (2013): e77916.;;Rei Enatsu, et al. “Combining stereo-electroencephalography and subdural electrodes in the diagnosis and treatment of medically intractable epilepsy.” Journal of Clinical Neuroscience 21.8 (2014): 1441-1445.;;Enatsu, Rei, et al. “Posterior cingulate epilepsy: clinical and neurophysiological analysis.” Journal of Neurology, Neurosurgery & Psychiatry (2013): jnnp-2013.;;Gonzalez-Martinez, Jorge et al. “Stereotactic placement of depth electrodes in medically intractable epilepsy: Technical note.” Journal of neurosurgery 120.3 (2014): 639-644.;;Gonzalez-Martinez, Jorge, et al. “Stereoelectroencephalography in the “difficult to localize” refractory focal epilepsy: early experience from a North American epilepsy center.” Epilepsia 54.2 (2013): 323-330.;;Gonzalez-Martinez, Jorge, and Deepak Lachhwani. “Stereoelectroencephalography in children with cortical dysplasia: technique and results.” Child's Nervous System 30.11 (2014): 1853-1857.;;Gonzalez-Martinez, Jorge and Imad M. Najm. “Indications and selection criteria for invasive monitoring in children with cortical dysplasia.” Child's Nervous System 30.11 (2014): 1823-1829.;;Gonzalez-Martinez, Jorge, et al. “Stereoelectroencephalography in children and adolescents with difficult-to localize refractory focal epilepsy.” Neurosurgery 75.3 (2014): 258-268.;;Serletis, Demitre, et al. “The stereotactic approach for mapping epileptic networks: a prospective study of 200 patients: Clinical article.” Journal of neurosurgery 121.5 (2014): 1239-1246.;;Vadera, Sumeet, Richard Burgess, and Jorge Gonzalez-Martinez. “Concomitant use of stereoelectroencephalography (SEEG) and magnetoencephalographic (MEG) in the surgical treatment of refractory focal epilepsy.” Clinical neurology and neurosurgery 122 (2014): 9-11.;;PCT International Search and Written Opinion for PCT/US2016/030151, dated Jul. 22, 2016, pp. 1-15.",ACTIVE
21,US,B2,US 8612005 B2,024-392-506-647-917,2013-12-17,2013,US 50282003 A,2003-01-31,US 50282003 A;;US 35369702 P;;US 0302860 W,2002-02-01,Neurostimulation for affecting sleep disorders,"A method of affecting a sleep disorder in a subject having the sleep disorder and a method of affecting a normal awakeness-sleep cycle in a subject having an abnormal awakeness-sleep cycle, said methods comprising: a) identifying at least one nucleus in a brain of the subject, said nucleus being a nucleus of the sleep circuitry of the brain; and b) stimulating the at least one identified nucleus so as to modulate the nucleus, thereby affecting the sleep disorder.",REZAI ALI;;GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI;;CLEVELAND CLINIC FOUNDATION,REZAI ALI;;GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI,CLEVELAND CLINIC FOUNDATION THE (2005-03-07),https://lens.org/024-392-506-647-917,Granted Patent,yes,14,29,5,86,0,A61N1/36082;;A61N1/36082;;A61N1/0529;;A61N1/0529,A61N1/36;;A61N/;;A61N1/05;;A61N1/18,607/45;;607/46,14,8,041-016-737-356-006;;040-660-042-962-879;;040-372-176-360-930;;022-279-786-005-646;;064-621-937-719-692;;021-077-434-540-256;;015-597-290-908-374;;032-042-285-074-149,1775508;;8235588;;10.1126/science.8235588;;2905197;;10.1016/0006-8993(88)90471-4;;pmc6570275;;10.1523/jneurosci.10-08-02541.1990;;2388079;;10.1111/j.1460-9568.1993.tb00519.x;;8261128;;4340664;;10.1007/3-540-05462-6_1;;4403272;;10.1007/3-540-05462-6_2;;10.1007/978-1-4757-4669-3,"U.S. Appl. No. 60/353,695, filed Feb. 2, 2002, Rezi et al.;;Jacobs, B. L. et al., ""Activity of Brain Serotonergic Neurons in the Behaving Animal,"" Pharmacol. Rev., The American Society for Pharmacology and Experimental Therapeutics, vol. 43, No. 4, 1991, pp. 563-578.;;Steriade, M. et al., ""Thalamocortical Oscillations in the Sleeping and Aroused Brain,"" Science, American Association for the Advancement of Science, vol. 262, No. 5134, Oct. 29, 1993, pp. 630, 631 and 679-685.;;Webster, H. et al., ""Neurotoxic Lesions of the Dorsolateral Pontomesencephalic Tegmentum-Cholinergic Cell Area in the Cat: Effects Upon Sleep-Waking States,"" Brain Research, Elsevier Science Publishers B.V. Amsterdam, vol. 458, No. 2, 1988, pp. 285-302.;;Steriade, M. et al., ""Neuronal Activities in Brain-Stem Cholinergic Nuclei Related to Tonic Activation Processes in Thalamocortical Systems,"" The J. of Neurosci., vol. 10, No. 8, Aug. 1990, pp. 2541-2559.;;Khateb, A. et al, ""Pharmacological and Immunohistochemical Evidence for a Serotonergic Modulation of Cholinergic Nucleus Basalis Neurons,"" Eur. J. of Neurosci., vol. 5, 1993, pp. 541-547.;;Kleitman, N. ""Sleep and Wakefulness,"" The University of Chicago Press, 1963, 3 pages of Table of Contents.;;Moruzzi, G. ""The Sleep-Waking Cycle,"" Reviews of Physiology Biochemistry and Experimental Pharmacology, 1972, pp. 1-65.;;Jouvet, M. ""The Role of Monoamines and Acetylcholine-Containing Neurons in the Regulation of the Sleep-Waking Cycle,"" Ergebn, Physical vol. 64, 1972, pp. 166-307.;;Sakai, K et al., ""The Posterior Hypothalamus in the Regulation of Wakefulness and Paradoxical Sleep,"" In Mancia, M. et al., ""The Diencephalon and Sleep "" Raven Press, Ltd., 1990, pp. 171-198.;;Sakai, K. ""Central Mechanisms of Paradoxical Sleep,"" C. Midbrain, Brainstem Structures and Stage Setting, vol. 8, 1986, pp. 402-407.;;Steriade, M. et al., ""Brainstem Control of Wakefulness and Sleep,"" Plenum Press, 1990, 9 pages of Table of Contents.;;Schaltenbrand, G. et al., ""Atlas for Stereotaxy of the Human Brain,"" Academic Press, 6 pages of Table of Contents, 1977.;;Schaltenbrand, G., et al., ""Introduction to Stereotaxis with an Atlas of the Human Brain,"" vols. I and II, 1959, 19 pages of Table of Context.",ACTIVE
22,WO,A2,WO 2003/072186 A2,099-523-736-523-248,2003-09-04,2003,US 0302860 W,2003-01-31,US 35369702 P,2002-02-01,NEUROSTIMULATION FOR AFFECTING SLEEP DISORDERS,"A method of affecting a sleep disorder in a subject having the sleep disorder and a method of affecting a normal awakeness-sleep cycle in a subject having an abnormal awakeness-sleep cycle, said methods comprising: a) identifying at least one nucleus in a brain of the subject, said nucleus being a nucleus of the sleep circuitry of the brain; and b) stimulating the at least one identified nucleus so as to modulate the nucleus, thereby affecting the sleep disorder.",CLEVELAND CLINIC FOUNDATION;;REZAI ALI;;GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI,REZAI ALI;;GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI,,https://lens.org/099-523-736-523-248,Patent Application,yes,0,0,5,86,0,A61N1/36082;;A61N1/36082;;A61N1/0529;;A61N1/0529,A61N/;;A61N1/05;;A61N1/18;;A61N1/36,,0,0,,,,PENDING
23,US,B2,US 9813078 B2,045-459-727-966-538,2017-11-07,2017,US 201615299615 A,2016-10-21,US 201615299615 A;;US 201562245449 P;;US 201662337938 P,2015-10-23,Systems and methods for automated electrical element addressing,"The present disclosure relates generally to automating the task of assignment of labels to identify electrical elements (e.g., electrode contacts, electrodes including a plurality of electrode contacts, and/or non-addressable electrical elements, like wires). A system that can automate the task of assignment of labels can include an electrical element, a microelectronic circuit associated with the electrical element, and an acquisition system. The microelectronic circuit can transmit a sequence comprising a label corresponding to the electrical element. The acquisition system can assign the label corresponding to the electrical element to a recording channel after decoding the sequence.",CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;NAJM IMAD,THE CLEVELAND CLINIC FOUNDATION (2016-11-02),https://lens.org/045-459-727-966-538,Granted Patent,yes,8,0,6,6,0,G06K19/06;;G06K17/0022;;G09F3/205;;H03M7/30;;A61B5/4362;;A61B5/0002;;G06K19/06;;G06K17/0022;;G09F3/205;;A61B5/282,A61B5/04;;A61B5/00;;A61B5/0408;;G06K19/06;;H03M7/30,,1,0,,,"International Search Report and Written Opinion for corresponding PCT/US2016/058038, dated Feb. 1, 2017, pp. 1-11.",ACTIVE
24,ES,T3,ES 2752625 T3,178-172-166-083-843,2020-04-06,2020,ES 16798305 T,2016-10-21,US 201562245449 P;;US 201662337938 P;;US 2016/0058038 W,2015-10-23,Sistemas y métodos para direccionamiento automatizado de elementos eléctricos,"Un método (70) que comprende: codificar (72), mediante un microcircuito asociado con un elemento eléctrico y situado en serie, en línea con el elemento eléctrico, una señal de direccionamiento con una secuencia (60) que comprende una etiqueta correspondiente al elemento eléctrico; trasmitir (74), por medio del microcircuito, la señal de direccionamiento a un sistema de adquisición; descodificar (76), por medio del sistema de adquisición, la secuencia procedente de la señal de direccionamiento para determinar la etiqueta correspondiente al elemento eléctrico; y asignar (78), por medio del sistema de adquisición, la etiqueta correspondiente al elemento eléctrico a un canal de grabación del sistema de adquisición, en donde el elemento eléctrico comprende un elemento eléctrico no direccionable.",CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;NAJM IMAD,,https://lens.org/178-172-166-083-843,Granted Patent,no,0,0,6,6,0,G06K19/06;;G06K17/0022;;G09F3/205;;H03M7/30;;A61B5/4362;;A61B5/0002;;G06K19/06;;G06K17/0022;;G09F3/205;;A61B5/282,G06K19/06,,0,0,,,,ACTIVE
25,US,A1,US 2016/0317241 A1,001-960-237-658-295,2016-11-03,2016,US 201615142730 A,2016-04-29,US 201615142730 A;;US 201562154279 P;;US 201562209558 P,2015-04-29,"SYSTEMS AND METHODS FOR SAFE, PRECISE STEREOTACTIC IMPLANTATION","The present disclosure relates generally to precise stereotactic implantation of an instrument (e.g., a recording electrode, a stimulating electrode, a biopsy instrument, a catheter, a delivery device, and the like) into a target area in a patient's brain. As such, one aspect of the present disclosure can relate to a stereotactic device that can be used to accomplish the precise implantation of the instrument. The stereotactic device can include a body to secure the stereotactic device to the patient's head. In some instances, the body can have a u-shape. The stereotactic device can also include a guide attached between sides of the body to move an instrument holder into place above a target area. The guide can be locked in position to lock the instrument holder in the place to facilitate injection of the instrument into the target area.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;GALE JOHN;;SHAWAN ANTHONY,THE CLEVELAND CLINIC FOUNDATION (2017-08-03),https://lens.org/001-960-237-658-295,Patent Application,yes,4,2,4,4,0,A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61N1/0526;;A61N1/0526,A61B90/11;;A61B90/14;;A61N1/05,,0,0,,,,ACTIVE
26,AU,A1,AU 2003/241269 A1,137-393-089-917-614,2003-09-09,2003,AU 2003/241269 A,2003-01-31,US 35369702 P;;US 0302860 W,2002-02-01,NEUROSTIMULATION FOR AFFECTING SLEEP DISORDERS,,CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE ALVARO;;SHARAN ASHWINI;;REZAI ALI,,https://lens.org/137-393-089-917-614,Patent Application,no,0,0,5,86,0,A61N1/0529;;A61N1/36082;;A61N1/36082;;A61N1/0529,A61N/;;A61N1/05;;A61N1/18;;A61N1/36,,0,0,,,,DISCONTINUED
27,BR,A2,BR 112018016156 A2,189-927-370-333-776,2018-12-18,2018,BR 112018016156 A,2016-02-08,MX 2016000010 W,2016-02-08,?extrator de suco de fruta cítrica?,"a invenção se refere a um extrator de suco de fruta cítrica que pode ser usado para cortar frutas cítricas em pelo menos duas partes, extrair o suco das mesmas e descartar a casca após a espremeção. o extrator de suco consiste em um elemento extrator de suco acoplado em um alojamento oco que tem aberturas nos lados do mesmo, um elemento de corte conectado acima do elemento extrator e meios de pressão localizados acima do alojamento oco.",YUSY INC S A DE C V,ALEJANDRO MARTINEZ TREVIÑO;;JORGE ALBERTO DE LA GARZA GONZALEZ,,https://lens.org/189-927-370-333-776,Patent Application,no,0,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A47J19/02;;A23N1/02,,0,0,,,,PENDING
28,US,A1,US 2016/0193008 A1,114-661-521-731-389,2016-07-07,2016,US 201614989342 A,2016-01-06,US 201614989342 A;;US 201562100208 P,2015-01-06,STEREOTACTIC GUIDE ASSEMBLIES AND METHODS OF USING SAME,"One aspect of the present disclosure relates to a stereotactic guide assembly comprising an implantable body and a fastener. The implantable body can have an interior chamber and a first passageway that extends through the implantable body into communication with the interior chamber. At least a portion of the interior chamber can be defined by a first coupling feature. The fastener can be configured to fit in the interior chamber. The fastener can have a second passageway extending therethrough, and a second coupling feature adapted to releasably engage the first coupling feature.",CLEVELAND CLINIC FOUNDATION,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;ANTHONY SHAWAN J,THE CLEVELAND CLINIC FOUNDATION (2016-10-18),https://lens.org/114-661-521-731-389,Patent Application,yes,4,3,3,3,0,A61B90/10;;A61B90/10;;A61B90/11;;A61B2090/103;;A61B2090/103;;A61B2090/376;;A61M27/006;;A61N1/0529,A61B90/10;;A61B90/00;;A61B90/11;;A61M27/00;;A61N1/05,,0,0,,,,ACTIVE
29,US,B2,US 10307218 B2,057-168-623-110-52X,2019-06-04,2019,US 201614989342 A,2016-01-06,US 201614989342 A;;US 201562100208 P,2015-01-06,Stereotactic guide assemblies and methods of using same,"One aspect of the present disclosure relates to a stereotactic guide assembly comprising an implantable body and a fastener. The implantable body can have an interior chamber and a first passageway that extends through the implantable body into communication with the interior chamber. At least a portion of the interior chamber can be defined by a first coupling feature. The fastener can be configured to fit in the interior chamber. The fastener can have a second passageway extending therethrough, and a second coupling feature adapted to releasably engage the first coupling feature.",CLEVELAND CLINIC FOUND,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;ANTHONY SHAWAN J,THE CLEVELAND CLINIC FOUNDATION (2016-10-18),https://lens.org/057-168-623-110-52X,Granted Patent,yes,12,0,3,3,0,A61B90/10;;A61B90/10;;A61B90/11;;A61B2090/103;;A61B2090/103;;A61B2090/376;;A61M27/006;;A61N1/0529,A61N1/05;;A61B90/00;;A61B90/10;;A61B90/11;;A61M27/00,,1,0,,,"PCT International Search Report and Written Opinion for PCT/US2016/012321, dated Apr. 21, 2016, pp. 1-11.",ACTIVE
30,WO,A1,WO 2016/112095 A1,148-192-797-151-179,2016-07-14,2016,US 2016/0012321 W,2016-01-06,US 201562100208 P,2015-01-06,STEREOTACTIC GUIDE ASSEMBLIES AND METHODS OF USING SAME,"One aspect of the present disclosure relates to a stereotactic guide assembly comprising an implantable body and a fastener. The implantable body can have an interior chamber and a first passageway that extends through the implantable body into communication with the interior chamber. At least a portion of the interior chamber can be defined by a first coupling feature. The fastener can be configured to fit in the interior chamber. The fastener can have a second passageway extending therethrough, and a second coupling feature adapted to releasably engage the first coupling feature.",CLEVELAND CLINIC FOUNDATION,GALE JOHN T;;GONZALEZ-MARTINEZ JORGE;;SHAWAN ANTHONY J,,https://lens.org/148-192-797-151-179,Patent Application,yes,4,0,3,3,0,A61B90/10;;A61B2090/103;;A61B90/10;;A61N1/0529;;A61B90/11;;A61M27/006;;A61B2090/103;;A61B2090/376,A61B90/10,,0,0,,,,PENDING
31,US,B2,US 10743576 B2,008-811-211-508-796,2020-08-18,2020,US 201616076323 A,2016-02-08,MX 2016000010 W,2016-02-08,Citrus fruit juice extractor,"The invention relates to a citrus fruit juice extractor which can be used to cut citrus fruits into at least two parts, extract the juice therefrom and discharge the peel following juicing. The juice extractor consists of a juice extractor element coupled in a hollow housing having openings in the sides thereof, a cutting element connected above the extractor element, and press means located above the hollow housing.",YUSY INC SA DE CV,MARTINEZ TREVIÑO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,YUSY INC S.A. DE C.V (2018-08-07),https://lens.org/008-811-211-508-796,Granted Patent,yes,8,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A23N1/00;;A47J19/02,,0,0,,,,ACTIVE
32,US,B2,US 10695122 B2,013-262-498-816-076,2020-06-30,2020,US 201715790466 A,2017-10-23,US 201715790466 A;;US 201662411880 P,2016-10-24,Systems and methods for creating one or more lesions in neurological tissue,"This disclosure relates to forming a lesion in a patient's neurological tissue without requiring general anesthesia. The lesion can be either temporary or permanent. In either case, the lesion can be created by a steerable probe that includes a steerable guide, a laser device, and at least one electrode. The steerable guide steers the probe to a target location in the subject's neurological tissue. When the probe reaches the target location, the laser can create the lesion. The at least one electrode can detect a progressive vanishing of neural activity from the portion of the neurological tissue due to the lesion.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE;;NAJM IMAD;;GALE JOHN T;;WEST KARL,THE CLEVELAND CLINIC FOUNDATION (2018-03-06),https://lens.org/013-262-498-816-076,Granted Patent,yes,17,0,3,3,0,A61B18/1492;;A61B2017/00053;;A61B2018/0022;;A61B2018/00434;;A61B2018/00642;;A61B2018/00839;;A61B2017/00128;;A61B2018/0044;;A61B2018/00446;;A61B2018/0066;;A61B2018/00666;;A61B2018/00875;;A61B2018/00577;;A61B2018/00434;;A61B18/1492;;A61B18/20;;A61B2017/00053;;A61B2018/00642;;A61B2018/00839;;A61B2018/0022;;A61B2018/00666;;A61B2018/00446;;A61B2018/0044;;A61B2018/00875;;A61B2017/00128;;A61B2018/0066;;A61B18/082;;A61B18/14;;A61B18/24;;A61B2018/00005;;A61B2018/00577;;A61B2018/00696;;A61B2018/00964;;A61N1/0502,A61B18/20;;A61B17/00;;A61B18/00;;A61B18/08;;A61B18/14;;A61B18/24;;A61N1/05,,1,0,,,"PCT International Search Report and Written Opinion for corresponding PCT Application No. PCT/US2017/057882, dated Jan. 23, 2018, pp. 1-17.",ACTIVE
33,EP,A1,EP 3415016 A1,178-917-529-515-996,2018-12-19,2018,EP 16890005 A,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,"The invention relates to a citrus fruit juice extractor which can be used to cut citrus fruits into at least two parts, extract the juice therefrom and discharge the peel following juicing. The juice extractor consists of a juice extractor element coupled in a hollow housing having openings in the sides thereof, a cutting element connected above the extractor element, and press means located above the hollow housing.",YUSY INC S A DE C V,MARTINEZ TREVIÑO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/178-917-529-515-996,Patent Application,yes,0,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,0,0,,,,ACTIVE
34,ES,B1,ES 2103673 B1,005-774-017-339-15X,1998-05-01,1998,ES 9402697 A,1994-12-30,ES 9402697 A,1994-12-30,INTERFAZ PCM MULTILINEA PARA PROCESADO DE SEÑAL.,"INTERFAZ PCM MULTILINEA PARA PROCESADO DE SEÑAL. DE ESPECIAL APLICACION EN TELEFONIA DIGITAL SIN HILOS, TIPO DECT, CANCELACION DE ECO Y CODIFICACION DE VOZ TIPO ADPCM. DISPONE DE UN CONJUNTO DE CODIFICADORES ADPCM (COD), DECODIFICADORES ADPCM (DEC), CONVERTIDORES DIGITAL-ANALOGICO (D/A) Y CONVERTIDORES ANALOGICO-DIGITAL (A/D). LAS SALIDAS DE LOS DECODIFICADORES ADPCM (DEC) Y CONVERTIDORES ANALOGICO-DIGITAL (A/D) SE ENCUENTRAN UNIDAS FORMANDO UN BUS PCM DE SALIDA (BPO), LAS ENTRADAS DE LOS CONVERTIDORES DIGITAL-ANALOGICO (D/A) Y CODIFICADORES ADPCM (COD) SE ENCUENTRAN UNIDAS FORMANDO UN BUS PCM DE ENTRADA (PI). CUENTA TAMBIEN CON MEDIOS DE PROCESADO DE SEÑAL (MSP) QUE RECIBEN RAFAGAS DE DATOS DEL BUS PCM DE SALIDA (BPO) Y ENTREGAN AL BUS PCM DE ENTRADA (PI) ESTAS MISMAS RAFAGAS CON UN RETARDO DE UNA TRAMA Y SIN ECO. UN GENERADOR DE SINCRONISMOS (SYGEN) ASIGNA RANURAS DE TIEMPO CONSECUTIVAS A LOS CONVERTIDORES INVOLUCRADOS EN UNA MISMA CONVERSACION DE FORMA QUE ESTOS UTILICEN UN MISMO PROCESADOR DE SEÑAL (DSP) PARA REALIZAR OPERACIONES DE CONFERENCIA ASOCIADAS.",ALCATEL CITESA,GUILABERT MELLADO AUGUSTO;;VALE PORBEN JOSE ANTONIO;;GONZALEZ MARTINEZ JORGE,,https://lens.org/005-774-017-339-15X,Granted Patent,no,0,0,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,,0,0,,,,EXPIRED
35,EP,A2,EP 0720401 A2,026-042-555-318-602,1996-07-03,1996,EP 95120270 A,1995-12-21,ES 9402697 A,1994-12-30,Multiline PCM interface for signal processing,"Of particular application in cordless digital telephony, type DECT, echo cancelling and ADPCM type voice encoding. It incorporates a set of ADPCM encoders (COD) and ADPCM decoders (DEC), digital-to-analogue (D/A) converters and analogue-to-digital converters (A/D). The outputs of the ADPCM decoders (DEC) and the analogue-to-digital converters (A/D) are joined to form a PCM output bus (BPO), the inputs of the digital-to-analogue (D/A) converters and ADPCM encoders (COD) are joined together to form a PCM input bus (PI). It also includes signal processing means (MSP) which receive data bursts from the PCM output bus (BPO) and applies these same bursts to the PCM input bus (PI) with a delay of one frame and echo-free. A synchronism generator (SYGEN) allocates consecutive time slots to converters involved in the same conversation, which therefore employ the same signal processor (DSP) to perform associated conference operations.",ALCATEL NV;;ALCATEL CITESA,GUILABERT MELLADO AUGUSTO;;GONZALEZ MARTINEZ JORGE;;VALE PORBEN JOSE A,,https://lens.org/026-042-555-318-602,Patent Application,yes,0,0,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,,0,0,,,,DISCONTINUED
36,US,A1,US 2019/0045829 A1,074-338-372-735-706,2019-02-14,2019,US 201616076323 A,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,"The invention relates to a citrus fruit juice extractor which can be used to cut citrus fruits into at least two parts, extract the juice therefrom and discharge the peel following juicing. The juice extractor consists of a juice extractor element coupled in a hollow housing having openings in the sides thereof, a cutting element connected above the extractor element, and press means located above the hollow housing.",YUSY INC S A DE C V,MARTINEZ TREVIÑO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,YUSY INC S.A. DE C.V (2018-08-07),https://lens.org/074-338-372-735-706,Patent Application,yes,0,3,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A23N1/00;;A47J19/02,,0,0,,,,ACTIVE
37,ES,A1,ES 2103673 A1,186-972-646-719-252,1997-09-16,1997,ES 9402697 A,1994-12-30,ES 9402697 A,1994-12-30,Multiline PCM interface for signal processing,"Of particular application in cordless digital telephony, type DECT, echo cancelling and ADPCM type voice encoding. It incorporates a set of ADPCM encoders (COD) and ADPCM decoders (DEC), digital-to-analogue (D/A) converters and analogue-to-digital converters (A/D). The outputs of the ADPCM decoders (DEC) and the analogue-to-digital converters (A/D) are joined to form a PCM output bus (BPO), the inputs of the digital-to-analogue (D/A) converters and ADPCM encoders (COD) are joined together to form a PCM input bus (PI). It also includes signal processing means (MSP) which receive data bursts from the PCM output bus (BPO) and applies these same bursts to the PCM input bus (PI) with a delay of one frame and echo-free. A synchronism generator (SYGEN) allocates consecutive time slots to converters involved in the same conversation, which therefore employ the same signal processor (DSP) to perform associated conference operations.",ALCATEL CITESA,GUILABERT MELLADO AUGUSTO;;VALE PORBEN JOSE ANTONIO;;GONZALEZ MARTINEZ JORGE,,https://lens.org/186-972-646-719-252,Patent Application,no,4,0,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,,0,0,,,,EXPIRED
38,DE,A1,DE 102017118142 A1,111-085-330-716-520,2019-02-14,2019,DE 102017118142 A,2017-08-09,DE 102017118142 A,2017-08-09,Reibscheibe für eine Reibkupplung,"Die Erfindung betrifft eine Reibscheibe (1) für eine Reibkupplung (2) eines Kraftfahrzeugs (3), aufweisend zumindest die folgenden Komponenten:- eine Mitnehmerscheibe (4) mit einer Rotationsachse (5), welche rotationsfest mit einer Ausgangswelle (6) verbindbar ist; und- ein Federelement (7), welches zur Aufnahme eines Reibbelags (8) zum reibschlüssigen Übertragen eines Drehmoments eingerichtet ist und mittels zumindest eines Segmentfußes (9) radial außenseitig an der Mitnehmerscheibe (4) befestigt ist, wobei die Mitnehmerscheibe (4) und das Federelement (7) miteinander vernietet sind. Die Reibscheibe (1) ist vor allem dadurch gekennzeichnet, dass die Mitnehmerscheibe (4) zumindest eine Stützerhebung (10) aufweist, welche formschlüssig in einer Stützaufnahme (11) des Federelements (7) aufgenommen ist.Mit der hier vorgeschlagenen Reibscheibe ist ein Montageaufwand reduziert und somit eine Reibscheibe kostengünstiger herstellbar.",SCHAEFFLER TECHNOLOGIES AG,MARTINEZ TORRES JORGE;;GONZALEZ NAGANO JAVIER TAKESHI;;PEREZ ANGEL CORTES,,https://lens.org/111-085-330-716-520,Patent Application,no,0,0,1,1,0,F16D13/68;;F16D13/46,F16D13/64;;F16D13/68;;F16D13/70,,0,0,,,,PENDING
39,AU,B2,AU 706570 B2,133-007-233-521-646,1999-06-17,1999,AU 1995/040418 A,1995-12-14,ES 9402697 A,1994-12-30,PCM multiline interface,,ALCATEL NV,MELLADO AUGUSTO GUILABERT;;PORBEN JOSE ANTONIO VALE;;MARTINEZ JORGE GONZALEZ,,https://lens.org/133-007-233-521-646,Granted Patent,no,3,0,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,,0,0,,,,EXPIRED
40,WO,A1,WO 2016/176589 A1,183-553-488-416-057,2016-11-03,2016,US 2016/0030151 W,2016-04-29,US 201562154279 P;;US 201562209558 P,2015-04-29,"SYSTEMS AND METHODS FOR SAFE, PRECISE STEREOTACTIC IMPLANTATION","The present disclosure relates generally to precise stereotactic implantation of an instrument (e.g., a recording electrode, a stimulating electrode, a biopsy instrument, a catheter, a delivery device, and the like) into a target area in a patient's brain. As such, one aspect of the present disclosure can relate to a stereotactic device that can be used to accomplish the precise implantation of the instrument. The stereotactic device can include a body to secure the stereotactic device to the patient's head. In some instances, the body can have a u-shape. The stereotactic device can also include a guide attached between sides of the body to move an instrument holder into place above a target area. The guide can be locked in position to lock the instrument holder in the place to facilitate injection of the instrument into the target area.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;GALE JOHN T;;SHAWAN ANTHONY J,,https://lens.org/183-553-488-416-057,Patent Application,yes,7,0,4,4,0,A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61N1/0526;;A61N1/0526,A61B90/11;;A61B17/34,,0,0,,,,PENDING
41,EP,A3,EP 0720401 A3,013-534-480-587-216,2000-07-12,2000,EP 95120270 A,1995-12-21,ES 9402697 A,1994-12-30,Multiline PCM interface for signal processing,"Of particular application in cordless digital telephony, type DECT, echo cancelling and ADPCM type voice encoding. It incorporates a set of ADPCM encoders (COD) and ADPCM decoders (DEC), digital-to-analogue (D/A) converters and analogue-to-digital converters (A/D). The outputs of the ADPCM decoders (DEC) and the analogue-to-digital converters (A/D) are joined to form a PCM output bus (BPO), the inputs of the digital-to-analogue (D/A) converters and ADPCM encoders (COD) are joined together to form a PCM input bus (PI). It also includes signal processing means (MSP) which receive data bursts from the PCM output bus (BPO) and applies these same bursts to the PCM input bus (PI) with a delay of one frame and echo-free. A synchronism generator (SYGEN) allocates consecutive time slots to converters involved in the same conversation, which therefore employ the same signal processor (DSP) to perform associated conference operations.",ALCATEL NV;;ALCATEL CITESA,GUILABERT MELLADO AUGUSTO;;GONZALEZ MARTINEZ JORGE;;VALE PORBEN JOSE A,,https://lens.org/013-534-480-587-216,Search Report,yes,2,0,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,,1,1,108-124-973-707-055,10.1109/vlsisp.1993.404494,"NOTE S. ; VANDEBROEK P. DEVISCH D.: ""Application of Advanced DSP tools for the design of an IC for Digital European Cordless Telephone systems"", VLSI SIGNAL PROCESSING, VI, PROCEEDINGS OF IEEE WORKSHOP ON VLSI SIGNAL PROCESSING, VELDHOVEN, NETHERLANDS, 20-22 OCTOBER 1993, no. ISBN 0-7803-0996-0, 1993, New York, USA, pages 132 - 140, XP002137788",DISCONTINUED
42,US,A1,US 2024/0006050 A1,145-081-012-554-031,2024-01-04,2024,US 202118255727 A,2021-12-09,US 202118255727 A;;US 202063123417 P;;US 2021/0062523 W,2020-12-09,LOCATING AN EPILEPTOGENIC ZONE FOR SURGICAL PLANNING,"A machine-implemented method, computing device, and at least one non-transitory computer-readable medium are provided. A dynamical network model is parameterized by state transition matrices based on monitored interictal brain data. A node influence-to network score for each respective node is calculated indicating how influential the respective node is. An influenced-by score is calculated for the each respective node indicating an amount by which the respective node is influenced by the nodes. A score is calculated for the each respective node based on a sink index, a source influence index, and a sink connectivity index. Nodes that are in the epileptogenic zone are determined based on the calculated score for each of the nodes. An indication of the nodes in the epileptogenic zone is provided.",UNIV JOHNS HOPKINS;;UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,SARMA SRIDEVI V;;GUNNARSDOTTIR KRISTIN M;;GONZALEZ-MARTINEZ JORGE A,UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (2021-07-30);;THE JOHNS HOPKINS UNIVERSITY (2021-02-22),https://lens.org/145-081-012-554-031,Patent Application,yes,0,0,4,4,0,G06N20/00;;A61B5/4094;;A61B5/7267;;G16H20/40;;G16H50/20;;A61B5/015;;A61B5/4094;;A61B5/7267,G16H20/40;;A61B5/00;;A61B5/01;;G16H50/20,,0,0,,,,PENDING
43,ES,T3,ES 2850399 T3,159-822-110-583-753,2021-08-30,2021,ES 16890005 T,2016-02-08,MX 2016000010 W,2016-02-08,Extractor de zumo de cítricos,"Aparato exprimidor de cítricos que permite cortar los cítricos en al menos dos partes, exprimirlos y liberar las cáscaras después de la acción de exprimido. El aparato exprimidor está compuesto de un elemento exprimidor acoplado en un alojamiento hueco con aberturas en sus caras laterales, un elemento de corte acoplado por encima del elemento exprimidor y unos medios de prensado ubicados por encima del alojamiento hueco.",YUSY INC S A DE C V,MARTINEZ TREVINO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/159-822-110-583-753,Granted Patent,no,0,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,0,0,,,,ACTIVE
44,WO,A1,WO 2017/138804 A1,045-291-387-002-508,2017-08-17,2017,MX 2016000010 W,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,"The invention relates to a citrus fruit juice extractor which can be used to cut citrus fruits into at least two parts, extract the juice therefrom and discharge the peel following juicing. The juice extractor consists of a juice extractor element coupled in a hollow housing having openings in the sides thereof, a cutting element connected above the extractor element, and press means located above the hollow housing.",YUSY INC S A DE C V,MARTINEZ TREVIÑO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/045-291-387-002-508,Patent Application,yes,5,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,0,0,,,,PENDING
45,EP,B1,EP 3415016 B1,114-677-445-160-508,2020-11-11,2020,EP 16890005 A,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,,YUSY INC S A DE C V,MARTINEZ TREVIÑO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/114-677-445-160-508,Granted Patent,yes,7,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,0,0,,,,ACTIVE
46,AU,A,AU 1995/040418 A,010-030-106-523-724,1996-07-11,1996,AU 1995/040418 A,1995-12-14,ES 9402697 A,1994-12-30,PCM multiline interface,,ALCATEL NV,MELLADO AUGUSTO GUILABERT;;PORBEN JOSE ANTONIO VALE;;MARTINEZ JORGE GONZALEZ,,https://lens.org/010-030-106-523-724,Patent Application,no,0,0,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,,0,0,,,,EXPIRED
47,US,A,US 5796731 A,035-672-083-083-528,1998-08-18,1998,US 57940695 A,1995-12-27,ES 9402697 A,1994-12-30,Multiline PCM interface for signal processing,"A multiline PCM interface for signal processing is of particular application in cordless digital telephony, type DECT, with echo cancelling and ADPCM type voice encoding. The interface incorporates a set of ADPCM encoders (COD) and ADPCM decoders (DEC), digital-to-analogue (D/A) converters and analogue-to-digital converters (A/D). The outputs of the ADPCM decoders (DEC) and the analogue-to-digital converters (A/D) are joined to form a PCM output bus (BPO), the inputs of the digital-to-analogue (D/A) converters and ADPCM encoders (COD) are joined together to form a PCM input bus (PI). The interface also includes signal processing means (MSP) which receive data bursts from the PCM output bus (BPO) and applies these same bursts to the PCM input bus (PI) with a delay of one frame and echo-free. A synchronism generator (SYGEN) allocates consecutive time slots to converters involved in the same conversation, which therefore employ the same signal processor (DSP) to perform associated conference operations.",ALCATEL NV,MELLADO AUGUSTO GUILABERT;;VALE PORBEN JOSE ANTONIO;;GONZALEZ MARTINEZ JORGE,ALCATEL N. V (1996-02-15),https://lens.org/035-672-083-083-528,Granted Patent,yes,4,10,8,8,0,H03M7/3046;;H04M1/725;;H04M2250/08;;H03M7/3046;;H04M2250/08;;H04M1/725,H03M7/38;;H04M1/725,370/362;;370/286;;375/242;;375/244;;379/61,1,0,,,"Catalog Semiconductors for Telecom Systems , 1993, reference IC03, published by Philips Semiconductors, p. 472.",EXPIRED
48,EP,A4,EP 3415016 A4,091-424-693-839-001,2019-11-20,2019,EP 16890005 A,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,,YUSY INC S A DE C V,MARTINEZ TREVIÑO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/091-424-693-839-001,Search Report,no,2,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,1,0,,,See also references of WO 2017138804A1,ACTIVE
49,EP,A1,EP 4260245 A1,180-473-122-324-60X,2023-10-18,2023,EP 21904368 A,2021-12-09,US 202063123417 P;;US 2021/0062523 W,2020-12-09,LOCATING AN EPILEPTOGENIC ZONE FOR SURGICAL PLANNING,,UNIV JOHNS HOPKINS;;UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,SARMA SRIDEVI V;;GUNNARSDOTTIR KRISTIN M;;GONZALEZ-MARTINEZ JORGE A,,https://lens.org/180-473-122-324-60X,Patent Application,yes,0,0,4,4,0,G06N20/00;;A61B5/4094;;A61B5/7267;;G16H20/40;;G16H50/20;;A61B5/015;;A61B5/4094;;A61B5/7267,G06N3/10;;A61B5/24,,0,0,,,,PENDING
50,CA,A1,CA 3013905 A1,101-980-572-886-942,2017-08-17,2017,CA 3013905 A,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,"The invention relates to a citrus fruit juice extractor which can be used to cut citrus fruits into at least two parts, extract the juice therefrom and discharge the peel following juicing. The juice extractor consists of a juice extractor element coupled in a hollow housing having openings in the sides thereof, a cutting element connected above the extractor element, and press means located above the hollow housing.",YUSY INC S A DE C V,MARTINEZ TREVINO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/101-980-572-886-942,Patent Application,no,0,0,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,0,0,,,,DISCONTINUED
51,US,A1,US 2018/0110558 A1,024-588-309-444-154,2018-04-26,2018,US 201715790466 A,2017-10-23,US 201715790466 A;;US 201662411880 P,2016-10-24,SYSTEMS AND METHODS FOR CREATING ONE OR MORE LESIONS IN NEUROLOGICAL TISSUE,"This disclosure relates to forming a lesion in a patient's neurological tissue without requiring general anesthesia. The lesion can be either temporary or permanent. In either case, the lesion can be created by a steerable probe that includes a steerable guide, a laser device, and at least one electrode. The steerable guide steers the probe to a target location in the subject's neurological tissue. When the probe reaches the target location, the laser can create the lesion. The at least one electrode can detect a progressive vanishing of neural activity from the portion of the neurological tissue due to the lesion.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE;;NAJM IMAD;;GALE JOHN T;;WEST KARL,THE CLEVELAND CLINIC FOUNDATION (2018-03-06),https://lens.org/024-588-309-444-154,Patent Application,yes,0,0,3,3,0,A61B18/1492;;A61B2017/00053;;A61B2018/0022;;A61B2018/00434;;A61B2018/00642;;A61B2018/00839;;A61B2017/00128;;A61B2018/0044;;A61B2018/00446;;A61B2018/0066;;A61B2018/00666;;A61B2018/00875;;A61B2018/00577;;A61B2018/00434;;A61B18/1492;;A61B18/20;;A61B2017/00053;;A61B2018/00642;;A61B2018/00839;;A61B2018/0022;;A61B2018/00666;;A61B2018/00446;;A61B2018/0044;;A61B2018/00875;;A61B2017/00128;;A61B2018/0066;;A61B18/082;;A61B18/14;;A61B18/24;;A61B2018/00005;;A61B2018/00577;;A61B2018/00696;;A61B2018/00964;;A61N1/0502,A61B18/14;;A61B18/24;;A61N1/05,,0,0,,,,ACTIVE
52,WO,A1,WO 2018/081002 A1,056-303-517-473-506,2018-05-03,2018,US 2017/0057882 W,2017-10-23,US 201662411880 P,2016-10-24,SYSTEMS FOR CREATING ONE OR MORE LESIONS IN NEUROLOGICAL TISSUE,"This disclosure relates to forming a lesion in a patient's neurological tissue without requiring general anesthesia. The lesion can be either temporary or permanent. In either case, the lesion can be created by a steerable probe that includes a steerable guide, a laser device, and at least one electrode. The steerable guide steers the probe to a target location in the subject's neurological tissue. When the probe reaches the target location, the laser can create the lesion. The at least one electrode can detect a progressive vanishing of neural activity from the portion of the neurological tissue due to the lesion.",CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE;;NAJM IMAD;;GALE JOHN T;;WEST KARL,,https://lens.org/056-303-517-473-506,Patent Application,yes,5,0,3,3,0,A61B18/1492;;A61B2017/00053;;A61B2018/0022;;A61B2018/00434;;A61B2018/00642;;A61B2018/00839;;A61B2017/00128;;A61B2018/0044;;A61B2018/00446;;A61B2018/0066;;A61B2018/00666;;A61B2018/00875;;A61B2018/00577;;A61B2018/00434;;A61B18/1492;;A61B18/20;;A61B2017/00053;;A61B2018/00642;;A61B2018/00839;;A61B2018/0022;;A61B2018/00666;;A61B2018/00446;;A61B2018/0044;;A61B2018/00875;;A61B2017/00128;;A61B2018/0066;;A61B18/082;;A61B18/14;;A61B18/24;;A61B2018/00005;;A61B2018/00577;;A61B2018/00696;;A61B2018/00964;;A61N1/0502,A61B18/20;;A61B17/00;;A61B18/00;;A61B18/14;;A61M25/01,,0,0,,,,PENDING
53,CN,A,CN 108697147 A,062-730-877-883-772,2018-10-23,2018,CN 201680081305 A,2016-02-08,MX 2016000010 W,2016-02-08,CITRUS FRUIT JUICE EXTRACTOR,"The invention relates to a citrus fruit juice extractor which can be used to cut citrus fruits into at least two parts, extract the juice therefrom and discharge the peel following juicing. The juiceextractor consists of a juice extractor element coupled in a hollow housing having openings in the sides thereof, a cutting element connected above the extractor element, and press means located abovethe hollow housing.",YUSY INC S A DE C V,MARTINEZ TREVINO ALEJANDRO ROBERTO;;DE LA GARZA GONZALEZ JORGE ALBERTO,,https://lens.org/062-730-877-883-772,Patent Application,no,13,1,13,13,0,A23N1/02;;A47J19/023;;A23N1/003;;A23N1/02;;A47J19/023;;A23N1/003,A23N1/02;;A47J19/02,,0,0,,,,ACTIVE
54,EP,A1,EP 3288484 A1,056-109-881-271-952,2018-03-07,2018,EP 16724773 A,2016-04-29,US 201562154279 P;;US 201562209558 P;;US 2016/0030151 W,2015-04-29,"SYSTEMS AND METHODS FOR SAFE, PRECISE STEREOTACTIC IMPLANTATION",,CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;GALE JOHN T;;SHAWAN ANTHONY J,,https://lens.org/056-109-881-271-952,Patent Application,yes,0,0,4,4,0,A61B90/11;;A61B90/11;;A61B90/14;;A61B90/14;;A61N1/0526;;A61N1/0526,A61B90/11;;A61B17/34,,1,0,,,See references of WO 2016176589A1,DISCONTINUED
55,CU,A1,CU 22268 A1,008-280-826-233-135,1995-01-31,1995,CU 1989228 A,1989-11-24,CU 1989228 A,1989-11-24,RETRIEVAL OF RARE EARTHS FROM THE MUD IN SALT PANS.,"SE RELACIONA CON LA RAMA DE LA GEOQUIMICA Y EN PARTICULAR CON UN PROCESO TECNOLOGICO PARA EL TRATAMIENTO DE LOS FANGOS PRESENTES EN LAS SALINAS QUE PERMITE EL RECOBRADO DE ELEMENTOS TIERRAS RARAS. POS SU CARACTER ACUMULATIVO- BIOGENICO ESTOS FANGOS CONSTITUYEN UN RECURSO NATURAL DE GRAN IMPORTANCIA ECONOMICA, YA QUE UNA VEZ PROCESADOS COBRAN UN ALTO PRECIO EN EL MERCADO INTERNACIONAL POR LA VARIEDAD DE APLICACIONES EN LAS DIFERENTES RAMAS DE LA CIENCIA Y LA TECNICA.\!",ENERGOPROYECTO,FRANKLIN SABURIDO CARMEN JULIA;;HERRERA GONZALEZ JORGE;;MARTINEZ LUZARDO FRANCISCO;;BORROTO PORTELA JORGE ISAIAS,,https://lens.org/008-280-826-233-135,Limited Patent,no,0,0,1,1,0,,C22B59/00,,0,0,,,,EXPIRED
56,CN,A,CN 112166625 A,132-357-148-859-89X,2021-01-01,2021,CN 201980034838 A,2019-05-13,US 201815990520 A;;US 2019/0031935 W,2018-05-25,DETECTING MOVEMENT OF A COMPUTING DEVICE BASED ON WIRELESS ACCESS POINT SIGNAL STRENGTH DATA AND ADAPTIVE THRESHOLDS,"The disclosure herein describes receiving wireless signal strength data and detecting movement of a computing device relative to wireless access points based thereon. The computing device receives a signal strength data stream based on a wireless signal from a wireless access point. A signal strength range is determined based on the signal strength data stream during a learning time period while the computing device is within a defined area. The signal strength range indicates that the computing device is within the defined area associated with the wireless access point. During a detection time period, signal strength values outside of the signal strength range are detected and, based on the detected values, a notification is provided that indicates the computing device has moved outside the defined area. The described method provides rapid detection of movements of a computing device using already-obtained data that does not rely on interaction with other devices.",MICROSOFT TECHNOLOGY LICENSING LLC,KHAWAND JEAN;;NUSCA GIANLUIGI;;DURAK MATTHEW T;;GONZALEZ MARTINEZ JORGE A,,https://lens.org/132-357-148-859-89X,Patent Application,no,4,0,5,5,0,H04W24/08;;H04W76/25;;H04W76/30;;H04W88/02;;H04B17/318;;H04W4/02,H04W24/08;;H04W88/02,,0,0,,,,PENDING
57,US,A1,US 2016/0287118 A1,133-349-390-067-248,2016-10-06,2016,US 201615089058 A,2016-04-01,US 201615089058 A;;US 201562141698 P,2015-04-01,COMPUTATIONAL TOOL FOR PRE-SURGICAL EVALUATION OF PATIENTS WITH MEDICALLY REFRACTORY EPILEPSY,"A method of identifying an epileptogenic zone of a brain includes receiving a plurality of electrical signals from a plurality of surgically implanted electrodes, calculating components of an adjacency matrix, calculating eigenvectors from the adjacency matrix, and selecting an eigenvector having a largest eigenvalue. The method includes assigning an integer rank to each component of the eigenvector, sliding the time window by a time increment and repeating the immediately preceding steps a plurality of times. The method includes normalizing each rank signal, extracting a multidimensional feature vector from each normalized signal, projecting each multidimensional feature vector onto a reduced dimensionality space, and receiving a plurality of training data points represented in the reduced dimensionality space. The method includes calculating grid weights for each feature vector, and assigning a numerical value to each electrode as an indication of whether the electrode is in an epileptogenic zone of the brain.",UNIV JOHNS HOPKINS;;CLEVELAND CLINIC FOUND,SARMA SRIDEVI;;CHENNURI BHASKAR;;GALE JOHN T;;GONZALEZ-MARTINEZ JORGE ALVARO,,https://lens.org/133-349-390-067-248,Patent Application,yes,4,18,1,1,0,A61B5/7257;;A61B5/4094;;A61B5/316;;A61B5/374;;A61B5/291;;A61B5/4094;;A61B5/7257;;A61B5/316;;A61B5/291;;A61B5/374,A61B5/04;;A61B5/00;;A61B5/0478,,2,1,080-064-372-442-702,23367090;;10.1109/embc.2012.6347155,"Kerr et al. Multivariate Analysis of SEEG Signals During Seizure. 33rd Annual International Conference of the IEEE EMBS, August 30 - September 3, 2011.;;Yaffe et al. Brain State Evolution During Seizure and Under Anesthesia: A Network-Based Analysis of Stereotaxic EEG Activity in Drug-Resistant Epilepsy Patients. 34th Annual International Conference of the IEEE EMBS, August 28 - September 1, 2012.",DISCONTINUED
58,WO,A2,WO 2012/069263 A2,095-942-139-947-107,2012-05-31,2012,EP 2011068513 W,2011-10-24,US 41690110 P,2010-11-24,METHOD FOR AUTHORIZING ACCESS TO PROTECTED CONTENT,"The invention refers to a method for authorizing access to a third party application, called client (2), to protected resources owned by a user (1) and hosted in a server (3). The method comprising: the client being used by the user asking for a temporary token to the server; the server sending a first SMS to the user, said first SMS providing means to authenticate the user; authenticating the user by the means provided in previous two steps; the user authorizing the client; the server sending a second SMS to the user providing some information needed to obtain an access token; the client getting the information of the previous step from the user and the access token; the client accessing protected resources using the access token.",TELEFONICA SA;;GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/095-942-139-947-107,Patent Application,yes,1,19,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06,,0,0,,,,PENDING
59,WO,A3,WO 2012/069263 A3,111-727-328-723-942,2012-10-18,2012,EP 2011068513 W,2011-10-24,US 41690110 P,2010-11-24,METHOD FOR AUTHORIZING ACCESS TO PROTECTED CONTENT,"The invention refers to a method for authorizing access to a third party application, called client (2), to protected resources owned by a user (1) and hosted in a server (3). The method comprising: the client being used by the user asking for a temporary token to the server; the server sending a first SMS to the user (51, 52), said first SMS providing means to authenticate the user; authenticating the user by the means provided in previous two steps (53, 54); the user authorizing the client (53); the server sending a second SMS to the user providing some information needed to obtain an access token (57, 58); the client getting the information of the previous step from the user and the access token (59, 60); the client accessing protected resources using the access token (391).",TELEFONICA SA;;GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/111-727-328-723-942,Search Report,yes,2,0,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06,,2,1,047-866-766-806-781,10.17487/rfc5849,"ANONYMOUS: ""9.0 Using the Invitation API"", 5 October 2010 (2010-10-05), XP055032919, Retrieved from the Internet <URL:http://web.archive.org/web/20101005004846/http://developer.veriplace.com/devportal/developerguide/invitation-api.html> [retrieved on 20120717];;HAMMER-LAHAV E ET AL: ""The OAuth 1.0 Protocol; rfc5849.txt"", THE OAUTH 1.0 PROTOCOL; RFC5849.TXT, INTERNET ENGINEERING TASK FORCE, IETF; STANDARD, INTERNET SOCIETY (ISOC) 4, RUE DES FALAISES CH- 1205 GENEVA, SWITZERLAND, 20 April 2010 (2010-04-20), pages 1 - 38, XP015070768",PENDING
60,CA,A1,CA 2818955 A1,114-482-830-910-897,2012-05-31,2012,CA 2818955 A,2011-10-24,US 41690110 P;;EP 2011068513 W,2010-11-24,METHOD FOR AUTHORIZING ACCESS TO PROTECTED CONTENT,"The invention refers to a method for authorizing access to a third party application, called client (2), to protected resources owned by a user (1) and hosted in a server (3). The method comprising: the client being used by the user asking for a temporary token to the server; the server sending a first SMS to the user (51, 52), said first SMS providing means to authenticate the user; authenticating the user by the means provided in previous two steps (53, 54); the user authorizing the client (53); the server sending a second SMS to the user providing some information needed to obtain an access token (57, 58); the client getting the information of the previous step from the user and the access token (59, 60); the client accessing protected resources using the access token (391).",TELEFONICA SA,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/114-482-830-910-897,Patent Application,no,0,0,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06,,0,0,,,,DISCONTINUED
61,US,A1,US 2014/0068746 A1,184-158-008-232-74X,2014-03-06,2014,US 201113989748 A,2011-10-24,US 201113989748 A;;US 41690110 P;;EP 2011068513 W,2010-11-24,METHOD FOR AUTHORIZING ACCESS TO PROTECTED CONTENT,"The invention refers to a method for authorizing access to a third party application, called client ( 2 ), to protected resources owned by a user ( 1 ) and hosted in a server ( 3 ). The method comprising: the client being used by the user asking for a temporary token to the server; the server sending a first SMS to the user, said first SMS providing means to authenticate the user; authenticating the user by the means provided in previous two steps; the user authorizing the client; the server sending a second SMS to the user providing some information needed to obtain an access token; the client getting the information of the previous step from the user and the access token; the client accessing protected resources using the access token.",GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,TELEFÓNICA S.A (2013-05-31),https://lens.org/184-158-008-232-74X,Patent Application,yes,19,70,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06,726/9,0,0,,,,INACTIVE
62,ES,T3,ES 2601009 T3,075-367-646-455-971,2017-02-13,2017,ES 11773463 T,2011-10-24,US 41690110 P;;EP 2011068513 W,2010-11-24,Procedimientos para autorizar el acceso a contenido protegido,"Procedimiento para autorizar el acceso a una aplicación de terceros, llamada cliente (2), para recursos protegidos propiedad de un usuario (1) y alojados en un servidor (3), comprendiendo el procedimiento: - el cliente pide un token temporal al servidor; - además de la respuesta al cliente con dicho token temporal, el servidor envía un primer SMS (51, 52) al usuario, con dicho primer SMS proporcionando medios para autentificar al usuario (53,54); - autentificar al usuario por los medios previstos en las dos etapas anteriores; - el usuario autoriza al cliente (55); estando el procedimiento caracterizado por que comprende: - después de la autentificación del usuario y de la autorización del cliente por el usuario, el servidor envía un segundo SMS al usuario incluyendo un código de verificación necesario para obtener un token de acceso; - el cliente recibe (59, 60) el código de verificación; - el cliente obtiene el token de acceso del código de verificación; - el cliente accede a recursos protegidos utilizando el token de acceso.",TELEFÓNICA S A,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/075-367-646-455-971,Granted Patent,no,0,0,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06;;G06F21/30;;H04L9/32,,0,0,,,,ACTIVE
63,EP,A2,EP 2643955 A2,102-986-697-371-188,2013-10-02,2013,EP 11773463 A,2011-10-24,US 41690110 P;;EP 2011068513 W,2010-11-24,METHODS FOR AUTHORIZING ACCESS TO PROTECTED CONTENT,,TELEFONICA SA,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/102-986-697-371-188,Patent Application,yes,0,0,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06;;G06F21/30;;H04L9/32,,0,0,,,,ACTIVE
64,TW,S,TW D221454 S,192-882-551-118-073,2022-10-01,2022,TW 111300974 F,2022-02-25,XH DM216754 F,2021-10-08,ELECTRIC JUICER MECHANISM,﻿【物品用途】;(省略之);【設計說明】;(無),西班牙商尚摩創新機械公司 &#x;;ZUMMO INNOVACIONES MECANICAS S A U,PEREZ MORILLO JAVIER;;GONZALEZ GENOVES JORGE;;PEREZ MUNOZ ALEX;;MARTINEZ ROCA JORGE;;ALONSO LERA NICO,,https://lens.org/192-882-551-118-073,Design Right,no,0,0,2,2,0,,,31-00,0,0,,,,ACTIVE
65,CN,A,CN 103283204 A,076-063-927-843-886,2013-09-04,2013,CN 201180062503 A,2011-10-24,EP 2011068513 W;;US 41690110 P,2010-11-24,Method for authorizing access to protected content,"The invention refers to a method for authorizing access to a third party application, called client (2), to protected resources owned by a user (1) and hosted in a server (3). The method comprising: the client being used by the user asking for a temporary token to the server; the server sending a first SMS to the user, said first SMS providing means to authenticate the user; authenticating the user by the means provided in previous two steps; the user authorizing the client; the server sending a second SMS to the user providing some information needed to obtain an access token; the client getting the information of the previous step from the user and the access token; the client accessing protected resources using the access token.",TELEFONICA SA,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/076-063-927-843-886,Patent Application,no,3,6,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,H04L29/06,,0,0,,,,INACTIVE
66,AR,A1,AR 083988 A1,140-612-378-251-033,2013-04-10,2013,AR P110104390 A,2011-11-24,US 41690110 P,2010-11-24,PROCEDIMIENTO PARA AUTORIZAR EL ACCESO A CONTENIDO PROTEGIDO,"La presente se refiere a un procedimiento para autorizar el acceso a una aplicación de terceras partes, denominada cliente (2), a recursos protegidos que son propiedad de un usuario (1) y se alojan en un servidor (3). Comprendiendo el procedimiento: pedir, el cliente usado por el usuario, un testigo temporal al servidor; enviar el servidor un primer SMS al usuario, proporcionando dicho primer SMS medios para autenticar el usuario; autenticar el usuario mediante los medios previstos en las dos etapas anteriores; autorizar el usuario al cliente; enviar el servidor un segundo SMS al usuario proporcionando cierta información necesaria para obtener un testigo de acceso; obtener el cliente la información de la etapa anterior del usuario y el testigo de acceso; acceder el cliente a los recursos protegidos usando el testigo de acceso.",TELEFONICA SA,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;GUILLEN NAVARRO JORGE,,https://lens.org/140-612-378-251-033,Patent Application,no,0,0,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,G06F19/00,,0,0,,,,DISCONTINUED
67,WO,A1,WO 2021/058825 A1,173-025-150-249-886,2021-04-01,2021,EP 2020077125 W,2020-09-28,EP 19382831 A,2019-09-26,OPTOELECTRONIC DEVICE FOR FLUID ANALYSIS AND RELATED METHOD FOR OPTICAL ANALYSIS,"Optoelectronic device comprising a housing (20), having an entrance opening (6), a detection zone (5) and an evacuating (7) opening; at least one light source (1), for generating a light beam to irradiate a stream of fluid in the detection zone (5), generating a beam of reflected light or photoluminescence light; at least two photodetectors (2, 13), a reference photodetector (2) for receiving the light beam generated by the light source (1) in a transmission mode, and a first analysis photodetector (13) for receiving the beam of reflected light in a reflection mode, the photodetectors (2, 13) generating an electric signal associated with the optical characteristics of the light beam received; a processing module, for analyzing the electric signals generated; and a communication module to connect the photodetectors (2, 13) to the processing module.",ACONDICIONAMIENTO TARRASENSE,GOROSPE BALLESTEROS JORGE;;RODRIGUEZ ESPAÑOL XAVIER;;GONZALEZ SANCHEZ MIGUEL;;MARTINEZ GARCIA JAVIER;;MARTINEZ NAVAS SERGIO,,https://lens.org/173-025-150-249-886,Patent Application,yes,3,0,4,4,0,G01N15/1459;;G01N15/02;;G01N2015/0053;;G01N2015/1486;;G01N2015/1493;;G01N1/12;;G01N2001/1025;;G01N1/12;;G01N15/02;;G01N15/1459;;G01N2001/1025;;G01N2015/0053;;G01N2015/1486;;G01N2015/1493,G01N1/12;;G01N1/10;;G01N15/00;;G01N15/02;;G01N15/14,,0,0,,,,PENDING
68,TW,S,TW D221453 S,006-308-574-043-536,2022-10-01,2022,TW 111300973 F,2022-02-25,XH DM216754 F,2021-10-08,ELECTRIC FRUIT JUICER,﻿【物品用途】;(省略之);【設計說明】;(無),西班牙商尚摩創新機械公司 &#x;;ZUMMO INNOVACIONES MECANICAS S A U,PEREZ MORILLO JAVIER;;GONZALEZ GENOVES JORGE;;PEREZ MUNOZ ALEX;;MARTINEZ ROCA JORGE;;ALONSO LERA NICO,,https://lens.org/006-308-574-043-536,Design Right,no,0,0,2,2,0,,,31-00,0,0,,,,ACTIVE
69,EP,A1,EP 3798605 A1,037-350-412-139-758,2021-03-31,2021,EP 19382831 A,2019-09-26,EP 19382831 A,2019-09-26,OPTOELECTRONIC DEVICE FOR FLUID ANALYSIS AND RELATED METHOD FOR OPTICAL ANALYSIS,"Optoelectronic device comprising a housing (20), having an entrance opening (6), a detection zone (5) and an evacuating (7) opening; at least one light source (1), for generating a light beam to irradiate a stream of fluid in the detection zone (5), generating a beam of reflected light or photoluminescence light; at least two photodetectors (2, 13), a reference photodetector (2) for receiving the light beam generated by the light source (1) in a transmission mode, and a first analysis photodetector (13) for receiving the beam of reflected light in a reflection mode, the photodetectors (2, 13) generating an electric signal associated with the optical characteristics of the light beam received; a processing module, for analyzing the electric signals generated; and a communication module to connect the photodetectors (2, 13) to the processing module.
",ACONDICIONAMIENTO TARRASENSE,GOROSPE BALLESTEROS JORGE;;RODRIGUEZ ESPAÑOL XAVIER;;GONZALEZ SANCHEZ MIGUEL;;MARTINEZ GARCIA JAVIER;;MARTINEZ NAVAS SERGIO,,https://lens.org/037-350-412-139-758,Patent Application,yes,2,1,4,4,0,G01N15/1459;;G01N15/02;;G01N2015/0053;;G01N2015/1486;;G01N2015/1493;;G01N1/12;;G01N2001/1025;;G01N1/12;;G01N15/02;;G01N15/1459;;G01N2001/1025;;G01N2015/0053;;G01N2015/1486;;G01N2015/1493,G01N1/12;;G01N15/02;;G01N15/14,,0,0,,,,DISCONTINUED
70,ES,U,ES 1054741 U,037-783-740-749-719,2003-08-16,2003,ES 200301178 U,2003-05-14,ES 200301178 U,2003-05-14,"Mechanical device for profiling of magnetic field based on a probe array hall (Machine-translation by Google Translate, not legally binding)","Mechanical device for the realization of magnetic field profiles based on an array of hall probes, is equipped with an array of hall probes (1) located parallel to the direction in which the profiling is performed. Because the array covers an important measurement distance by itself, the step that must be performed for the measurement is of a considerable size so that it can be done manually. This is achieved by moving the sample holder (8) that holds the sample to be measured (7) with respect to the array (the array is attached to the support (3), which in turn is attached to the fixed structural part (15)). Said movement is achieved by means of a vertical bar (9) which activates a screw (10) connected to the sample holder (8) by means of a gear. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,DOMARCO ALVAREZ GERARDO;;GONZALEZ JORGE HIGINIO;;PELETEIRO SALGADO JOSE;;ROMANI MARTINEZ LUIS F;;CARBALLO GONZALEZ ENRIQUE;;GONZALEZ SALGADO DIEGO,,https://lens.org/037-783-740-749-719,Patent Application,no,0,0,2,2,0,,G01R33/38,,0,0,,,,EXPIRED
71,ES,B1,ES 2257121 B1,081-443-569-497-543,2007-07-01,2007,ES 200301836 A,2003-07-31,ES 200301836 A,2003-07-31,SUSPENSION HIBRIDA DE ANILLO SUPERCONDUCTOR Y BARRA DE MATERIAL FERROMAGNETICO.,"Suspensión híbrida de anillo superconductor y barra de material ferromagnético. Consiste en utilizar la fuerza de atracción magnética existente entre un anillo superconductor (2), por el que circula una corriente persistente, y una barra de material ferromagnético (3) situada a través de su orificio central. Dicha atracción provoca que el anillo superconductor se sitúe en la zona central de la barra, oponiéndose elásticamente a cualquier esfuerzo realizado sobre el mismo que trate de apartarlo de dicha posición. Por otra parte, el hecho de que el superconductor se mueva guiado por la mencionada barra ferromagnética, le confiere a esta suspensión una gran estabilidad frente a esfuerzos laterales, en comparación con las típicas suspensiones superconductoras basadas en la levitación por efecto Meissner.",UNIV VIGO,GONZALEZ JORGE HIGINIO;;GONZALEZ SALGADO DIEGO;;DOMARCO ALVAREZ GERARDO;;PELETEIRO SALGADO JOSE;;CARBALLO GONZALEZ ENRIQUE;;ROMANI MARTINEZ LUIS FERNANDO,,https://lens.org/081-443-569-497-543,Granted Patent,no,0,0,2,2,0,B60L13/04;;B61B13/08;;H01F6/00,H01F6/00;;B60L13/04;;B61B13/08,,0,0,,,,EXPIRED
72,ES,Y,ES 1054741 Y,174-918-648-863-511,2003-12-01,2003,ES 200301178 U,2003-05-14,ES 200301178 U,2003-05-14,DISPOSITIVO MECANICO PARA LA REALIZACION DE PERFILES DE CAMPO MAGNETICO BASADO EN UN ARRAY DE SONDAS HALL,,UNIV VIGO,DOMARCO ALVAREZ GERARDO;;GONZALEZ JORGE HIGINIO;;PELETEIRO SALGADO JOSE;;ROMANI MARTINEZ LUIS F;;CARBALLO GONZALEZ ENRIQUE;;GONZALEZ SALGADO DIEGO,,https://lens.org/174-918-648-863-511,Limited Patent,no,0,0,2,2,0,,G01R33/38,,0,0,,,,EXPIRED
73,ES,B1,ES 2235615 B1,198-702-318-125-477,2006-02-16,2006,ES 200301835 A,2003-07-31,ES 200301835 A,2003-07-31,DISPOSITIVO REDUCTOR DE LA CORRIENTE PERSISTENTE QUE CIRCULA POR UN ANILLO SUPERCONDUCTOR O UNA BOBINA SUPERCONDUCTORA CORTOCIRCUITADA,"Dispositivo reductor de la corriente persistente que circula por un anillo superconductor o una bobina superconductora cortocircuitada. Consiste en utilizar un núcleo realizado por un material ferromagnético (1 - 2), de forma que al introducir en el mismo un anillo superconductor (3) o una bobina superconductora cortocircuitada, la corriente que circula por los mismos disminuye. Esto es debido a la ley de conservación del flujo magnético en los superconductores, por lo que el anillo superconductor tiende a mantener constante el flujo magnético que atraviesa su orificio central. De esta forma, el superconductor se puede extraer del líquido criogénico sin que exista peligro alguno de daño estructural en el mismo, por culpa de la energía disipada al ser calentado y alcanzar el estado resistivo. Además, el dispositivo consta de dos barras (4) soldadas al núcleo para su manipulación.",UNIV VIGO,GONZALEZ JORGE HIGINIO;;GONZALEZ SALGADO DIEGO;;DOMARCO ALVAREZ GERARDO;;PELETEIRO SALGADO JOSE;;CARBALLO GONZALEZ ENRIQUE;;ROMANI MARTINEZ LUIS FERNANDO,,https://lens.org/198-702-318-125-477,Granted Patent,no,0,0,2,2,0,Y02E40/60;;H02H9/023;;H01F6/02;;H10N60/30,H02H9/02;;H01F6/02;;H01L39/16,,0,0,,,,EXPIRED
74,ES,Y,ES 1054740 Y,065-354-368-141-722,2003-12-01,2003,ES 200301177 U,2003-05-14,ES 200301177 U,2003-05-14,DISPOSITIVO PARA LA INDUCCION DE CORRIENTES PERSISTENTES EN ANILLOS SUPERCONDUCTORES,,UNIV VIGO,GONZALEZ JORGE HIGINIO;;DOMARCO ALVAREZ GERARDO;;PELETEIRO SALGADO JOSE;;CARBALLO GONZALEZ ENRIQUE;;ROMANI MARTINEZ LUIS F;;GONZALEZ SALGADO DIEGO,,https://lens.org/065-354-368-141-722,Limited Patent,no,0,0,2,2,0,,H01F6/00;;H02K3/04,,0,0,,,,EXPIRED
75,ES,A1,ES 2257121 A1,111-003-828-516-671,2006-07-16,2006,ES 200301836 A,2003-07-31,ES 200301836 A,2003-07-31,"Hybrid suspension, has superconductor ring arranged in central section of ferromagnetic bar to generate magnetic force that circulates between superconductor ring and ferromagnetic bar",The suspension consists of a superconductor ring and a bar made of ferromagnetic material. The superconductor ring is arranged in the central section of the ferromagnetic bar to generate a magnetic force that circulates between the superconductor ring and ferromagnetic bar. The superconductor ring moves in guided motion in the ferromagnetic bar to ensure stability in the suspension.,UNIV VIGO,GONZALEZ JORGE HIGINIO;;GONZALEZ SALGADO DIEGO;;DOMARCO ALVAREZ GERARDO;;PELETEIRO SALGADO JOSE;;CARBALLO GONZALEZ ENRIQUE;;ROMANI MARTINEZ LUIS FERNANDO,,https://lens.org/111-003-828-516-671,Patent Application,no,4,0,2,2,0,B60L13/04;;B61B13/08;;H01F6/00,B60L13/04;;B61B13/08;;G05B19/10;;G08B29/06;;H01F6/00,,0,0,,,,EXPIRED
76,ES,A1,ES 2235615 A1,090-478-460-295-581,2005-07-01,2005,ES 200301835 A,2003-07-31,ES 200301835 A,2003-07-31,Superconductor ring remanent current attenuator for short circuited superconductor windings and comprising a ferromagnetic insert,Superconductor ring remanent current attenuator comprising a ferromagnetic insert.,UNIV VIGO,GONZALEZ JORGE HIGINIO;;GONZALEZ SALGADO DIEGO;;DOMARCO ALVAREZ GERARDO;;PELETEIRO SALGADO JOSE;;CARBALLO GONZALEZ ENRIQUE;;ROMANI MARTINEZ LUIS FERNANDO,,https://lens.org/090-478-460-295-581,Patent Application,no,4,0,2,2,0,Y02E40/60;;H02H9/023;;H01F6/02;;H10N60/30,H01F6/02;;H01L39/16;;H02H9/02,,0,0,,,,EXPIRED
77,ES,U,ES 1054740 U,183-724-004-781-116,2003-08-16,2003,ES 200301177 U,2003-05-14,ES 200301177 U,2003-05-14,"Device for the induction of persistent currents in superconducting rings (Machine-translation by Google Translate, not legally binding)","Device for induction of persistent currents in superconducting rings, which being of the type which induce flow through a cooling process with field has a magnetic circuit based on traversing the opening of the superconducting ring configuration (3 ). This circuit is formed by a ferromagnetic core consisting of two parts (1) and (2) and a permanent magnet (4). The device two bars (5) welded to each of the core pieces for handling also it endows. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,GONZALEZ JORGE HIGINIO;;DOMARCO ALVAREZ GERARDO;;PELETEIRO SALGADO JOSE;;CARBALLO GONZALEZ ENRIQUE;;ROMANI MARTINEZ LUIS F;;GONZALEZ SALGADO DIEGO,,https://lens.org/183-724-004-781-116,Patent Application,no,0,0,2,2,0,,H01F6/00;;H02K3/04,,0,0,,,,EXPIRED
78,US,B2,US 11484711 B2,113-338-229-359-421,2022-11-01,2022,US 201715659686 A,2017-07-26,US 201715659686 A;;US 201662366654 P,2016-07-26,Stereo-thermo-lesioning to treat a patient's neurological condition,This disclosure relates to using stereo-thermo-lesioning (STL) to create lesions at one or more locations in the patient's nervous system at the patient's bedside without general anesthesia. A method that uses STL to treat a patient's neurological condition includes: using a plurality of stereotactically-implanted thermo-coupled multi-contact electrodes to record conduction data within a predetermined theoretical zone of activity within the patient's neurological tissue; detecting abnormal neurological activity of a neurological condition within the conduction data and localize a portion of the predetermined theoretical zone of activity that is responsible for a primary organization of the abnormal neurological activity; creating a lesion at the portion of the predetermined theoretical zone of activity that is responsible for a primary organization of the abnormal neurological activity using at least one contact of the plurality of thermo-coupled multi-contact electrodes.,CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;GALE JOHN T;;MACHADO ANDRE G;;NAJM IMAD,THE CLEVELAND CLINIC FOUNDATION (2020-09-15),https://lens.org/113-338-229-359-421,Granted Patent,yes,10,0,2,2,0,A61B18/1477;;A61B2018/00446;;A61B2018/00577;;A61B2018/00678;;A61B2018/00708;;A61B2018/00791;;A61B2018/00839;;A61B2018/1467;;A61N1/36014;;A61N1/3606;;A61N1/08;;A61N1/36082;;A61N1/0551;;A61B2018/00678;;A61B2018/1467;;A61B2018/00446;;A61B18/12;;A61B2018/00708;;A61B18/1477;;A61B2018/00577;;A61B2018/00791;;A61B2018/00839,A61B18/14;;A61B18/00;;A61B18/12;;A61N1/05;;A61N1/08;;A61N1/36,,0,0,,,,ACTIVE
79,ES,A1,ES 2650964 A1,045-857-376-847-206,2018-01-23,2018,ES 201600608 A,2016-07-22,ES 201600608 A,2016-07-22,"Procedure for the measurement of thicknesses and volumes of shotcrete in newly constructed slopes, reinforced with bolts, using terrestrial lidar data (Machine-translation by Google Translate, not legally binding)","The present invention describes a process for obtaining semi-automatic mode, the point thickness, average and the actual volume of the shotcrete on a newly constructed bolted slope. It includes a terrestrial lidar system, responsible for the capture of the slope data, a reference system through bolts that allows the registration of both physical models and a program that calculates the point thickness, average and associated volumes. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,GONZALEZ JORGE HIGINIO;;ARIAS SANCHEZ PEDRO;;PUENTE LUNA IVÁN;;MARTINEZ SANCHEZ JOAQUÍN,,https://lens.org/045-857-376-847-206,Patent Application,no,0,0,2,2,0,E01C23/01;;E21D11/00;;G01B11/03;;G01S17/89,G01B11/03;;E01C23/01;;E21D11/00;;G01S17/89,,0,0,,,,ACTIVE
80,US,B2,US 9118648 B2,155-795-809-912-606,2015-08-25,2015,US 201113989748 A,2011-10-24,US 201113989748 A;;US 41690110 P;;EP 2011068513 W,2010-11-24,Method for authorizing access to protected content,"The invention refers to a method for authorizing access to a third party application, called client ( 2 ), to protected resources owned by a user ( 1 ) and hosted in a server ( 3 ). The method comprising: the client being used by the user asking for a temporary token to the server; the server sending a first SMS to the user, said first SMS providing means to authenticate the user; authenticating the user by the means provided in previous two steps; the user authorizing the client; the server sending a second SMS to the user providing some information needed to obtain an access token; the client getting the information of the previous step from the user and the access token; the client accessing protected resources using the access token.",GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE;;TELEFÓNICA S A,GONZALEZ MARTINEZ DIEGO;;LOZANO LLANOS DAVID;;MUNUERA ANDREO JORGE;;VELEZ TARILONTE ENRIQUE,TELEFÓNICA S.A (2013-05-31),https://lens.org/155-795-809-912-606,Granted Patent,yes,21,5,12,12,0,H04L63/0884;;H04L63/10;;H04L63/18;;G06F2221/2103;;H04W4/14;;G06F21/335;;G06F2221/2101;;G06F21/6218;;H04W12/06;;G06F2221/2129;;H04L63/0838;;G06F21/31;;G06F21/43;;H04L67/563;;H04L63/0846;;H04L9/3213;;H04L9/3228;;H04L63/105;;H04L9/32;;H04L63/083;;H04L63/0838;;G06F21/30;;G06F21/31;;G06F21/43;;H04L63/0884;;H04L63/10;;H04L63/18;;H04W12/06;;H04L67/563;;H04L63/08,G06F7/04;;G06F15/16;;G06F17/30;;G06F21/30;;G06F21/31;;G06F21/43;;H04L9/32;;H04L29/06;;H04L29/08,,3,1,047-866-766-806-781,10.17487/rfc5849,"Hammer-Lahav E et al: ""The OAuth 1.0 Protocol; rfc5849.txt"". The Oauth 1.0 Protocol; RFC5849.Txt.; Internet Engineering Task Force. IETF; Standard. Internet Society (ISOC) 4. Rue Des Falaises CH-1205 Geneva. Switzerland. Apr. 20, 2010. pp. 1-38. XP015070768.;;HTTP Get Access Token Operation; Global Giving API; 2014; https://www.globalgiving.org/api/get-access-token.html.;;Anonymous: 9.0 Using the Invitation 1-15 API II Oct. 5, 2010. XP55032919. Retrieved from the Internet: URL:http:jjweb.archive.orgjweb/20101005004846/http://developer.veriplace.comjdevportaljdeveloperguidejinvitation-api.html.",INACTIVE
81,US,A1,US 2018/0028807 A1,055-556-979-097-655,2018-02-01,2018,US 201715659686 A,2017-07-26,US 201715659686 A;;US 201662366654 P,2016-07-26,STEREO-THERMO-LESIONING TO TREAT A PATIENT'S NEUROLOGICAL CONDITION,This disclosure relates to using stereo-thermo-lesioning (STL) to create lesions at one or more locations in the patient's nervous system at the patient's bedside without general anesthesia. A method that uses STL to treat a patient's neurological condition includes: using a plurality of stereotactically-implanted thermo-coupled multi-contact electrodes to record conduction data within a predetermined theoretical zone of activity within the patient's neurological tissue; detecting abnormal neurological activity of a neurological condition within the conduction data and localize a portion of the predetermined theoretical zone of activity that is responsible for a primary organization of the abnormal neurological activity; creating a lesion at the portion of the predetermined theoretical zone of activity that is responsible for a primary organization of the abnormal neurological activity using at least one contact of the plurality of thermo-coupled multi-contact electrodes.,CLEVELAND CLINIC FOUND,GONZALEZ-MARTINEZ JORGE A;;GALE JOHN T;;MACHADO ANDRE G;;NAJM IMAD,THE CLEVELAND CLINIC FOUNDATION (2020-09-15),https://lens.org/055-556-979-097-655,Patent Application,yes,2,1,2,2,0,A61B18/1477;;A61B2018/00446;;A61B2018/00577;;A61B2018/00678;;A61B2018/00708;;A61B2018/00791;;A61B2018/00839;;A61B2018/1467;;A61N1/36014;;A61N1/3606;;A61N1/08;;A61N1/36082;;A61N1/0551;;A61B2018/00678;;A61B2018/1467;;A61B2018/00446;;A61B18/12;;A61B2018/00708;;A61B18/1477;;A61B2018/00577;;A61B2018/00791;;A61B2018/00839,A61N1/36;;A61N1/08,,0,0,,,,ACTIVE
82,ES,B1,ES 2650964 B1,167-908-585-436-922,2018-08-29,2018,ES 201600608 A,2016-07-22,ES 201600608 A,2016-07-22,"Procedimiento para la medición de espesores y volúmenes de hormigón proyectado en taludes de nueva construcción, reforzados con bulones, mediante datos Lidar terrestre",,UNIV VIGO,GONZALEZ JORGE HIGINIO;;ARIAS SANCHEZ PEDRO;;PUENTE LUNA IVÁN;;MARTINEZ SANCHEZ JOAQUÍN,,https://lens.org/167-908-585-436-922,Granted Patent,no,0,0,2,2,0,E01C23/01;;E21D11/00;;G01B11/03;;G01S17/89,G01B11/03;;E01C23/01;;E21D11/00;;G01S17/89,,0,0,,,,ACTIVE
83,ES,Y,ES 1203337 Y,040-063-887-345-64X,2018-04-12,2018,ES 201731456 U,2017-11-28,ES 201731456 U,2017-11-28,DISPOSITIVO INMOVILIZADOR DE CABEZA PARA UN APARATO DE IMAGEN MEDICA DEDICADO DE CEREBRO,,GENERAL EQUIPMENT FOR MEDICAL IMAGING S A,ALAMO VALENZUELA JORGE;;CATRET MASCARELL JUAN VICENTE;;DIAZ GONZALEZ KAREL;;MARTINEZ BENEDITO JOSÉ,,https://lens.org/040-063-887-345-64X,Limited Patent,no,0,0,2,2,0,,A61B6/04;;A61B90/14;;A61G7/07;;A61G13/12,,0,0,,,,ACTIVE
84,ES,U,ES 1203337 U,172-554-117-034-645,2018-01-19,2018,ES 201731456 U,2017-11-28,ES 201731456 U,2017-11-28,"HEAD IMMOBILIZER DEVICE FOR A DEDICATED BRAIN MEDICAL IMAGE APPARATUS (Machine-translation by Google Translate, not legally binding)","An immobilizing device of the head of an individual for a dedicated brain imaging apparatus comprising: - an inflatable turban (1) - means for inflating said turban (1) with a fluid (4), - means to regulate the amount of fluid and - fixing means to the image recording apparatus. (Machine-translation by Google Translate, not legally binding)",GENERAL EQUIPMENT FOR MEDICAL IMAGING S A,ALAMO VALENZUELA JORGE;;CATRET MASCARELL JUAN VICENTE;;DIAZ GONZALEZ KAREL;;MARTINEZ BENEDITO JOSÉ,,https://lens.org/172-554-117-034-645,Patent Application,no,0,0,2,2,0,,A61B6/04;;A61B90/14;;A61G7/07;;A61G13/12,,0,0,,,,ACTIVE
85,ES,B1,ES 2188411 B1,156-634-170-790-386,2004-06-01,2004,ES 200102488 A,2001-11-12,ES 200102488 A,2001-11-12,VEHICULO ROBOTICO CON CAPACIDAD DE NAVEGACION AUTONOMA DOTADO DE BRAZO ARTICULADO PARA LA MANIPULACION REMOTA DE OBJETOS.,"Vehículo robótico con capacidad de navegación autónoma dotado de brazo articulado para la manipulación remota de objetos. La presente invención consiste en una máquina programable de uso general compuesta de un vehículo con capacidad de navegación en interiores y de un brazo articulado dotado de una garra servo- controlada para el manejo remoto de objetos. El sistema robot comprende un sistema de manipulación autónomo, un sistema de locomoción que emplea ruedas, un sistema sensorial complejo y diverso, un sistema de control basado en una red de computadores, un sistema de alimentación eléctrica por baterías y un sistema de comunicaciones radio con estaciones remotas. El robot está preparado para desenvolverse en entornos estructurados, como edificios, almacenes o fábricas. Las tareas que es capaz de realizar el sistema robot incluyen coger, transportar y soltar pequeños objetos tales como libros o cintas de video y presionar o girar dispositivos sencillos como interruptores o picaportes.",UNIV MALAGA,MARTINEZ RODRIGUEZ JORGE LUIS;;GONZALEZ JIMENEZ JAVIER;;MARTINEZ SANCHEZ MARIA ALCAZAR;;MUNOZ MARTINEZ VICTOR;;REINA TEROL ANTONIO JESUS;;FERNANDEZ MADRIGAL JUAN ANTONI,,https://lens.org/156-634-170-790-386,Granted Patent,no,0,0,2,2,0,B25J5/007;;B25J9/1689;;G05D1/02,B25J5/00;;B25J9/06;;B25J15/02;;G05D1/02,,0,0,,,,EXPIRED
86,ES,A1,ES 2188411 A1,120-602-200-184-254,2003-06-16,2003,ES 200102488 A,2001-11-12,ES 200102488 A,2001-11-12,Robotic vehicle with capacity of autonomous traveling endowed with an articulated arm for the remote manipulation of objects.,"Robotic vehicle with capacity of autonomous traveling endowed with an articulated arm for the remote manipulation of objects. The present invention consists on a programmable machine of general use made up of a vehicle with traveling capacity indoor and of an articulate arm endowed with a power-controlled claw for the remote handling of objects. The robot system includes a system of autonomous manipulation, a locomotion system that uses wheels, a complex sensorial and diverse system, a control system based on a computers network, an electrical battery-operated feeding system, a radio communication with remote stations. The robot is prepared to perform in structured settings, such as buildings, warehouses or factories. The tasks that the robotic system is capable to carry out include to catch, transport and release small objects such as books or videotapes, and to press or to turn simple devices such as switches or latches.<IMAGE>",UNIV MALAGA,MARTINEZ RODRIGUEZ JORGE LUIS;;GONZALEZ JIMENEZ JAVIER;;MARTINEZ SANCHEZ MARIA ALCAZAR;;MUNOZ MARTINEZ VICTOR;;REINA TEROL ANTONIO JESUS;;FERNANDEZ MADRIGAL JUAN ANTONI,,https://lens.org/120-602-200-184-254,Patent Application,no,6,0,2,2,0,B25J5/007;;B25J9/1689;;G05D1/02,B25J5/00;;B25J9/06;;B25J15/02;;G05D1/02,,0,0,,,,EXPIRED
87,EP,A1,EP 4063049 A1,017-955-046-924-962,2022-09-28,2022,EP 21382241 A,2021-03-24,EP 21382241 A,2021-03-24,DEVICE AND METHOD FOR DRILLING WITH AUTOMATIC DRILLING PARAMETERS ADAPTATION,"The invention relates to a drilling machine and a drilling method comprising drilling a first bore in a material with a drilling machine by applying a torque to a drilling tool for imparting a rotation at a first rotation speed to said drilling tool, and applying a thrust to said drilling tool for advancing the drilling tool at a first feed speed into the material, characterized in that a drilling parameter is measured while drilling the first bore, and a second rotation speed and a second feed speed are determined based on the drilling parameter, then drilling a second bore at said second rotation speed and at said second feed speed.
",AIRBUS OPERATIONS SLU,RAMIREZ ALCALA CARLOS;;VAZQUEZ MARTINEZ JUAN MANUEL;;GONZALEZ LEAL JUAN MARIA;;SALGUERO GOMEZ JORGE,,https://lens.org/017-955-046-924-962,Patent Application,yes,3,0,3,3,0,B23Q15/12;;B23B35/00;;B23B39/00;;B23B35/00;;B23B2260/062;;B23B2260/128;;G05B19/4065;;G05B2219/45129;;G05B2219/41109;;G05B2219/37344;;G05B2219/49099;;B23B35/00;;B23Q15/013;;B23Q15/08;;B23Q17/0961,B23B35/00;;G05B19/4065,,0,0,,,,PENDING
88,CN,A,CN 115122150 A,199-659-099-828-601,2022-09-30,2022,CN 202210289893 A,2022-03-23,EP 21382241 A,2021-03-24,Drilling machine with automatic drilling parameter adaptation and drilling method,"The present invention relates to a drilling machine and a drilling method comprising drilling a first bore in a material with a drilling machine by applying a torque to a drilling tool for applying rotation to the drilling tool at a first rotational speed; and applying a thrust to the drilling tool for advancing the drilling tool into the material at a first feed speed, characterized in that drilling parameters are measured while drilling the first bore, and a second rotational speed and a second feed speed are determined based on the drilling parameters, a second bore is then drilled at the second rotational speed and at the second feed speed.",AIRBUS OPERATIONS SL,RAMIREZ-ALCALA CARLOS;;VAZQUEZ MARTINEZ JUAN MANUEL;;GONZALEZ LEAL JUAN MARIA;;SALGUERO GOMEZ JORGE,,https://lens.org/199-659-099-828-601,Patent Application,no,0,1,3,3,0,B23Q15/12;;B23B35/00;;B23B39/00;;B23B35/00;;B23B2260/062;;B23B2260/128;;G05B19/4065;;G05B2219/45129;;G05B2219/41109;;G05B2219/37344;;G05B2219/49099;;B23B35/00;;B23Q15/013;;B23Q15/08;;B23Q17/0961,B23Q15/12;;B23B35/00;;B23B39/00,,0,0,,,,PENDING
89,WO,A1,WO 2023/038658 A1,168-147-429-908-345,2023-03-16,2023,US 2021/0071413 W,2021-09-10,US 2021/0071413 W,2021-09-10,PRINTERS AND ENCODERS,"Examples relate to machine readable storage storing machine readable instructions, arranged when implemented, to process a roller encoder signal, associated with rotation of a substrate engaging roller, and a drive encoder signal, associated with a drive for rotating a carrier bearing the substrate, to determine a characteristic associated with the substrate.",HEWLETT PACKARD DEVELOPMENT CO,URRUTIA NEBREDA MARTIN;;VELASCO FIGUERAS JOAN MARTI;;LOPEZ GONZALEZ JOSE ANTONIO;;PORRAS MARTINEZ JORGE,,https://lens.org/168-147-429-908-345,Patent Application,yes,4,0,1,1,0,B41J11/0075;;B41J11/0095;;B41J15/04;;B41J11/006;;B65H2801/03;;B65H23/195;;B65H23/182;;B65H2403/942,G06F3/12;;B65H5/06,,0,0,,,,PENDING
90,US,A1,US 2022/0341311 A1,021-995-577-646-376,2022-10-27,2022,US 202217702455 A,2022-03-23,EP 21382241 A,2021-03-24,DEVICE AND METHOD FOR DRILLING WITH AUTOMATIC DRILLING PARAMETERS ADAPTATION,"A drilling machine and a drilling method including drilling a first bore in a material with a drilling machine by applying a torque to a drilling tool for imparting a rotation at a first rotational speed to the drilling tool, and applying a thrust to the drilling tool for advancing the drilling tool at a first feed speed into the material, wherein a drilling parameter is measured while drilling the first bore, and a second rotational speed and a second feed speed are determined based on the drilling parameter, then drilling a second bore at the second rotational speed and at the second feed speed.",AIRBUS OPERATIONS SL,RAMIREZ-ALCALA CARLOS;;VAZQUEZ MARTINEZ JUAN MANUEL;;GONZALEZ LEAL JUAN MARIA;;SALGUERO GOMEZ JORGE,,https://lens.org/021-995-577-646-376,Patent Application,yes,10,0,3,3,0,B23Q15/12;;B23B35/00;;B23B39/00;;B23B35/00;;B23B2260/062;;B23B2260/128;;G05B19/4065;;G05B2219/45129;;G05B2219/41109;;G05B2219/37344;;G05B2219/49099;;B23B35/00;;B23Q15/013;;B23Q15/08;;B23Q17/0961,E21B44/04;;E21B45/00,,0,0,,,,PENDING
91,WO,A1,WO 2020/160284 A1,043-785-930-040-715,2020-08-06,2020,US 2020/0015904 W,2020-01-30,US 201962798909 P;;US 201962802101 P;;US 201962934371 P,2019-01-30,"RECOVERY, DECARBOXYLATION, AND PURIFICATION OF CANNABINOIDS FROM ENGINEERED CELL CULTURES","Methods of recovering cannabinoids from cell cultures include methods comprising steps of separating the cell culture at a temperature above the melting point of the cannabinoid to separate a light phase comprising liquid state cannabinoid from a heavy phase; and methods comprising treating the cell culture at a temperature below the melting point of the cannabinoid to separate a light phase from a heavy phase comprising solid state cannabinoid. Other methods include contacting the culture with a water-miscible solvent to form a water-miscible phase and an aqueous phase, separating the two phases and recovering the cannabinoid. Other methods include contacting the culture with a water-immiscible solvent to form a water-immiscible phase and an aqueous phase, separating the two phases, and recovering the cannabinoid. Other methods include washing the inner surface of a fermentation vessel with alkaline solution to recover cannabinoid attached to the vessel surface. Various methods make use of aqueous solvent systems comprising no organic solvent, aqueous solvent systems comprising added water-miscible organic solvent, and dual-phase aqueous/water-immiscible solvent systems.",GENOMATICA INC,SUOMINEN LAURI;;LIEVENSE JEFFEREY;;LIU AIGUO;;MARTINEZ-GONZALEZ JORGE;;KO MYONG KON;;NAN WEI,,https://lens.org/043-785-930-040-715,Patent Application,yes,4,3,6,6,0,C12M47/10;;A01H6/28;;A01H5/12;;C07C51/48;;C07C51/47;;C07C37/72;;C07C37/82;;C07C37/50;;B01D11/028;;B01D11/0288;;C12P7/42;;C07D311/80;;C07D311/58;;C07D307/91;;B01D11/0288;;B01D11/0292;;C12M33/10;;C12P7/22,B01D17/038;;B01D17/025;;C02F1/38,,1,0,,,See also references of EP 3917642A4,PENDING
92,ES,A1,ES 2306578 A1,151-311-562-057-660,2008-11-01,2008,ES 200601253 A,2006-05-16,ES 200601253 A,2006-05-16,"Hybrid procedure for induction of persistent current in superconductor rings. (Machine-translation by Google Translate, not legally binding)","Hybrid procedure for induction of persistent current in superconducting rings. It consists of a method for the induction of current in a superconducting ring that combines the characteristics of zero field cooling (zero field cooling) and field cooling (field cooling). It is based on zero-field cooling of the superconducting ring (1) to a lower temperature than the critical temperature and subsequent heating of a small region of said superconducting ring with a perfectly insulated constantan wire resistance (4) (5 and 6). It uses an iron core and a small coil for induction. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,QUELLE VIDAL IRIA;;GONZALEZ JORGE HIGINIO;;DOMARCO ALVAREZ GERARDO;;CARBALLO GONZALEZ ENRIQUE;;PELETEIRO SALGADO JOSE;;ROMANI MARTINEZ LUIS F,,https://lens.org/151-311-562-057-660,Patent Application,no,2,0,2,2,0,H01F6/00;;H10N60/30,H01L39/16;;H01F6/00,,1,1,000-636-017-713-263,10.1016/j.physc.2005.10.005,"GONZALEZ-JORGE y otros ""Inducting technique and trapped field in ring-shaped superconductors"" 15.11.2005, todo el documento.",ACTIVE
93,ES,B1,ES 2306578 B1,087-534-735-472-90X,2009-09-03,2009,ES 200601253 A,2006-05-16,ES 200601253 A,2006-05-16,PROCEDIMIENTO HIBRIDO PARA LA INDUCCION DE CORRIENTE PERSISTENTE EN ANILLOS SUPERCONDUCTORES.,,UNIV VIGO,QUELLE VIDAL IRIA;;GONZALEZ JORGE HIGINIO;;DOMARCO ALVAREZ GERARDO;;CARBALLO GONZALEZ ENRIQUE;;PELETEIRO SALGADO JOSE;;ROMANI MARTINEZ LUIS F,,https://lens.org/087-534-735-472-90X,Granted Patent,no,0,0,2,2,0,H01F6/00;;H10N60/30,H01L39/16;;H01F6/00,,0,0,,,,ACTIVE
94,WO,A1,WO 2023/220471 A1,158-716-406-111-573,2023-11-16,2023,US 2023/0022238 W,2023-05-15,US 202263341761 P,2022-05-13,THALAMIC STIMULATION SYSTEM FOR THE TREATMENT OF MOTOR DISORDERS,"Disclosed herein are methods for treating motor disorders characterized by a motor impairment; For example, particular methods comprise applying specific stimuli to ventral thalamic neurons with axons that project to premotor or motor cortex. Stimulation of areas in the ventral thalamus of a human subject with one or more electrodes with a motor disorder leads to improvement of at least one motor output associated with the motor disorder.",UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION,PIRONDINI ELVIRA;;CAPOGROSSO MARCO;;GONZALEZ-MARTINEZ JORGE;;LIANG LUCY;;CHU-AN HO JONATHAN;;GRIGSBY ERINN,,https://lens.org/158-716-406-111-573,Patent Application,yes,4,0,1,1,0,A61N1/36067;;A61N1/36171;;A61N1/36175;;A61N1/36139,A61N1/05;;A61B5/00;;A61B5/11;;A61N1/36,,0,0,,,,PENDING
95,AU,A1,AU 2021/281511 A1,110-657-568-176-442,2023-01-05,2023,AU 2021/281511 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,Nucleic acids for inhibiting expression of CNNM4 in a cell,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/110-657-568-176-442,Patent Application,no,0,0,7,7,0,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02,,0,0,,,,PENDING
96,CA,A1,CA 3184050 A1,168-046-689-896-480,2021-12-02,2021,CA 3184050 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/168-046-689-896-480,Patent Application,no,0,0,7,7,554,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02;;C12N15/113,,0,0,,,,PENDING
97,EP,A1,EP 4158023 A1,071-273-573-903-901,2023-04-05,2023,EP 21731058 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,,ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/071-273-573-903-901,Patent Application,yes,0,0,7,7,0,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02,,0,0,,,,PENDING
98,WO,A1,WO 2021/239825 A1,114-948-821-003-293,2021-12-02,2021,EP 2021064077 W,2021-05-26,EP 20382449 A;;EP 20382947 A,2020-05-27,NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL,"The invention relates to nucleic acid products that interfere with or inhibit CNNM4 (Cyclin M4) gene expression. It further relates to therapeutic uses of CNNM4 inhibition for the treatment of diseases, such as liver diseases including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver steatosis, liver fibrosis, liver cirrhosis, liver cancer and other diseases associated with magnesium dysregulation.",SILENCE THERAPEUTICS GMBH;;ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/114-948-821-003-293,Patent Application,yes,5,1,7,7,554,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61P3/06;;A61P3/12;;A61P11/00;;A61P13/12;;C07H21/02,,36,28,177-219-146-369-560;;000-603-861-384-601;;020-889-810-184-118;;042-817-626-361-589;;050-465-752-695-671;;018-020-177-526-297;;059-393-958-757-089;;030-947-399-044-830;;050-860-384-249-941;;030-380-024-697-291;;117-083-651-038-635;;000-603-861-384-601;;016-226-735-201-149;;107-369-963-620-633;;074-645-636-920-586;;098-128-668-802-045;;037-328-887-183-014;;162-192-995-063-548;;007-399-576-302-194;;016-369-411-268-45X;;017-844-374-123-898;;020-889-810-184-118;;029-953-786-324-918;;005-316-633-999-516;;055-262-725-856-021;;007-731-741-746-293;;000-051-774-250-370;;019-544-082-144-273,24339795;;pmc3854942;;10.1371/journal.pgen.1003983;;10.1093/jb/mvy095;;30476181;;pmc4348944;;10.1172/jci76614;;25347473;;pmc7321783;;10.1016/j.omtn.2020.05.026;;32590173;;33571553;;10.1016/j.jhep.2021.01.043;;pmc8217299;;9486653;;10.1038/35888;;10.1038/35078107;;11373684;;22069063;;10.1002/path.2993;;pmc3916955;;10.1002/hep.28431;;26707365;;31065991;;10.1007/s12325-019-00960-3;;pmc6824389;;26069819;;pmc4455825;;10.1093/ndtplus/sfr163;;10.1093/jb/mvy095;;30476181;;15486293;;10.1126/science.1103160;;24462317;;10.1016/j.metabol.2013.12.003;;12526714;;10.1021/bc0256244;;12223279;;10.1016/s0304-4165(02)00318-5;;7961705;;10.1016/s0021-9258(18)46855-x;;10.1021/jm00009a014;;7739012;;10.1038/mt.2010.85;;pmc2911264;;20461061;;18358718;;10.1016/j.bmcl.2008.03.013;;10.1016/s0021-9258(19)83641-4;;3838314;;pmc4348944;;10.1172/jci76614;;25347473;;10.1038/labinvest.2014.151;;25531568;;pmc4310762;;13428781;;10.1016/s0021-9258(18)64849-5;;27750004;;10.1021/jacs.6b07927;;25434769;;10.1021/ja505986a;;25753666;;pmc4381059;;25539914;;10.1093/nar/gku1336;;10.1093/nar/gkv137;;pmc4381043;;25712100;;pmc4381071;;pmc5570069;;10.1093/nar/gkx507;;28591791,"DAISUKE YAMAZAKI ET AL: ""Basolateral Mg2+ Extrusion via CNNM4 Mediates Transcellular Mg2+ Transport across Epithelia: A Mouse Model"", PLOS GENETICS, vol. 9, no. 12, 5 December 2013 (2013-12-05), pages e1003983, XP055592421, DOI: 10.1371/journal.pgen.1003983;;FUNATO YOSUKE ET AL: ""Molecular function and biological importance of CNNM family Mg2+ transporters"", JOURNAL OF BIOCHEMISTRY, vol. 165, no. 3, 11 November 2018 (2018-11-11), GB, pages 219 - 225, XP055793932, ISSN: 0021-924X, DOI: 10.1093/jb/mvy095;;YOSUKE FUNATO ET AL: ""Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression"", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 12, 27 October 2014 (2014-10-27), GB, pages 5398 - 5410, XP055592288, ISSN: 0021-9738, DOI: 10.1172/JCI76614;;WEINGÄRTNER ADRIEN ET AL: ""Less Is More: Novel Hepatocyte-Targeted siRNA Conjugates for Treatment of Liver-Related Disorders"", MOLECULAR THERAPY: NUCLEIC ACIDS., vol. 21, 1 September 2020 (2020-09-01), US, pages 242 - 250, XP055794193, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2020.05.026;;SIMÓN JORGE ET AL: ""Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH"", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 1, 9 February 2021 (2021-02-09), pages 34 - 45, XP086627269, ISSN: 0168-8278, [retrieved on 20210209], DOI: 10.1016/J.JHEP.2021.01.043;;FIRE ET AL., NATURE, vol. 391, no. 6669, 19 February 1998 (1998-02-19), pages 806 - 11;;ELBASHIR ET AL., NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 8;;WATTSCOREY, JOURNAL OF PATHOLOGY, vol. 226, 2012, pages 365 - 379;;YOUNOSSI ET AL., HEPATOLOGY, vol. 64, 2016, pages 73 - 84;;POVSIC ET AL., ADV. THER., vol. 36, 2019, pages 1574 - 1594;;YOUNOSSI ET AL., CLIN. GASTROENTEROL. HEPATOL., vol. 4, 2018, pages 748 - 755;;BAAIJ ET AL., PHYSIOL. REV., vol. 1920, 2015, pages 1 - 46;;JAHNEN-DECHENT, CLIN. KIDNEY J., vol. 5, 2012, pages i3 - i14;;FUNATOMIKI, J. BIOCHEM., vol. 165, no. 3, 2019, pages 219 - 225;;OZCAN ET AL., SCIENCE, vol. 306, no. 80, 2004, pages 457;;BARBAGALLO ET AL., METABOLISM, vol. 63, 2014, pages 502 - 509;;DUBBER ET AL., BIOCONJUG. CHEM., vol. 14, no. 1, January 2003 (2003-01-01), pages 239 - 46;;WEIGEL, P.H., BIOCHIM. BIOPHYS. ACTA, vol. 1572, no. 2-3, 19 September 2002 (2002-09-19), pages 341 - 63;;ISHIBASHI,S., J BIOL. CHEM., vol. 269, no. 45, 11 November 1994 (1994-11-11), pages 27803 - 6;;BIESSEN EA ET AL., J MED CHEM., vol. 38, no. 9, 28 April 1995 (1995-04-28), pages 1538 - 46;;AKINC ET AL., MOL THER, vol. 18, no. 7, July 2010 (2010-07-01), pages 1357 - 64;;PARK, H. ET AL., BIOORG MED CHEM LETT, vol. 18, no. 7, 2008, pages 2250 - 5;;""Remington: The Science and Practice of Pharmacy"", 2005, LIPPINCOTT WILLIAMS & WILKINS;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;GRYNKIEWIZ ET AL., J BIOL CHEM., vol. 260, no. 6, 1985, pages 3440 - 50;;""Encyclopaedia of Pharmaceutical Technology"", 2007, INFORMA HEALTHCARE USA (INC.;;J. PHARM. SCI., vol. 66, 1977, pages 2;;FUNATO ET AL., J CLIN INVEST, vol. 124, no. 12, 2014, pages 5398 - 5410;;FERNANDEZ-ALVAREZ ET AL., LAB INVEST, vol. 95, no. 2, 2015, pages 223 - 36;;WAGNER ET AL., TOXICOL APPL PHARMACOL, vol. 237, no. 2, 2009, pages 246;;FOLCH ET AL., J BIOL CHEM., vol. 226, no. 1, 1957, pages 497 - 509;;GRUSKOS ET AL., J. AM. CHEM. SOC., vol. 138, no. 44, 2016, pages 14639 - 14649;;HOEVELMANN ET AL., CHEM. SCI., vol. 7, 2016, pages 128 - 135;;NAIR ET AL., J. AM. CHEM. SOC., vol. 136, no. 49, 2014, pages 16958 - 1696;;PRAKASH, NUCLEIC ACIDS RES., vol. 43, no. 6, 2015, pages 2993 - 3011;;HARASZTI, NUCLEIC ACIDS RES., vol. 45, no. 13, 2017, pages 7581 - 7592",PENDING
99,KR,A,KR 20230018429 A,180-173-503-312-181,2023-02-07,2023,KR 20227045417 A,2021-05-26,EP 20382449 A;;EP 20382947 A;;EP 2021064077 W,2020-05-27,세포에서 CNNM4의 발현을 억제하기 위한 핵산,"본 발명은 CNNM4(사이클린 M4) 유전자 발현을 방해하거나 억제하는 핵산 생성물에 관한 것이다. 또한 비-알코올성 지방간 질환 (NAFLD), 비-알코올성 지방간염 (NASH), 간 지방증, 간 섬유증, 간경변증, 간암 및 마그네슘 조절장애와 연관된 다른 질환을 포함하여 간 질환과 같은 질환의 치료에서의 CNNM4 억제의 치료적 용도에 관한 것이다.",ASOCIACION CENTRO DE INVESTIG COOPERATIVA EN BIOCIENCIAS CIC BIOGUNE,SCHAEPER UTE;;DAMES SIBYLLE;;SCHUBERT STEFFEN;;DE LA CRUZ ALFONSO MARTINEZ;;ESPINOSA JORGE SIMON;;RECIO IRENE GONZALEZ;;CHANTAR MARIA LUZ MARTINEZ,,https://lens.org/180-173-503-312-181,Patent Application,no,0,0,7,7,0,C12N15/1138;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;C12N15/113;;A61K48/00;;A61K31/713;;A61K47/549;;A61P1/16;;A61P13/12;;A61P11/00;;C12N2310/312;;C12N2310/14;;C12N2310/313;;C12N2310/315;;C12N2310/344;;C12N2310/351;;A61K47/549;;A61P1/16;;A61K31/713;;C12N15/1138,C12N15/113;;A61K31/713;;A61K47/54;;A61K48/00;;A61P1/16;;A61P11/00;;A61P13/12,,0,0,,,,PENDING
100,US,A1,US 2022/0098625 A1,033-493-734-242-857,2022-03-31,2022,US 202017426973 A,2020-01-30,US 202017426973 A;;US 201962934371 P;;US 201962802101 P;;US 201962798909 P;;US 2020/0015904 W,2019-01-30,"RECOVERY, DECARBOXYLATION, AND PURIFICATION OF CANNABINOIDS FROM ENGINEERED CELL CULTURES","Methods of recovering cannabinoids from cell cultures include methods comprising steps of separating the cell culture at a temperature above the melting point of the cannabinoid to separate a light phase comprising liquid state cannabinoid from a heavy phase; and methods comprising treating the cell culture at a temperature below the melting point of the cannabinoid to separate a light phase from a heavy phase comprising solid state cannabinoid. Other methods include contacting the culture with a water-miscible solvent to form a water-miscible phase and an aqueous phase, separating the two phases and recovering the cannabinoid. Other methods include contacting the culture with a water-immiscible solvent to form a water-immiscible phase and an aqueous phase, separating the two phases, and recovering the cannabinoid. Other methods include washing the inner surface of a fermentation vessel with alkaline solution to recover cannabinoid attached to the vessel surface. Various methods make use of aqueous solvent systems comprising no organic solvent, aqueous solvent systems comprising added water-miscible organic solvent, and dual-phase aqueous/water-immiscible solvent systems.",GENOMATICA INC,SUOMINEN LAURI H;;LIEVENSE JEFFERSON;;LIU AIGUO;;MARTINEZ-GONZALEZ JORGE JESUS;;KO MYONG KON;;NAN WEI,GENOMATICA INC (2021-07-22),https://lens.org/033-493-734-242-857,Patent Application,yes,0,1,6,6,0,C12M47/10;;A01H6/28;;A01H5/12;;C07C51/48;;C07C51/47;;C07C37/72;;C07C37/82;;C07C37/50;;B01D11/028;;B01D11/0288;;C12P7/42;;C07D311/80;;C07D311/58;;C07D307/91;;B01D11/0288;;B01D11/0292;;C12M33/10;;C12P7/22,C12P7/22;;B01D11/02;;C12M1/26,,0,0,,,,PENDING
101,ES,T3,ES 2942576 T3,070-548-513-531-476,2023-06-02,2023,ES 18382831 T,2018-11-20,EP 18382831 A,2018-11-20,"Dispositivo de verificación de un circuito integrado con un emisor optoelectrónico, sistema de fabricación y procedimiento de verificación y de fabricación correspondiente","1. Dispositivo de verificación de un circuito integrado que tiene un emisor optoelectrónico que define un eje de emisión de un haz de radiación electromagnética que comprende medios de conexión eléctrica para conectar el emisor optoelectrónico a una fuente de energía eléctrica, medios reflectores (13) aptos para colocarse alrededor del optoelectrónico emisor, una lente convergente (17) cuyo eje óptico coincide con el eje de emisión, una lámina opaca (18) que presenta una pluralidad de orificios, y un módulo de medida (4) apto para recibir la radiación electromagnética procedente de la lente convergente (17).El dispositivo puede incluirse en una planta de fabricación y realizar un proceso de comprobación en el que se realiza una evaluación de unos valores reales indicativos de la cantidad de radiación electromagnética emitida por dicho emisor optoelectrónico en función de la dirección y se compara con unos rangos de pre -establecer valores de referencia. (Traducción automática con Google Translate, sin valor legal)",SIMULACIONS OPTIQUES S L;;UNIV CATALUNYA POLITECNICA,PIZARRO BONDIA CARLES;;SANCHEZ MARTINEZ JORGE JULIÁN;;BLANCO NIETO PATRICIA;;CASTILLA GONZALEZ PAU;;DOMINGUEZ ALVAREZ NOEMÍ,,https://lens.org/070-548-513-531-476,Granted Patent,no,0,0,3,3,0,G01J1/0266;;G01J1/0411;;G01J1/0437;;G01J1/0474;;G01J1/42;;G01J2001/4252;;G01N2021/8887;;G01N2021/9583,H01L21/66;;G01J1/02;;G01J1/04;;G01J1/42;;G01N21/88;;G01N21/958,,0,0,,,,ACTIVE
102,ES,A2,ES 2400426 A2,066-888-602-266-973,2013-04-09,2013,ES 201100747 A,2011-07-04,ES 201100747 A,2011-07-04,Energy harnessing self-supporting industrialized system for buildings,"The present invention relates to an energy harnessing self-supporting industrialized system for buildings formed by a transparent or translucent enclosure assembly made up of an outer sheet (1) and an inner sheet (2), in which there are arranged closing and opening means (4) in the form of grids, windows or doors, said sheets (1 and 2) being separated by an intermediate chamber (3), in which there is arranged a technical shade (7) and a tank (8) containing a liquid, the inner sheet (2) having in the lower part and in the upper part holes (5 and 6) provided with operable closures for the passage of air.",CONSTRUCCIONES ACR S A U,SANCHEZ-OSTIZ GUTIERREZ ANA;;MONGE BARRIO AURORA;;GONZALEZ MARTINEZ PURIFICACION;;DOMINGO IRIGOYEN SILVIA;;BUSTINZA ESPARTA JORGE,,https://lens.org/066-888-602-266-973,Patent Application,no,0,0,5,5,0,E06B7/02;;E06B7/02;;E04B2/00;;E06B7/10;;E06B9/264;;E06B2009/2643;;F24S20/63;;F24F13/18;;F24F13/18;;F24F2221/20;;F24S20/63;;F24S20/66;;F24S20/66;;Y02B10/20;;Y02E10/40,E04B2/00,,0,0,,,,INACTIVE
103,ES,B1,ES 2400426 B1,196-760-406-191-995,2014-02-12,2014,ES 201100747 A,2011-07-04,ES 201100747 A,2011-07-04,SISTEMA AUTOPORTANTE INDUSTRIALIZADO DE APROVECHAMIENTO DE ENERGIA PARA EDIFICIOS,,CONSTRUCCIONES ACR S A U,SANCHEZ-OSTIZ GUTIERREZ ANA;;MONGE BARRIO AURORA;;GONZALEZ MARTINEZ PURIFICACION;;DOMINGO IRIGOYEN SILVIA;;BUSTINZA ESPARTA JORGE,,https://lens.org/196-760-406-191-995,Granted Patent,no,0,0,5,5,0,E06B7/02;;E06B7/02;;E04B2/00;;E06B7/10;;E06B9/264;;E06B2009/2643;;F24S20/63;;F24F13/18;;F24F13/18;;F24F2221/20;;F24S20/63;;F24S20/66;;F24S20/66;;Y02B10/20;;Y02E10/40,E04B2/00;;E06B7/10;;F24F13/18;;F24J2/04,,0,0,,,,INACTIVE
104,EP,A4,EP 3917642 A4,125-642-176-615-808,2023-04-05,2023,EP 20748144 A,2020-01-30,US 201962798909 P;;US 201962802101 P;;US 201962934371 P;;US 2020/0015904 W,2019-01-30,"RECOVERY, DECARBOXYLATION, AND PURIFICATION OF CANNABINOIDS FROM ENGINEERED CELL CULTURES",,GENOMATICA INC,SUOMINEN LAURI H;;LIEVENSE JEFFERSON;;LIU AIGUO;;MARTINEZ-GONZALEZ JORGE JESUS;;KO MYONG KON;;NAN WEI,,https://lens.org/125-642-176-615-808,Search Report,no,7,0,6,6,0,C12M47/10;;A01H6/28;;A01H5/12;;C07C51/48;;C07C51/47;;C07C37/72;;C07C37/82;;C07C37/50;;B01D11/028;;B01D11/0288;;C12P7/42;;C07D311/80;;C07D311/58;;C07D307/91;;B01D11/0288;;B01D11/0292;;C12M33/10;;C12P7/22,B01D17/038;;A01H5/12;;A01H6/28;;B01D11/02;;B01D17/025;;C02F1/38;;C07C37/50;;C07C37/72;;C07C37/82;;C07C39/19;;C07C51/47;;C07C51/48;;C07C65/05;;C07D307/91;;C07D311/58;;C07D311/80;;C12M1/00;;C12P7/04;;C12P7/06;;C12P7/22;;C12P7/42,,2,1,013-440-282-571-03X,28694184;;10.1016/j.jbiotec.2017.07.008,"ZIRPEL BASTIAN ET AL: ""Engineering yeasts as platform organisms for cannabinoid biosynthesis"", JOURNAL OF BIOTECHNOLOGY, ELSEVIER, AMSTERDAM NL, vol. 259, 8 July 2017 (2017-07-08), pages 204 - 212, XP085167531, ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2017.07.008;;See also references of WO 2020160284A1",PENDING
105,EP,A1,EP 3917642 A1,048-874-217-495-243,2021-12-08,2021,EP 20748144 A,2020-01-30,US 201962798909 P;;US 201962802101 P;;US 201962934371 P;;US 2020/0015904 W,2019-01-30,"RECOVERY, DECARBOXYLATION, AND PURIFICATION OF CANNABINOIDS FROM ENGINEERED CELL CULTURES",,GENOMATICA INC,SUOMINEN LAURI H;;LIEVENSE JEFFERSON;;LIU AIGUO;;MARTINEZ-GONZALEZ JORGE JESUS;;KO MYONG KON;;NAN WEI,,https://lens.org/048-874-217-495-243,Patent Application,yes,0,0,6,6,0,C12M47/10;;A01H6/28;;A01H5/12;;C07C51/48;;C07C51/47;;C07C37/72;;C07C37/82;;C07C37/50;;B01D11/028;;B01D11/0288;;C12P7/42;;C07D311/80;;C07D311/58;;C07D307/91;;B01D11/0288;;B01D11/0292;;C12M33/10;;C12P7/22,B01D17/038;;B01D17/025;;C02F1/38,,0,0,,,,PENDING
106,ES,R1,ES 2400426 R1,134-434-954-356-903,2013-05-24,2013,ES 201100747 A,2011-07-04,ES 201100747 A,2011-07-04,SISTEMA AUTOPORTANTE INDUSTRIALIZADO DE APROVECHAMIENTO DE ENERGIA PARA EDIFICIOS,"Sistema autoportante industrializado de aprovechamiento de energía para edificios, formado por un conjunto de cerramiento transparente o traslúcido, compuesto por una hoja exterior (1) y una hoja interior (2), en las cuales se disponen medios (4) de cierre y apertura, en forma de rejillas, ventanas o puertas, quedando dichas hojas (1 y 2) separadas por una cámara intermedia (3), en la cual se dispone un estor técnico (7) y un depósito (8) contenedor de un líquido, poseyendo la hoja interior (2) en la parte inferior y en la parte superior unas aberturas (5 y 6) de paso de aire provistas con cierres practicables.",CONSTRUCCIONES ACR S A U,SANCHEZ-OSTIZ GUTIERREZ ANA;;MONGE BARRIO AURORA;;GONZALEZ MARTINEZ PURIFICACION;;DOMINGO IRIGOYEN SILVIA;;BUSTINZA ESPARTA JORGE,,https://lens.org/134-434-954-356-903,Unknown,no,7,0,5,5,0,E06B7/02;;E06B7/02;;E04B2/00;;E06B7/10;;E06B9/264;;E06B2009/2643;;F24S20/63;;F24F13/18;;F24F13/18;;F24F2221/20;;F24S20/63;;F24S20/66;;F24S20/66;;Y02B10/20;;Y02E10/40,E04B2/00;;E06B7/10;;F24F13/18;;F24J2/04,,0,0,,,,INACTIVE
107,EP,B1,EP 2543937 B1,053-922-077-716-001,2014-02-26,2014,EP 12174708 A,2012-07-03,ES 201100747 A,2011-07-04,Energy harnessing self-supporting industrialized system for buildings,,CONSTRUCCIONES ACR S A U,SANCHEZ-OSTIZ GUTIERREZ ANA;;MONGE BARRIO AURORA;;GONZALEZ MARTINEZ PURIFICACION;;DOMINGO IRIGOYEN SILVIA;;BUSTINZA ESPARTA JORGE,,https://lens.org/053-922-077-716-001,Granted Patent,yes,5,0,5,5,0,E06B7/02;;E06B7/02;;E04B2/00;;E06B7/10;;E06B9/264;;E06B2009/2643;;F24S20/63;;F24F13/18;;F24F13/18;;F24F2221/20;;F24S20/63;;F24S20/66;;F24S20/66;;Y02B10/20;;Y02E10/40,F24J2/04;;E06B7/10;;F24F13/18,,0,0,,,,ACTIVE
108,US,A1,US 2017/0335897 A1,013-235-775-111-944,2017-11-23,2017,US 201615159102 A,2016-05-19,US 201615159102 A,2016-05-19,CLUTCH DISC SEGMENT WITH ELONGATED FOOT AND CLUTCH DISC ASSEMBLY INCLUDING CLUTCH DISC SEGMENTS WITH ELONGATED FEET,"A clutch disc segment, including: an inner circumference; a body portion including an outer circumference and a plurality of holes arranged to receive a plurality of rivets for securing friction material to the body portion, and a segment including at least a first portion of the inner circumference and conforming to a plane; a first foot protrusion including a first hole for receiving a first rivet for securing the clutch disc segment to a retainer plate; and a second foot protrusion including a second hole for receiving a second rivet for securing the clutch disc segment to the retainer plate. One of the first or second foot protrusions is off-set from the plane in a first direction orthogonal to the plane.",SCHAEFFLER TECHNOLOGIES AG,MARTINEZ TORRES JORGE ARTURO;;JIMENEZ RODRIGUEZ JUAN MANUEL;;GONZALEZ NAGANO JAVIER TAKESHI;;CORTES PEREZ ANGEL ROBERTO,,https://lens.org/013-235-775-111-944,Patent Application,yes,0,0,1,1,0,F16D13/646;;F16D13/68;;F16D2300/12;;F16D13/68;;F16D2300/12;;F16D13/646,F16D13/68,,0,0,,,,DISCONTINUED
109,CA,A1,CA 3128196 A1,026-637-133-490-595,2021-08-06,2021,CA 3128196 A,2020-01-30,US 201962798909 P;;US 201962802101 P;;US 201962934371 P;;US 2020/0015904 W,2019-01-30,"RECOVERY, DECARBOXYLATION, AND PURIFICATION OF CANNABINOIDS FROM ENGINEERED CELL CULTURES","Methods of recovering cannabinoids from cell cultures include methods comprising steps of separating the cell culture at a temperature above the melting point of the cannabinoid to separate a light phase comprising liquid state cannabinoid from a heavy phase; and methods comprising treating the cell culture at a temperature below the melting point of the cannabinoid to separate a light phase from a heavy phase comprising solid state cannabinoid. Other methods include contacting the culture with a water-miscible solvent to form a water-miscible phase and an aqueous phase, separating the two phases and recovering the cannabinoid. Other methods include contacting the culture with a water-immiscible solvent to form a water-immiscible phase and an aqueous phase, separating the two phases, and recovering the cannabinoid. Other methods include washing the inner surface of a fermentation vessel with alkaline solution to recover cannabinoid attached to the vessel surface. Various methods make use of aqueous solvent systems comprising no organic solvent, aqueous solvent systems comprising added water-miscible organic solvent, and dual-phase aqueous/water-immiscible solvent systems.",GENOMATICA INC,SUOMINEN LAURI H;;LIEVENSE JEFFERSON;;LIU AIGUO;;MARTINEZ-GONZALEZ JORGE JESUS;;KO MYONG KON;;NAN WEI,,https://lens.org/026-637-133-490-595,Patent Application,no,0,0,6,6,0,C12M47/10;;A01H6/28;;A01H5/12;;C07C51/48;;C07C51/47;;C07C37/72;;C07C37/82;;C07C37/50;;B01D11/028;;B01D11/0288;;C12P7/42;;C07D311/80;;C07D311/58;;C07D307/91;;B01D11/0288;;B01D11/0292;;C12M33/10;;C12P7/22,B01D17/038;;B01D17/025;;C02F1/38,,0,0,,,,PENDING
110,EP,A1,EP 2543937 A1,038-618-618-483-31X,2013-01-09,2013,EP 12174708 A,2012-07-03,ES 201100747 A,2011-07-04,Energy harnessing self-supporting industrialized system for buildings,"The present invention relates to an energy harnessing self-supporting industrialized system for buildings formed by a transparent or translucent enclosure assembly made up of an outer sheet (1) and an inner sheet (2), in which there are arranged closing and opening means (4) in the form of grids, windows or doors, said sheets (1 and 2) being separated by an intermediate chamber (3), in which there is arranged a technical shade (7) and a tank (8) containing a liquid, the inner sheet (2) having in the lower part and in the upper part holes (5 and 6) provided with operable closures for the passage of air.
",CONSTRUCCIONES ACR S A U,SANCHEZ-OSTIZ GUTIERREZ ANA;;MONGE BARRIO AURORA;;GONZALEZ MARTINEZ PURIFICACION;;DOMINGO IRIGOYEN SILVIA;;BUSTINZA ESPARTA JORGE,,https://lens.org/038-618-618-483-31X,Patent Application,yes,5,0,5,5,0,E06B7/02;;E06B7/02;;E04B2/00;;E06B7/10;;E06B9/264;;E06B2009/2643;;F24S20/63;;F24F13/18;;F24F13/18;;F24F2221/20;;F24S20/63;;F24S20/66;;F24S20/66;;Y02B10/20;;Y02E10/40,F24J2/04;;E06B7/10;;F24F13/18,,0,0,,,,ACTIVE
111,AU,A1,AU 2020/216405 A1,177-101-643-095-915,2021-08-12,2021,AU 2020/216405 A,2020-01-30,US 201962798909 P;;US 201962802101 P;;US 201962934371 P;;US 2020/0015904 W,2019-01-30,"Recovery, decarboxylation, and purification of cannabinoids from engineered cell cultures","Methods of recovering cannabinoids from cell cultures include methods comprising steps of separating the cell culture at a temperature above the melting point of the cannabinoid to separate a light phase comprising liquid state cannabinoid from a heavy phase; and methods comprising treating the cell culture at a temperature below the melting point of the cannabinoid to separate a light phase from a heavy phase comprising solid state cannabinoid. Other methods include contacting the culture with a water-miscible solvent to form a water-miscible phase and an aqueous phase, separating the two phases and recovering the cannabinoid. Other methods include contacting the culture with a water-immiscible solvent to form a water-immiscible phase and an aqueous phase, separating the two phases, and recovering the cannabinoid. Other methods include washing the inner surface of a fermentation vessel with alkaline solution to recover cannabinoid attached to the vessel surface. Various methods make use of aqueous solvent systems comprising no organic solvent, aqueous solvent systems comprising added water-miscible organic solvent, and dual-phase aqueous/water-immiscible solvent systems.",GENOMATICA INC,SUOMINEN LAURI H;;LIEVENSE JEFFEREY;;LIU AIGUO;;MARTINEZ-GONZALEZ JORGE JESUS;;KO MYONG KON;;NAN WEI,,https://lens.org/177-101-643-095-915,Patent Application,no,0,0,6,6,0,C12M47/10;;A01H6/28;;A01H5/12;;C07C51/48;;C07C51/47;;C07C37/72;;C07C37/82;;C07C37/50;;B01D11/028;;B01D11/0288;;C12P7/42;;C07D311/80;;C07D311/58;;C07D307/91;;B01D11/0288;;B01D11/0292;;C12M33/10;;C12P7/22,B01D17/038;;B01D17/025;;C02F1/38,,0,0,,,,PENDING
112,MX,A,MX 2010012413 A,161-671-402-713-990,2012-05-17,2012,MX 2010012413 A,2010-11-12,MX 2010012413 A,2010-11-12,METHOD FOR DIFFERENTIATING MESENCHYMAL STEM CELLS FROM CELLS WITH DOPAMINERGIC NEURON CHARACTERISTICS.,"The present invention provides a method and culture medium for differentiating mesenchymal stem cells from cells with dopaminergic neuron characteristics. The purpose of the invention is to provide a culture medium for the in vitro differentiation of mesenchymal stem cells obtained from bone marrow in cells with neuronal characteristics with dopaminergic functions, said culture medium being designed for performing the culture and differentiation of dopamine producing cells in a reduced period of time, this cells having a potential use in the preparation of therapeutic agents for neurodegenerative diseases.",ITESM,CUEVAS JORGE EUGENIO MORENO;;BARRON MARIA TERESA GONZALEZ GARZA Y;;ARCOS JUDITH ZAVALA;;MARTINEZ HECTOR RAMON,,https://lens.org/161-671-402-713-990,Patent Application,no,0,0,1,1,0,,C12N5/00,,0,0,,,,DISCONTINUED
113,MX,A,MX 2015013847 A,145-551-126-683-134,2017-03-29,2017,MX 2015013847 A,2015-09-29,MX 2015013847 A,2015-09-29,MECHANICAL JOINT AND LOAD ASSEMBLY FOR A SELF-SUSTAINING AIRSHIP.,"A self-sustained airship mechanical structure for attachment and load can be used to improve and supply old existing airship gondolas, as it allows the incorporation of complementary systems which depends on the space and the maximum operational height. Furthermore, depending on aerodynamic studies of the profile thereof, this structure may also comprise different structural profiles to fulfill the advantages provided by a suitable hydrodynamic and aerodynamic profile. The invention includes a plurality of anchoring points comprising at least two perforated sheet fasteners for fixedly attaching the rings of perforated sheets located in the sustaining chamber structure, and at least four rods or perforated sheets that are projected at predetermined angles and attached to rods or perforated sheets extending from an opposite anchoring point and through an attaching assembly.",UNIV AUTONOMA DE NUEVO LEON,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;JULIO MARTINEZ TORRES;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;MARCO ANTONIO SANROMÁN RESÉNDIZ;;JORGE ALBERTO GONZALEZ GUEVARA;;VICTOR MAXIMO ARREDONDO SOLIS;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ;;JOEL GONZALEZ MARROQUIN;;MIGUEL GARCIA YERA,,https://lens.org/145-551-126-683-134,Patent Application,no,0,0,1,1,0,,E04B1/00,,0,0,,,,PENDING
114,MX,A,MX 2015013729 A,166-977-934-680-484,2017-03-24,2017,MX 2015013729 A,2015-09-25,MX 2015013729 A,2015-09-25,SLIDING SYSTEM FOR PROPULSION ENGINES.,"The present invention relates to a mechanism that allows a vessel to rotate on its central axis, said sliding system being formed by at least one propulsion motor joint to a retaining clamp, attached to a servo motor to the gear wheel activated by a toothed drive that engages and disengages the gear wheel by the operator. The present invention is coupled to a vessel bow, a central part and/or stern and allows the vessel to rotate on its central axis. The servo motor coupled to the outer casing of the gear wheel allows axial movement of the retaining clamp.",UNIV AUTONOMA DE NUEVO LEON,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;IVAN ESTEBAN MORALES NIÑO;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;JORGE ALBERTO GONZALEZ GUEVARA;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ;;ARMANDO ACOSTA PEREZ,,https://lens.org/166-977-934-680-484,Patent Application,no,0,0,1,1,0,,B64D27/26,,0,0,,,,PENDING
115,DE,D1,DE 602004022266 D1,011-588-783-883-988,2009-09-10,2009,DE 602004022266 T,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,LKARZINOMS DER BLASE,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SAENZ JIMENEZ MARIA;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORINA;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,,https://lens.org/011-588-783-883-988,Granted Patent,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,ACTIVE
116,MX,A,MX 2015013844 A,000-932-740-040-703,2017-03-29,2017,MX 2015013844 A,2015-09-29,MX 2015013844 A,2015-09-29,A MULTIPLE MODULAR SYSTEM FOR BALLAST COMPRESSION AND INDEPENDENT FLUID CHAMBERS FOR SUSTAINING CRAFTS.,"The invention discloses an independent chamber or fluid compartment, for sustaining and/or allowing a craft to float or submerge, depending on whether the craft is developed for travelling by air or water. Currently, airships comprise unique ballast compartments that can be ventrally located, i.e., at the lower portion of the airship, depending on the center of mass thereof. The invention comprises two sections: one section with a higher volume containing the lift fluid and one section with a lower volume containing the ballast fluid which comprises a higher density. Each of the annular and toroidal chambers are duplicated along the craft length and width, depending on the aerodynamic or hydrodynamic type of said craft, thereby dividing most of the load into many sections and not in a single reservoir, like current ships do.",UNIV AUTONOMA DE NUEVO LEON,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;MARCO ANTONIO SANROMÁN RESÉNDIZ;;JORGE ALBERTO GONZALEZ GUEVARA;;VICTOR MAXIMO ARREDONDO SOLIS;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ,,https://lens.org/000-932-740-040-703,Patent Application,no,0,0,1,1,0,,B63G8/22,,0,0,,,,PENDING
117,EP,A1,EP 3906469 A1,139-453-938-776-516,2021-11-10,2021,EP 19845879 A,2019-12-30,US 201862786665 P;;US 201962886644 P;;US 2019/0068916 W,2018-12-31,PRODUCTION-READY ATTRIBUTES CREATION AND MANAGEMENT FOR SOFTWARE DEVELOPMENT,,EQUIFAX INC,SANKARAN YUVARAJ;;CARVAJAL FELIPE ERNESTO CASTILLO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,,https://lens.org/139-453-938-776-516,Patent Application,yes,0,0,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F8/30;;G06F8/60;;G06F9/445,,0,0,,,,PENDING
118,AU,A1,AU 2019/418585 A1,183-674-034-071-155,2021-08-12,2021,AU 2019/418585 A,2019-12-30,US 201862786665 P;;US 201962886644 P;;US 2019/0068916 W,2018-12-31,Production-ready attributes creation and management for software development,"In some aspects, a computing system can determine a set of attributes based on analyzing input data using attribute templates written in a production-ready programming language. The computing system can generate attribute definitions for the set of attributes using the attribute templates and deploy the attribute definitions for the set of attributes to a production environment of a software program. The software program is written in a programming language compatible with the production-ready programming language. The computing system can monitor the performance of the set of attributes in the production environment of the software program and cause the attribute definitions of the plurality of attributes to be modified based on the monitoring.",EQUIFAX INC,SANKARAN YUVARAJ;;CARVAJAL FELIPE ERNESTO CASTILLO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,,https://lens.org/183-674-034-071-155,Patent Application,no,0,0,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F8/30;;G06F8/60;;G06F9/445,,0,0,,,,PENDING
119,ES,A1,ES 2571005 A1,018-383-828-365-54X,2016-05-23,2016,ES 201400928 A,2014-11-20,ES 201400928 A,2014-11-20,"Liquid dispersion system in unmanned aerial vehicle (Machine-translation by Google Translate, not legally binding)","The present invention allows fumigations to be performed on insect nests located far from ground level and within the visual range of the operator. Likewise, for a safe operation of the device, it is recommended that the work environment be as unobstructed as possible. The drive of the pump is achieved by means of a relay whose control winding is connected to a microprocessor through an optocoupler and a transistor. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,NEIRA LOPEZ PABLO;;ROCA BERNARDEZ DAVID;;DIAZ VILARINO LUCÍA;;MARTINEZ SANCHEZ JOAQUÍN;;GONZALEZ JORGE HIGINIO;;LORENZO CIMADEVILA HENRIQUE,,https://lens.org/018-383-828-365-54X,Patent Application,no,4,1,2,2,0,B64C39/024;;B64D1/18;;B64U2101/00,B64D1/18;;B64C39/02,,0,0,,,,ACTIVE
120,MX,A,MX 2017000510 A,143-462-039-464-50X,2018-06-14,2018,MX 2017000510 A,2016-12-15,MX 2017000510 A,2016-12-15,METHOD AND SYSTEM FOR THE RECONSTRUCTION OF PIPE LAYING AND THICKNESS INSPECTION BY AN INSTRUMENTED EQUIPMENT.,"The present invention relates to a method and system for the reconstruction of the pipe laying by the analysis of the curvature and thickness inspection by an instrumented equipment. Said method and system comprises an ultrasound transducers mounted directly to the body of the capsule and distributed radially, three odometers and two inclinometers for the reconstruction of the pipe laying by the curvature, thereby providing information on the orientation of the sections of pipe, the length of the segments and for the inspection of thicknesses of the wall of the pipe. For the calculation of the curvature radii of the pipe curved sections, the property of the circumference called Sagitta is used in combination with the properties of the ultrasound signals. The spatial localization tools called Homogeneous Transformation Matrices (MTH) are used to store the distance data of the straight and curved sections, recorded by the odometers, as well as the orientation of the equipment recorded b y two inclinometers.",CENTRO DE INGENIERIA Y DESARROLLO IND,CARLOS RUBIO GONZALEZ;;ANTONIO RAMIREZ MARTINEZ;;JORGE ALBERTO SOTO CAJIGA;;JOSE LUIS SANCHEZ GAYTAN;;ABASAI JAIME RESÉNDIZ BARRÓN,,https://lens.org/143-462-039-464-50X,Patent Application,no,0,0,1,1,0,,H02G3/00,,0,0,,,,PENDING
121,MX,A,MX 2020011924 A,156-486-797-496-971,2022-05-09,2022,MX 2020011924 A,2020-11-06,MX 2020011924 A,2020-11-06,"PORTABLE DEVICE FOR CLEANING TANKS, INSTALLATION, AND HANDLING FROM THE OUTSIDE.","The present invention relates to an apparatus for washing cisterns, deposits, water tanks, or tanks, removing adhesions by hydro washing with pressurized water spray through nozzles placed on a cleaning arm with rotation movement around an axis and vertical translation automatically, controlled by an operator. Also, it allows the cleaning of rectangular cisterns, cylindrical tanks, or any geometry following a cleaning pattern by placing the nozzles on the arm, one fixed and the other moving along it. Said equipment facilitates the maintenance of the deposit, being collapsible and easy to move, and simplifying assembly and disassembly of the cleaning mechanism for its transfer and placement.",UNIV GUANAJUATO,AGUILERA GÓMEZ EDUARDO;;GONZALEZ MARTINEZ VICTOR;;LERMA PÉREZ JORGE HUMBERTO;;MIRANDA MENDOZA CINTIA ROXANA;;SÁNCHEZ MONTERO NOÉ ERNESTO,,https://lens.org/156-486-797-496-971,Patent Application,no,0,0,1,1,0,,B08B9/093,,0,0,,,,PENDING
122,ES,B1,ES 2571005 B1,119-832-716-199-551,2016-12-01,2016,ES 201400928 A,2014-11-20,ES 201400928 A,2014-11-20,Sistema de dispersión de líquido en vehículo aéreo no tripulado,,UNIV VIGO,NEIRA LOPEZ PABLO;;ROCA BERNARDEZ DAVID;;DIAZ VILARINO LUCÍA;;MARTINEZ SANCHEZ JOAQUÍN;;GONZALEZ JORGE HIGINIO;;LORENZO CIMADEVILA HENRIQUE,,https://lens.org/119-832-716-199-551,Granted Patent,no,0,0,2,2,0,B64C39/024;;B64D1/18;;B64U2101/00,B64D1/18;;B64C39/02,,0,0,,,,ACTIVE
123,US,A1,US 2023/0214198 A1,140-007-154-783-801,2023-07-06,2023,US 202318183854 A,2023-03-14,US 202318183854 A;;US 202117418740 A;;US 2019/0068916 W;;US 201862786665 P;;US 201962886644 P,2018-12-31,PRODUCTION-READY ATTRIBUTES CREATION AND MANAGEMENT FOR SOFTWARE DEVELOPMENT,"In some aspects, a computing system can determine a set of attributes based on analyzing input data using attribute templates written in a production-ready programming language. The computing system can generate attribute definitions for the set of attributes using the attribute templates and deploy the attribute definitions for the set of attributes to a production environment of a software program. The software program is written in a programming language compatible with the production-ready programming language. The computing system can monitor the performance of the set of attributes in the production environment of the software program and cause the attribute definitions of the plurality of attributes to be modified based on the monitoring.",EQUIFAX INC,SANKARAN YUVARAJ;;CASTILLO CARVAJAL FELIPE ERNESTO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,EQUIFAX INC (2021-09-17),https://lens.org/140-007-154-783-801,Patent Application,yes,0,1,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F8/10;;G06F8/30,,0,0,,,,PENDING
124,WO,A1,WO 2016/092400 A1,063-962-451-946-034,2016-06-16,2016,IB 2015059107 W,2015-11-25,MX 2014014761 A,2014-12-03,ABSORBENT DISPOSABLE RE-FASTENABLE UNDERPANTS,"The invention relates to absorbent disposable underpants comprising a shell and a pair of, left and right, lateral panels. The shell has a front part, a rear part, a part between the legs between the front and rear parts, two transverse edges and two longitudinal edges, and is formed by a permeable internal layer, an impermeable external layer and an absorbent matrix positioned therebetween, and it can also have elastic regions between the legs and at the waist, a transfer layer, and anti-leakage barriers, and the lateral panels have an internal part facing towards the user during use, an external part, a front edge, a rear edge, an upper edge and a lower edge, such that the left and right lateral panels are joined in a re-fastenable manner to the shell, by the front and rear parts thereof via its front and rear edges, respectively.",GRUPO P I MABE SA DE C V,GONZALEZ MARTINEZ RAÚL;;JARAMILLO SILVA JORGE ANDRÉS;;SÁNCHEZ FERNÁNDEZ LUCÍA DEL CARMEN;;CANALES ESPINOSA DE LOS MONTEROS CARLOS,,https://lens.org/063-962-451-946-034,Patent Application,yes,4,0,2,2,0,A61F13/49,A61F13/49,,0,0,,,,PENDING
125,WO,A1,WO 2020/142417 A1,103-390-742-382-804,2020-07-09,2020,US 2019/0068916 W,2019-12-30,US 201862786665 P;;US 201962886644 P,2018-12-31,PRODUCTION-READY ATTRIBUTES CREATION AND MANAGEMENT FOR SOFTWARE DEVELOPMENT,"In some aspects, a computing system can determine a set of attributes based on analyzing input data using attribute templates written in a production-ready programming language. The computing system can generate attribute definitions for the set of attributes using the attribute templates and deploy the attribute definitions for the set of attributes to a production environment of a software program. The software program is written in a programming language compatible with the production-ready programming language. The computing system can monitor the performance of the set of attributes in the production environment of the software program and cause the attribute definitions of the plurality of attributes to be modified based on the monitoring.",EQUIFAX INC,SANKARAN YUVARAJ;;CARVAJAL FELIPE ERNESTO CASTILLO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,,https://lens.org/103-390-742-382-804,Patent Application,yes,4,7,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F8/30;;G06F8/60;;G06F9/445,,1,1,186-851-418-283-134,10.1109/cesys.2018.8723918,"SANGEETHA R ET AL: ""Preprocessing Using Attribute Selection in Data Stream Mining"", 2018 3RD INTERNATIONAL CONFERENCE ON COMMUNICATION AND ELECTRONICS SYSTEMS (ICCES), IEEE, 15 October 2018 (2018-10-15), pages 431 - 438, XP033552855, DOI: 10.1109/CESYS.2018.8723918",PENDING
126,US,A1,US 2022/0066749 A1,091-879-960-458-053,2022-03-03,2022,US 201917418740 A,2019-12-30,US 201917418740 A;;US 201862786665 P;;US 201962886644 P;;US 2019/0068916 W,2018-12-31,PRODUCTION-READY ATTRIBUTES CREATION AND MANAGEMENT FOR SOFTWARE DEVELOPMENT,"In some aspects, a computing system can determine a set of attributes based on analyzing input data using attribute templates written in a production-ready programming language. The computing system can generate attribute definitions for the set of attributes using the attribute templates and deploy the attribute definitions for the set of attributes to a production environment of a software program. The software program is written in a programming language compatible with the production-ready programming language. The computing system can monitor the performance of the set of attributes in the production environment of the software program and cause the attribute definitions of the plurality of attributes to be modified based on the monitoring.",EQUIFAX INC,SANKARAN YUVARAJ;;CARVAJAL FELIPE ERNESTO CASTILLO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,EQUIFAX INC (2021-09-17),https://lens.org/091-879-960-458-053,Patent Application,yes,2,5,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F8/36;;G06F8/60;;G06F8/73,,2,0,,,"JP 4759848, “Information Extraction Device From Printing Plate Making Data” (translation), 08-31-2011, 11 pgs < JP_4759848.pdf>;;JP 60116489, “Image Processing Apparatus, Image Processing Apparatus Control Method, and Program” (translation) 10-16-2016, 28 pgs <JP_6016489.pdf >",ACTIVE
127,US,B2,US 11640286 B2,151-794-998-345-232,2023-05-02,2023,US 201917418740 A,2019-12-30,US 201917418740 A;;US 201862786665 P;;US 201962886644 P;;US 2019/0068916 W,2018-12-31,Production-ready attributes creation and management for software development,"In some aspects, a computing system can determine a set of attributes based on analyzing input data using attribute templates written in a production-ready programming language. The computing system can generate attribute definitions for the set of attributes using the attribute templates and deploy the attribute definitions for the set of attributes to a production environment of a software program. The software program is written in a programming language compatible with the production-ready programming language. The computing system can monitor the performance of the set of attributes in the production environment of the software program and cause the attribute definitions of the plurality of attributes to be modified based on the monitoring.",EQUIFAX INC,SANKARAN YUVARAJ;;CARVAJAL FELIPE ERNESTO CASTILLO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,EQUIFAX INC (2021-09-17),https://lens.org/151-794-998-345-232,Granted Patent,yes,6,1,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F9/44;;G06F8/20;;G06F8/36;;G06F8/60;;G06F8/70;;G06F8/73,,5,1,186-851-418-283-134,10.1109/cesys.2018.8723918,"JP 4759848, “Information Extraction Device From Printing Plate Making Data” (translation), Aug. 31, 2011, 11 pgs < JP_4759848.pdf>.;;JP 60116489, “Image Processing Apparatus, Image Processing Apparatus Control Method, and Program” (translation) Oct. 16, 2016, 28 pgs <JP_6016489.pdf >.;;International Application No. PCT/US2019/068916, “International Search Report and Written Opinion”, dated May 12, 2020, 14 pages.;;Sangeetha, et al., “Preprocessing Using Attribute Selection in Data Stream Mining”, 3rd International Conference or Communication and Electronics Systems (ICCES), IEEE, Oct. 15, 2018, pp. 431-438.;;IN202117033250, “First Examination Report”, dated Jan. 9, 2023, 6 pages.",ACTIVE
128,CA,A1,CA 3125188 A1,034-384-052-536-800,2020-07-09,2020,CA 3125188 A,2019-12-30,US 201862786665 P;;US 201962886644 P;;US 2019/0068916 W,2018-12-31,PRODUCTION-READY ATTRIBUTES CREATION AND MANAGEMENT FOR SOFTWARE DEVELOPMENT,"In some aspects, a computing system can determine a set of attributes based on analyzing input data using attribute templates written in a production-ready programming language. The computing system can generate attribute definitions for the set of attributes using the attribute templates and deploy the attribute definitions for the set of attributes to a production environment of a software program. The software program is written in a programming language compatible with the production-ready programming language. The computing system can monitor the performance of the set of attributes in the production environment of the software program and cause the attribute definitions of the plurality of attributes to be modified based on the monitoring.",EQUIFAX INC,SANKARAN YUVARAJ;;CARVAJAL FELIPE ERNESTO CASTILLO;;PINZON PINTO CARLOS AUGUSTO;;VILLARROEL GONZALEZ GERARDO JORGE;;MARTINEZ CASTRO PABLO ANDRES,,https://lens.org/034-384-052-536-800,Patent Application,no,0,0,7,7,0,G06F8/30;;G06F8/60;;G06F9/44526;;G06F8/36;;G06F8/60;;G06F8/73;;G06F8/70;;G06F8/24;;G06F8/10;;G06F8/30;;G16H10/20;;G06F40/174;;G06F40/166;;G06F8/35,G06F8/30;;G06F8/60;;G06F9/445,,0,0,,,,PENDING
129,ES,A1,ES 2485540 A1,083-205-163-023-355,2014-08-13,2014,ES 201330171 A,2013-02-11,ES 201330171 A,2013-02-11,"Compounds useful in the treatment of methylmalonic aciduria (Machine-translation by Google Translate, not legally binding)","Useful compounds in the treatment of methylmalonic aciduria. The present invention relates to the use of a chemical or pharmacological chaperone containing at least one aryl group for the preparation of a medicament for the treatment and/or prevention of methylmalonic aciduria, as well as to a pharmaceutical composition particularly useful in said treatment. . (Machine-translation by Google Translate, not legally binding)",UNIV MADRID AUTONOMA;;UNIV BERGEN;;UNIV MICHIGAN,PEREZ GONZALEZ BELÉN;;RUIZ DESVIAT LOURDES;;JORGE FINNIGAN ANA;;UGARTE PEREZ MAGDALENA;;MARTINEZ RUIZ AURORA;;UNDERHAUG JARL;;BARNEJEE RUMA,UNIVERSIDAD AUTONOMA DE MADRID (2015-08-25),https://lens.org/083-205-163-023-355,Patent Application,no,0,0,2,2,0,A61K31/175,A61K31/175,,3,0,,,"JORGE-FINNIGAN A et al. POTENTIAL PHARMACOLOGYCAL CHAPERONE THERAPY FOR ISOLATED METHYLMALONIC ACIDURIA cbIB TYPE.Journal of Inherited Metabolic Disease AUG 2010 00/08/2010 VOL: 33 No: Suppl. 1 Pags: S40 ISSN 0141-8955, resumen;;KUCUKGUZEL G et al. Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 20060301 EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR 01/03/2006 VOL: 41 No: 3 Pags: 353 - 359 ISSN 0223-5234 Doi: doi:10.1016/j.ejmech.2005.11.005, página 355, compuesto 4 a- g.;;ABU-SAFIEH KAYED A et al. 4-(4-Chloro-phen-yl)-1-(2-hydr-oxy-2,2-di-phenyl-acet-yl)thio-semicarbazide..Acta crystallographica. Section E, Structure reports online England 2008 00/00/2008 VOL: 64 No: Pt 12 Pags: o2305 ISSN 1600-5368 (Electronic) Doi: doi:10.1107/S1600536808035964 pubmed:21581282. página 02305",ACTIVE
130,WO,A2,WO 2007/110001 A2,186-746-714-143-182,2007-10-04,2007,CU 2007000012 W,2007-03-29,CU 20060073 A,2006-03-29,"CHIMERIC MOLECULES FUSED TO MATRILIN-1, FOR THERAPEUTIC USE",Chimeric molecules fused to the corresponding peptide at the carboxyl end of human matrilin-1 by means of a flexible spacer that confers on them a longer blood half-life and superior specific activity as compared with non-fused molecules.,CT INGENIERIA GENETICA BIOTECH;;PAEZ MEIRELES ROLANDO;;CHINEA SANTIAGO GLAY;;GONZALEZ ROCHE DIAMILE;;GAVILONDO COWLEY JORGE VICTOR;;BELLO RIVERO IRALDO;;MARTINEZ NUNEZ ANAZURIA,PAEZ MEIRELES ROLANDO;;CHINEA SANTIAGO GLAY;;GONZALEZ ROCHE DIAMILE;;GAVILONDO COWLEY JORGE VICTOR;;BELLO RIVERO IRALDO;;MARTINEZ NUNEZ ANAZURIA,,https://lens.org/186-746-714-143-182,Patent Application,yes,0,0,3,3,18,A61K47/6435;;A61K47/6811;;A61K47/6853;;A61K2039/505;;C07K16/3007;;C07K2317/622;;C07K2319/00,,,0,0,,,,PENDING
131,KR,A,KR 20230117591 A,158-042-862-311-933,2023-08-08,2023,KR 20237022683 A,2020-12-04,MX 2020050050 W,2020-12-04,"통증 경감을 위한 오피오이드 진통제 및 항경련제를함유하는 안정한 코팅된, 고형의 약학적 조성물","본 발명은 트라마돌 및 프레가발린, 또는 이의 약학적으로 허용되는 염 으로 이루어지는 신경병성 통증의 치료용 제약 조성물을 포함한다. 이는 하나 또는 둘 모두의 화합물의 감소된 용량으로 인한 부작용 감소와 함께 진통 효과를 제공할 뿐만 아니라, 개선된 안정성을 보유하여서 투여되는 조성물의 용해 및 생체이용률을 유지한다. 본 조성물은 습도와 빛에 민감한 두 약물을 흡수에 영향을 미치지 않는 조제 매질에 넣어야 하는 기술적 어려움을 두 약물의 방출에 영향을 미치지 않으면서 무수 공정과 광 보호 코팅을 통해 극복하였다.",LABORATORIOS SILANES S A DE C V,MUNOZ MARTINEZ CECILIA JANNETTE;;GONZALEZ CANUDAS JORGE ALEJANDRO;;OLLERVIDES RUBIO PAOLA YAZMIN;;ESPINOZA LEON SIXTO SERAFIN;;CUAHUTENCOS ESCOBAR ERNESTO,,https://lens.org/158-042-862-311-933,Patent Application,no,12,0,9,9,0,A61K31/197;;A61P25/04;;A61K31/135;;A61K9/284;;A61K9/2866;;A61K9/5047;;A61K9/5026;;A61K9/2009;;A61K9/2054;;A61K9/1652;;A61K9/1611;;A61K9/2866;;A61K9/284;;A61K31/197;;A61K31/135;;A61P29/00;;A61P25/04;;A61K2300/00;;A61K9/2009;;A61K9/2013;;A61K9/2054;;A61K9/28;;A61K31/135;;A61K31/197,A61K9/28;;A61K31/135;;A61K31/197;;A61P25/04;;A61P29/00,,0,0,,,,PENDING
132,CA,A1,CA 3199166 A1,046-355-722-980-373,2022-06-09,2022,CA 3199166 A,2020-12-04,MX 2020050050 W,2020-12-04,"STABLE, COATED, AND SOLID PHARMACEUTICAL DRUG COMPOSITION CONTAINING AN OPIOID ANALGESIC AND AN ANTIEPILEPTIC TO RELIEVE PAIN","The present invention relates to pharmaceutical compositions comprising tramadol and pregabalin, or a pharmaceutically acceptable salt thereof, for the treatment of neuropathic pain which, in addition to offering the possibility of an analgesic effect with reduced adverse side effects due to the reduction of the 5 dose of one or both compounds, has improved stability, maintaining the dissolution and bioavailability of the composition to be administered. The composition overcomes the technological complexity of having these two moisture- and light-sensitive drugs in a dispensing medium that does not affect their absorption by means of a water-free process, with 0 light protection coating, without affecting the release of the two drugs.",LABORATORIOS SILANES S A DE C V,MUNOZ MARTINEZ CECILIA JANNETTE;;GONZALEZ CANUDAS JORGE ALEJANDRO;;OLLERVIDES RUBIO PAOLA YAZMIN;;ESPINOZA LEON SIXTO SERAFIN;;CUAHUTENCOS ESCOBAR ERNESTO,,https://lens.org/046-355-722-980-373,Patent Application,no,0,0,9,9,0,A61K31/197;;A61P25/04;;A61K31/135;;A61K9/284;;A61K9/2866;;A61K9/5047;;A61K9/5026;;A61K9/2009;;A61K9/2054;;A61K9/1652;;A61K9/1611;;A61K9/2866;;A61K9/284;;A61K31/197;;A61K31/135;;A61P29/00;;A61P25/04;;A61K2300/00;;A61K9/2009;;A61K9/2013;;A61K9/2054;;A61K9/28;;A61K31/135;;A61K31/197,A61K31/197;;A61P25/04,,0,0,,,,PENDING
133,US,A1,US 2016/0164193 A1,110-361-893-802-731,2016-06-09,2016,US 201414905581 A,2014-07-15,US 201414905581 A;;US 201361846464 P;;ES 2014070577 W,2013-07-15,TELECOMMUNICATIONS PLUG FOR HIGH DATA RATE APPLICATIONS,"A telecommunications plug includes a housing having an insertion portion sized to be received in a telecommunications jack, and a circuit board at least partially disposed within the housing. The circuit board includes a plurality of contacts exposed through the insertion portion to electrically connect to contact springs of the telecommunications jack and a plurality of wire connections receiving wires of a telecommunications cable. The plug further includes a switching mechanism movable relative to the circuit board and configured to switch between first and second positions, wherein the first and second positions selectably provide capacitive crosstalk between wire pairs within the plug.",TE CONNECTIVITY AMP ESPAÑA S L U,GATNAU NAVARRO JORGE;;MAQUEDA GONZALEZ MARIA;;MARTINEZ GARCIA ANDRES;;PACHON MUNOZ ARTURO;;SANABRA JANSA JOSE JAIME;;MATEO FERRUS RAFAEL,COMMSCOPE CONNECTIVITY SPAIN S.L (2015-09-30);;TE CONNECTIVITY AMP ESPANA S.L.U (2014-09-29),https://lens.org/110-361-893-802-731,Patent Application,yes,5,3,7,7,0,H01R13/04;;H01R24/64;;H01R4/2433;;H01R13/6466;;H01R13/6658;;H01R13/7039;;H01R24/64;;H01R29/00;;H01R2201/04;;H01R4/2433;;H01R13/6466;;H01R13/6658;;H01R13/7039;;H01R24/64;;H01R29/00;;H01R2201/04;;H01R4/2416;;H01R13/6461;;H01R13/665;;H01R24/28;;H01R43/26,H01R4/24;;H01R13/6461;;H01R13/66;;H01R24/28;;H01R43/26,,0,0,,,,ACTIVE
134,AR,A1,AR 060795 A1,183-073-608-941-735,2008-07-16,2008,AR P070101321 A,2007-03-29,CU 20060073 A,2006-03-29,"MOLECULAS QUIMERICAS FUSIONADAS A MATRILINA 1, DE USO TERAPEUTICO","Moléculas quiméricas fusionadas al péptido correspondiente al extremo carboxilo-de la Matrilina 1 humana mediante un espaciador flexible que les confiere un mayor tiempo de vida media en sangre y una actividad específica superior respecto a las moléculas no fusionadas. Reivindicacion 1: Proteína quimérica caracterizada porque contiene esencialmente el extremo carboxilo de la Matrilina 1, identificada en el listado de secuencias como Seq. ID. N°:19 desde el aminoácido numero 206 hasta el 246, y una proteína de uso terapéutico, fusionadas mediante un espaciador aminoacídico, la cual tiene una vida media y una actividad específica mayor que la proteína de uso terapéutico no fusionada.",CT INGENIERIA GENETICA BIOTECH,BELLO RIVERO IRALDO;;GONZALEZ ROCHE DIAMILE;;GAVILONDO COWLEY JORGE VICTOR;;PAEZ MEIRELES ROLANDO;;MARTINEZ NUNEZ ANAZURIA;;CHINEA SANTIAGO GLAY,,https://lens.org/183-073-608-941-735,Patent Application,no,0,0,3,3,0,A61K47/6435;;A61K47/6811;;A61K47/6853;;A61K2039/505;;C07K16/3007;;C07K2317/622;;C07K2319/00,,,0,0,,,,DISCONTINUED
135,ES,B1,ES 2485540 B1,157-822-760-209-808,2015-05-22,2015,ES 201330171 A,2013-02-11,ES 201330171 A,2013-02-11,Compuestos útiles en el tratamiento de la aciduría metilmalónica,,UNIV MADRID AUTONOMA;;UNIV BERGEN;;UNIV MICHIGAN,PEREZ GONZALEZ BELÉN;;RUIZ DESVIAT LOURDES;;JORGE FINNIGAN ANA;;UGARTE PEREZ MAGDALENA;;MARTINEZ RUIZ AURORA;;UNDERHAUG JARL;;BARNEJEE RUMA,UNIVERSIDAD AUTONOMA DE MADRID (2015-08-25),https://lens.org/157-822-760-209-808,Granted Patent,no,0,0,2,2,0,A61K31/175,A61K31/175,,0,0,,,,ACTIVE
136,US,B2,US 10056703 B2,086-121-629-187-847,2018-08-21,2018,US 201414905581 A,2014-07-15,US 201414905581 A;;US 201361846464 P;;ES 2014070577 W,2013-07-15,Telecommunications plug for high data rate applications,"A telecommunications plug includes a housing having an insertion portion sized to be received in a telecommunications jack, and a circuit board at least partially disposed within the housing. The circuit board includes a plurality of contacts exposed through the insertion portion to electrically connect to contact springs of the telecommunications jack and a plurality of wire connections receiving wires of a telecommunications cable. The plug further includes a switching mechanism movable relative to the circuit board and configured to switch between first and second positions, wherein the first and second positions selectably provide capacitive crosstalk between wire pairs within the plug.",TE CONNECTIVITY AMP ESPANA S L U;;COMMSCOPE CONNECTIVITY SPAIN SL,GATNAU NAVARRO JORGE;;MAQUEDA GONZALEZ MARIA;;MARTINEZ GARCIA ANDRES;;PACHON MUNOZ ARTURO;;SANABRA JANSA JOSE JAIME;;MATEO FERRUS RAFAEL,COMMSCOPE CONNECTIVITY SPAIN S.L (2015-09-30);;TE CONNECTIVITY AMP ESPANA S.L.U (2014-09-29),https://lens.org/086-121-629-187-847,Granted Patent,yes,29,2,7,7,0,H01R13/04;;H01R24/64;;H01R4/2433;;H01R13/6466;;H01R13/6658;;H01R13/7039;;H01R24/64;;H01R29/00;;H01R2201/04;;H01R4/2433;;H01R13/6466;;H01R13/6658;;H01R13/7039;;H01R24/64;;H01R29/00;;H01R2201/04;;H01R4/2416;;H01R13/6461;;H01R13/665;;H01R24/28;;H01R43/26,H01R29/00;;H01R4/2416;;H01R4/2433;;H01R13/6461;;H01R13/6466;;H01R13/66;;H01R13/703;;H01R24/28;;H01R24/64;;H01R43/26,,1,0,,,"International Search Report and Written Opinion for International Application No. PCT/ES2014/070577 dated Jan. 22, 2015 (18 pages).",ACTIVE
137,WO,A3,WO 2007/110001 A3,060-684-722-089-892,2007-11-15,2007,CU 2007000012 W,2007-03-29,CU 20060073 A,2006-03-29,CHIMERIC PROTEINS COMPRISING MATRILIN 1 FOR THERAPEUTIC USE,Chimeric molecules fused to the corresponding peptide at the carboxyl end of human matrilin-1 by means of a flexible spacer that confers on them a longer blood half-life and superior specific activity as compared with non-fused molecules.,CT INGENIERIA GENETICA BIOTECH;;PAEZ MEIRELES ROLANDO;;CHINEA SANTIAGO GLAY;;GONZALEZ ROCHE DIAMILE;;GAVILONDO COWLEY JORGE VICTOR;;BELLO RIVERO IRALDO;;MARTINEZ NUNEZ ANAZURIA,PAEZ MEIRELES ROLANDO;;CHINEA SANTIAGO GLAY;;GONZALEZ ROCHE DIAMILE;;GAVILONDO COWLEY JORGE VICTOR;;BELLO RIVERO IRALDO;;MARTINEZ NUNEZ ANAZURIA,,https://lens.org/060-684-722-089-892,Search Report,yes,5,0,3,3,0,A61K47/6435;;A61K47/6811;;A61K47/6853;;A61K2039/505;;C07K16/3007;;C07K2317/622;;C07K2319/00,A61K47/48;;C07K14/505;;C07K16/00,,0,0,,,,PENDING
138,CA,A1,CA 3199168 A1,141-284-727-858-930,2022-06-09,2022,CA 3199168 A,2020-12-04,MX 2020050051 W,2020-12-04,PHARMACEUTICAL COMPOSITION OF AN ANALGAESIC AND AN ANTIHISTAMINE FORTHE TREATMENT OF RESPIRATORY DISEASES,"The present invention relates to a pharmaceutical composition against respiratory diseases and acute upper respiratory tract infection (URTI), which has immediate release and improved bioavailability, is stable and comprises an analgaesic such as ibuprofen, an antihistamine such as loratadine, and one or more excipients such as suspending agents, solubilisers, cosolvents, sweeteners or flavourings, colouring agents, preservatives or antimicrobials, and solvents. The method for manufacturing the composition overcomes the technological complexity of having both drugs in liquid form, thus preserving the physicochemical properties of the drugs.",LABORATORIOS SILANES S A DE C V,GONZALEZ CANUDAS JORGE ALEJANDRO;;MUNOZ MARTINEZ CECILIA JANNETTE;;OLLERVIDES RUBIO PAOLA YAZMIN;;ESPINOZA LEON SIXTO SERAFIN;;MARQUEZ MEJIA JANNETTE,,https://lens.org/141-284-727-858-930,Patent Application,no,0,0,7,7,0,A61K31/192;;A61P11/00;;A61K31/4545;;A61K9/10;;A61K31/192;;A61K31/4545;;A61K47/10;;A61K47/26,A61K31/192;;A61K31/435;;A61P11/00,,0,0,,,,PENDING
139,CN,A,CN 105531881 A,167-440-140-560-778,2016-04-27,2016,CN 201480050230 A,2014-07-15,ES 2014070577 W;;US 201361846464 P,2013-07-15,Telecommunication plug for high data transmission,"The invention relates to a telecommunications plug connector comprising a housing having an insertion part dimensioned to be received in a telecommunications port, and a circuit board disposed at least partially inside the housing. The circuit board comprises a plurality of contacts that are exposed through the insertion part in order to be electrically connected to the spring contacts of the telecommunications port, and a plurality of wire connections for receiving the wires of a telecommunications cable. The plug connector also comprises a switching mechanism that is movable in relation to the circuit board and is designed to switch between the first and second positions, the first and second positions selectively providing capacitive crosstalk between pairs of wires within the plug connector.",TE CONNECTIVITY AMP ESPANA SLU,GATNAU NAVARRO JORGE;;MAQUEDA GONZALEZ MARIA;;MARTINEZ GARCIA ANDRES;;PACHON MUOZ ARTURO;;SANABRA JANSA JOSE JAIME;;MATEO FERRUS RAFAEL,,https://lens.org/167-440-140-560-778,Patent Application,no,6,0,7,7,0,H01R13/04;;H01R24/64;;H01R4/2433;;H01R13/6466;;H01R13/6658;;H01R13/7039;;H01R24/64;;H01R29/00;;H01R2201/04;;H01R4/2433;;H01R13/6466;;H01R13/6658;;H01R13/7039;;H01R24/64;;H01R29/00;;H01R2201/04;;H01R4/2416;;H01R13/6461;;H01R13/665;;H01R24/28;;H01R43/26,H01R13/04;;H01R24/64,,0,0,,,,ACTIVE
140,DK,T3,DK 1611252 T3,089-621-286-915-223,2009-11-23,2009,DK 04723215 T,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORINA,,https://lens.org/089-621-286-915-223,Granted Patent,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,ACTIVE
141,AT,T1,AT E437963 T1,107-347-605-832-284,2009-08-15,2009,AT 04723215 T,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,IN-VITRO VERFAHREN ZUM NACHWEIS EINES ÜBERGANGSZELLKARZINOMS DER BLASE,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORINA;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,,https://lens.org/107-347-605-832-284,Granted Patent,no,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,INACTIVE
142,ES,T3,ES 2697400 T3,028-614-587-984-988,2019-01-23,2019,ES 14744427 T,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,Sistema de posicionamiento de los pies para estudios de imágenes de resonancia magnética,"La presente invención se relaciona con un sistema y un método que garantizan la reproducibilidad de la posición de los pies, y de las partes bajas de las piernas, durante los estudios con Imágenes de Resonancia Magnética (IRM), para obtener información cuantitativa robusta a lo largo del tiempo. El sistema comprende un dispositivo que se incorpora a las bobinas de radiofrecuencia de cualquier equipo de IRM. Dicho dispositivo comprende una sección de soporte del pie, una sección de soporte para la pierna y una base adaptada para que se fijen en ella las secciones antes mencionadas. Con este dispositivo y método, a través de marcadores externos e internos, se realizan determinaciones cuantitativas de la evolución de fenómenos fisiopatológicos que afectan la anatomía y la fisiología de los pies y las partes bajas de las piernas.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/028-614-587-984-988,Granted Patent,no,0,0,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61B90/00;;A61G13/12;;A61N5/10,,0,0,,,,ACTIVE
143,CA,A1,CA 2916112 A1,054-175-351-349-129,2014-12-31,2014,CA 2916112 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/054-175-351-349-129,Patent Application,no,0,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,0,0,,,,DISCONTINUED
144,CA,A1,CA 3199160 A1,129-458-644-466-598,2022-06-09,2022,CA 3199160 A,2020-12-04,MX 2020050048 W,2020-12-04,PHARMACEUTICAL COMBINATION OF A CORTICOSTEROID AND AN ANTIHISTAMINE FOR THE TREATMENT AND CONTROL OF THE INFLAMMATORY COMPONENT OF ALLERGIC PROCESSES,"The present invention combines the drugs desloratadine and betamethasone in a single dosage unit, which represents a set of major technological challenges due to the physico-chemical properties and difference in doses required to guarantee a stable product for the treatment of allergic and inflammatory processes in a patient.",LABORATORIOS SILANES S A DE C V,MUNOZ MARTINEZ CECILIA JANNETTE;;FARFAN SALAZAR CLAUDIA DELFINA;;ESPINOZA LEON SIXTO SERAFIN;;GONZALEZ CANUDAS JORGE ALEJANDRO;;OLLERVIDES RUBIO PAOLA YAZMIN,,https://lens.org/129-458-644-466-598,Patent Application,no,0,0,7,7,0,A61K31/4545;;A61P37/08;;A61K31/573;;A61K9/2054;;A61K9/2059;;A61K9/2893;;A61K31/4545;;A61K31/573;;A61K47/02;;A61K47/20;;A61K47/32;;A61K47/38,A61K31/573;;A61K31/4545;;A61P37/08,,0,0,,,,PENDING
145,CN,A,CN 105431083 A,012-741-607-090-596,2016-03-23,2016,CN 201480043321 A,2014-06-23,CU 2014000003 W;;CU 20130086 A,2013-06-24,Feet positioning system for magnetic resonance imaging studies,"The invention relates to a system and method that guarantee that the position of the feet and the lower parts of the legs can be reproduced during studies with magnetic resonance imaging (MRI) in order to obtain robust quantitative information over time. The system comprises a device that is built into the radio frequency coils of any MRI equipment. Said device comprises a foot-supporting section, a leg-supporting section and a base designed for the aforementioned sections to be secured therein. This device and method are used, together with external and internal markers, for the quantitative determination of the evolution of pathophysiological phenomena that affect the anatomy and the physiology of the feet and the lower parts of the legs.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/012-741-607-090-596,Patent Application,no,7,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/055;;A61B5/00;;A61B6/04;;A61G13/12;;A61N5/10,,1,1,008-776-374-807-28X,10.1016/j.clinbiomech.2006.05.006;;16844273,"M. SANGEUX, F. MARIN, F. CHARLEUX, L. DURSELEN: ""Quantification of the 3D relative movement of external marker sets vs. bones based on magnetic resonance imaging"", 《CLINICAL BIOMECHANICS》",INACTIVE
146,CA,A1,CA 3199162 A1,173-217-271-112-305,2022-06-09,2022,CA 3199162 A,2020-12-04,MX 2020050049 W,2020-12-04,FIXED-DOSE COMBINATION DRUG FOR THE CONTROL AND MANAGEMENT OF NEUROPATHIC PAIN,"The present invention relates to the manufacture of combination anti-inflammatory, antineuritic and neuropathic pain control and management drugs, in particular, acute pain of moderate to severe intensity of diverse etiology, selected from: peripheral neuropathies, lumbalgias, sciatica, cervicalgias, radiculitis, post-herpetic neuralgia, spondylitis, carpal tunnel syndrome, fibromyalgia, etc., of various etiologies such as inflammatory, medicinal, diabetic, alcoholic, nutritional, etc., and comprising a therapeutically effective amount of (a) a non-steroidal anti-inflammatory agent (NSAID) or a pharmaceutically acceptable salt thereof; (b) an antineuritic agent or a pharmaceutically acceptable salt thereof; (c) at least one pharmaceutically acceptable amount of a pharmaceutically acceptable excipient.",LABORATORIOS SILANES S A DE C V,MUNOZ MARTINEZ CECILIA JANNETTE;;GONZALEZ CANUDAS JORGE ALEJANDRO;;OLLERVIDES RUBIO PAOLA YAZMIN;;ESPINOZA LEON SIXTO SERAFIN;;FARFAN SALAZAR CLAUDIA DELFINA,,https://lens.org/173-217-271-112-305,Patent Application,no,0,0,7,7,0,A61P29/00;;A61K31/4415;;A61K31/51;;A61K31/714;;A61K31/192;;A61K45/06;;A61K9/48;;A61K31/192;;A61K31/4415;;A61K31/51;;A61K31/714,A61K31/192;;A61K31/51;;A61K31/714,,0,0,,,,PENDING
147,KR,A,KR 20160023875 A,007-618-412-542-332,2016-03-03,2016,KR 20167002047 A,2014-06-23,CU 20130086 A;;CU 2014000003 W,2013-06-24,FEET POSITIONING SYSTEM FOR MAGNETIC RESONANCE IMAGING STUDIES,"본 발명은 시간을 통해 강력한 정량적 정보를 얻기 위해서 자기 공명 영상(MRI) 연구 동안, 발과 다리의 하부의 위치의 재현 가능성을 보장하는 시스템과 방법에 관련된 것이다. 시스템은 임의의 MRI 장비의 무선주파수 코일 내로 삽입되는 장치를 포함한다. 상기 장치는 발 지지부, 다리 지지부 및 상술한 부분들이 그 내부에 고정되는 것을 가능하게 하도록 채용된 베이스를 포함한다. 이러한 장치와 방법으로, 외부 및 내부 마커를 통해서, 발과 다리의 하부의 해부학적 구조(anatomy)와 생리(physiology)에 영향을 주는 병리생리학 현상들의 진전의 정량적 연구가 수행된다.",CT INGENIERIA GENETICA BIOTECH,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;FLORES DIAZ LUIS MANUEL;;BERLANGA ACOSTA JORGE AMADOR;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/007-618-412-542-332,Patent Application,no,0,1,21,21,0,A61B5/6829;;A61G13/1245;;A61G13/125;;A61B5/055;;A61N2005/1055;;A61N2005/1097;;A61B2090/363;;A61B2090/3954;;A61B90/39;;A61B5/055;;A61B5/6829;;A61B2090/3954;;A61B5/6829;;A61B5/055;;A61N2005/1055;;A61G13/1245;;A61G13/125;;A61N2005/1097;;A61B2090/363;;A61B5/702;;A61B5/706;;A61B90/39,A61B5/00;;A61B90/00;;A61G13/12;;A61N5/10,,0,0,,,,DISCONTINUED
148,US,B2,US 8124331 B2,005-290-035-143-897,2012-02-28,2012,US 55060804 A,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,In vitro method to detect bladder transitional cell carcinoma,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",MARTINEZ MARTINEZ ANTONIO;;BUELA LAUREANO SIMON;;SANTA CRUZ SIMON;;JIMENEZ MARIA PILAR SAENZ;;SANCHEZ-VALLEJO CORINA JUNQUERA;;ROMAN JOSE JAVIER GOMEZ;;GONZALEZ JORGE CUEVAS;;VILA MIGUEL MOLINA;;PROGENIKA BIOPHARMA SA,MARTINEZ ANTONIO MARTINEZ;;BUELA LAUREANO SIMON;;SANTA CRUZ SIMON;;JIMENEZ MARIA PILAR SAENZ;;SANCHEZ-VALLEJO CORINA JUNQUERA;;ROMAN JOSE JAVIER GOMEZ;;GONZALEZ JORGE CUEVAS;;VILA MIGUEL MOLINA,PROGENIKA BIOPHARMA S.A (2005-10-24);;ONCONOMATRIX S.L (2011-12-19),https://lens.org/005-290-035-143-897,Granted Patent,yes,3,2,9,9,18,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/00;;C12Q1/68;;G01N33/53;;G01N33/574,435/4;;435/7.1,5,4,051-074-275-622-311;;047-918-434-329-239;;034-655-610-437-746;;000-840-121-185-93X,14520460;;pmc2394287;;10.1038/sj.bjc.6601249;;10471491;;10.1038/12615;;9207791;;10.1038/ng0797-260;;pmc3901950;;pmc83965;;10.1128/mcb.19.3.1720;;10022859,"Matsumoto et al. (Oncol Rep. Nov. 2004;12(5):967-71, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/15492779?ordinalpos=85&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed-ResultsPanel.Pubmed-DefaultReportPanel.Pubmed-RVDocSum> on Oct. 5, 2009).;;Sturla et al. (FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells, British Journal of Cancer (2003) 89, pp. 1276-1284, published online on Sep. 30, 2003).;;Capellan, D., et al., Frequent Activating Mutations of FGFR3 in Human Bladder and Cervix Carcinomas, Nature Genetics, vol. 23, Sep. 1999.;;Chesi, M., et al., Frequent Translocation t(4;14)(p16.3;q32.3) in Multiple Myeloma is Associated with Increased Expression and Activating Mutations of Fibrolast Growth Factor Receptor 3, Nature Genetics, vol. 15, Jul. 1997.;;Gygi et al., Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, Mar. 1999, vol. 19 No. 3 p. 1720-1730.",ACTIVE
149,WO,A1,WO 2004/085676 A1,155-584-292-802-681,2004-10-07,2004,EP 2004003219 W,2004-03-25,ES 200300708 A,2003-03-26,IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",MEDPLANT GENETICS S L;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,,https://lens.org/155-584-292-802-681,Patent Application,yes,2,12,9,9,18,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,2,2,047-918-434-329-239;;034-655-610-437-746,10471491;;10.1038/12615;;9207791;;10.1038/ng0797-260;;pmc3901950,"CAPPELLEN ET AL: ""Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas"", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 23, September 1999 (1999-09-01), pages 18 - 20, XP002181676, ISSN: 1061-4036;;CHESI M ET AL: ""FREQUENT TRANSLOCATION T(4;14)(P16.3;Q32.3) IN MULTIPLE MYELOMA IS ASSOCIATED WITH INCREASED EXPRESSION AND ACTIVATING MUTATIONS OF FIBROBLAST GROWTH FACTOR RECEPTOR 3"", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 16, no. 3, July 1997 (1997-07-01), pages 260 - 264, XP001030990, ISSN: 1061-4036",PENDING
150,EP,B1,EP 1611252 B1,193-124-853-616-928,2009-07-29,2009,EP 04723215 A,2004-03-25,EP 2004003219 W;;ES 200300708 A,2003-03-26,IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,"ONCOMATRIX, S.L. (2012-03-21);;PROGENIKA BIOPHARMA, S.A. (2009-02-25);;ONCOMATRIX, S.L., ES (2012-05-24);;ONCOMATRIX, S.L., DERIO, ES (2012-05-24)",https://lens.org/193-124-853-616-928,Granted Patent,yes,0,3,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,1,1,000-840-121-185-93X,pmc83965;;10.1128/mcb.19.3.1720;;10022859,"GYGI ET AL: ""Correlation between protein and mRNA abundance in yeast"", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 1720 - 1730, XP002923559",ACTIVE
151,EP,A1,EP 1611252 A1,096-446-889-802-664,2006-01-04,2006,EP 04723215 A,2004-03-25,EP 2004003219 W;;ES 200300708 A,2003-03-26,IN VITRO METHOD TO DETECT BLADDER TRANSITIONAL CELL CARCINOMA,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;SANTA CRUZ SIMON;;SAENZ JIMENEZ MARIA PILAR;;MOLINA VILA MIGUEL;;JUNQUERA SANCHEZ-VALLEJO CORIN;;GOMEZ ROMAN JOSE JAVIER;;CUEVAS GONZALEZ JORGE,"ONCOMATRIX, S.L. (2012-03-21);;PROGENIKA BIOPHARMA, S.A. (2009-02-25);;ONCOMATRIX, S.L., ES (2012-05-24);;ONCOMATRIX, S.L., DERIO, ES (2012-05-24)",https://lens.org/096-446-889-802-664,Patent Application,yes,0,0,9,9,0,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/574,,0,0,,,,ACTIVE
152,US,A1,US 2008/0274968 A1,073-647-874-103-170,2008-11-06,2008,US 10442908 A,2008-04-16,US 10442908 A;;ES 200301518 A;;US 56302507 A;;EP 2004007195 W,2003-06-30,IN VITRO METHODS FOR DETECTING RENAL CANCER,"The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.",PROGENIKA BIOPHARMA SA,ROMAN JOSE JAVIER GOMEZ;;JIMENEZ MARIA PILAR SAENZ;;GARAY JORGE OCHOA;;IRIBARREN JOKIN DEL AMO;;IBAYONDO CRISTINA SANZ;;SANCHEZ-VALLEJO CORINA JUNQUERA;;BUELA LAUREANO SIMON;;MARTINEZ ANTONIO MARTINEZ;;VAL BERNAL JOSE FERNANDO;;GONZALEZ JORGE CUEVAS,VALDELLORMA RIO (2008-06-23);;PROGENIKA BIPHARMA S.A (2008-06-23),https://lens.org/073-647-874-103-170,Patent Application,yes,1,1,10,10,23,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,A61K38/16;;A61K48/00;;A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12N15/00;;C12Q1/68;;G01N33/574,514/12;;514/44;;435/6;;435/7.23;;435/320.1,0,0,,,,DISCONTINUED
153,US,A1,US 2011/0098191 A1,032-239-651-300-484,2011-04-28,2011,US 87709210 A,2010-09-07,US 87709210 A;;ES 200301518 A;;US 10442908 A;;US 56302507 A;;EP 2004007195 W,2003-06-30,IN VITRO METHODS FOR DETECTING RENAL CANCER,"The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.",PROGENIKA BIOPHARMA SA,GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;SANCHEZ-VALLEJO CORINA JUNQUERA;;SIMON BUELA LAUREANO;;MARTINEZ MARTINEZ ANTONIO;;VAL BERNAL JOSE FERNANDO;;GONZALEZ JORGE CUEVAS,,https://lens.org/032-239-651-300-484,Patent Application,yes,3,1,10,10,23,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,C40B30/04;;A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12Q1/68;;G01N33/53;;G01N33/566;;G01N33/574,506/9;;435/6;;435/7.1;;435/7.92;;436/501,1,1,043-720-376-263-833,12123608;;10.1016/s0896-6273(02)00750-x,"Swiercz et al., Plexin-B1 Directly Interacts with PDZ-RhoGEF/LARG to Regulate RhoA and Growth Cone Morphology, Neuron, Vol. 35, 51-63, July 3, 2002",DISCONTINUED
154,US,A1,US 2008/0015143 A1,140-762-997-999-490,2008-01-17,2008,US 56302504 A,2004-06-30,ES 200301518 A;;EP 2004007195 W,2003-06-30,In Vitro Methods for Detecting Renal Cancer,"The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.",ROMAN JOSE JAVIER GOMEZ;;JIMENEZ MARIA PILAR SAENZ;;GARAY JORGE OCHOA;;IRIBARREN JOKIN DEL AMO;;IBAYONDO CRISTINA SANZ;;SANCHEZ-VALLEJO CORINA JUNQUER;;BUELA LAUREANO SIMON;;MARTINEZ ANTONIO MARTINEZ;;VAL BERNAL JOSE FERNANDO;;CUEVAS-GONZALEZ JORGE,ROMAN JOSE JAVIER GOMEZ;;JIMENEZ MARIA PILAR SAENZ;;GARAY JORGE OCHOA;;IRIBARREN JOKIN DEL AMO;;IBAYONDO CRISTINA SANZ;;SANCHEZ-VALLEJO CORINA JUNQUER;;BUELA LAUREANO SIMON;;MARTINEZ ANTONIO MARTINEZ;;VAL BERNAL JOSE FERNANDO;;CUEVAS-GONZALEZ JORGE,PROGENIKA BIOPHARMA S.A (2006-02-21),https://lens.org/140-762-997-999-490,Patent Application,yes,0,4,10,10,23,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,G01N33/574;;A61K31/7088;;A61K38/16;;A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12N15/00;;C12Q1/68;;G01N33/566;;G01N33/68,514/12;;435/29;;435/320.1;;435/6;;435/7.23;;435/7.92;;435/7.93;;435/7.94;;436/501;;436/86;;436/94;;514/44,0,0,,,,DISCONTINUED
155,MX,A,MX 2007013195 A,096-428-663-436-674,2009-04-23,2009,MX 2007013195 A,2007-10-23,MX 2007013195 A,2007-10-23,PORTABLE SYSTEM FOR ANALYSING VIBRATIONS IN POWER TRANSMISSION LINES.,"Disclosed is a system able to detect the vibrations experimented by a conducting cable and analyse the detected data. The system is autonomous for up to three months; it may be directly installed in power cables of up to 400 KV and has less than 500 g of mass. The instrument consists of a vibration sensor, a clamp to be fastened to a conductor and a closed and hollow metallic structure (for insulating the instrument from the electromagnetic field generated about the conductor). The inventive system includes two digital processors, electronic circuits, a voltage source, a temperature sensor and a ultrasonic sensor for sensing the wind speed. There is no other device currently available on the market able to measure and detect said parameters in a single equipment.",COMISION FED DE ELECTRICIDAD,VARGAS JULIO CESAR SOLANO;;GONZALEZ CARLOS RUBIO;;RODRIGUEZ LEONARDO BARRIGA;;MARTINEZ ANTONIO RAMIREZ;;CAJIGA JORGE ALBERTO SOTO;;ORTEGA JESUS CARLOS PEDRAZA,,https://lens.org/096-428-663-436-674,Patent Application,no,0,0,1,1,0,,H02G7/14;;G01R31/00,,0,0,,,,DISCONTINUED
156,CN,A,CN 116867964 A,107-151-905-476-977,2023-10-10,2023,CN 202280013585 A,2022-01-12,EP 21382095 A;;EP 2022050522 W,2021-02-05,Method and system for optimizing power output of wind turbine with yaw offset,"A system comprising a wind turbine (1) and a first control device for controlling the wind turbine (1) is described. The first control device is configured to: acquire a yaw offset (gamma) of the wind turbine (1), the yaw offset (gamma) being a difference between the actual yaw angle and a wind direction at the wind turbine (1); and determining at least one of a target pitch angle (beta) of the blade (6) and a target torque (TCtrl) of the generator (5) based on the yaw offset (gamma) to optimize power output from the wind turbine (1). A wind farm comprising such a system and a method of controlling a wind turbine (1) are also described.",SIEMENS GAMESA RENEWABLE ENERGY INNOVATION & TECHNOLOGY SL,MORAL GONZALEZ CARLOS;;PAROLA LA NAGA FERNANDO;;PENA MARTINEZ JUAN JOSE;;PIZARRO DE LA FUENTE CARMEN;;BASQUESADA JOAO;;SUAREZ ASPON JORGE,,https://lens.org/107-151-905-476-977,Patent Application,no,0,0,4,4,0,F03D7/0224;;F03D7/0272;;F05B2270/329,F03D7/02,,0,0,,,,PENDING
157,ES,B2,ES 2249979 B2,129-134-933-553-806,2007-07-16,2007,ES 200400889 A,2004-04-13,ES 200400889 A,2004-04-13,DISPOSITIVO DEFLECTOR PARA EVITAR LA ROTURA DE GRANO EN LOS ELEVADORES DE CANGILONES EN MOLINOS ARROCEROS Y SIMILARES.,"Dispositivo deflector para evitar la rotura de grano en los elevadores de cangilones en molinos arroceros y similares. En el sistema de transporte y elevación de arroz y otros cereales, actualmente utilizado mediante cintas sinfín (2) provistas de cangilones (1), se produce un porcentaje significativo de grano roto que tiene un precio sensiblemente inferior en el mercado y reduce la calidad de producción. Se minimiza este problema al incorporar en la parte baja del elevador, sobre la polea (3) de la cinta sinfín (2), una placa metálica oblicua (11) que se extiende verticalmente por los laterales para quedar sujeta a las placas de anclaje de los soportes de cojinete (7) del eje horizontal (9) de la polea aludida (3). El dispositivo deflector que materializa la placa metálica (11), se forma con dos piezas (12 y 13) que se acoplan entre sí mediante tornillos periféricos. Los bordes laterales de la superficie oblicua (14) están provistos de cintas de flecos (22) de apoyo sobre los ramales de lacinta de transporte (2). Ambas piezas (12 y 13) están provistas de sendas ranuras longitudinales centrales (18 y 19) para permitir su montaje independiente y que por ellas pase la chapa (6) de separación de los conductos de elevación y bajada del elevador.",IND LUIS PERIS S A,GOMEZ-SENENT MARTINEZ ELISEO;;ALCAIDE MARZAL JORGE;;DIEGO MAS JOSE ANTONIO;;FERRER GISBERT PABLO;;GOMEZ NAVARRO TOMAS;;GONZALEZ CRUZ M CARMEN,,https://lens.org/129-134-933-553-806,Granted Patent,no,0,0,2,2,0,B65G17/30,B65G17/30,,0,0,,,,INACTIVE
158,ES,A1,ES 2249979 A1,067-162-274-365-625,2006-04-01,2006,ES 200400889 A,2004-04-13,ES 200400889 A,2004-04-13,"Baffle plate device for avoiding breakage of bucket elevator in rice mills, has metallic plate that vertically extends between lateral anchor plates of bearing supports arranged with respect to horizontal axis of pulleys of bucket elevator",The device has a metallic plate that vertically extends between lateral anchor plates of bearing supports arranged with respect to horizontal axis of pulleys of a bucket elevator. A deflector with two sections is coupled to the metallic plate with the use of peripheral screws. The metallic plate has an oblique surface whose lateral edges are provided with fringe support tapes branching over transport tape of bucket elevator. The sections of the deflector have longitudinal central grooves for permitting independent assembly and passage of separation plate of the elevator conduits and elevator slope. The bucket elevator is included in the transport and elevation of rice and other cereals.,IND LUIS PERIS S A,GOMEZ-SENENT MARTINEZ ELISEO;;ALCAIDE MARZAL JORGE;;DIEGO MAS JOSE ANTONIO;;FERRER GISBERT PABLO;;GOMEZ NAVARRO TOMAS;;GONZALEZ CRUZ M CARMEN,,https://lens.org/067-162-274-365-625,Patent Application,no,5,0,2,2,0,B65G17/30,B65G17/30,,0,0,,,,INACTIVE
159,MX,B,MX 339419 B,114-567-109-532-109,2016-05-17,2016,MX 2010008631 A,2010-08-05,MX 2010008631 A,2010-08-05,DEVICE FOR MEASURING WIND VIBRATIONS IN AERIAL CONDUCTORS OF TRANSMISSION LINES.,"A portable and autonomous device (Figure 1) which includes: a vibration sensor (Figure 5), a wind speed sensor (Figure 3) ingeniously designed to be applied, a room temperature sensor and a conductor temperature sensor, which is mounted over an aerial conductor (Figure 6) of transmission lines using an exchangeable clamp (Figure 4) chosen according to the conductor diameter; an electronic system for controlling the method of self-compensation in the average value of the vibration sensor length (figure 8), also acquiring and storing the vibrations, speed of the wind in an straight angle with regard to the conductor, room temperature and the conductor temperature in non-volatile memories, also including operation electronic protections; the device along with the parts thereof has a weight not suitable to be directly mounted over the conductor, thus not affecting the dampening of the conductor nor the real vibration levels.",COMISION FED DE ELECTRICIDAD,GONZALEZ CARLOS RUBIO;;RODRIGUEZ LEONARDO BARRIGA;;MARTINEZ ANTONIO RAMIREZ;;CAJIGA JORGE ALBERTO SOTO;;ORTEGA JESUS CARLOS PEDRAZA;;VARGAS JULIO CESAR SOLANO,,https://lens.org/114-567-109-532-109,Granted Patent,no,0,0,2,2,0,,H02G7/02,,0,0,,,,ACTIVE
160,MX,A,MX 2010008631 A,029-173-246-325-349,2012-02-20,2012,MX 2010008631 A,2010-08-05,MX 2010008631 A,2010-08-05,DEVICE FOR MEASURING WIND VIBRATIONS IN AERIAL CONDUCTORS OF TRANSMISSION LINES.,"A portable and autonomous device (Figure 1) which includes: a vibration sensor (Figure 5), a wind speed sensor (Figure 3) ingeniously designed to be applied, a room temperature sensor and a conductor temperature sensor, which is mounted over an aerial conductor (Figure 6) of transmission lines using an exchangeable clamp (Figure 4) chosen according to the conductor diameter; an electronic system for controlling the method of self-compensation in the average value of the vibration sensor length (figure 8), also acquiring and storing the vibrations, speed of the wind in an straight angle with regard to the conductor, room temperature and the conductor temperature in non-volatile memories, also including operation electronic protections; the device along with the parts thereof has a weight not suitable to be directly mounted over the conductor, thus not affecting the dampening of the conductor nor the real vibration levels.",COMISION FED DE ELECTRICIDAD,GONZALEZ CARLOS RUBIO;;RODRIGUEZ LEONARDO BARRIGA;;MARTINEZ ANTONIO RAMIREZ;;CAJIGA JORGE ALBERTO SOTO;;ORTEGA JESUS CARLOS PEDRAZA;;VARGAS JULIO CESAR SOLANO,,https://lens.org/029-173-246-325-349,Patent Application,no,0,0,2,2,0,,H02G7/02,,0,0,,,,ACTIVE
161,ES,B2,ES 2887832 B2,088-185-868-305-842,2022-12-28,2022,ES 202030626 A,2020-06-23,ES 202030626 A,2020-06-23,"ELECTRODOS NANOESTRUCTURADOS PARA LA ESTIMULACION ELECTRICA DE CELULAS EN CULTIVO, DISPOSITIVOS, SISTEMAS Y PROCEDIMIENTOS ASOCIADOS",,CONSEJO SUPERIOR INVESTIGACION;;UNIV MADRID AUTONOMA;;UNIV OF FLORIDA RESEARCH FOUNDATION INC UFRF,MOBINI SAHBA;;GARCIA MARTIN JOSÉ MIGUEL;;GONZALEZ SAGARDOY MARÍA UJUÉ;;MARTIN GONZALEZ MARIA SOLEDAD;;CABALLERO CALERO OLGA;;GARCIA MARTINEZ JORGE M;;DIEZ GUERRA FRANCISCO JAVIER;;PATRICK ERIN E,,https://lens.org/088-185-868-305-842,Granted Patent,no,0,0,5,5,0,Y02E60/10;;G01N33/4836;;B82Y30/00;;C12M35/02;;C12M23/12;;H01M4/0426;;A61N1/04;;C12M1/42;;B82Y40/00;;G01N27/02;;G01N33/483,H01M4/04;;A61N1/04;;B82Y40/00;;C12M1/42;;G01N27/02;;G01N33/483,,0,0,,,,ACTIVE
162,ES,A1,ES 2887832 A1,195-506-961-623-072,2021-12-28,2021,ES 202030626 A,2020-06-23,ES 202030626 A,2020-06-23,"NANOSTRUCTURED ELECTRODES FOR THE ELECTRICAL STIMULATION OF CELLS IN CULTURE, DEVICES, SYSTEMS AND PROCEDURES ASSOCIATES (Machine-translation by Google Translate, not legally binding)","Nanostructured electrodes for the electrical stimulation of cells in culture, devices, systems and associated procedures. The present invention refers to an electrode (1) for cellular electrical stimulation, adapted for insertion in a miniaturized plate (2) with mini-wells (3) for cell culture, comprising at least one material arranged as substrate (4) and an electrically conductive material arranged on said substrate (4). Advantageously, the electrically conductive material is formed by metallic nanopillars (5), deposited on the substrate (4) through deposition with angle of incidence (GLAD) with magnetron sputtering. The invention also refers to different devices, systems, uses and procedures associated with said electrodes (1). (Machine-translation by Google Translate, not legally binding)",CONSEJO SUPERIOR INVESTIGACION;;UNIV MADRID AUTONOMA;;UNIV OF FLORIDA RESEARCH FOUNDATION INC UFRF,MOBINI SAHBA;;GARCIA MARTIN JOSÉ MIGUEL;;GONZALEZ SAGARDOY MARÍA UJUÉ;;MARTIN GONZALEZ MARIA SOLEDAD;;CABALLERO CALERO OLGA;;GARCIA MARTINEZ JORGE M;;DIEZ GUERRA FRANCISCO JAVIER;;PATRICK ERIN E,,https://lens.org/195-506-961-623-072,Patent Application,no,2,0,5,5,0,Y02E60/10;;G01N33/4836;;B82Y30/00;;C12M35/02;;C12M23/12;;H01M4/0426;;A61N1/04;;C12M1/42;;B82Y40/00;;G01N27/02;;G01N33/483,H01M4/04;;A61N1/04;;B82Y40/00;;C12M1/42;;G01N27/02;;G01N33/483,,2,2,054-018-087-491-388;;083-601-904-783-859,10.1016/j.orgel.2012.01.035;;10.1016/j.snb.2016.08.092,"HSU SUI-YING ET AL. Nanoporous platinum counter electrodes by glancing angle deposition for dye-sensitized solar cells. Organic Electronics, 20120213 ELSEVIER, AMSTERDAM, NL. Bulovi Vladimir; Adachi Chihaya, 13/02/2012, Vol. 13, Páginas 856 - 863 ISSN 1566-1199, (DOI: doi:10.1016/j.orgel.2012.01.035);;MARTÏ¿¿N M ET AL. Cholesterol biosensing with a polydopamine-modified nanostructured platinum electrode prepared by oblique angle physical vacuum deposition. Sensors and Actuators B: Chemical Elsevier BV, NL. McDonagh Colette; MacCraith Brian, 30/11/0002, Vol. 240, Páginas 37 - 45 ISSN 0925-4005, (DOI: doi:10.1016/j.snb.2016.08.092)",ACTIVE
163,MX,A,MX 2015017839 A,011-905-892-338-571,2017-06-19,2017,MX 2015017839 A,2015-12-18,MX 2015017839 A,2015-12-18,DOUBLE STEERABLE VESSEL.,"The present invention consists of a double steerable vessel, constituted by an aerodynamic and hydrodynamic profile between two balloons and a mechanical connection and load structure. This section possesses a structure that allows joining the balloons and distributing the vessel loads efficiently. The invention also enables to house the control systems and those relating to their handling and exploitation functions. Additionally, it possesses the capability to vary its altitude due to it support fluid chamber with a modular ballast compression manifold system, serving as an aid to save lifting fluid. This dual steerable vessel is capable of maintaining and generating a self-contained, autonomous navigation plan according to the application required, as well as the use of all of its functions in the form of manual control. The present invention belongs to the field of aeronautics and marine navigation.",UNIV AUTONOMA DE NUEVO LEON *,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;JULIO MARTINEZ TORRES;;IVAN ESTEBAN MORALES NIÑO;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;JORGE ALBERTO GONZALEZ GUEVARA;;VICTOR MAXIMO ARREDONDO SOLIS;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ;;ARMANDO ACOSTA PEREZ;;JOEL GONZALEZ MARROQUIN;;JOSE RUBEN MORONES IBARRA;;MARCO ANTONIO SANROMÁN RESÉNDIZ;;CARLOS ULISES ACOSTA MUÑIZ,,https://lens.org/011-905-892-338-571,Patent Application,no,0,1,1,1,0,,B64B1/06;;B64B1/08;;B64B1/34,,0,0,,,,PENDING
164,MX,A,MX 2014015397 A,005-727-040-854-609,2016-06-08,2016,MX 2014015397 A,2014-12-09,MX 2014015397 A,2014-12-09,PROCESS FOR EXTRACTING ZINC FROM SOLID RESIDUES OF ELECTROPLATING.,"The present invention relates to a process for the extraction of Zinc from residues resulting from electroplating processes, using an aqueous system of two phases (ATPS). The invention also relates to the compounds used in the ATPS system in suitable concentrations. The compounds comprise a) a polyethylene glycol polymer with an average molecular weight of 3350, b) a salt of sodium sulfate (Na2SO4), c) a binder of potassium thiocyanate (KSCN). All components are present in concentrations suitable for extracting Zinc in the form of complex ZNCS +, with recoveries greater than 90% weight/weight.",CT DE INVESTIGACIÓN Y DESARROLLO TECNOLÓGICO EN ELECTROQUÍMICA S C,LOPEZ RENE ANTAÑO;;HERNANDEZ JORGE MORALES;;GONZALEZ JULIETA TORRES;;ZALDIVAR FEDERICO CASTAÑEDA;;VILLALOBOS IVAN RAMON TEROL;;HADDAD ROBERTA MARTINEZ;;SANCHEZ ANAHI SILVA,,https://lens.org/005-727-040-854-609,Patent Application,no,0,1,1,1,0,Y02P10/20,C01G9/06;;C22B3/00,,0,0,,,,PENDING
165,MX,A,MX 2015013846 A,062-067-303-361-379,2017-03-29,2017,MX 2015013846 A,2015-09-29,MX 2015013846 A,2015-09-29,RIGID MECHANICAL STRUCTURE FOR SUSTAINING CHAMBERS OF AIRSHIPS.,"The invention discloses a rigid mechanical structure for ships, thereby achieving an appropriate fuselage by providing security and stability to the systems which integrate a self-sustained craft, such as airships, and allowing support by providing operability to the systems which protects cameras, storages and/or compartments. This rigid mechanical structure warrants a suitable distribution of loads in airships even better than that provided by state-of-the-art devices since said structure is based on the geometry of a diamond-like structure of silicon carbide which comprises a tetrahedral section, thereby increasing axial and transversal resistance that improves strength and stability when said sections are projected into the classical ellipsoid shapes, of these airships. However, the aforementioned diamond-like structure is not only applied to the ellipsoid, but may also be applied to oblate- or oblong-like forms for a high-altitude, rigid airship.",UNIV AUTONOMA DE NUEVO LEON,MAX SALVADOR HERNANDEZ;;SIMON MARTINEZ MARTINEZ;;FAUSTO ALEJANDRO SANCHEZ CRUZ;;GENRRY ROSSVIER CAVAZOS ALMAGUER;;MARCO ANTONIO SANROMÁN RESÉNDIZ;;JORGE ALBERTO GONZALEZ GUEVARA;;VICTOR MAXIMO ARREDONDO SOLIS;;JOSE VALENTIN GUZMAN GONZALEZ;;RENE MAURICIO CHAVEZ RODRIGUEZ;;JOSE RUBEN MORONES IBARRA,,https://lens.org/062-067-303-361-379,Patent Application,no,0,0,1,1,0,,B64C1/00,,0,0,,,,PENDING
166,ES,T3,ES 2386058 T3,102-387-422-865-571,2012-08-08,2012,ES 07817382 T,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,Uso del factor del crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética,"La presente invención es aplicable en medicina humana, y se relaciona con el uso del Factor de Crecimiento Epidérmico (del inglésEpidermal Growth Factor, abreviado EGF) para preparar una composición farmacéutica, que se administra mediante infiltración en laperiferia de troncos y/o ganglios nerviosos, para la restauraciónmorfofuncional de nervios periféricos en la neuropatía sensitivo-motora, dolorosa, así como las manifestaciones de neuritis isquémica. También incluye una composición que comprende EGF, el que puede ser formulado junto a anestésicos o analgésicos, o encapsulado en microesferas; y su uso para la restauración morfofuncionalde nervios periféricos en la neuropatía diabética de tipo sensitivo-motora, dolorosa; y las manifestaciones de neuritis isquémica.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE;;HERRERA MARTINEZ LUIS;;BERLANGA ACOSTA JORGE;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/102-387-422-865-571,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61P25/00,,0,0,,,,ACTIVE
167,US,B2,US 9371875 B2,018-967-751-073-854,2016-06-21,2016,US 201414299808 A,2014-06-09,US 201414299808 A,2014-06-09,Ventilated brake rotors,A brake rotor for attachment to a wheel of a vehicle may include an outer friction member and an inner friction member. The brake rotor may further include a plurality of fin elements connecting the outer friction member to the inner friction member. Each fin element may include first and second pillars that are connected by a bridge portion to define an opening in the fin element. The opening is configured to allow air to pass through the fin element.,FORD GLOBAL TECH LLC,NORIEGA GONZALEZ LUIS MANUEL;;MARTINEZ LAURENT JUAN CARLOS;;GUERRA MEZA JORGE SILVESTRE;;CANALES MONTE FRANCISCO ALEJANDRO;;ALCANTAR GARCIA JOEL;;AVILA MAGANA LUIS RICARDO,FORD GLOBAL TECHNOLOGIES LLC (2014-06-02),https://lens.org/018-967-751-073-854,Granted Patent,yes,7,9,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/12;;F16D65/02;;F16D65/847,,0,0,,,,ACTIVE
168,CN,U,CN 204755673 U,123-696-129-946-47X,2015-11-11,2015,CN 201520392706 U,2015-06-08,US 201414299808 A,2014-06-09,Stopper rotor,"The utility model provides a stopper rotor, stopper rotor are used for attaching the wheel that connects to the vehicle, and stopper rotor includes: outside friction member, the internal friction component, and be connected to a plurality of fin components of internal friction member with outside friction member, and every fin component includes first pillar and second pillar, and first pillar and second pillar are connected in order to prescribe a limit to the opening in the fin component by bridge portion, and wherein, the opening is constructed into the permission air and is passed the fin component. Another kind of stopper rotor is still provided. The utility model discloses a stopper rotor has improved the heat dissipation and alleviateed the quality.",FORD GLOBAL TECH LLC,FRANCISCO ALEJANDRO CANALES MONTE;;LUIS MANUEL NORIEGA GONZALEZ;;JUAN CARLOS MARTINEZ LAURENT;;JORGE SILVESTRE GUERRA MEZA;;JOEL ALCANTAR GARCIA;;LUIS RICARDO AVILA MAGANA,,https://lens.org/123-696-129-946-47X,Limited Patent,no,0,4,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/12;;F16D65/847,,0,0,,,,ACTIVE
169,US,A1,US 2016/0298709 A1,035-941-772-713-76X,2016-10-13,2016,US 201615186635 A,2016-06-20,US 201615186635 A;;US 201414299808 A,2014-06-09,VENTILATED BRAKE ROTORS,"A brake rotor for attachment to a wheel of a vehicle may include outer and inner friction members, and a plurality of fin elements connecting the outer friction member to the inner friction member. Each fin element may include radially spaced first and second pillars that are connected by a single bridge portion to define an opening in the fin element. The opening may also be defined by an interior surface of one of the annular disks. The opening may be tapered along an entire length between a first pillar and a second pillar. A width of each fin element may taper toward a center of the brake rotor.",FORD GLOBAL TECH LLC,NORIEGA GONZALEZ LUIS MANUEL;;MARTINEZ LAURENT JUAN CARLOS;;GUERRA MEZA JORGE SILVESTRE;;CANALES MONTE FRANCISCO ALEJANDRO;;ALCANTAR GARCIA JOEL;;AVILA MAGANA LUIS RICARDO,,https://lens.org/035-941-772-713-76X,Patent Application,yes,7,1,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/12;;F16D65/847,,0,0,,,,ACTIVE
170,CU,A1,CU 22482 A1,173-274-730-530-102,1997-12-24,1997,CU 1095 A,1995-02-07,CU 1095 A,1995-02-07,PROCEDIMIENTO PARA EL SECUESTRO DE METALES QUE FORMEN SULFUROS POCO SOLUBLES EN AGUA,"Relacionado con la Rama Química y otras especialmente interesadas en la eliminación de metales de disoluciones acuosas. Por medio d e este procedimiento es posible secuestrar de una forma efectiva iones de metales pesados mediante el empleo de sorbentes constituidos estructuralmente por un soporte (red polimérica de naturaleza diversa) y microcorpúsculos de un precipitante (sulfuro metálico poco soluble) ocluídos en sus poros o travéculas . La preparación de dichos sorbentes es sencilla desde el punto de vista tecnológico, utilizando materias primas relativamente económicas y accesibles. El proceso de basa en la reacción entre el precipitante y los iones metálicos que determina la formación de un producto aun menos soluble, que queda retenido en el soporte. Esta invención es aplicable en la descontaminación de masas de aguas conteniendo iones de metales pesados y en la recuperación de metales valiosos.",CNIC CT NAC INVESTIGACIONES,RIVAS HERNANDEZ DIANA FABIOLA;;ROJAS CASANA JORGE ANTONIO;;GONZALEZ HERNANDEZ PATRICIA;;MARTINEZ MARRERO LUCINIA ROSARIO;;ALFONSO HERNANDEZ LUIS MAXIMO;;GARCIA SUAREZ-VILLAMIL ADINA,,https://lens.org/173-274-730-530-102,Limited Patent,no,0,0,1,1,0,,B01D15/00;;B01J20/24,,0,0,,,,EXPIRED
171,MX,B,MX 359441 B,056-902-246-102-723,2018-09-27,2018,MX 2015006980 A,2015-06-02,US 201414299808 A,2014-06-09,VENTILATED BRAKE ROTORS.,A brake rotor for attachment to a wheel of a vehicle may include an outer friction member and an inner friction member. The brake rotor may further include a plurality of fin elements connecting the outer friction member to the inner friction member. Each fin element may include first and second pillars that are connected by a bridge portion to define an opening in the fin element. The opening is configured to allow air to pass through the fin element.,FORD GLOBAL TECH LLC,NORIEGA GONZALEZ LUIS MANUEL;;MARTINEZ LAURENT JUAN CARLOS;;GUERRA MEZA JORGE SILVESTRE;;CANALES MONTE FRANCISCO ALEJANDRO;;ALCANTAR GARCIA JOEL;;AVILA MAGANA RICARDO LUIS,,https://lens.org/056-902-246-102-723,Granted Patent,no,0,0,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/12;;F16D65/847,,0,0,,,,ACTIVE
172,US,B2,US 9841073 B2,060-792-763-219-84X,2017-12-12,2017,US 201615186635 A,2016-06-20,US 201615186635 A;;US 201414299808 A,2014-06-09,Ventilated brake rotors,"A brake rotor for attachment to a wheel of a vehicle may include outer and inner friction members, and a plurality of fin elements connecting the outer friction member to the inner friction member. Each fin element may include radially spaced first and second pillars that are connected by a single bridge portion to define an opening in the fin element. The opening may also be defined by an interior surface of one of the annular disks. The opening may be tapered along an entire length between a first pillar and a second pillar. A width of each fin element may taper toward a center of the brake rotor.",FORD GLOBAL TECH LLC,NORIEGA GONZALEZ LUIS MANUEL;;MARTINEZ LAURENT JUAN CARLOS;;GUERRA MEZA JORGE SILVESTRE;;CANALES MONTE FRANCISCO ALEJANDRO;;ALCANTAR GARCIA JOEL;;AVILA MAGANA LUIS RICARDO,,https://lens.org/060-792-763-219-84X,Granted Patent,yes,12,2,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/12;;F16D65/02;;F16D65/847,,6,0,,,"Non-Final Office Action dated Jun. 26, 2015 from U.S. Appl. No. 14/299,808.;;Response to Non-Final Office Action dated Sep. 28, 2015 from U.S. Appl. No. 14/299,808.;;Final Office Action dated Oct. 8, 2015 from U.S. Appl. No. 14/299,808.;;Response to Final Office Action dated Jan. 5, 2016 from U.S. Appl. No. 14/299,808.;;Advisory Action dated Jan. 22, 2016 from U.S. Appl. No. 14/299,808.;;Notice of Allowance dated Feb. 22, 2016 from U.S. Appl. No. 14/299,808.",ACTIVE
173,MX,A,MX 2015006980 A,073-997-877-721-96X,2015-12-08,2015,MX 2015006980 A,2015-06-02,US 201414299808 A,2014-06-09,VENTILATED BRAKE ROTORS.,A brake rotor for attachment to a wheel of a vehicle may include an outer friction member and an inner friction member. The brake rotor may further include a plurality of fin elements connecting the outer friction member to the inner friction member. Each fin element may include first and second pillars that are connected by a bridge portion to define an opening in the fin element. The opening is configured to allow air to pass through the fin element.,FORD GLOBAL TECH LLC,NORIEGA GONZALEZ LUIS MANUEL;;MARTINEZ LAURENT JUAN CARLOS;;GUERRA MEZA JORGE SILVESTRE;;CANALES MONTE FRANCISCO ALEJANDRO;;ALCANTAR GARCIA JOEL;;AVILA MAGANA RICARDO LUIS,,https://lens.org/073-997-877-721-96X,Patent Application,no,0,0,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/00,,0,0,,,,ACTIVE
174,US,A1,US 2015/0354648 A1,170-538-667-880-27X,2015-12-10,2015,US 201414299808 A,2014-06-09,US 201414299808 A,2014-06-09,VENTILATED BRAKE ROTORS,A brake rotor for attachment to a wheel of a vehicle may include an outer friction member and an inner friction member. The brake rotor may further include a plurality of fin elements connecting the outer friction member to the inner friction member. Each fin element may include first and second pillars that are connected by a bridge portion to define an opening in the fin element. The opening is configured to allow air to pass through the fin element.,FORD GLOBAL TECH LLC,NORIEGA GONZALEZ LUIS MANUEL;;MARTINEZ LAURENT JUAN CARLOS;;GUERRA MEZA JORGE SILVESTRE;;CANALES MONTE FRANCISCO ALEJANDRO;;ALCANTAR GARCIA JOEL;;AVILA MAGANA LUIS RICARDO,FORD GLOBAL TECHNOLOGIES LLC (2014-06-02),https://lens.org/170-538-667-880-27X,Patent Application,yes,0,5,11,11,0,F16D65/128;;F16D65/128;;F16D65/847;;F16D65/128;;F16D65/847;;F16D2065/1328;;F16D2065/1328;;F16D2065/1344;;F16D2065/1344;;F16D2250/0007;;F16D2250/0084;;Y10T29/49828;;Y10T29/49828,F16D65/12;;F16D65/847,,0,0,,,,ACTIVE
175,CU,A1,CU 22973 A1,008-094-340-664-358,2004-07-14,2004,CU 20010115 A,2001-05-11,CU 20010115 A,2001-05-11,SISTEMA DE CONTROL DE TEMPERATURA PARA LA UNIDAD DE ATEMPERACIÓN DE UN TERMOCICLADOR,"Sistema de control de la temperatura del conjunto de partes que componen la unidad de atemperación de un termociclador por medio de 4 elementos de acción final, que son: Un dispositivo de efecto Peltier, capaz de calentar enfriar, dos resistencias generadoras de calor y un ventilador. En la unidad de atemperación existen dos subsistemas a controlar. Uno de ellos es el bloque donde se colocan las muestras, que recibe la acción del ejemplo Peltier, el cual se auxilia también de una de las resistencias mencionadas para lograr una mayor velocidad de calentamiento, y de la misma forma lo hace con el ventilador para acelerar el proceso de enfriamiento. El otro subsistema es la tapa superior que solo es controlada por la acción de una resistencia. El sistema de control, cuenta con un bloque central de procesamiento que toma las decisiones para manejar los elementos de acción final (EAF) a través de un circuito de potencia, realimentándose de la senal que dan los sensores de temperatura que se colocan en diferentes puntos de la unidad de atemperación por medio de un circuito conversor análogo digital. El bloque central de procesamiento realiza la función de control por medio de la aplicación de un método que, además de permitir el control de la temperatura deseada, es el encargado de determinar cuándo se deben poner a funcionar los EAF, en dependencia del efecto que se quiera lograr sobre la temperatura de las diferentes partes a controlar. Dicho método fue obtenido a partir de la identificación del modelo matemático de comportamiento de los subsistemas, posteriormente la simulación para comprobar su validez, utilizando herramientas de computación y a continuación el ajuste final del mismo de forma práctica.",CT DE INMUNOENSAYO,GENTILE MARTINEZ-CASADO JORGE FRANCISCO MA;;VALDES REAL JULIO ANTONIO ONI;;HERRERA HERNANDEZ HIGMAR AR;;SANCHEZ GONZALEZ NADIEZHDA IEZ;;PICO GARCIA JOSE FELIX,,https://lens.org/008-094-340-664-358,Limited Patent,no,0,0,1,1,0,,G05D23/19,,0,0,,,,EXPIRED
176,WO,A2,WO 2005/003776 A2,143-027-471-072-875,2005-01-13,2005,EP 2004007195 W,2004-06-30,ES 200301518 A,2003-06-30,IN VITRO METHODS FOR DETECTING RENAL CANCER,"The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.",PROGENIKA BIOPHARMA SA;;GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORIN;;SIMON BUELA LAUREANO;;MARTINEZ MARTINEZ ANTONIO;;ARGUEELLES SANCHEZ MARIA ELADI;;VAL BERNAL JOSE FERNANDO;;CUEVAS GONZALEZ JORGE,GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORIN;;SIMON BUELA LAUREANO;;MARTINEZ MARTINEZ ANTONIO;;ARGUEELLES SANCHEZ MARIA ELADI;;VAL BERNAL JOSE FERNANDO;;CUEVAS GONZALEZ JORGE,,https://lens.org/143-027-471-072-875,Patent Application,yes,0,4,10,10,23,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12Q1/68;;G01N33/574,,0,0,,,,PENDING
177,WO,A3,WO 2005/003776 A3,060-758-541-501-162,2005-04-21,2005,EP 2004007195 W,2004-06-30,ES 200301518 A,2003-06-30,IN VITRO METHODS FOR DETECTING RENAL CANCER,"The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression.",PROGENIKA BIOPHARMA SA;;GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORIN;;SIMON BUELA LAUREANO;;MARTINEZ MARTINEZ ANTONIO;;ARGUEELLES SANCHEZ MARIA ELADI;;VAL BERNAL JOSE FERNANDO;;CUEVAS GONZALEZ JORGE,GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORIN;;SIMON BUELA LAUREANO;;MARTINEZ MARTINEZ ANTONIO;;ARGUEELLES SANCHEZ MARIA ELADI;;VAL BERNAL JOSE FERNANDO;;CUEVAS GONZALEZ JORGE,,https://lens.org/060-758-541-501-162,Search Report,yes,3,0,10,10,0,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12Q1/68;;G01N33/574,,2,1,029-147-443-005-548,pmc130042;;12356337;;10.1186/1471-2105-3-26,"CIRCOSTA PAOLA ET AL: ""CD100/Plexin-B1 interaction emphasizes the role of bone marrow microenvironment in B-CLL"", BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), & 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 360a, XP009041247, ISSN: 0006-4971;;GIESEG MICHAEL A ET AL: ""Expression profiling of human renal carcinomas with functional taxonomic analysis."", BMC BIOINFORMATICS [ELECTRONIC RESOURCE]. 30 SEP 2002, vol. 3, no. 26, 30 September 2002 (2002-09-30), XP002309629, ISSN: 1471-2105",PENDING
178,CN,A,CN 116964023 A,107-132-043-963-937,2023-10-27,2023,CN 202280010567 A,2022-01-19,EP 21197479 A;;EP 2022051107 W,2021-09-17,Sulfur coated fertilizer with polymer coating,"The present invention relates to a sulfur-coated granulated fertilizer having a polymer coating on a sulfur layer, wherein the polymer coating comprises polycaprolactone. A sulfur-coated granulated fertilizer can have an aliphatic polyester (one polymer coating) on a sulfur layer and have the following properties when tested in a standardized water immersion test: a. The initial release of about 20% or less, preferably about 15% or less, of nutrients within 24 hours; b. Release of a nutrient content of more than 4%, preferably about 5% or more, between the fourteenth day and the twenty-first day from the beginning of the water immersion test.",ELOS INTERNATIONAL LTD,VAN NAIJS PAUL LEONARDUS HENDRIKUS;;SIJSTERMANS SEBASTIAAN TINE KATRIEN;;MORA ANGEL MARIA GONZALEZ;;HERNANDEZ MARTINEZ JORGE;;PAQUEY JOHN BRIAN GEORGE;;OTTE GERARDUS JACOBUS JOSEPH,,https://lens.org/107-132-043-963-937,Patent Application,no,0,0,1,9,0,,C05G5/30,,0,0,,,,PENDING
179,ES,Y,ES 1229930 Y,171-310-528-830-091,2019-08-13,2019,ES 201930718 U,2018-02-27,ES 201930718 U,2018-02-27,DISPOSITIVO PARA PROSUMO ELECTRICO INTELIGENTE,,UNIV LEON,DE SIMON MARTIN MIGUEL;;DE LA PUENTE GIL ALVARO;;GONZALEZ MARTINEZ ALBERTO;;DIEZ SUAREZ ANA MARÍA;;ALVAREZ DE PRADO LAURA;;BLANES PEIRO JORGE JUAN,,https://lens.org/171-310-528-830-091,Limited Patent,no,0,0,2,2,0,,H02J3/38,,0,0,,,,ACTIVE
180,ES,U,ES 1229930 U,086-909-341-131-610,2019-05-23,2019,ES 201930718 U,2018-02-27,ES 201930718 U,2018-02-27,"DEVICE FOR INTELLIGENT ELECTRICAL PROSUME (Machine-translation by Google Translate, not legally binding)","Device for intelligent electrical gain, characterized in that the device (1) comprises: a user interface to obtain the manageable loads of an installation with self-consumption and the energy demand of each manageable load in a given management period; reading means (14) configured to obtain the consumption of the installation through the reading of the energy meters of the installation; data processing means configured for: determine the self-consumption potential of the installation based on the power generation capacity, the energy accumulation and the consumption of the installation; generate, for each manageable load, an optimized consumption profile that determines the instants of connection and disconnection of the manageable load in the management period, where said instants of connection and disconnection are calculated based on the self-consumption potential available in the installation, the energy demand of manageable loads and an optimization criterion; means for activating the manageable loads, configured to send connection and disconnection orders of the manageable loads in the management period according to the consumption profile generated for each manageable load. (Machine-translation by Google Translate, not legally binding)",UNIV LEON,DE SIMON MARTIN MIGUEL;;DE LA PUENTE GIL ALVARO;;GONZALEZ MARTINEZ ALBERTO;;DIEZ SUAREZ ANA MARÍA;;ALVAREZ DE PRADO LAURA;;BLANES PEIRO JORGE JUAN,,https://lens.org/086-909-341-131-610,Patent Application,no,0,0,2,2,0,,H02J3/38,,0,0,,,,ACTIVE
181,ES,A1,ES 2685868 A1,011-431-396-770-996,2018-10-11,2018,ES 201830178 A,2018-02-27,ES 201830178 A,2018-02-27,"METHOD AND DEVICE FOR INTELLIGENT ELECTRICAL PROSUME (Machine-translation by Google Translate, not legally binding)","Method and device for intelligent electric consumption, intelligent management of loads in self-consumption facilities. The method includes determining the manageable loads of the installation and its energy demand in a management period; obtain the consumption of the installation; determine the self-consumption potential of the installation according to the generation capacity and energy accumulation and the consumption of the installation; generate, for each manageable load, an optimized consumption profile that determines the moments of connection and disconnection of the manageable load in the management period, calculated on the basis of the self-consumption potential available in the installation, the energy demand of the manageable loads and an optimization criterion; and connect the manageable loads in the management period according to the consumption profile generated for each manageable load. (Machine-translation by Google Translate, not legally binding)",UNIV LEON,DE SIMON MARTIN MIGUEL;;DE LA PUENTE GIL ALVARO;;GONZALEZ MARTINEZ ALBERTO;;DIEZ SUAREZ ANA MARIA;;ALVAREZ DE PRADO LAURA;;BLANES PEIRO JORGE JUAN,,https://lens.org/011-431-396-770-996,Patent Application,no,7,0,2,2,0,H02J3/32;;H02J2203/20;;Y02E10/56;;Y04S40/20;;Y02E60/00;;H02J3/383;;H02J3/32;;H02J3/32;;H02J2203/20,H02J3/38,,0,0,,,,ACTIVE
182,CU,A1,CU 22278 A1,127-022-343-017-019,1995-01-31,1995,CU 1990104 A,1990-06-13,CU 1990104 A,1990-06-13,"A RECOMBINING STRAIN OF YEAST WHICH PRODUCES AN ASPARTIC PROTEASE WHICH SERVES TO COAGULATE MILK, AND THE PROCEDURE FOR OBTAINING IT.","SE RELACIONA CON LA RAMA DE LA BIOTECNOLOGIA Y LA INGENIERIA GENETICA, Y EN PARTICULAR CON UNA NUEVA CEPA DE LEVADURA RECOMBINANTE PRODUCTORA DE UNA PROTEASA ASPARTICA, ASI COMO CON EL PROCEDIMIENTO PARA SU OBTENCION. EL OBJETIVO TECNICO QUE PERSIGUE LA MISMA ES LOGRAR UNA CEPA CAPAZ DE EXPRESAR Y EXCRETAR EN CANTIDADES COMERCIALMENTE UTILES, ESTA ENZIMA CON ACTIVIDAD COAGULANTE DE LA LECHE PARA SU EMPLEO EN LA INDUSTRIA QUESERA. PARA LOGRAR ESTE OBJETIVO SE CLONO EL GEN QUE CODIFICA PARA LA PROTEASA ASPARTICA PROVENIENTE DEL HONGO MUCOR PUSILLUS EN LA LEVADURA PICHIA PASTORIS, OBTENIENDOSE UNA CEPA HIPERPRODUCTORA DE LA PROTEINA QUE ALCANZA RENDIMIENTOS DE 7 G/L DE LA MISMA, CUANDO ES INDUCIDA CON METANOL Y EN CONDICIONES DE FERMENTACION SEMICONTINUA. ESTA CEPA PUEDE SER EMPLEADA EN LA PRODUCCION A GRAN ESCALA DE DICHA ENZIMA, LA CUAL ES DE GRAN UTILIDAD PARA LA FABRICACION DE QUESOS.\!",CIGB,MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARMEN;;AGUIAR SANTIAGO JORGE AGUSTIN;;FERBEYRE BINELFA GERARDO;;VILLAREAL BARRIOS ADELAIDE;;MARTINEZ SANTANA VLADIMIR;;SOSA ESPINOSA ANGELA ESTELA;;GONZALEZ LOPEZ TANIA;;HERRERA MARTINE LUIS SATURNINO;;GONZALEZ BADILLO BEATRIZ;;MAESTRE MESA JORGE LUIS;;SILVA RODRIGUEZ ALEJANDRO,,https://lens.org/127-022-343-017-019,Limited Patent,no,0,0,1,12,0,,C12N9/60;;C12N15/57,,0,0,,,,EXPIRED
183,CU,A1,CU 22829 A1,086-730-119-707-922,2003-01-29,2003,CU 1999049 A,1999-04-14,CU 1999049 A,1999-04-14,DISPOSITIVO PARA LABORES AGRÍCOLAS SIN INVERSIÓN DEL PRISMA DEL SUELO,"Dispositivo para labores agrícolas sin inversión del prisma del suelo, que disminuye la fuerza de tracción y el consumo de combustible durante el trabajo. El establecimiento de ángulos de ataque adecuados en el cincel y las saetas; la inclusión del ángulo de evacuación en el perfil delantero de la pata, ejecutado hacia uno de sus lados y que proporciona una componente más aguda; el hecho de que el perfil delantero de la pata responda a una curva fisicamente de ascensión suave del material de suelo cortado, así como la utilización de un cincel cilíndrico con distribución uniforme de las cargas que actúan sobre él, hace que se disminuyan substancialmente las fuerzas de rozamiento suelo-metal en los diferentes elementos que conforman el implemento. Todas estas soluciones le permite ser utilizado en todo tipo de suelo agrícola y con bajos consumos de potencia de tracción.",INST DE INVESTIGACIONES DE MECANIZACION AGROPECUAR,CASTILLO LOUKACHEVA GALINA;;HERRERA SARDINAS LUIS MANUEL;;COCA ABASCAL JORGE;;NAVARRO BAENA GAMAL;;HERNANDEZ ORTEGA SIGFREDO;;SERPA RODRIGUEZ GUALBERTO;;MARTINEZ MARTINEZ ISIDRO;;CARDENAL NOVO PABLO ORESTES;;RONZONI REBELINO CARLOS DANTE;;BOUZA GONZALEZ HERIBERTO,,https://lens.org/086-730-119-707-922,Limited Patent,no,0,0,1,1,0,,A01B13/08,,0,0,,,,EXPIRED
184,US,A1,US 2014/0105990 A1,061-656-583-570-296,2014-04-17,2014,US 201314140849 A,2013-12-26,US 201314140849 A;;CU 20060192 A;;US 44383710 A;;CU 2007000018 W,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,"The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as in ischemic neuritis.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/061-656-583-570-296,Patent Application,yes,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61K9/16,424/490;;530/324;;514/9.6,0,0,,,,INACTIVE
185,US,B2,US 9034826 B2,099-331-190-519-434,2015-05-19,2015,US 201314140849 A,2013-12-26,US 201314140849 A;;CU 20060192 A;;US 44383710 A;;CU 2007000018 W,2006-10-03,Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy,"The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as in ischemic neuritis.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/099-331-190-519-434,Granted Patent,yes,14,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61P25/02;;A61K9/16;;A61K38/18;;C07K14/485,514/18.2;;514/9.2;;530/399;;930/120,28,28,046-213-659-127-738;;109-838-506-733-044;;047-034-187-679-149;;031-087-211-663-859;;012-153-934-281-639;;056-772-122-954-630;;021-687-257-691-448;;001-288-716-224-846;;017-347-345-261-813;;058-498-162-092-725;;020-376-210-796-117;;051-320-944-751-630;;068-261-285-048-481;;001-551-359-637-313;;036-878-033-081-911;;031-046-804-582-359;;032-435-118-782-567;;005-520-333-818-806;;046-727-902-354-198;;013-080-869-629-310;;015-711-901-873-374;;005-579-179-221-679;;012-177-818-988-764;;135-189-263-983-537;;038-640-408-064-257;;057-370-081-506-982;;014-739-166-664-338;;140-326-549-830-789,9753192;;10.1002/(sici)1097-4547(19980915)53:6<645::aid-jnr2>3.0.co;2-5;;12357247;;10.1038/nm781;;10416991;;10.1111/j.1750-3639.1999.tb00539.x;;pmc8098555;;14515331;;10.1002/glia.10280;;10.1080/0010751031000095107;;10.1210/en.140.7.3063;;10385398;;10.1210/endo.140.7.6754;;pmc1602279;;10.1016/s0002-9440(10)63151-3;;14742267;;10.1097/00005072-199805000-00006;;9596413;;12739742;;10.1007/bf03345143;;12962024;;15269225;;10.1152/jn.00352.2004;;10.1111/j.1460-9568.2004.03606.x;;15355312;;15196666;;10.1016/j.neulet.2004.04.086;;14734521;;10.1084/jem.20031677;;pmc2211762;;10.1016/s1074-7613(04)00111-6;;15142520;;12376594;;10.1126/science.1075958;;10.1146/annurev.immunol.21.120601.141122;;15032588;;10.1210/en.2002-220261;;12239123;;12663929;;10.1385/jmn:20:1:1;;10.1530/eje.0.1490377;;14585082;;10.1016/0196-9781(91)90115-6;;1923940;;10.1016/s0014-4827(04)00080-1;;15149844;;10.1016/j.yexcr.2004.02.007;;10.1016/j.mcn.2004.01.003;;15207849;;pmc6573198;;10.1523/jneurosci.17-15-05820.1997;;9221780;;pmc6792940;;9482798;;10.1523/jneurosci.18-06-02118.1998;;10.1016/j.brainres.2005.05.050;;15993864;;10.1086/383266;;15306983;;10.1111/j.1742-481x.2006.00237.x;;pmc7951497;;16984579;;15952441,"Bianchi, et al., ""Interleukin-1 and Nociception in the Rat"", Journal of Neuroscience Research, 53:645-650 (1998).;;John, et al., ""Multiple Sclerosis: Re-Expression of a Developmental Pathway that Restricts Oligodendrocyte Maturation"", Nature Medicine, 8(10):1115-1121(2002).;;Mehler, et al., ""Postnatal Cerebral Cortical Multipotent Progenitors: Regulatory Mechanisms and Potential Role in the Development of Novel Neural Regenerative Strategies"", Brain Pathology, 9(3):515-526(1999).;;Wilson, et al., ""Human Oligodendrocyte Precursor Cells in Vitro: Phenotypic Analysis and Differential Response to Growth Factors"", GLIA, 44(2):153-165(2003).;;Ye, et al., ""Insulin-Like Growth Factor I Protects Oligodendrocytes from Tumor Necrosis Factor-alpha-Induced Injury"", Endocrinology, 140(7):3063-3072(1999).;;Ito, et al., ""Collapse and Restoration of MHC Class-I-Dependent Immune Privilege"", American Journal of Pathology, 164(2):623-634(2004).;;Li, et al., ""Chronic Relapsing Experimental Autoimmune Encephalomyelitis: Effects of Insulin-Like Growth Factor-I Treatment on Clinical Deficits, Lesion Severity, Glial Responses, and Blood Brain Barrier Defects"", Journal of Neuropathology and Experimental Neurology, 57(5):426-438(1998).;;Martins, et al., ""GH-releasing Peptide (GHRP-6)-Induced ACTH Release in Patients with Addison's Disease: Effect of Glucocorticoid Withdrawal"", J. Endocrinaol. Invest., 26(2):143-147(2003).;;Oishi et al., ""Steroid Therapy for Multiple Sclerosis"", Nippon Rinsho, 61(8):1361-1366(2003).;;Thorne, et al., ""Diffusion of Epidermal Growth Factor in Rat Brain Extracellular Space Measured by Integrative Optical Imaging"", J. Neurophysiology, 92(6):3471-3481(2004).;;Crang et al., ""The Remyelinating Potential and In Vitro Differentiation of MOG-expressing Oligodendrocyte Precursors Isolated from the Adult Rat CNS"", European Journal of Neuroscience, 20(6):1445-1460(2004).;;Wang et al., ""Infusion of Epidermal Growth Factor and Basic Fibroblast Growth Factor into the Striatum of Parkinsonian Rates Leads to In Vitro Proliteration and Differentiation of Adult Neural Progenitor Cells"", Neuroscience Letter, 364(3):154-158(2004).;;Gotter, et al., ""Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-Specific Genes Colocalized in Chromosomal Clusters"", Journal of Experimental Medicine, 199(2):155-166(2004).;;Mathis et al., ""Back to Central Tolerance"", Immunity, 20:509-516(2004).;;Anderson et al., ""Profection of an Immunological Self Shadow Within the Thymus by the Aire Protein"", Science, 298:1395-1400(2002).;;Sakaguchi et al., ""Naurally Arising CD4+ Regulatory T Cells for Immunological Self-Tolerance and Negative Control of Immune Responses"", Annual Review of Immunology, 22:531-562(2004).;;Frago et al., ""Growth Hormone (GH) and GH-Releasing Peptide-6 Increase Brain Insulin-Like Growth Factor-I Expression and Activate Intracellular Signaling Pathways Involved in Neuroprotection"", Endocrinology, 143:10:4113-4122(2002).;;Harvey et al., ""Neural Growth Hormone: An Update"", Journal of Molecular Neuroscience:MN, 20:1:1-14(2003).;;Schneider et al., ""Central Effects of the Somatotropic System"", European Journal of Endocrinology, 149:5:377-392 (2003).;;Plata-Salaman, C.R., ""Epidermal Growth Factor and the Nervous System"", Peptides, Elsevier, Amsterdam, US, 12:3:653-663(1991).;;Knapp et al., ""Epidermal Growth Factor Promotes Oligodendrocyte Process Formation and Regrowth After Injury"", Experimental Cell Research, 296:2:135-144(2004).;;Raineteau et al., ""Neurogenesis in Hippocampal Slice Cultures"", Molecular and Cellular Neuroscience, 26:2:241-250 (2004).;;Kuhn et al., ""Epidermal Growth Factor and Fibroblast Growth Factor-2 Have Different Effects on Neural Progenitors in the Adult Rat Brain"", Journal of Neuroscience, 17:15:5820-5829(1997).;;Arsenijevic et al., ""Insulin-Like Growth Factor-I is a Differentiation Factor for Postmitotic CNS Stem Cell-Derived Neural Precursors: Distinct Actions from those of Brain-Derived Neurotrophic Factor"", Journal of Neuroscience, 18:6:2118-2128(1998).;;Rom et al., ""Glutamate Receptor Antagonists and Growth Factors Modulate Dentate Granule Cell Neurogenesis in Organotypic, Rat Hippocampal Slice Cultures"", Brain Research, 1051:1-2:35-49(2005).;;Ulbrecht et al., Clinical Infectious Diseases, 39(2): S73-82 (2004).;;Acosta et al., International Wound Journal, 3(3): 232-239 (2006).;;Aring et al, Am Fam Physician, 71:2123-2128 (2005).",INACTIVE
186,US,B2,US 8642552 B2,140-419-184-969-931,2014-02-04,2014,US 44383707 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA;;CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2009-12-01),https://lens.org/140-419-184-969-931,Granted Patent,yes,15,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61P25/02;;A61K38/18;;C07K14/485,514/18.2;;514/9.2;;530/399;;930/120,28,28,140-326-549-830-789;;057-370-081-506-982;;014-739-166-664-338;;046-213-659-127-738;;109-838-506-733-044;;047-034-187-679-149;;031-087-211-663-859;;012-153-934-281-639;;056-772-122-954-630;;021-687-257-691-448;;001-288-716-224-846;;017-347-345-261-813;;058-498-162-092-725;;020-376-210-796-117;;051-320-944-751-630;;068-261-285-048-481;;001-551-359-637-313;;036-878-033-081-911;;031-046-804-582-359;;032-435-118-782-567;;005-520-333-818-806;;046-727-902-354-198;;013-080-869-629-310;;015-711-901-873-374;;005-579-179-221-679;;012-177-818-988-764;;135-189-263-983-537;;038-640-408-064-257,15952441;;10.1086/383266;;15306983;;10.1111/j.1742-481x.2006.00237.x;;pmc7951497;;16984579;;9753192;;10.1002/(sici)1097-4547(19980915)53:6<645::aid-jnr2>3.0.co;2-5;;12357247;;10.1038/nm781;;10416991;;10.1111/j.1750-3639.1999.tb00539.x;;pmc8098555;;14515331;;10.1002/glia.10280;;10.1080/0010751031000095107;;10.1210/en.140.7.3063;;10385398;;10.1210/endo.140.7.6754;;pmc1602279;;10.1016/s0002-9440(10)63151-3;;14742267;;10.1097/00005072-199805000-00006;;9596413;;12739742;;10.1007/bf03345143;;12962024;;15269225;;10.1152/jn.00352.2004;;10.1111/j.1460-9568.2004.03606.x;;15355312;;15196666;;10.1016/j.neulet.2004.04.086;;14734521;;10.1084/jem.20031677;;pmc2211762;;10.1016/s1074-7613(04)00111-6;;15142520;;12376594;;10.1126/science.1075958;;10.1146/annurev.immunol.21.120601.141122;;15032588;;10.1210/en.2002-220261;;12239123;;12663929;;10.1385/jmn:20:1:1;;10.1530/eje.0.1490377;;14585082;;10.1016/0196-9781(91)90115-6;;1923940;;10.1016/s0014-4827(04)00080-1;;15149844;;10.1016/j.yexcr.2004.02.007;;10.1016/j.mcn.2004.01.003;;15207849;;pmc6573198;;10.1523/jneurosci.17-15-05820.1997;;9221780;;pmc6792940;;9482798;;10.1523/jneurosci.18-06-02118.1998;;10.1016/j.brainres.2005.05.050;;15993864,"Aring et al (2005; Am Fam Physician; 71: 2123-2128).;;Ulbrecht et al (2004. Clinical Infectious Diseases. 39(2): S73-82).;;Acosta et al, 2006. International Wound Journal. 3(3): 232-239.;;Bianchi, et al., ""Interleukin-1 and Nociception in the Rat"", Journal of Neuroscience Research, 53:645-650 (1998).;;John, et al., ""Multiple Sclerosis: Re-Expression of a Developmental Pathway that Restricts Oligodendrocyte Maturation"", Nature Medicine, 8(10):1115-1121(2002).;;Mehler, et al., ""Postnatal Cerebral Cortical Multipotent Progenitors: Regulatory Mechanisms and Potential Role in the Development of Novel Neural Regenerative Strategies"", Brain Pathology, 9(3):515-526(1999).;;Wilson, et al., ""Human Oligodendrocyte Precursor Cells in Vitro: Phenotypic Analysis and Differential Response to Growth Factors"", GLIA, 44(2):153-165(2003).;;Ye, et al., ""Insulin-Like Growth Factor I Protects Oligodendrocytes from Tumor Necrosis Factor-alpha-Induced Injury"", Endocrinology, 140(7):3063-3072(1999).;;Ito, et al., ""Collapse and Restoration of MHC Class-I-Dependent Immune Privilege"", American Journal of Pathology, 164(2):623-634(2004).;;Li, et al., ""Chronic Relapsing Experimental Autoimmune Encephalomyelitis: Effects of Insulin-Like Growth Factor-I Treatment on Clinical Deficits, Lesion Severity, Glial Responses, and Blood Brain Barrier Defects"", Journal of Neuropathology and Experimental Neurology, 57(5):426-438(1998).;;Martins, et al., ""GH-releasing Peptide (GHRP-6)-Induced ACTH Release in Patients with Addison's Disease: Effect of Glucocorticoid Withdrawal"", J. Endocrinaol. Invest., 26(2):143-147(2003).;;Oishi et al., ""Steroid Therapy for Multiple Sclerosis"", Nippon Rinsho, 61(8):1361-1366(2003).;;Thorne, et al., ""Diffusion of Epidermal Growth Factor in Rat Brain Extracellular Space Measured by Integrative Optical Imaging"", J. Neurophysiology, 92(6):3471-3481(2004).;;Crang et al., ""The Remyelinating Potential and in Vitro Differentiation of MOG-expressing Oligodendrocyte Precursors Isolated from the Adult Rat CNS"", European Journal of Neuroscience, 20(6):1445-1460(2004).;;Wang et al., ""Infusion of Epidermal Growth Factor and Basic Fibroblast Growth Factor into the Striatum of Parkinsonian Rates Leads to in Vitro Proliteration and Differentiation of Adult Neural Progenitor Cells"", Neuroscience Letter, 364(3):154-158(2004).;;Gotter, et al., ""Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-Specific Genes Colocalized in Chromosomal Clusters"", Journal of Experimental Medicine, 199(2):155-166(2004).;;Mathis et al., ""Back to Central Tolerance"", Immunity, 20:509-516(2004).;;Anderson et al., ""Profection of an Immunological Self Shadow Within the Thymus by the Aire Protein"", Science, 298:1395-1400(2002).;;Sakaguchi et al., ""Naurally Arising CD4+ Regulatory T Cells for Immunological Self-Tolerance and Negative Control of Immune Responses"", Annual Review of Immunology, 22:531-562(2004).;;Frago et al., ""Growth Hormone (GH) and GH-Releasing Peptide-6 Increase Brain Insulin-Like Growth Factor-I Expression and Activate Intracellular Signaling Pathways Involved in Neuroprotection"", Endocrinology, 143:10:4113-4122(2002).;;Harvey et al., ""Neural Growth Hormone: An Update"", Journal of Molecular Neuroscience:MN, 20:1:1-14(2003).;;Schneider et al., ""Central Effects of the Somatotropic System"", European Journal of Endocrinology, 149:5:377-392 (2003).;;Plata-Salaman, C.R., ""Epidermal Growth Factor and the Nervous System"", Peptides, Elsevier, Amsterdam, US, 12:3:653-663(1991).;;Knapp et al., ""Epidermal Growth Factor Promotes Oligodendrocyte Process Formation and Regrowth After Injury"", Experimental Cell Research, 296:2:135-144(2004).;;Raineteau et al., ""Neurogenesis in Hippocampal Slice Cultures"", Molecular and Cellular Neuroscience, 26:2:241-250 (2004).;;Kuhn et al., ""Epidermal Growth Factor and Fibroblast Growth Factor-2 Have Different Effects on Neural Progenitors in the Adult Rat Brain"", Journal of Neuroscience, 17:15:5820-5829(1997).;;Arsenijevic et al., ""Insulin-Like Growth Factor-I is a Differentiation Factor for Postmitotic CNS Stem Cell-Derived Neural Precursors: Distinct Actions from those of Brain-Derived Neurotrophic Factor"", Journal of Neuroscience, 18:6:2118-2128(1998).;;Rom et al., ""Glutamate Receptor Antagonists and Growth Factors Modulate Dentate Granule Cell Neurogenesis in Organotypic, Rat Hippocampal Slice Cultures"", Brain Research, 1051:1-2:35-49(2005).",ACTIVE
187,MX,A,MX 2009003678 A,011-778-487-084-10X,2009-04-22,2009,MX 2009003678 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY.,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,CT INGENIERIA GENETICA BIOTECH,UBIETA GOMEZ RAIMUNDO;;HERRERA MARTINEZ LUIS SATURNINO;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;GARCIA DEL BARCO HERRERA DIANA;;GONZALEZ BLANCO SONIA;;BERLANGA ACOSTA JORGE AMADOR;;SAEZ MARTINEZ VIVIAN MARIA;;FERNANDEZ MONTEQUIN JOSE IGNACIO,,https://lens.org/011-778-487-084-10X,Patent Application,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/00;;A61P25/00,,0,0,,,,ACTIVE
188,EP,A1,EP 2075004 A1,036-475-079-535-484,2009-07-01,2009,EP 07817382 A,2007-10-01,CU 2007000018 W;;CU 20060192 A,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,"The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensitive-motor neuropathy, as well as in ischemic neuritis.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNAC;;HERRERA MARTINEZ LUIS SATURNIN;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/036-475-079-535-484,Patent Application,yes,0,3,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61P25/00,,0,0,,,,ACTIVE
189,WO,A1,WO 2008/040260 A1,028-541-506-689-772,2008-04-10,2008,CU 2007000018 W,2007-10-01,CU 20060192 A,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,CT INGENIERIA GENETICA BIOTECH;;FERNANDEZ MONTEQUIN JOSE IGNAC;;HERRERA MARTINEZ LUIS SATURNIN;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,FERNANDEZ MONTEQUIN JOSE IGNAC;;HERRERA MARTINEZ LUIS SATURNIN;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/028-541-506-689-772,Patent Application,yes,11,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61P25/00;;A61K38/00,,8,7,046-213-659-127-738;;029-657-802-659-747;;050-472-351-713-328;;113-005-658-363-263;;004-407-203-255-629;;030-441-701-622-120;;062-680-933-948-970,9753192;;10.1002/(sici)1097-4547(19980915)53:6<645::aid-jnr2>3.0.co;2-5;;15609460;;10.1016/j.diabres.2004.04.008;;12164406;;8799632;;10.2337/diacare.19.7.751;;10.1016/s1056-8727(97)00121-9;;9647338;;10480774;;10.2337/diacare.22.8.1296;;pmc209283;;11342572;;10.1172/jci12188,"BIANCHI, M; DIB, BASSAM; PANERAI, A.: ""Interleukin-1 and Noniception in the Rat"", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 53, 1998, pages 645 - 650, XP002466080;;SADIKOT SM; NIGAM A; DAS S ET AL.: ""The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS)"", DIABETES RES CLIN PRACT, vol. 66, 2004, pages 301 - 7;;ASHOK S; RAMU M; DEEPA R ET AL.: ""Prevalence of neuropathy in type 2 diabetes patients attending diabetes center in South India"", J ASSOC PHYSICIANS INDIA, vol. 50, 2002, pages 546 - 50;;LEVITT NS; STANSBERRY KB; WYCHANCK S ET AL.: ""Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM"", DIABETES CARE, vol. 19, 1996, pages 751 - 54;;OH SJ.: ""Nerve conduction in polyneuropathies"", 1993, WILLIAMS AND WILKINS, article ""Clinical electromyography: nerve conduction studies"", pages: 579 - 91;;DIDANGELOS TP; KARAMITSOS DT; ATHYROS VG ET AL.: ""Effect of Aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy"", J DIABETES COMPLICATIONS, vol. 12, 1998, pages 201 - 7;;ZIEGLER D; HANEFELD M; RUHNAU KJ ET AL.: ""Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7 month multicenter randomized controlled trial (ALADIN III study). ALADIN III study group. Alpha-lipoic acid in diabetic neuropathy"", DIABETES CARE, vol. 22, 1999, pages 1296 - 301;;SCHRATZBERGER P; WALTER DH; RITTIG K ET AL.: ""Reversal of experimental diabetic neuropathy by VEGF gene transfer"", J CLIN INVEST, vol. 107, 2001, pages 1083 - 92",PENDING
190,AU,B2,AU 2007/304640 B2,079-320-772-998-472,2013-01-17,2013,AU 2007/304640 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,CT INGENIERIA GENETICA BIOTECNOLOGIA,UBIETA GOMEZ RAIMUNDO;;HERRERA MARTINEZ LUIS SATURNINO;;GARCIA DEL BARCO HERRERA DIANA;;GUILLEN NIETO GERARDO ENRIQUE;;GONZALEZ BLANCO SONIA;;BERLANGA ACOSTA JORGE AMADOR;;FERNANDEZ MONTEQUIN JOSE IGNACIO;;CIBRIAN VERA DANAY;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/079-320-772-998-472,Granted Patent,no,1,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/00;;A61P25/00,,0,0,,,,INACTIVE
191,AU,A1,AU 2007/304640 A1,130-277-999-469-440,2008-04-10,2008,AU 2007/304640 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy,,CT INGENIERIA GENETICA BIOTECH,HERRERA DIANA GARCIA DEL BARCO;;VERA DANAY CIBRIAN;;MONTEQUIN JOSE IGNACIO FERNAND;;MARTINEZ VIVIAN MARIA SAEZ;;NIETO GERARDO ENRIQUE GUILLEN;;MARTINEZ LUIS SATURNINO HERRERA;;GOMEZ RAIMUNDO UBIETA;;ACOSTA JORGE AMADOR BERLANGA;;BLANCO SONIA GONZALEZ,,https://lens.org/130-277-999-469-440,Patent Application,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/00;;A61P25/00,,0,0,,,,INACTIVE
192,DK,T3,DK 2075004 T3,125-523-562-411-828,2012-05-14,2012,DK 07817382 T,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,Anvendelse af epidermal vækstfaktor til morphofunktionel genoprettelse af perifere nerver ved diabetisk neuropati,,CT INGENIERIA GENETICA BIOTECH,HERRERA MARTINEZ LUIS SATURNINO;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;FERNANDEZ MONTEQUIN JOSE IGNACIO;;BERLANGA ACOSTA JORGE AMADOR;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/125-523-562-411-828,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61P25/00,,0,0,,,,ACTIVE
193,CA,C,CA 2665117 C,028-844-713-138-154,2015-04-14,2015,CA 2665117 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/028-844-713-138-154,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/00;;A61P25/00,,0,0,,,,INACTIVE
194,CN,B,CN 101573130 B,127-780-133-488-683,2012-10-31,2012,CN 200780042215 A,2007-10-01,CU 2007000018 W;;CU 20060192 A,2006-10-03,Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,CT INGENIERIA GENETICA BIOTECH,IGNAC FERNANDEZ MONTEQUIN JOSE;;SATURNIN HERRERA MARTINEZ LUIS;;AMADOR BERLANGA ACOSTA JORGE;;DIANA GARCIA DEL BARCO HERRERA;;DANAY CIBRIAN VERA;;ENRIQUE GUILLEN NIETO GERARDO;;RAIMUNDO UBIETA GOMEZ;;SONIA GONZALEZ BLANCO;;MARIA SAEZ MARTINEZ VIVIAN,,https://lens.org/127-780-133-488-683,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/00;;A61P25/00,,0,0,,,,ACTIVE
195,PT,E,PT 2075004 E,046-076-614-182-25X,2012-05-02,2012,PT 07817382 T,2007-10-01,CU 20060192 A,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,,CT INGENIERIA GENETICA BIOTECH,NIETO GERARDO ENRIQUE GUILLEN;;VERA DANAY CIBRIAN;;MARTINEZ VIVIAN MARIA SAEZ;;ACOSTA JORGE AMADOR BERLANGA;;MONTEQUIN JOSE IGNACIO FERNANDEZ;;MARTINEZ LUIS SATURNINO HERRERA;;HERRERA DIANA GARCIA DEL BARCO;;GOMEZ RAIMUNDO UBIETA;;BLANCO SONIA GONZALEZ,,https://lens.org/046-076-614-182-25X,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61P25/00,,0,0,,,,ACTIVE
196,CU,B6,CU 23526 B6,062-725-284-756-632,2010-05-19,2010,CU 20060192 A,2006-10-03,CU 20060192 A,2006-10-03,MÉTODO PARA LA RESTAURACIÓN MORFOFUNCIONAL DE NERVIOS PERIFÉRICOS EN LA NEUROPATÍA DIABÉTICA,"La presente invención es aplicable en medicina humana, y se relaciona con un método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética de tipo sensitivo motora, dolorosa; y las manifestaciones de neuritis isquémica, mediante la infiltración del Factor de Crecimiento Epidérmico (del inglés Epidermal Growth Factor, abreviado EGF). También incluye una composición que comprende EGF, el que puede ser formulado junto a anestésicos o analgésicos, o encapsulado en microesferas; que se administra mediante infiltración en la periferia de troncos y/o ganglios neviosos, para la restauración morfofuncional de nervios periféricos en la neuropatía sensitivo-motora, dolorosa, así como las manifestaciones de neuritis isquémica.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNASIO;;SAEZ MARTINEZ VIVIAN MARIA;;CIBRIAN VERA DANAY;;BERLANGA ACOSTA JORGE AMADOR;;UBIETA GOMEZ RAIMUNDO;;GARCIA DEL BARCO HERRERA DIANA;;GONZALEZ BLANCO SONIA;;GUILLEN NIETO GERARDO ENRIQUE;;HERRERA MARTINEZ LUIS SATURNINO,,https://lens.org/062-725-284-756-632,Limited Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K9/14;;A61K9/16;;A61K9/50;;A61K38/18;;C07K14/00;;C07K14/435,,0,0,,,,ACTIVE
197,ZA,B,ZA 200902311 B,128-348-889-815-06X,2010-04-28,2010,ZA 200902311 A,2009-04-02,CU 20060192 A,2006-10-03,Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy,,CT DE INGENIERIA GENETICAL Y B,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/128-348-889-815-06X,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K/;;A61P/,,0,0,,,,ACTIVE
198,CA,A1,CA 2665117 A1,073-767-295-817-087,2008-04-10,2008,CA 2665117 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,The invention relates to human medicine and to the use of epidermal growt h factor (EGF) for preparing a pharmaceutical composition which is administe red by infiltration into the periphery of nerve ganglia and/or trunks for th e morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention al so includes a composition containing EGF which can be formulated together wi th anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painfu l sensitive-motor-type diabetic neuropathy and the manifestations of ischemi c neuritis.,CT INGENIERIA GENETICA BIOTECH,GUILLEN NIETO GERARDO ENRIQUE;;BERLANGA ACOSTA JORGE AMADOR;;UBIETA GOMEZ RAIMUNDO;;CIBRIAN VERA DANAY;;HERRERA MARTINEZ LUIS SATURNINO;;GONZALEZ BLANCO SONIA;;GARCIA DEL BARCO HERRERA DIANA;;SAEZ MARTINEZ VIVIAN MARIA;;FERNANDEZ MONTEQUIN JOSE IGNAC,,https://lens.org/073-767-295-817-087,Patent Application,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/00;;A61P25/00,,0,0,,,,INACTIVE
199,US,A1,US 2010/0136062 A1,169-199-640-489-909,2010-06-03,2010,US 44383707 A,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anaesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2009-12-01),https://lens.org/169-199-640-489-909,Patent Application,yes,3,9,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61K9/00;;A61P25/02;;C07K14/485,424/400;;530/324;;514/12,2,2,057-370-081-506-982;;014-739-166-664-338,10.1086/383266;;15306983;;10.1111/j.1742-481x.2006.00237.x;;pmc7951497;;16984579,"Ulbrecht et al (2004. Clinical Infectious Diseases. 39(2): S73-82).;;Acosta et al, 2006. International Wound Journal. 3(3): 232-239",ACTIVE
200,EP,B1,EP 2075004 B1,096-895-705-177-387,2012-02-08,2012,EP 07817382 A,2007-10-01,CU 2007000018 W;;CU 20060192 A,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,,CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/096-895-705-177-387,Granted Patent,yes,11,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61P25/00,,1,0,,,"BIANCHI, M; DIB, BASSAM; PANERAI, A.: ""Interleukin-1 and Noniception in the Rat"" JOURNAL OF NEUROSCIENCE RESEARCH, vol. 53, 1998, pages 645-650, XP002466080",ACTIVE
201,BR,A,BR PI0513136 A,106-685-274-336-678,2008-04-29,2008,BR PI0513136 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,composição farmacêutica contendo fragmentos de polipeptìdeo das serralisinas,"COMPOSIçãO FARMACêUTICA CONTENDO FRAGMENTOS DE POLIPEPTìDEO DAS SERRALISINAS. A presente invenção refere-se a uma composição capaz de inibir o crescimento de células tumorais de diferentes origens histológicas e de células endoteliais ativadas. Os componentes das ditas composições são fragmentos de polipeptídeo das serralisinas, correspondendo ao fragmento C-terminal, da metionina interna até a extremidade da molécula, que poderiam ser combinados entre eles e opcionalmente com as prodigiosinas que potencializam os efeitos antitumorais da composição. As prodigiosinas na composição poderiam estar em uma concentração de 0,1-100 nM. A ação antiproliferativa desta composição é mediada através de mecanismo apoptótico. Sua administração ""in vivo"" tem efeito antitumoral, antiangiogênico e protetor contra tumores malignos.",CT INGENIERIA GENETICA BIOTECH,PEREZ MARIA DEL CARMEN ABRAHAN;;GONZALEZ JESUS REYES;;RIOS GLORIA VELIZ;;DIAZ EDUARDO MARTINEZ;;GONZALEZ CARIDAD ANAIS GASMURI;;SUAREZ JOSE GARCIA;;ROMERO MONICA BEQUET;;LOPEZ LUIS JAVIER GONZALEZ;;SERRA LILA ROSA CASTELLANOS;;SOSA MANUEL SELMAN-HOUSEIN;;RIERA RAUL GOMEZ;;COWLEY JORGE VICTOR GAVILONDO,,https://lens.org/106-685-274-336-678,Patent Application,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,DISCONTINUED
202,AU,A1,AU 2005/262159 A1,076-077-333-349-298,2006-01-19,2006,AU 2005/262159 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,Pharmaceutical composition containing polypeptide fragments of serralysins,,CT INGENIERIA GENETICA BIOTECH,RIERA RAUL GOMEZ;;DIAZ EDUARDO MARTINEZ;;SUAREZ JOSE GARCIA;;SELMAN-HOUSEIN SOSA MANUEL;;GONZALEZ CARIDAD ANAIS GASMURI;;PEREZ MARIA DEL CARMEN ABRAHAN;;ROMERO MONICA BEQUET;;COWLEY JORGE VICTOR GAVILONDO;;SERRA LILA ROSA CASTELLANOS;;GONZALEZ JESUS REYES;;LOPEZ LUIS JAVIER GONZALEZ;;RIOS GLORIA VELIZ,,https://lens.org/076-077-333-349-298,Patent Application,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,INACTIVE
203,CA,A1,CA 2572984 A1,111-265-763-094-681,2006-01-19,2006,CA 2572984 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS,,CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CAR;;BEQUET ROMERO MONICA;;GARCIA SUAREZ JOSE;;CASTELLANOS SERRA LILA ROSA;;GONZALEZ LOPEZ LUIS JAVIER;;VELIZ RIOS GLORIA;;GASMURI GONZALEZ CARIDAD ANAIS;;REYES GONZALEZ JESUS;;SELMAN-HOUSEIN SOSA MANUEL;;MARTINEZ DIAZ EDUARDO;;GAVILONDO COWLEY JORGE VICTOR;;GOMEZ RIERA RAUL,,https://lens.org/111-265-763-094-681,Patent Application,no,0,0,30,30,16,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,INACTIVE
204,CU,A1,CU 23475 A1,109-042-011-817-787,2009-12-17,2009,CU 20040147 A,2004-07-08,CU 20040147 A,2004-07-08,COMPOSICIÓN FARMACÉUTICA CONTENIENDO FRAGMENTOS POLIPEPTÍDICOS DE SERRALISINAS,"La presente invención está relacionada con una composición capaz de inhibir el crecimiento de células tumorales de diferentes orígenes histológicos y de célulasendoteliales activadas. Lo scomponentes de dicha composición son fragmentos polipeptídicos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molécula los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto antitumoral de la composición. Las prodigiosinas en la composición pueden estar a ubna concentración de 0.1-100nM. La acción anti-proliferativa de la composición está mediada por mecanismos apoptóticos. Su administración "" in vivo"" tiene efecto anti-tumoral, antiangiogénico y protecdtor contra tumores malignos.",CT INGENIERIA GENETICA BIOTECH,GONZALEZ LOPEZ LUIS JAVIER;;GASMURI GONZALEZ CARIDAD ANAIS;;MARTINEZ DIAZ EDUARDO;;BEQUET ROMERO MONICA;;GOMEZ RIERA RAUL;;REYES GONZALEZ JESUS;;ABRAHANTES PEREZ MARIA DEL CARMEN;;SELMAN-HOUSEIN SOSA MANUEL;;VELIZ RIO GLORIA;;GAVILONDO COWLEY JORGE VICTOR;;CASTELLANOS SERRA LILA ROSA;;GARCIA SUAREZ JOSE,,https://lens.org/109-042-011-817-787,Limited Patent,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K9/00;;A61K39/00,,0,0,,,,EXPIRED
205,US,A1,US 2011/0218138 A1,180-668-601-873-956,2011-09-08,2011,US 63188005 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,Pharmaceutical composition containing polypeptide fragments of serralysins,"The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.",ABRAHANTES PEREZ MARIA DEL CARMEN;;GONZALEZ JESUS REYES;;RIOS GLORIA VELIZ;;DIAZ EDUARDO MARTINEZ;;GASMURI GONZALEZ CARIDAD ANAIS;;SUAREZ JOSE GARCIA;;ROMERO MONICA BEQUET;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LISA ROSA;;SOSA MANUEL SELMAN-HOUSEIN;;RIERA RAUL GOMEZ;;GAVILONDO COWLEY JORGE VICTOR,ABRAHANTES PEREZ MARIA DEL CARMEN;;GONZALEZ JESUS REYES;;RIOS GLORIA VELIZ;;DIAZ EDUARDO MARTINEZ;;GASMURI GONZALEZ CARIDAD ANAIS;;SUAREZ JOSE GARCIA;;ROMERO MONICA BEQUET;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LISA ROSA;;SOSA MANUEL SELMAN-HOUSEIN;;RIERA RAUL GOMEZ;;GAVILONDO COWLEY JORGE VICTOR,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2007-08-07),https://lens.org/180-668-601-873-956,Patent Application,yes,1,2,30,30,16,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/00;;A61P35/00;;A61P37/02;;A61P37/04;;C07K14/24,514/2.3;;514/19.2;;530/350;;514/13.3;;514/18.9,0,0,,,,INACTIVE
206,WO,A3,WO 2006/005268 A3,199-218-505-331-040,2006-03-09,2006,CU 2005000003 W,2005-07-05,CU 20040147 A,2004-07-08,PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS,"The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours.",CT INGENIERIA GENETICA BIOTECH;;ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/199-218-505-331-040,Search Report,yes,4,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,PENDING
207,ES,T3,ES 2389126 T3,110-304-684-061-200,2012-10-23,2012,ES 05762122 T,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,Composición farmacéutica antitumoral que contiene fragmentos polipeptídicos de serralisinas,"La presente invención está relacionada con una composición capazde inhibir el crecimiento de células tumorales de diferentes orígenes histológicos y de células endoteliales activadas. Los componentes de dicha composición son fragmentos polipeptídicos de Serralisinas, correspondientes al fragmento C-terminal, a partir de lametionina interna de la secuencia hasta el final de la molécula,los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto anti-tumoral de la composición. Las prodigiosinas en la composición pueden estar a una concentración de 0.1 - 100 nM. La acción anti-proliferativa de la composición está mediada por mecanismos apoptóticos. Su administración ""in vivo"" tiene efecto antitumoral, antiangiogénico y protector contra tumores malignos.",CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CARMEN;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/110-304-684-061-200,Granted Patent,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61P31/04;;A61K38/16;;A61P35/00;;C07K14/265,,0,0,,,,ACTIVE
208,EP,B1,EP 1787653 B1,038-308-792-917-693,2012-06-06,2012,EP 05762122 A,2005-07-05,CU 2005000003 W;;CU 20040147 A,2004-07-08,Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins,,CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CARMEN;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/038-308-792-917-693,Granted Patent,yes,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,2,2,053-502-667-369-985;;011-948-186-710-428,11015311;;pmc1572367;;10.1038/sj.bjp.0703614;;10.1179/joc.2006.18.2.172;;16736886,"MONTANER B ET AL.: ""Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines"", BRITISH JOURNAL OF PHARMACOLOGY, vol. 3, no. 131, October 2000 (2000-10-01), pages 585 - 593, XP001091105;;ABRAHANTES-PEREZ M C ET AL.,: ""Cytotoxic proteins combined with prodigiosin obtained from Serratia marcescens have both broad and selective cytotoxic activity on tumor cells"", JOURNAL OF CHEMOTHERAPY, vol. 2, no. 18, April 2006 (2006-04-01), pages 172 - 181, XP008111361",ACTIVE
209,MX,A,MX 2007000339 A,112-538-363-940-815,2007-03-12,2007,MX 2007000339 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS.,"The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours.",CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;MARTINEZ DIAZ EDUARDO;;GARCIA SUAREZ JOSE;;VELIZ RIOS GLORIA;;GASMURI GONZALEZ CARIDAD ANAIS;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILIA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/112-538-363-940-815,Patent Application,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/00;;A61P35/00;;A61P31/04;;C07K14/265,,0,0,,,,ACTIVE
210,US,B2,US 8076297 B2,130-341-606-066-063,2011-12-13,2011,US 63188005 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,Pharmaceutical composition containing polypeptide fragments of serralysins,"The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors.",PEREZ MARIA DEL CARMEN ABRAHANTES;;GONZALEZ JESUS REYES;;RIOS GLORIA VELIZ;;DIAZ EDUARDO MARTINEZ;;GONZALEZ CARIDAD ANAIS GASMURI;;SUAREZ JOSE GARCIA;;ROMERO MONICA BEQUET;;LOPEZ LUIS JAVIER GONZALEZ;;SERRA LILA ROSA CASTELLANOS;;SOSA MANUEL SELMAN-HOUSEIN;;RIERA RAUL GOMEZ;;COWLEY JORGE VICTOR GAVILONDO;;CT INGENIERIA GENETICA BIOTECH,PEREZ MARIA DEL CARMEN ABRAHANTES;;GONZALEZ JESUS REYES;;RIOS GLORIA VELIZ;;DIAZ EDUARDO MARTINEZ;;GONZALEZ CARIDAD ANAIS GASMURI;;SUAREZ JOSE GARCIA;;ROMERO MONICA BEQUET;;LOPEZ LUIS JAVIER GONZALEZ;;SERRA LILA ROSA CASTELLANOS;;SOSA MANUEL SELMAN-HOUSEIN;;RIERA RAUL GOMEZ;;COWLEY JORGE VICTOR GAVILONDO,CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA (2007-08-07),https://lens.org/130-341-606-066-063,Granted Patent,yes,4,1,30,30,16,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/43;;C12N9/52,514/19.3;;514/21.2;;435/220,0,0,,,,INACTIVE
211,EP,A2,EP 1787653 A2,189-885-986-410-44X,2007-05-23,2007,EP 05762122 A,2005-07-05,CU 2005000003 W;;CU 20040147 A,2004-07-08,Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins,"The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1 - 100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's ""in vivo"" administration has antitumoral, antiangiogenic and protective effect against malignant tumors.",CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/189-885-986-410-44X,Patent Application,yes,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,ACTIVE
212,KR,A,KR 20070042542 A,028-867-997-369-801,2007-04-23,2007,KR 20077002589 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS,,CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/028-867-997-369-801,Patent Application,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,ACTIVE
213,AR,A1,AR 039982 A1,195-683-860-358-019,2005-03-09,2005,AR P030101613 A,2003-05-08,CU 20020091 A,2002-05-08,"COMPOSICION VACUNAL CONTRA LAS ALERGIAS, METODO PARA SU OBTENCION Y EMPLEO EN EL TRATAMIENTO DE LAS MISMAS","Empleo de adyuvantes o portadores para modular la respuesta inmunológica hacia los alergenos. El objetivo técnico que se persigue es obtener una preparación farmacéutica de uso terapéutico o profiláctico utilizando proteoliposomas bacterianos, la cual al ser aplicada en individuos alérgicos transforma la respuesta alérgica Th2 e IgE dependiente, hacia una respuesta Th1 protectora; así como logre prevenir la aparición y el desarrollo de alergias en individuos aún no alérgicos. La composición vacunal consiste en proteoliposomas de bacterias Gram-negativas acoplados a alergenos y opcionalmente otros antígenos o adyuvantes. Se provee el método para su obtención y se incluye el esquema de 2 dosis para la inmunización con dicha composición vacunal.",INST FINLAY CT DE INVESTIGACIO;;CT NAC BIOPREPARADOS,PEREZ MARTIN OLIVER GERMAN;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADO GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;ZAYAS VIGNIER CARIDAD;;SIERRA GONZALEZ VICTORIANO GUSTAVO;;LASTRE GONZALEZ MIRIAM DE SAN JUAN BOSCO;;FACENDA RAMOS ELISA;;RODRIGUEZ MARTINEZ CLAUDIO,,https://lens.org/195-683-860-358-019,Patent Application,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,0,0,,,,PENDING
214,AU,B2,AU 2005/262159 B2,125-927-479-955-307,2011-08-18,2011,AU 2005/262159 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,Pharmaceutical composition containing polypeptide fragments of serralysins,"The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours.",CT INGENIERIA GENETICA BIOTECNOLOGIA,RAUL GOMEZ RIERA;;EDUARDO MARTINEZ DIAZ;;JOSE GARCIA SUAREZ;;MANUEL SELMAN-HOUSEIN SOSA;;ANAIS GASMURI GONZALEZ CARIDAD;;CARMEN ABRAHANTES PEREZ MARIA DEL;;MONICA BEQUET ROMERO;;VICTOR GAVILONDO COWLEY JORGE;;ROSA CASTELLANOS SERRA LILA;;JESUS REYES GONZALEZ;;JAVIER GONZALEZ LOPEZ LUIS;;GLORIA VELIZ RIOS,,https://lens.org/125-927-479-955-307,Granted Patent,no,4,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,C07K14/265;;A61K38/16;;A61P31/04;;A61P35/00,,2,2,011-948-186-710-428;;053-502-667-369-985,10.1179/joc.2006.18.2.172;;16736886;;11015311;;pmc1572367;;10.1038/sj.bjp.0703614,"ABRAHANTES-PEREZ M 0 C ET AL.,: ""Cytotoxic proteins combined with prodigiosin obtained from Serratia marcescens have both broad and selective cytotoxic activity on tumor cells"" JOURNAL OF CHEMOTHERAPY, vol. 2, no. 18, April 2006 (2006-04),;;MONTANER B ET AL.: ""Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines"" BRITISH JOURNAL OF PHARMACOLOGY, vol. 3, no. 131, October 2002 (2002-10), pages 585-593",INACTIVE
215,MX,A,MX 2015014433 A,090-124-239-378-662,2017-04-13,2017,MX 2015014433 A,2015-10-14,MX 2015014433 A,2015-10-14,AUTOMATED SYSTEM FOR SIMULATING THE HUMAN DIGESTIVE TRACT.,"The present invention relates to an automated system for simulating the human digestive tract, in which digestion in the human digestive tract is simulated and in which it is possible to: control the operation times of each reactor (stomach, small intestine, ascending colon, transverse colon, descending colon); quantify and control gases; monitor and control temperature; monitor and control pH; and establish an interface with a user for the input and modification of operational data, obtaining a simulation system that closely resembles human physiology.",ATQIA S DE R L DE C V,MARISELA GONZALEZ AVILA;;BLANCA ELIZABETH RUIZ ALVAREZ;;PAOLA VAZQUEZ CASTRO;;FERNANDO VAZQUEZ GARCIA;;JOSUE ROMAN MARTINEZ MIRELES;;SILVESTRE DE JESUS CHAVEZ BAUTISTA;;JORGE ENRIQUE PLIEGO SANDOVAL,CENTRO DE INVESTIGACION Y ASISTENCIA EN TECNOLOGIA (2019-06-14),https://lens.org/090-124-239-378-662,Patent Application,no,0,0,4,4,0,G09B23/30,G09B23/10,,0,0,,,,ACTIVE
216,WO,A2,WO 2006/005268 A2,062-887-849-125-814,2006-01-19,2006,CU 2005000003 W,2005-07-05,CU 20040147 A,2004-07-08,PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS,"The invention relates to a composition that can inhibit the growth of tumour cells of different histological origins and activated endothelial cells. The components of said composition are polypeptide fragments of serralysins, corresponding to the C-terminal fragment, from the internal methionine of the sequence to the end of the molecule, which can be combined with one another and, optionally, with prodigiosins which potentiate the anti-tumour effect of the composition. The prodigiosins in the composition can be at a concentration of between 0.1 - 100 nM. The anti-proliferative action of the composition is provided by apoptotic mechanisms. The in vivo administration of the inventive composition has an anti-tumour effect, an anti-angiogenic effect and protects against malignant tumours.",CT INGENIERIA GENETICA BIOTECH;;ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/062-887-849-125-814,Patent Application,yes,0,7,30,30,16,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61P31/04;;A61K38/16;;A61P35/00;;C07K14/265,,7,6,109-015-386-988-618;;092-969-744-367-048;;013-532-356-605-668;;061-041-584-151-025;;003-032-611-481-807;;039-406-182-351-309,10.1038/sj.cdd.4400345;;10200476;;9721092;;10.1126/science.281.5381.1309;;11782314;;10.1016/s1534-5807(01)00116-2;;10.1126/science.2416056;;2416056;;10216103;;10.1182/blood.v93.9.3064;;11969310;;10.1006/mvre.2001.2389,"HERNANDEZ, P.; MERINA, N.; LOPEZ-OCEJO, O.; ARANA, M. J., BIOCHEM BIOPHYS RES COMMUN, vol. 270, 2000, pages 119 - 124;;SOLDATENKOV, V. A.; PRASAD, S.; VOLOSHIN, Y.; DRITSCHILO, A., CELL DEATH DIFFER., vol. 5, 1998, pages 307 - 12;;GREEN, D.R.; REED, J.C., SCIENCE, vol. 28, 1998, pages 1309 - 1312;;SCORRANO, L.; ASHIYA, M.; BUTTLE, K.; WEILER, S.; OAKES, S.A.; MANNELLA, C.A.; KORSMEYER, S.J., DEV CELL., vol. 2, 2002, pages 55 - 67;;CRUM R; SZABO S; FOLKMAN J., SCIENCE, vol. 230, 1985, pages 1375 - 8;;VACCA, A.; RIBATTI, D.; PRESTA, M.; MINISCHETTTI, M.; LURLARO, M; RIA, R; ALBINI, A; BUSSOLINO, F.; DAMMAACCO, F., BLOOD, vol. 93, 1999, pages 3064;;SANZ, L.; PASCUAL, M.; MUNOZ, A.; GONZÁLEZ, M.A.; SALVADOR CH; ALVAREZ-VALLINA L., MICROVASCULAR RESEARCH, vol. 63, 2002, pages 335 - 339",PENDING
217,MX,B,MX 366432 B,002-899-076-657-019,2019-06-14,2019,MX 2015014433 A,2015-10-14,MX 2015014433 A,2015-10-14,AUTOMATED SYSTEM FOR SIMULATING THE HUMAN DIGESTIVE TRACT.,"The present invention relates to an automated system for simulating the human digestive tract, in which digestion in the human digestive tract is simulated and in which it is possible to: control the operation times of each reactor (stomach, small intestine, ascending colon, transverse colon, descending colon); quantify and control gases; monitor and control temperature; monitor and control pH; and establish an interface with a user for the input and modification of operational data, obtaining a simulation system that closely resembles human physiology.",CENTRO DE INVESTIG Y ASISTENCIA EN TECNOLOGIA Y DISENO DEL ESTADO DE JALISCO A C,MARISELA GONZALEZ AVILA;;BLANCA ELIZABETH RUIZ ALVAREZ;;PAOLA VAZQUEZ CASTRO;;FERNANDO VAZQUEZ GARCIA;;JOSUE ROMAN MARTINEZ MIRELES;;SILVESTRE DE JESUS CHAVEZ BAUTISTA;;JORGE ENRIQUE PLIEGO SANDOVAL,CENTRO DE INVESTIGACION Y ASISTENCIA EN TECNOLOGIA (2019-06-14),https://lens.org/002-899-076-657-019,Granted Patent,no,0,0,4,4,0,G09B23/30,G09B23/30,,0,0,,,,ACTIVE
218,US,B2,US 7648709 B2,033-319-329-316-695,2010-01-19,2010,US 51349303 A,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"Allergy vaccine composition, production method thereof and use of same in allergy treatment","The present invention relates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic use using bacterial proteoliposomes, which transform the allergic response Th2 and IgE when being applied in allergic individuals, toward a protector response Th1; as well as it is able to prevent the appearance and the development of allergies in individuals non-allergic yet. The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided.",LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;BRACHO GRANADO GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUSTAVO;;PEREZ LASTRE JORGE ERNESTO,LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;BRACHO GRANADO GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUSTAVO;;PEREZ LASTRE JORGE ERNESTO,,https://lens.org/033-319-329-316-695,Granted Patent,yes,1,1,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/095;;A61K39/35,424/249.1;;424/275.1;;424/282.1,4,3,131-634-223-525-790;;001-953-821-983-016;;032-333-028-128-61X,10.1067/mai.2000.104551;;10719295;;11112861;;10.1159/000024450;;10.1159/000023946;;9693268,"Slater et al., J. Allergy Clin. Immunol., 105:468-474, 2000.;;Ferrandiz et al., Abstract 175, J. Allergy Clin. Immunol., 97:226, 1996.;;Sewer et al., Int. Arch. Allergy Immunol., 123:242-248, 2000.;;Ferrandiz et al., Int. Arch. Allergy Immunol., 116:206-214, 1998.",EXPIRED
219,MY,A,MY 146106 A,051-133-896-256-454,2012-06-29,2012,MY PI20031710 A,2003-05-07,CU 20020091 A,2002-05-08,"ANTIALLERGIC VACCINE COMPOSITION, METHOD FOR ITS PREPARATION AND USE IN THE TREATMENT OF ALLERGIC DISEASES","THE PRESENT INVENTION RELATES TO THE FIELD OF IMMUNOLOGY, SPECIFICALLY WITH THE BRANCH OF IMMUNO-ALLERGY AND IN PARTICULAR WITH THE USE OF ADJUVANT OR CARRIER COMPOUNDS, CAPABLE OF MODULATING THE IMMUNE RESPONSE TO ALLERGENS. THE TECHNICAL OBJECTIVE THAT IS PURSUED IS TO OBTAIN A PHARMACEUTICAL PREPARATION OF THERAPEUTIC OR PROPHYLACTIC USE USING BACTERIAL PROTEOLIPOSOMES, WHICH TRANSFORM THE ALLERGIC RESPONSE TH2 AND IGE WHEN BEING APPLIED IN ALLERGIC INDIVIDUALS, TOWARDS A PROTECTOR RESPONSE TH1; AS WELL AS IT IS ABLE TO PREVENT THE APPEARANCE AND THE DEVELOPMENT OF ALLERGIES IN INDIVIDUALS NON-ALLERGIC YET. THE VACCINE COMPOSITION CONSISTS OF PROTEOLIPOSOMES DERIVED FROM GRAM-NEGATIVE BACTERIA COUPLED TO ALLERGENS AND OPTIONALLY CONTAINS OTHER ADJUVANTS OR ANTIGENS. THE METHOD FOR ITS PREPARATION AND AN IMMUNIZATION SCHEME OF TWO DOSES ARE PROVIDED.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT NAC BIOPREPARADOS,BOSCO LASTRE GONZALEZ MIRIAM DE SAN JUAN;;CLAUDIO RODRIGUEZ MARTINEZ;;GUSTAVO SIERRA GONZALEZ VICTORIANO;;GERMAN PEREZ MARTIN OLIVER;;IGOR BIDOT MARTINEZ;;ERNESTO PEREZ LASTRE JORGE;;RAFAEL BRACHO GRANADO GUSTAVO;;MONICA DEL CAMPO ALONSO JUDITH;;ALEIDA PEREZ LASTRE DAINERYS;;ELISA FACENDA RAMOS;;CARIDAD ZAYAS VIGNIER,,https://lens.org/051-133-896-256-454,Granted Patent,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,0,0,,,,EXPIRED
220,WO,A1,WO 2003/094964 A1,055-239-754-071-519,2003-11-20,2003,CU 0300007 W,2003-05-08,CU 20020091 A,2002-05-08,"ALLERGY VACCINE COMPOSITION, PRODUCTION METHOD THEREOF AND USE OF SAME IN ALLERGY TREATMENT","The invention relates to the field of immunology, immunoallergy and, in particular, the use of adjuvants or carriers in order to modulate the immunological response to allergens. The technical objective of the invention is: to produce a therapeutic or prophylactic pharmaceutical preparation using bacterial proteoliposomes, which, when applied to allergic individuals, transforms the Th2- and IgE-dependent allergic response into a protective Th1 response; and to prevent the appearance and development of allergies in not-yet allergic individuals. The vaccine composition consists of proteoliposomes of gram-negative bacteria coupled with allergens and, optionally, other antigens or adjuvants. The invention also relates to the method of producing the inventive vaccine composition and to the two-dose schedule for immunisation with said vaccine composition.",INST FINLAY CT DE INVESTIGACIO;;CT NAC BIOPREPARADOS;;LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUS,LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUS,,https://lens.org/055-239-754-071-519,Patent Application,yes,10,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,5,4,001-953-821-983-016;;020-210-509-713-398;;010-722-879-328-725;;032-841-286-995-362,11112861;;10.1159/000024450;;2732406;;10.1016/0091-6749(89)90447-8;;10.1034/j.1398-9995.2001.056006478.x;;11421891;;pmc2138651;;4977282;;10.1084/jem.129.6.1349,"FERRANDIZ, R.: ""Allergenic characterization of the domestic mite Dermatophagoides siboney."", LINKÖPING UNIVERSITY MEDICAL DISSERTATIONS. NUM. 531, 1997. HTTP://WWW.BIBL.LIU.SE/LIUPUBL/DISP/DISP97/MED532S.HTM, XP002248650;;SEWER ET AL., INT ARCH ALLERGY IMMUNOL, vol. 123, 2000, pages 242 - 248;;HEYMANN PW; CHAPMAN MD, J ALLERGY CLIN IMMUNOL, vol. 83, 1989, pages 1055 - 1067;;ALLERGY, vol. 56, no. 6, 2001, pages 478 - 490;;GOTSCHLICH ET AL., J. EXP. MED., vol. 129, 1969, pages 1349 - 1365",PENDING
221,AR,A1,AR 050255 A1,172-816-140-356-068,2006-10-11,2006,AR P050102834 A,2005-07-08,CU 20040147 A,2004-07-08,COMPOSICION FARMACEUTICA CONTENIENDO FRAGMENTOS POLIPEPTIDICOS DE SERRALISINAS,"La presente está relacionada con una composicion capaz de inhibir el crecimiento de células tumorales de diferentes orígenes histologicos y de células endoteliales activadas. Los componentes de dicha composicion son fragmentos polipéptidos de Serralisinas, correspondientes al fragmento C-terminal, a partir de la metionina interna de la secuencia hasta el final de la molécula, los cuales pueden combinarse entre ellos y opcionalmente con prodigiosinas que potencian el efecto anti-tumoral de la composicion. Las prodigiosinas en la composicion pueden estar a una concentracion de 0.1-100 nM. La accion anti-proliferativa de la composicion está mediada por mecanismos apoptoticos. Su administracion ""in vivo"" tiene efecto antitumoral, antiangiogénico y protector contra tumores malignos.",CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CAR;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ MARIANAO EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR;;BEQUET ROMERO MONICA,,https://lens.org/172-816-140-356-068,Patent Application,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,,,0,0,,,,ACTIVE
222,PT,E,PT 1787653 E,171-793-823-082-97X,2012-09-06,2012,PT 05762122 T,2005-07-05,CU 20040147 A,2004-07-08,ANTITUMORAL PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYSINS,,CT INGENIERIA GENETICA BIOTECH,PEREZ MARIA DEL CARMEN ABRAHANTES;;GONZALEZ JESUS REYES;;RIOS GLORIA VELIZ;;DIAZ EDUARDO MARTINEZ;;GONZALEZ CARIDAD ANAIS GASMURI;;SUAREZ JOSE GARCIA;;ROMERO MONICA BEQUET;;LOPEZ LUIS JAVIER GONZALEZ;;SERRA LILA ROSA CASTELLANOS;;SOSA MANUEL SELMAN-HOUSEIN;;RIERA RAUL GOMEZ;;COWLEY JORGE VICTOR GAVILONDO,,https://lens.org/171-793-823-082-97X,Granted Patent,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,ACTIVE
223,CA,C,CA 2572984 C,182-077-411-885-233,2014-12-09,2014,CA 2572984 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,A PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF THE SERRALYSINS,"The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralysins, corresponding to the C-terminal fragment, from the internal methionine through the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the anti-tumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1 - 100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. Its in vivo administration has anti-tumoral, anti-angiogenic and protective effect against malignant tumors.",CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CARMEN;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR,,https://lens.org/182-077-411-885-233,Granted Patent,no,0,0,30,30,16,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,INACTIVE
224,RS,B,RS 52448 B,098-487-878-689-874,2013-02-28,2013,RS P20120391 A,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,ANTITUMORAL PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDE FRAGMENTS OF SERRALYYSINS,"Farmaceutska kompozicija, naznačena time, što sadrži jedan ili nekoliko fragmenata Seralizina koji imaju aminokiselinsku sekvencu odabranu iz grupe koja sadrži SEQ. ID. No. 1, SEQ. ID. No. 2, SEQ. ID. No. 3, SEQ. ID. No. 4, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, i SEQ ID NO. 16, za primenu u indukovanju antitumorskih efekata u organizmu recipijenta, i navedeni antitumorski efekti su terapeutski ili preventivni.Prijava sadrži još 11 patentnih zahteva.",CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CARMEN;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;CASTELLANOS SERRA LILA ROSA;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR;;GARCIA SUAREZ JOSE,,https://lens.org/098-487-878-689-874,Granted Patent,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,ACTIVE
225,US,A1,US 2006/0110435 A1,170-633-213-641-675,2006-05-25,2006,US 51349303 A,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"Allergy vaccine composition, production method thereof and use of same in allergy treatment","The present invention relates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic use using bacterial proteoliposomes, which transform the allergic response Th2 and IgE when being applied in allergic individuals, toward a protector response Th1; as well as it is able to prevent the appearance and the development of allergies in individuals non-allergic yet. The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided.",LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER G;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;BRACHO GRANADO GUSTAVO R;;DEL CAMPO ALONSO JUDITH M;;PEREZ LASTRE DAINERYS A;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO G;;PEREZ LASTRE JORGE E,LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER G;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;BRACHO GRANADO GUSTAVO R;;DEL CAMPO ALONSO JUDITH M;;PEREZ LASTRE DAINERYS A;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO G;;PEREZ LASTRE JORGE E,,https://lens.org/170-633-213-641-675,Patent Application,yes,0,8,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K9/127;;A61K39/095;;A61K39/35,424/450;;424/250.1;;424/275.1,0,0,,,,EXPIRED
226,MX,A,MX 2017002123 A,086-336-291-695-155,2018-08-07,2018,MX 2017002123 A,2017-02-08,MX 2017002123 A,2017-02-08,METHOD FOR DETERMINING FAILURE CONSEQUENCES IN INDUSTRIAL FACILITIES.,"The present disclosure is related to a system and method for determining failure consequences in industrial facilities. The system comprises a memory unit, a data entry unit, a graphical interface, a central processing unit; configured together to execute an algorithm that makes possible the execution of a method for determining failure consequences in industrial facilities, comprising: The main purpose of the present invention is to establish a procedure to determine the associated costs of the possible consequences generated from faults in the components present in industrial facilities. This method is based on a mathematical model with financial focus, considering the impacts associated with an undesired event, allowing the operator to visualize by impact categories in the analyzed components and generate different scenarios to identify the variables that contribute with a higher index of affectation on the installation to be able to implement actions or measures to reduce and/or mitigate hazards. The proposed method considers the structure definition of the model, the relationship of three main impacts: Population, Environment and Business; and of three 20 basic factors: Receiver, Danger and Reduction. The consequence of the installation failure is the sum of the financial exposures by impact type. For a more specific analysis, the result can be obtained determining failure consequences from the component level, up to the installation level in economic terms.",SERVIN SOLUCIONES Y SERVICIOS INTEGRALES,LORENZO MARTINEZ GOMEZ;;JORGE JOAQUÍN CANTÓ IBÁÑEZ;;DIEGO MARTÍNEZ MARTÍNEZ DE LA ESCALERA;;JAIME CERVANTES AGUILAR;;JESÚS ESCOBAR LINARES;;GUILLERMO JAVIER MARTÍNEZ RIVERA;;JOSÉ LUIS MARTÍNEZ GONZALEZ,,https://lens.org/086-336-291-695-155,Patent Application,no,0,1,1,1,0,,G06Q10/06;;G06F9/44;;G06Q30/04;;G06Q40/08,,0,0,,,,PENDING
227,AR,A1,AR 063088 A1,167-681-520-676-657,2008-12-23,2008,AR P070104350 A,2007-10-01,CU 20060192 A,2006-10-03,USO DEL FACTOR DE CRECIMIENTO EPIDERMICO PARA LA RESTAURACION MORFOFUNCOIONAL DE NERVIOS PERIFERICOS EN LA NEUROPATIA DIABETICA,"La presente es aplicable en medicina humana, y se relaciona con el uso del Factor de Crecimiento Epidérmico (del inglés Epidermal Growth Factor, abreviado EGF) para preparar una composicion farmacéutica, que se administra mediante infiltracion en la periferia de troncos y/o ganglios nerviosos, para la restauracion morfofuncional de nervios periféricos en la neuropatía sensitivo-motora, dolorosa, así como las manifestaciones de neuritis isquémica. También incluye una composicion que comprende EGF, el que puede ser formulado junto a anestésicos o analgésicos, o encapsulado en microesferas; y su uso para la restauracion morfofuncional de nervios periféricos en la neuropatía diabética de tipo sensitivo-motora, dolorosa; y las manifestaciones de neuritis isquémica.",CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUIN JOSE IGNACIO;;BERLANGA ACOSTA JORGE;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLOT LAURENT;;UBIETA GOMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTINEZ VIVIAN MARIA,,https://lens.org/167-681-520-676-657,Patent Application,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,,,0,0,,,,PENDING
228,US,A1,US 2007/0092878 A1,111-012-849-866-085,2007-04-26,2007,US 55060804 A,2004-03-25,ES 200300708 A;;EP 2004003219 W,2003-03-26,In vitro method to detect bladder transitional cell carcinoma,"The present invention refers to an in vitro method to detect a bladder transitional cell carcinoma, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the FGFR3 protein and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,MARTINEZ ANTONIO M;;BUELA LAUREANO S;;CRUZ SIMON S;;JIMENEZ MARIA P S;;SANCHEZ-VALLEJO CORINA J;;ROMAN JOSE J G;;GONZALEZ JORGE C;;VILA MIGUEL M,PROGENIKA BIOPHARMA S.A (2005-10-24);;ONCONOMATRIX S.L (2011-12-19),https://lens.org/111-012-849-866-085,Patent Application,yes,1,11,9,9,18,C12Q1/6886;;C12Q2600/112;;C12Q2600/158;;G01N33/57407;;G01N2333/71;;G01N33/57407;;C12Q2600/112;;C12Q1/6886;;C12Q2600/158;;G01N2333/71,C12Q1/68;;G01N33/53;;G01N33/574,435/6;;435/7.1;;435/7.23,0,0,,,,ACTIVE
229,DK,T3,DK 1787653 T3,014-687-372-324-922,2012-09-17,2012,DK 05762122 T,2005-07-05,CU 20040147 A;;CU 2005000003 W,2004-07-08,Antitumoral farmaceutisk sammensætning indeholdende polypeptidfragmenter af serralysiner,,CT INGENIERIA GENETICA BIOTECH,CASTELLANOS SERRA LILA ROSA KOHLY;;SELMAN-HOUSEIN SOSA MANUEL;;GAVILONDO COWLEY JORGE VICTOR;;ABRAHANTES PEREZ MARIA DEL CARMEN;;REYES GONZALEZ JESUS;;VELIZ RIOS GLORIA;;MARTINEZ DIAZ EDUARDO;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER;;GOMEZ RIERA RAUL,,https://lens.org/014-687-372-324-922,Granted Patent,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/16;;A61P31/04;;A61P35/00;;C07K14/265,,0,0,,,,ACTIVE
230,PT,E,PT 1520587 E,032-344-868-998-240,2011-09-27,2011,PT 03724819 T,2003-05-08,CU 20020091 A,2002-05-08,"ALLERGY VACCINE COMPOSITION, PRODUCTION METHOD THEREOF AND USE OF SAME IN ALLERGY TREATMENT",,INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT NAC BIOPREPARADOS,GONZALEZ MIRIAM DE SAN JUAN LASTRE;;MARTIN OLIVER GERMAN PEREZ;;ROSADO ALEXIS LABRADA;;MARTINEZ IGOR BIDOT;;LASTRE JORGE ERNESTO PEREZ;;GRANADA GUSTAVO RAFAEL BRACHO;;ALONSO JUDITH MONICA DEL CAMPO;;LASTRE DAINERYS ALEIDA PEREZ;;RAMOS ELISA FACENDA;;VIGNIER CARIDAD ZAYAS;;MARTINEZ CLAUDIO RODRIGUEZ;;GONZALEZ VICTORIANO GUSTAVO SIERRA,,https://lens.org/032-344-868-998-240,Granted Patent,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/39;;A61K39/35,,0,0,,,,EXPIRED
231,AU,A1,AU 2003/229258 A1,049-541-186-483-143,2003-11-11,2003,AU 2003/229258 A,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"ALLERGY VACCINE COMPOSITION, PRODUCTION METHOD THEREOF AND USE OF SAME IN ALLERGY TREATMENT",,INST FINLAY CT DE INVESTIGACIO,MARTINEZ IGOR BIDOT;;LASTRE JORGE ERNESTO PEREZ;;GRANADA GUSTAVO RAFAEL BRACHO;;ALONSO JUDITH MONICA DEL CAMPO;;LASTRE DAINERYS ALEIDA PEREZ;;RAMOS ELISA FACENDA;;VIGNIER CARIDAD ZAYAS;;MARTINEZ CLAUDIO RODRIGUEZ;;GONZALEZ VICTORIANO GUSTAVO SI;;GONZALEZ MIRIAM DE SAN JUAN LA;;MARTIN OLIVER GERMAN PEREZ;;ROSADO ALEXIS LABRADA,,https://lens.org/049-541-186-483-143,Patent Application,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,0,0,,,,DISCONTINUED
232,ES,T3,ES 2368731 T3,121-019-645-992-025,2011-11-21,2011,ES 03724819 T,2003-05-08,CU 20020091 A,2002-05-08,"COMPOSICION DE VACUNA CONTRA LA ALERGIA, PROCEDIMIENTO DE PRODUCCION DE LA MISMA Y USO DE LA MISMA EN EL TRATAMIENTO DE ALERGIAS.","La presente invención se relaciona con el campo de la Inmunología, la Inmunoalergia y en particular con el empleo de adyuvantes o portadores para modular la respuesta inmunológica hacia los alergenos. El objetivo técnico que se persigue es obtener una preparación farmacéutica de uso terapéutico o profiláctico utilizando proteoliposomas bacterianos, la cual al ser aplicada en individuos alérgicos transforma la respuesta alérgica Th2 e IgE dependiente, hacia una respuesta Th1 protectora; así como logre prevenir la aparición y el desarrollo de alergias en individuos aún no alérgicos. La composición vacunal consiste en proteoliposomas de bacterias Gram-negativas acoplados a alergenos y opcionalmente otros antígenos o adyuvantes. Se provee el método para su obtención y se incluye el esquema de 2 dosis para la inmunización con dicha composición vacunal.",INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT NAC BIOPREPARADOS,LASTRE GONZALEZ MIRIAM DE SAN JUAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUSTAVO,,https://lens.org/121-019-645-992-025,Granted Patent,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/39;;A61K39/35,,0,0,,,,EXPIRED
233,AU,A8,AU 2003/229258 A8,034-441-399-805-289,2003-11-11,2003,AU 2003/229258 A,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"Allergy vaccine composition, production method thereof and use of same in allergy treatment",,CT NAC BIOPREPARADOS;;INST FINLAY CT DE INVESTIGACIO,MARTINEZ IGOR BIDOT;;LASTRE JORGE ERNESTO PEREZ;;GRANADA GUSTAVO RAFAEL BRACHO;;ALONSO JUDITH MONICA DEL CAMPO;;LASTRE DAINERYS ALEIDA PEREZ;;RAMOS ELISA FACENDA;;VIGNIER CARIDAD ZAYAS;;MARTINEZ CLAUDIO RODRIGUEZ;;GONZALEZ VICTORIANO GUSTAVO SI;;GONZALEZ MIRIAM DE SAN JUAN LA;;MARTIN OLIVER GERMAN PEREZ;;ROSADO ALEXIS LABRADA,,https://lens.org/034-441-399-805-289,Patent Application,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,0,0,,,,DISCONTINUED
234,AT,T1,AT E514431 T1,009-720-381-310-443,2011-07-15,2011,AT 03724819 T,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"ALLERGIE-VAKZINE-ZUSAMMENSETZUNG, HERSTELLUNGSVERFAHREN DAFÜR UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON ALLERGIEN",,INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT NAC BIOPREPARADOS,LASTRE GONZALEZ MIRIAM DE SAN JUAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUSTAVO,,https://lens.org/009-720-381-310-443,Granted Patent,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,0,0,,,,EXPIRED
235,EP,B1,EP 1520587 B1,030-674-699-715-930,2011-06-29,2011,EP 03724819 A,2003-05-08,CU 0300007 W;;CU 20020091 A,2002-05-08,"ALLERGY VACCINE COMPOSITION, PRODUCTION METHOD THEREOF AND USE OF SAME IN ALLERGY TREATMENT",,INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT NAC BIOPREPARADOS,LASTRE GONZALEZ MIRIAM DE SAN JUAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUSTAVO,,https://lens.org/030-674-699-715-930,Granted Patent,yes,4,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/39;;A61K39/35,,1,0,,,"FERRANDIZ, R.: ""Allergenic characterization of the domestic mite Dermatophagoides siboney."" LINKÖPING UNIVERSITY MEDICAL DISSERTATIONS. NUM. 531, 1997. HTTP://WWW.BIBL.LIU.SE/LIUPUBL/DISP/DISP97 /MED532S.HTM, XP002248650",EXPIRED
236,DK,T3,DK 1520587 T3,044-207-050-916-039,2011-10-17,2011,DK 03724819 T,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"Allergivaccinesammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf til allergibehandling",,INST FINLAY CT DE INVESTIGACION PRODUCCION DE VACUNAS Y SUEROS;;CT NAC BIOPREPARADOS,LABRADA ROSADO ALEXIS;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;LASTRE GONZALEZ MIRIAM DE SAN JUAN;;PEREZ MARTIN OLIVER GERMAN;;BIDOT MARTINEZ IGOR;;DEL CAMPO ALONSO JUDITH MONICA;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZALEZ VICTORIANO GUSTAVO,,https://lens.org/044-207-050-916-039,Granted Patent,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/39;;A61K39/35,,0,0,,,,EXPIRED
237,EP,A1,EP 1526380 A1,092-460-189-910-23X,2005-04-27,2005,EP 03380236 A,2003-10-21,EP 03380236 A,2003-10-21,Methods for in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas,"The present invention refers to an  in vitro  method to detect a cancer of the pancreas, especially a ductal adenocarcinoma of the pancreas, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the EFNB2 protein and/or the EDNRA protein, and/or the effects of this expression.",PROGENIKA BIOPHARMA SA,DEL AMON IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUREDO GARCIA DE GALDEANO PE;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;ARGUELLES SANCHEZ MARIA ELADIA;;DE LOS TOYOS GONZALEZ JUAN RAM;;BARNEO SERRA LUIS,,https://lens.org/092-460-189-910-23X,Patent Application,yes,4,0,1,1,28,G01N33/57438;;G01N33/6893;;G01N2500/00,G01N33/574;;G01N33/68,,5,4,005-752-186-572-254;;002-124-695-618-648;;090-433-846-511-962;;052-187-065-750-38X,10.1002/cncr.10122;;11920461;;10.1007/s00432-002-0355-0;;12136247;;12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;10.2165/00128413-200012390-00013,"LIU W ET AL: ""COEXPRESSION OF EPHRIN-BS AND THEIR RECEPTORS IN COLON CARCINOMA"", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 94, no. 4, 15 February 2002 (2002-02-15), pages 934 - 939, XP001156840, ISSN: 0008-543X;;KATAOKA, H. ET AL: ""Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer"", J CANCER RES CLIN ONCOL, vol. 128, 2002, pages 343 - 348, XP001179752;;IACOBUZIO-DONAHUE, C.A. ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays"", AMERICAN JOURNAL OF PATHOLOGY, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP009027111;;HOTZ, H.G. ET AL: ""The effect of selective endothelin-A-receptor blockade on human pancreatic cancer in vivo"", PANCREAS, vol. 21, no. 4, 2000, pages 448, XP009036713;;MAITRE NATHALIE L ET AL: ""Endothelin receptor A (ETA) expressing tumors as potential targets for endothelin receptor antagonist therapy"", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 528, XP001183532, ISSN: 0197-016X",DISCONTINUED
238,WO,A1,WO 2005/040813 A1,074-532-299-202-768,2005-05-06,2005,EP 2004012063 W,2004-10-22,ES 200302458 A,2003-10-22,XAG PROTEIN IN THE IN VITRO DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA,"The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma in an individual, to determine the stage or severity of said condition in an individual, or to monitor the effect of therapy administered to an individual with either one or both of said condition; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said condition of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the XAG protein (anterior gradient 2 homolog-Xenopus laevis-aliases: AGR2, AG2, GOB-4, HAG-2, XAG-2. UniGene: Hs.226391, GeneBank: NM&lowbar;006408) and/or the effects of said expression.",PROGENIKA BIOPHARMA SA;;DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;SIMON BUELA LAUREANO,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;SIMON BUELA LAUREANO,,https://lens.org/074-532-299-202-768,Patent Application,yes,2,3,3,3,15,A61K38/00;;A61P35/00;;G01N33/57438;;G01N33/68;;G01N33/57438,G01N33/574;;G01N33/68,,5,5,090-433-846-511-962;;022-468-759-873-205;;002-697-867-701-594;;012-723-831-077-784;;042-543-946-920-903,12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;11830538;;9790916;;10.1006/bbrc.1998.9440;;12592373;;pmc2377166;;10.1038/sj.bjc.6600740;;15305381;;10.1002/ijc.20376,"IACOBUZIO-DONAHUE CHRISTINE A ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays."", AMERICAN JOURNAL OF PATHOLOGY, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP002319210, ISSN: 0002-9440;;RYU, BYUNGWOO ET AL RYU, BYUNGWOO ET AL: ""Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression Synthesis and crystal structure of"", CANCER RESEARCH , 62(3), 819-826 CODEN: CNREA8; ISSN: 0008-5472 CANCER RESEARCH , 62(3), 819-826 CODEN: CNREA8; ISSN: 0008-5472, 2002, XP002319211;;THOMPSON DEVON A ET AL: ""hAG-2, the human homologue of the Xenopus laevis cement gland gene 4 XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 251, no. 1, 9 October 1998 (1998-10-09), pages 111 - 116, XP002319212, ISSN: 0006-291X;;FLETCHER G C ET AL: ""hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan."", BRITISH JOURNAL OF CANCER, vol. 88, no. 4, 24 February 2003 (2003-02-24), pages 579 - 585, XP002319213, ISSN: 0007-0920;;MISSIAGLIA EDOARDO ET AL: ""Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis"", INTERNATIONAL JOURNAL OF CANCER, vol. 112, no. 1, 20 October 2004 (2004-10-20), pages 100 - 112, XP008043556, ISSN: 0020-7136",PENDING
239,EP,A1,EP 1526381 A1,140-893-318-217-419,2005-04-27,2005,EP 03380238 A,2003-10-21,EP 03380238 A,2003-10-21,Methods for in vitro diagnosis and in vitro prognosis of cancer of the pancreas and for the development of drugs against cancer of the pancreas,"The present invention refers to an  in vitro  method to detect a cancer of the pancreas, especially a ductal adenocarcinoma of the pancreas, in an individual, to determine the stage or severity of this cancer in an individual or to monitor the effect of therapy administered to an individual with this cancer; to screen for, identify, develop and evaluate the efficacy of therapeutic compounds against this cancer in order to develop new medicinal products, and also agents that inhibit the expression and/or activity of the DDEF2 protein and/or the effects of this expression.",MEDPLANT GENETICS S L,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUREDO GARCIA DE GALDEANO PE;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;SIMON BUELA LAUREANO;;ARGUELLES SANCHEZ MARIA ELADIA;;DE LOS TOYOS GONZALEZ JUAN RAM;;BARNEO SERRA LUIS,"PROGENIKA BIOPHARMA, S.A. (2006-05-31)",https://lens.org/140-893-318-217-419,Patent Application,yes,1,2,1,1,15,G01N33/57438;;G01N33/6893;;G01N2500/00,G01N33/574;;G01N33/68,,8,7,151-593-502-617-118;;001-038-756-378-653;;090-433-846-511-962;;000-840-121-185-93X;;030-593-846-723-97X;;014-919-172-223-051;;058-074-005-829-851,10022920;;10.1128/mcb.19.3.2338;;pmc84026;;11820787;;10.1006/bbrc.2002.6350;;12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;pmc83965;;10.1128/mcb.19.3.1720;;10022859;;12750293;;pmc1867224;;10.1016/s0002-9440(10)62551-5;;11943709;;11704875;;10.1038/sj.onc.1204935,"ANDREEV, J. ET AL: ""Identification of a new Pyk2 target protein with Arf-GAP activity"", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, March 1999 (1999-03-01), pages 2338 - 2350, XP002273219;;KEOGH, R. J. ET AL: ""Human endothelial Pyk2 is expressed in two isoforms and associates with paxilin and p130Cas"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 290, 2002, pages 1470 - 1477, XP002273220;;IACOBUZIO-DONAHUE C. A. ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays"", AMERCIAN JOURNAL OF PATHOLOGY, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1152, XP009027111;;GYGI ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 3, 1999, pages 1720 - 1730;;SATO ET AL., AMERICAN JOURNAL OF PATHOLOGY, vol. 164, 1 May 2004 (2004-05-01), pages 903 - 914;;LOGSDON ET AL., CANCER RESEARCH, vol. 63, 1 May 2003 (2003-05-01), pages 2649 - 2657;;IACBUZIO-BONAHUE ET A.: ""Discovery of novel tumor markers of pancreatic cancer using global gene expression technology"", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, 2002, pages 1239 - 1249, XP008003747;;CRNOGORAC-JURCEVOC ET AL.: ""Gene expression profiles of pancreatic cancer and stromal desmoplasia"", ONCOGENE, vol. 20, 2001, pages 7437 - 7446, XP002267284, DOI: 10.1038/sj.onc.1204935",DISCONTINUED
240,US,A1,US 2011/0225660 A1,124-580-679-763-194,2011-09-15,2011,US 200813123295 A,2008-10-10,IB 2008002697 W,2008-10-10,ORALLY ADMINISTRABLE IMMUNOSTIMULANT PRODUCT FOR AQUACULTURE,"An orally administrable immunostimulant product comprises a microencapsulated cytokine and an enteric protection polymer to protect the cytokine, the cytokine is a fish, mollusc or crustacean cytokine, preferably a recombinant cytokine such as tumor necrosis factor α (TNFα) over-expressed in a host microorganism.",PROBELTE PHARMA S A,STREITENBERGER SERGIO A;;PENALVER MELLADO MARCOS;;LOPEZ MAS JOSE A;;PEDRENO LOPEZ YOLANDA;;SOLA GONZALEZ JUAN P;;MARTINEZ ORTIZ PEDRO;;MULERO MENDEZ VICTORIANO;;ROCA SOLER FRANCISCO;;GALINDO VILLEGAS JORGE,PROBELTE PHARMA S.A (2011-04-20),https://lens.org/124-580-679-763-194,Patent Application,yes,5,0,9,9,0,A61K9/5026;;A61K9/5026;;A23K20/147;;A23K20/147;;A23K40/30;;A23K40/30;;A23K50/80;;A23K50/80;;A61K38/1706;;A61K38/1706;;A61K38/191;;A61K38/191;;A61P37/02;;A61P37/04,A01K67/00;;A61K9/50;;A61K39/00;;C12N11/08,800/8;;424/497;;424/184.1;;435/180,5,2,005-755-285-520-090;;036-919-890-424-972,10.1111/j.1742-4658.2005.04544.x;;15720388;;10.1016/j.molimm.2006.02.028;;16616958,"Wang et al. (2005, FEBS J 272:1136-1147);;Ordás et al. (January 2007, Molecular Immunology 44:389-400);;Immunostimulant, http://medical-dictionary.thefreedictionary.com, p. 1, accessed 30 May 2013;;Immunostimulant, http://en.wikipedia.org, p. 1, accessed 30 May 2013;;Immunostimulant, http://health.doctissimo.com/health-a-z/immunostimulant-drugs.html, p. 1, accessed 30 May 2013",INACTIVE
241,EP,A2,EP 1642133 A2,043-655-999-307-574,2006-04-05,2006,EP 04740556 A,2004-06-30,EP 2004007195 W;;ES 200301518 A,2003-06-30,IN VITRO METHODS FOR DETECTING RENAL CANCER,,PROGENIKA BIOPHARMA SA,GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORINA;;SIMON BUELA LAUREANO;;MARTIINEZ MARTINEZ ANTONIO;;ARGUEELLES SANCHEZ MARIA ELADIA;;VAL BERNAL JOSE FERNANDO;;CUEVAS GONZALEZ JORGE,"ONCOMATRIX, S.L. (2013-10-23);;ONCOMATRYX BIOPHARMA, S.L. (2014-03-19)",https://lens.org/043-655-999-307-574,Patent Application,yes,0,0,10,10,0,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12Q1/68;;G01N33/574,,0,0,,,,ACTIVE
242,EP,B1,EP 1642133 B1,167-852-462-799-969,2014-04-09,2014,EP 04740556 A,2004-06-30,EP 2004007195 W;;ES 200301518 A,2003-06-30,IN VITRO METHODS FOR DETECTING RENAL CANCER,,ONCOMATRYX BIOPHARMA S L,GOMEZ ROMAN JOSE JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORINA;;SIMON BUELA LAUREANO;;MARTIINEZ MARTINEZ ANTONIO;;ARGUEELLES SANCHEZ MARIA ELADIA;;VAL BERNAL JOSE FERNANDO;;CUEVAS GONZALEZ JORGE,"ONCOMATRIX, S.L. (2013-10-23);;ONCOMATRYX BIOPHARMA, S.L. (2014-03-19)",https://lens.org/167-852-462-799-969,Granted Patent,yes,2,0,10,10,0,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,G01N33/574;;A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12Q1/68,,0,0,,,,ACTIVE
243,ES,T3,ES 2476375 T3,094-182-117-868-541,2014-07-14,2014,ES 04740556 T,2004-06-30,ES 200301518 A;;EP 2004007195 W,2003-06-30,Procedimientos in vitro para detectar cáncer renal,"Procedimiento in vitro para detectar la presencia de cáncer renal en un individuo, para determinar el estadio o la gravedad de este cáncer en un individuo, o para monitorizar el efecto de la terapia administrada a un individuo con este cáncer, que comprende. a) la detección y/o cuantificación de la proteína Plexina-B1, del ARNm del gen plexina-B1 o el correspondiente ADNc en una muestra de un individuo, y b) la comparación de la cantidad de proteína Plexina-B1, de la cantidad de ARNm del gen plexina-B1 o de la cantidad del correspondiente ADNc detectada en una muestra de un individuo con sus valores normales de referencia.",PROGENIKA BIOPHARMA SA;;ONCOMATRYX BIOPHARMA S L,GOMEZ ROMAN JOSÉ JAVIER;;SAENZ JIMENEZ MARIA PILAR;;OCHOA GARAY JORGE;;DEL AMO IRIBARREN JOKIN;;SANZ IBAYONDO CRISTINA;;JUNQUERA SANCHEZ-VALLEJO CORINA;;SIMON BUELA LAUREANO;;MARTIINEZ MARTINEZ ANTONIO;;ARGÜELLES SANCHEZ MARIA ELADIA;;VAL BERNAL JOSÉ FERNANDO;;CUEVAS GONZALEZ JORGE,,https://lens.org/094-182-117-868-541,Granted Patent,no,0,0,10,10,0,C07K14/4703;;C07K14/705;;C07K14/71;;C12Q1/6886;;C12Q2600/112;;C12Q2600/136;;G01N33/57438;;Y10T436/143333;;A61P35/00;;G01N33/57438;;Y10T436/143333;;G01N33/57438;;C07K14/71;;C07K14/705;;C12Q2600/136;;C12Q1/6886;;C07K14/4703;;C12Q2600/112,G01N33/574;;A61P35/00;;C07K14/47;;C07K14/705;;C07K14/71;;C12Q1/68,,0,0,,,,ACTIVE
244,ES,B1,ES 2572188 B1,131-893-966-644-842,2016-12-01,2016,ES 201400966 A,2014-11-28,ES 201400966 A,2014-11-28,Sistema de alimentación alámbrico para vehículos aéreos no tripulados,,UNIV VIGO,NEIRA LOPEZ PABLO;;ROCA BERNARDEZ DAVID;;DIAZ VILARINO LUCÍA;;LAGÜELA LOPEZ SUSANA;;MARTINEZ SANCHEZ JOAQUÍN;;CONDE CARNERO BORJA;;RIVEIRO RODRIGUEZ BELÉN;;GONZALEZ JORGE HIGINIO;;ARIAS SANCHEZ PEDRO;;LORENZO CIMADEVILA HENRIQUE,,https://lens.org/131-893-966-644-842,Granted Patent,no,0,0,2,2,0,B64C39/022;;B64C39/024;;B64U10/13;;B64U50/19;;B64U30/20;;B64U2101/30;;B64U2201/202,B64C39/02,,0,0,,,,ACTIVE
245,JP,A,JP 2014198722 A,140-002-340-031-096,2014-10-23,2014,JP 2014135544 A,2014-07-01,JP 2014135544 A,2014-07-01,ORALLY ADMINISTRABLE IMMUNOSTIMULANT FOR AQUACULTURE,"PROBLEM TO BE SOLVED: To provide a novel immunostimulant suitable to be orally administered that does not undergo to hydrolysis or degradation and that can be completely absorbed by an organism to which it is administered.SOLUTION: An orally administrable immunostimulant product for aquaculture comprises a microencapsulated cytokine and an enteric protection polymer to protect the cytokine. The cytokine is a fish, shellfish or crustacean cytokine, preferably a recombinant cytokine such as tumor necrosis factor α (TNFα) overexpressed in a host microorganism.",PROBELTE PHARMA SA,SERGIO A STREITENBERGER;;PENALVER MELLADO MARCOS;;LOPEZ MAS JASE A;;PEDRENO LOPEZ YOLANDA;;JUAN P SOLA GONZALEZ;;PEDRO MARTINEZ ORTIZ;;MULERO MENDEZ VIOTORIANO;;ROCA SOLER FRANCISCO J;;JORGE GALINDO VILLEGAS,,https://lens.org/140-002-340-031-096,Patent Application,no,10,0,2,2,24,Y02A40/81,A61K9/50;;A01K61/00;;A01K61/13;;A61K35/66;;A61K36/06;;A61K38/00;;A61K38/19;;A61K39/00;;A61K39/39;;A61K47/32;;A61K47/36;;A61K47/38;;A61K47/42;;C07K14/52;;C12N1/19;;C12N15/09;;C12P21/02,,4,0,,,"JPN6013027621; ＢＵＯＮＯＣＯＲＥ，Ｆ． ｅｔ ａｌ: 'Ｅｘｐｒｅｓｓｉｏｎ ｉｎ Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ ａｎｄ Ｐｕｒｉｆｉｃａｔｉｏｎ ｏｆ Ｓｅａ Ｂａｓｓ （Ｄｉｃｅｎｔｒａｒｃｈｕｓ ｌａｂｒａｘ） Ｉｎｔｅｒｌｅｕｋｉｎ １beta，' Ｍａｒ Ｂｉｏｔｅｃｈｎｏｌ Ｖｏｌ．６， Ｎｏ．１, 2004, ｐ．５３-５９;;JPN6013027623; ＢＵＯＮＯＣＯＲＥ，Ｆ． ｅｔ ａｌ: 'Ｂｉｏｌｏｇｉｃａｌ Ａｃｔｉｖｉｔｙ ｏｆ Ｓｅａ Ｂａｓｓ （Ｄｉｃｅｎｔｒａｒｃｈｕｓ ｌａｂｒａｘ Ｌ．） Ｒｅｃｏｍｂｉｎａｎｔ Ｉｎｔｅｒｌｅｕｋｉｎ-１beta' Ｍａｒ Ｂｉｏｔｅｃｈｎｏｌ Ｖｏｌ．７， Ｎｏ．６, 2005, ｐ．６０９-６１７;;JPN6013027621; ＢＵＯＮＯＣＯＲＥ，Ｆ． ｅｔ ａｌ: 'Ｅｘｐｒｅｓｓｉｏｎ ｉｎ Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ ａｎｄ Ｐｕｒｉｆｉｃａｔｉｏｎ ｏｆ Ｓｅａ Ｂａｓｓ （Ｄｉｃｅｎｔｒａｒｃｈｕｓ ｌａｂｒａｘ） Ｉｎｔｅｒｌｅｕｋｉｎ １beta，' Ｍａｒ Ｂｉｏｔｅｃｈｎｏｌ Ｖｏｌ．６， Ｎｏ．１, 2004, ｐ．５３-５９;;JPN6013027623; ＢＵＯＮＯＣＯＲＥ，Ｆ． ｅｔ ａｌ: 'Ｂｉｏｌｏｇｉｃａｌ Ａｃｔｉｖｉｔｙ ｏｆ Ｓｅａ Ｂａｓｓ （Ｄｉｃｅｎｔｒａｒｃｈｕｓ ｌａｂｒａｘ Ｌ．） Ｒｅｃｏｍｂｉｎａｎｔ Ｉｎｔｅｒｌｅｕｋｉｎ-１beta' Ｍａｒ Ｂｉｏｔｅｃｈｎｏｌ Ｖｏｌ．７， Ｎｏ．６, 2005, ｐ．６０９-６１７",INACTIVE
246,AT,T1,AT E544462 T1,023-087-190-186-845,2012-02-15,2012,AT 07817382 T,2007-10-01,CU 20060192 A;;CU 2007000018 W,2006-10-03,VERWENDUNG DES EPIDERMALEN WACHSTUMSFAKTORS ZUR MORPHOFUNKTIONELLEN WIEDERHERSTELLUNG VON PERIPHEREN NERVEN BEI DIABETISCHER NEUROPATHIE,,CT INGENIERIA GENETICA BIOTECH,FERNANDEZ MONTEQUOEN JOSE;;HERRERA MARTINEZ LUIS;;BERLANGA ACOSTA JORGE;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO;;UBIETA GAMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SAEZ MARTOENEZ VIVIAN MARIA,,https://lens.org/023-087-190-186-845,Granted Patent,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,,,0,0,,,,ACTIVE
247,EP,A1,EP 0875594 A1,039-164-335-354-860,1998-11-04,1998,EP 97911242 A,1997-11-10,ES 9700269 W;;ES 9602439 A,1996-11-12,METHOD FOR IMPROVING THE OSTEOINTEGRATION OF OSSEOUS FIXING IMPLANTS,"The osteointegration of osseous fixing implants may be improved through a series of surface treatments. Said treatments comprise a cleaning and passivation process, tha application of a coating in the system Ca-P-H-O-C through the laser ablation technique and a sterilization process by irradiation. The flexibility of this method provides for the control of physico-chemical properties of the obtained surface in order to match said properties with those of the bone in which the implant will be placed.",UNIV VIGO;;EROTHITAN TITANIMPLANTATE AG I;;EURO TRS;;KLOCKNER;;IMPLANTES AB;;BONE SYSTEM,LEON FONG BETTY MIREYA;;POU SARACHO JUAN MARIA;;ARIAS OTERO JORGE LUIS;;GARCIA SANZ FRANCISCO JOSE;;MAYOR LEIROS MERCEDES BELEN;;GONZALEZ FERNANDEZ PIO MANUEL;;PEREZ-MARTINEZ Y PEREZ-AMOR MA,,https://lens.org/039-164-335-354-860,Patent Application,yes,0,3,6,8,0,A61F2/30767;;A61F2/30767;;A61F2/3094;;A61F2/3094;;A61F2002/30084;;A61F2002/30084;;A61F2002/30929;;A61F2002/30929;;A61F2002/3097;;A61F2002/3097;;A61F2310/00017;;A61F2310/00017;;A61F2310/00023;;A61F2310/00023;;A61F2310/00029;;A61F2310/00029;;A61F2310/00203;;A61F2310/00203;;A61F2310/00796;;A61F2310/00796;;A61L27/32;;A61L27/32;;C23C14/5813;;C23C14/5813;;C23C14/021;;C23C14/021;;C23C14/08;;C23C14/08;;C23C14/28;;C23C14/28;;C23C14/564;;C23C14/564;;C23C14/58;;C23C14/58,A61C8/00;;A61F2/00;;A61F2/28;;A61F2/30;;A61L27/00;;A61L27/32;;C23C14/02;;C23C14/08;;C23C14/28;;C23C14/56;;C23C14/58,,1,0,,,See references of WO 9821380A1,DISCONTINUED
248,CA,A1,CA 2242790 A1,048-909-847-290-557,1998-05-22,1998,CA 2242790 A,1997-11-10,ES 9700269 W;;ES 9602439 A,1996-11-12,METHOD FOR IMPROVING THE OSTEOINTEGRATION OF OSSEOUS FIXING IMPLANTS,"The osteointegration of osseous fixing implants may be improved through a series of surface treatments. Said treatments comprise a cleaning and passivation process, the application of a coating in the system Ca-P-H-O-C through the laser ablation technique and a sterilisation process by irradiation. The flexibility of this method provides for the control of physico-chemical properties of the obtained surface in order to match said properties with those of the bone in which the implant will be placed.",UNIV VIGO;;BONE SYSTEM;;KLOCKNER;;IMPLANTES AB;;EURO TRS;;EROTHITAN TITANIMPLANTATE AG I,LEON FONG BETTY MIREYA;;ARIAS OTERO JORGE LUIS;;GONZALEZ FERNANDEZ PIO MANUEL;;MAYOR LEIROS MERCEDES BELEN;;POU SARACHO JUAN MARIA;;GARCIA SANZ FRANCISCO JOSE;;PEREZ-MARTINEZ Y PEREZ-AMOR MA,,https://lens.org/048-909-847-290-557,Patent Application,no,0,0,2,8,0,A61F2/30767;;A61F2/3094;;A61F2002/30084;;A61F2002/30929;;A61F2002/3097;;A61F2310/00017;;A61F2310/00023;;A61F2310/00029;;A61F2310/00203;;A61F2310/00796;;A61L27/32;;C23C14/021;;C23C14/08;;C23C14/28;;C23C14/564;;C23C14/58;;C23C14/5813,A61C8/00;;A61F2/00;;A61F2/28;;A61F2/30;;A61L27/00;;A61L27/32;;C23C14/02;;C23C14/08;;C23C14/28;;C23C14/56;;C23C14/58,,0,0,,,,EXPIRED
249,CA,C,CA 2242790 C,004-957-949-781-007,2007-02-06,2007,CA 2242790 A,1997-11-10,ES 9700269 W;;ES 9602439 A,1996-11-12,METHOD FOR IMPROVING THE OSTEOINTEGRATION OF OSSEOUS FIXING IMPLANTS,"The osteointegration of osseous fixing implants may be improved through a series of surface treatments. Said treatments comprise a cleaning and passivation process, the application of a coating in the system Ca-P-H-O-C through the laser ablation technique and a sterilisation process by irradiation. The flexibility of this method provides for the control of physico-chemical properties of the obtained surface in order to match said properties with those of the bone in which the implant will be placed.",BONE SYSTEM;;KLOCKNER;;EURO TRS;;EROTHITAN TITANIMPLANTATE AG I;;UNIV VIGO;;IMPLANTES AB,POU SARACHO JUAN MARIA;;GONZALEZ FERNANDEZ PIO MANUEL;;LEON FONG BETTY MIREYA;;GARCIA SANZ FRANCISCO JOSE;;MAYOR LEIROS MERCEDES BELEN;;ARIAS OTERO JORGE LUIS;;PEREZ-MARTINEZ Y PEREZ-AMOR MA,,https://lens.org/004-957-949-781-007,Granted Patent,no,0,0,2,8,0,A61F2/30767;;A61F2/3094;;A61F2002/30084;;A61F2002/30929;;A61F2002/3097;;A61F2310/00017;;A61F2310/00023;;A61F2310/00029;;A61F2310/00203;;A61F2310/00796;;A61L27/32;;C23C14/021;;C23C14/08;;C23C14/28;;C23C14/564;;C23C14/58;;C23C14/5813,A61C8/00;;C23C14/28;;A61F2/00;;A61F2/02;;A61F2/28;;A61F2/30;;A61L27/00;;A61L27/32;;C23C14/02;;C23C14/06;;C23C14/08;;C23C14/56;;C23C14/58,,0,0,,,,EXPIRED
250,PE,A1,PE 20110936 A1,037-206-952-256-625,2012-01-09,2012,PE 2010000224 A,2010-04-13,PE 2010000224 A,2010-04-13,PRODUCTO INMUNOESTIMULANTE ADMINISTRABLE POR VIA ORAL PARA ACUICULTURA,"SE REFIERE A UN PRODUCTO INMUNOESTIMULANTE QUE COMPRENDE: A) CITOQUINA RECOMBINANTE MICROENCAPSULADA QUE ES EL FACTOR DE NECROSIS TUMORAL a (TNFa) QUE SE SOBREEXPRESA EN UN MICROORGANISMO HUESPED QUE ES LA LEVADURA PICHIA PASTORIS, EN DONDE DICHA CITOQUINA DERIVA DE UN ORGANISMO MARINO ADECUADO PARA LA ACUICULTURA TAL COMO SPARUS AURATA, DICENTRARCHUS LABRAX, ANGUILLA ANGUILLA, ENTRE OTROS; Y B) UN POLIMERO DE PROTECCION ENTERICA TAL COMO ACETATO-FTALATO DE CELULOSA, FTALATO DE HIDROXIPROPILCELULOSA, CARBOXIMETILCELULOSA, ENTRE OTROS, QUE MICROENCAPSULA A LA CITOQUINA O EL MICROORGANISMO HUESPED QUE COMPRENDE LA CITOQUINA. TAMBIEN SE REFIERE A UN PROCESO DE PREPARACION. DICHO PRODUCTO INMUNOESTIMULANTE ADEMAS COMPRENDE UNA VACUNA PARA PECES, MOLUSCOS O CRUSTACEOS QUE SE ENCUENTRA MICROENCAPSULADA CON LA CITOQUINA",PROBELTE PHARMA S A,STREITENBERGER SERGIO A;;PENALVER MELLADO MARCOS;;LOPEZ MAS JOSE A;;PEDRENO LOPEZ YOLANDA;;SOLA GONZALEZ JUAN P;;MARTINEZ ORTIZ PEDRO;;MULERO MENDEZ VICTORIANO;;ROCA SOLER FRANCISCO J;;GALINDO VILLEGAS JORGE,,https://lens.org/037-206-952-256-625,Patent Application,no,0,0,1,1,0,,A61K9/50;;A61K38/19;;A61K39/39,,0,0,,,,ACTIVE
251,CN,A,CN 102209530 A,071-682-878-927-418,2011-10-05,2011,CN 200880131935 A,2008-10-10,IB 2008002697 W,2008-10-10,Orally administrable immunostimulant product for aquaculture,"An orally administrable immunostimulant product comprises a microencapsulated cytokine and an enteric protection polymer to protect the cytokine, the cytokine is a fish, mollusc or crustacean cytokine, preferably a recombinant cytokine such as tumor necrosis factor a (TNFa) over-expressed in a host microorganism.",PROBELTE PHARMA S A,STREITENBERGER SERGIO A;;MARCOS PENALVER MELLADO;;LOPEZ MAS JOSE A;;YOLANDA PEDRENO LOPEZ;;SOLA GONZALEZ JUAN P;;PEDRO MARTINEZ ORTIZ;;VICTORIANO MULERO MENDEZ;;ROCA SOLER FRANCISCO J;;JORGE GALINDO VILLEGAS,,https://lens.org/071-682-878-927-418,Patent Application,no,0,2,9,9,0,A61K9/5026;;A61K9/5026;;A23K20/147;;A23K20/147;;A23K40/30;;A23K40/30;;A23K50/80;;A23K50/80;;A61K38/1706;;A61K38/1706;;A61K38/191;;A61K38/191;;A61P37/02;;A61P37/04,A61K9/50;;A61K38/19;;A61K39/39,,0,0,,,,INACTIVE
252,EP,A1,EP 2349224 A1,184-612-254-915-690,2011-08-03,2011,EP 08875709 A,2008-10-10,IB 2008002697 W,2008-10-10,ORALLY ADMINISTRABLE IMMUNOSTIMULANT PRODUCT FOR AQUACULTURE,,PROBELTE PHARMA S A,STREITENBERGER SERGIO A;;PENALVER MELLADO MARCOS;;LOPEZ MAS JOSE A;;PEDRENO LOPEZ YOLANDA;;SOLA GONZALEZ JUAN P;;MARTINEZ ORTIZ PEDRO;;MULERO MENDEZ VICTORIANO;;ROCA SOLER FRANCISCO J;;GALINDO VILLEGAS JORGE,,https://lens.org/184-612-254-915-690,Patent Application,yes,0,0,9,9,0,A61K9/5026;;A61K9/5026;;A23K20/147;;A23K20/147;;A23K40/30;;A23K40/30;;A23K50/80;;A23K50/80;;A61K38/1706;;A61K38/1706;;A61K38/191;;A61K38/191;;A61P37/02;;A61P37/04,A61K9/50;;A23K20/147;;A23K40/30;;A23K50/80;;A61K38/17;;A61K38/19;;A61K39/39,,1,0,,,See references of WO 2010041096A1,ACTIVE
253,US,B1,US 6339913 B1,118-980-517-921-618,2002-01-22,2002,US 11358498 A,1998-07-10,ES 9602439 A;;ES 9700269 W,1996-11-12,Method for improving the osteointegration of osseus fixing implants,"
    The osteointegration of osseous fixing implants may be improved through a series of surface treatments. These treatments comprise a cleaning and passivation process, the application of a coating of Ca _{ U } P _{ V } H _{ X } O _{ Y } C _{ Z } to the implant, where subindexes u, v, x, y, and z are natural numbers including zero with variable stoichiometry, and a sterilization process by irradiation. The flexibility of this method provides for the control of physical and chemical properties of the obtained surface in order to match the properties with those of the bone in which the implant will be placed. 
",UNIV VIGO,LEON FONG BETTY MIREYA;;POU SARACHO JUAN MARIA;;ARIAS OTERO JORGE LUIS;;GARCIA SANZ FRANCISCO JOSE;;MAYOR LEIROS MERCEDES BELEN;;GONZALEZ FERNANDEZ PIO MANUEL;;PEREZ-MARTINEZ Y PEREZ-AMOR MA,UNIVERSIDAD DE VIGO (1998-11-03),https://lens.org/118-980-517-921-618,Granted Patent,yes,14,16,6,8,0,A61F2/30767;;A61F2/30767;;A61F2/3094;;A61F2/3094;;A61F2002/30084;;A61F2002/30084;;A61F2002/30929;;A61F2002/30929;;A61F2002/3097;;A61F2002/3097;;A61F2310/00017;;A61F2310/00017;;A61F2310/00023;;A61F2310/00023;;A61F2310/00029;;A61F2310/00029;;A61F2310/00203;;A61F2310/00203;;A61F2310/00796;;A61F2310/00796;;A61L27/32;;A61L27/32;;C23C14/5813;;C23C14/5813;;C23C14/021;;C23C14/021;;C23C14/08;;C23C14/08;;C23C14/28;;C23C14/28;;C23C14/564;;C23C14/564;;C23C14/58;;C23C14/58,A61C8/00;;A61F2/00;;A61F2/28;;A61F2/30;;A61L27/00;;A61L27/32;;C23C14/02;;C23C14/08;;C23C14/28;;C23C14/56;;C23C14/58,53/425;;53/432;;427/2.27;;623/16.11,0,0,,,,EXPIRED
254,WO,A1,WO 1998/021380 A1,168-868-686-458-20X,1998-05-22,1998,ES 9700269 W,1997-11-10,ES 9602439 A,1996-11-12,METHOD FOR IMPROVING THE OSTEOINTEGRATION OF OSSEOUS FIXING IMPLANTS,"The osteointegration of osseous fixing implants may be improved through a series of surface treatments. Said treatments comprise a cleaning and passivation process, the application of a coating in the system Ca-P-H-O-C through the laser ablation technique and a sterilisation process by irradiation. The flexibility of this method provides for the control of physico-chemical properties of the obtained surface in order to match said properties with those of the bone in which the implant will be placed.",UNIV VIGO;;EROTHITAN TITANIMPLANTATE AG I;;EURO TRS;;KLOCKNER;;IMPLANTES AB;;BONE SYSTEM;;LEON FONG BETTY MIREYA;;POU SARACHO JUAN MARIA;;ARIAS OTERO JORGE LUIS;;GARCIA SANZ FRANCISCO JOSE;;MAYOR LEIROS MERCEDES BELEN;;GONZALEZ FERNANDEZ PIO MANUEL;;PEREZ MARTINEZ Y PEREZ AMOR MA,LEON FONG BETTY MIREYA;;POU SARACHO JUAN MARIA;;ARIAS OTERO JORGE LUIS;;GARCIA SANZ FRANCISCO JOSE;;MAYOR LEIROS MERCEDES BELEN;;GONZALEZ FERNANDEZ PIO MANUEL;;PEREZ-MARTINEZ Y PEREZ-AMOR MA,,https://lens.org/168-868-686-458-20X,Patent Application,yes,8,3,6,8,0,A61F2/30767;;A61F2/30767;;A61F2/3094;;A61F2/3094;;A61F2002/30084;;A61F2002/30084;;A61F2002/30929;;A61F2002/30929;;A61F2002/3097;;A61F2002/3097;;A61F2310/00017;;A61F2310/00017;;A61F2310/00023;;A61F2310/00023;;A61F2310/00029;;A61F2310/00029;;A61F2310/00203;;A61F2310/00203;;A61F2310/00796;;A61F2310/00796;;A61L27/32;;A61L27/32;;C23C14/5813;;C23C14/5813;;C23C14/021;;C23C14/021;;C23C14/08;;C23C14/08;;C23C14/28;;C23C14/28;;C23C14/564;;C23C14/564;;C23C14/58;;C23C14/58,A61C8/00;;A61F2/00;;A61F2/28;;A61F2/30;;A61L27/00;;A61L27/32;;C23C14/02;;C23C14/08;;C23C14/28;;C23C14/56;;C23C14/58,,0,0,,,,PENDING
255,ES,A1,ES 2572188 A1,045-304-476-561-520,2016-05-30,2016,ES 201400966 A,2014-11-28,ES 201400966 A,2014-11-28,"Wired power system for unmanned aerial vehicles (Machine-translation by Google Translate, not legally binding)","The present invention offers a system for feeding an unmanned aerial vehicle from the ground using a cable that connects it to a power supply battery. The feeding system consists of a reel that allows the collection and transport of the cable, to make its use easier. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,NEIRA LOPEZ PABLO;;ROCA BERNARDEZ DAVID;;DIAZ VILARINO LUCÍA;;LAGÜELA LOPEZ SUSANA;;MARTINEZ SANCHEZ JOAQUÍN;;CONDE CARNERO BORJA;;RIVEIRO RODRIGUEZ BELÉN;;GONZALEZ JORGE HIGINIO;;ARIAS SANCHEZ PEDRO;;LORENZO CIMADEVILA HENRIQUE,,https://lens.org/045-304-476-561-520,Patent Application,no,3,1,2,2,0,B64C39/022;;B64C39/024;;B64U10/13;;B64U50/19;;B64U30/20;;B64U2101/30;;B64U2201/202,B64C39/02,,0,0,,,,ACTIVE
256,WO,A1,WO 2010/041096 A1,072-827-351-516-007,2010-04-15,2010,IB 2008002697 W,2008-10-10,IB 2008002697 W,2008-10-10,ORALLY ADMINISTRABLE IMMUNOSTIMULANT PRODUCT FOR AQUACULTURE,"An orally administrable immunostimulant product comprises a microencapsulated cytokine and an enteric protection polymer to protect the cytokine, the cytokine is a fish, mollusc or crustacean cytokine, preferably a recombinant cytokine such as tumor necrosis factor α (TNFα) over-expressed in a host microorganism.",PROBELTE PHARMA S A;;STREITENBERGER SERGIO A;;PENALVER MELLADO MARCOS;;LOPEZ MAS JOSE A;;PEDRENO LOPEZ YOLANDA;;SOLA GONZALEZ JUAN P;;MARTINEZ ORTIZ PEDRO;;MULERO MENDEZ VICTORIANO;;ROCA SOLER FRANCISCO J;;GALINDO VILLEGAS JORGE,STREITENBERGER SERGIO A;;PENALVER MELLADO MARCOS;;LOPEZ MAS JOSE A;;PEDRENO LOPEZ YOLANDA;;SOLA GONZALEZ JUAN P;;MARTINEZ ORTIZ PEDRO;;MULERO MENDEZ VICTORIANO;;ROCA SOLER FRANCISCO J;;GALINDO VILLEGAS JORGE,,https://lens.org/072-827-351-516-007,Patent Application,yes,12,3,9,9,24,A61K9/5026;;A61K9/5026;;A23K20/147;;A23K20/147;;A23K40/30;;A23K40/30;;A23K50/80;;A23K50/80;;A61K38/1706;;A61K38/1706;;A61K38/191;;A61K38/191;;A61P37/02;;A61P37/04,A61K9/50;;A61K38/19;;A61K39/39,,1,1,022-424-862-757-494,10.1023/a:1010963307097;;11496947,"HANES J ET AL: ""Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors."", PHARMACEUTICAL RESEARCH JUL 2001, vol. 18, no. 7, July 2001 (2001-07-01), pages 899 - 906, XP002529199, ISSN: 0724-8741",PENDING
257,CN,B,CN 102209530 B,010-707-496-458-236,2013-05-15,2013,CN 200880131935 A,2008-10-10,IB 2008002697 W,2008-10-10,Orally administrable immunostimulant product for aquaculture,,PROBELTE PHARMA S A,STREITENBERGER SERGIO A;;PENALVER MELLADO MARCOS;;LOPEZ MAS JOSE A;;PEDRENO LOPEZ YOLANDA;;SOLA GONZALEZ JUAN P;;MARTINEZ ORTIZ PEDRO;;MULERO MENDEZ VICTORIANO;;ROCA SOLER FRANCISCO J;;GALINDO VILLEGAS JORGE,,https://lens.org/010-707-496-458-236,Granted Patent,no,0,0,9,9,0,A61K9/5026;;A61K9/5026;;A23K20/147;;A23K20/147;;A23K40/30;;A23K40/30;;A23K50/80;;A23K50/80;;A61K38/1706;;A61K38/1706;;A61K38/191;;A61K38/191;;A61P37/02;;A61P37/04,A61K38/19;;A61K39/39;;A61P37/04,,0,0,,,,INACTIVE
258,ES,B1,ES 2572181 B1,055-490-739-490-811,2016-12-01,2016,ES 201400965 A,2014-11-28,ES 201400965 A,2014-11-28,Sistema de acoplamiento entre vehículos aéreos no tripulados y estructuras tipo viga para medición por contacto,,UNIV VIGO,NEIRA LOPEZ PABLO;;ROCA BERNARDEZ DAVID;;DIAZ VILARINO LUCÍA;;LAGÜELA LOPEZ SUSANA;;MARTINEZ SANCHEZ JOAQUÍN;;CONDE CARNERO BORJA;;RIVEIRO RODRIGUEZ BELÉN;;GONZALEZ JORGE HIGINIO;;ARIAS SANCHEZ PEDRO;;LORENZO CIMADEVILA HENRIQUE,,https://lens.org/055-490-739-490-811,Granted Patent,no,0,0,2,2,0,G01N27/20;;B64C39/024;;B64D47/00;;G01N2201/0214;;B64U10/13;;B64U50/19;;B64U30/20;;B64U2101/00,G01N27/20;;B64C39/02;;B64D47/00,,0,0,,,,ACTIVE
259,CL,A1,CL 2009001959 A1,084-964-030-775-59X,2010-12-24,2010,CL 2009001959 A,2009-10-13,IB 2008002697 W,2008-10-10,"Producto inmunoestimulante administrable por via oral, que comprende al menos una citoquina recombinante autologa microencapsulada de peces, moluscos o crustaceos y un polimero de proteccion enterica; procedimiento de preparacion y uso de dicho producto para inducir inmunoestimulacion.","<br /> UN PRODUCTO INMUNOESTIMULANTE ADMINISTRABLE POR VÍA ORAL COMPRENDE UNA CITOQUINA<br /> MICROENCAPSULADAY UN POLÍMERO DE PROTECCIÓN ENTÉRICA PARA PROTEGER A LA CITOQUINA, LA CITOQUINA<br /> ES UNA CITOQUINA DE PECES, DE MOLUSCOS O DE CRUSTÁCEOS, PREFERIBLEMENTE UNA CITOQUINA<br /> RECOMBINANTE, TAL COMO EL FACTOR DE NECROSIS TUMORAL (TNF ), SOBREEXPRESADA EN UN<br /> MICROORGANISMO HUÉSPED.",PROBELTE PHARMA S A,JOSE A LOPEZ MAS;;SERGIO A STREITENBERGER;;MARCOS PEÑALVER MELLADO;;YOLANDA PEDREÑO LOPEZ;;JUAN P SOLA GONZALEZ;;PEDRO MARTINEZ ORTIZ;;VICTORIANO MULERO MENDEZ;;FRANCISCO J ROCA SOLER;;JORGE GALINDO VILLEGAS,,https://lens.org/084-964-030-775-59X,Patent Application,no,0,0,9,9,0,A61K9/5026;;A61K9/5026;;A23K20/147;;A23K20/147;;A23K40/30;;A23K40/30;;A23K50/80;;A23K50/80;;A61K38/1706;;A61K38/1706;;A61K38/191;;A61K38/191;;A61P37/02;;A61P37/04,A61K35/60;;A61K38/19;;A61P37/02;;C07K14/265;;C07K14/525;;C12N15/19,,0,0,,,,PENDING
260,MX,A,MX 2013004901 A,109-039-069-396-244,2014-10-31,2014,MX 2013004901 A,2013-04-30,MX 2013004901 A,2013-04-30,PROCESS FOR OBTAINING FRUCTANES FROM YOUNG AGAVE AND USE THEREOF AS FUNCTIONAL INGREDIENT.,"The invention refers to agave fructanes obtained from young agave, the process for obtaining and applying the same specifically as a functional ingredient with nutraceutical properties for reducing triglycerides in serum in normal, overweight and obese patients with dyslipidemia. The product has the characteristic of being constituted by a mixture of fructanes of different degree of polymerization DP, which are agaves with a degree of ripeness of about 3 years, in a ratio that varies from about 30/70 to about 50/50 referred to long-chain fructanes /short-chain fructanes. The process through which this product is obtained, using young agave, consists in washing the core, crush it and tear the fiber for being lixiviated with hot water and obtaining an aqueous extract that contains the soluble solids of the agave. The extract is clarified by coagulation, sedimentation and filtration for separating the insoluble solids present therein. The extract may be concentrated or dehydrated for obt aining a product in powder.",CT DE INVESTIGACION Y ASISTENCIA EN TECNOLOGIA Y DISEÑO DEL ESTADO DE JALISCO A C,MARTINEZ FRANCISCO JAVIER PEREZ;;MONTAÑO JOSE LUIS FLORES;;GAVIÑO JAVIER PLACIDO ARRIZON;;DIAZ JUAN CARLOS MATEOS;;SEGURA DIANA ALONSO;;AVILA MARISELA GONZALEZ;;RUIZ ROSA MARIA CAMACHO;;AGUIRRE ANA LAURA MARQUEZ;;RAMIREZ ROGELIO PRADO;;GONZALEZ JORGE ALBERTO RODRIGUEZ;;GSCHAEDLERMATHIS ANNE CHRISTINE,,https://lens.org/109-039-069-396-244,Patent Application,no,0,0,2,2,0,,A23L1/00,,0,0,,,,ACTIVE
261,ES,A1,ES 2572181 A1,167-731-787-545-931,2016-05-30,2016,ES 201400965 A,2014-11-28,ES 201400965 A,2014-11-28,"Coupling system between unmanned aerial vehicles and beam structures for contact measurement (Machine-translation by Google Translate, not legally binding)","The present invention offers a coupling system between unmanned aerial vehicles and beam type structures using an inverted landing gear system, which allows the interaction between the vehicle and the structural element in a safe way for the first, also allowing the realization of measurements with contact sensors if applicable, for the detection of structural pathologies in concrete or steel. (Machine-translation by Google Translate, not legally binding)",UNIV VIGO,NEIRA LOPEZ PABLO;;ROCA BERNARDEZ DAVID;;DIAZ VILARINO LUCÍA;;LAGÜELA LOPEZ SUSANA;;MARTINEZ SANCHEZ JOAQUÍN;;CONDE CARNERO BORJA;;RIVEIRO RODRIGUEZ BELÉN;;GONZALEZ JORGE HIGINIO;;ARIAS SANCHEZ PEDRO;;LORENZO CIMADEVILA HENRIQUE,,https://lens.org/167-731-787-545-931,Patent Application,no,1,3,2,2,0,G01N27/20;;B64C39/024;;B64D47/00;;G01N2201/0214;;B64U10/13;;B64U50/19;;B64U30/20;;B64U2101/00,G01N27/20;;B64C39/02;;B64D47/00,,2,2,062-567-547-905-505;;074-370-154-950-950,10.1109/carpi.2012.6473361;;10.1109/ramech.2010.5513152,"MARCONI, L. et al: ""Aerial service robotics: the AIRobots perspective"", 2012 2nd INTERNATIONAL CONFERENCE ON APPLIED ROBOTICS FOR THE POWER INDUSTRY (CARPI 2012); 11-13 SEPTIEMBRE 2012, ZURICH; p?ginas 64-69; IEEE Piscataway, NJ, USA; DOI: 10.1109/CARPI.2012.6473361; print-ISBN: 978-1-4673-4585-9; e-ISBN: 978-1-4673-4587-3. Ver especialmente: p?g. 64, columna derecha, l?neas 1-6; p?g. 64, primer p?rrafo del apartado A. Main objectives and ideas, dentro de II. The Airobots Project; p?g. 66, segundo p?rrafo del apartado D. Technologies, dentro de II. The Airobots Project; p?g. 67, apartado B. Coaxial Rotor UAV, dentro de III. First prototypes; fig. 1, 3.;;ALBERS, a. et al: ""Semi-autonomous flying robot for physical interaction with environment"", 2010 IEEE CONFERENCE ON ROBOTICS, AUTOMATION AND MECHATRONICS (RAM 2010); 28-30 JUNIO 2010, SINGAPUR; p?ginas 441-446; XP031710205; IEEE Piscataway, NJ, USA; DOI: 10.1109/RAMECH.2010.5513152; print-ISBN: 978-1-4244-6503-3; e-ISBN: 978-1-4244-6506-4. Ver especialmente: p?g. 441, cuarto p?rrafo de I. Introduction; p?g. 442, tercer p?rrafo de III. Concept; p?g 443, tercer p?rrafo del apartado B-Systems extensions, dentro de IV. Physical platform; primer p?rrafo de VIII. Conclusi?n; fig. 1-2.",ACTIVE
262,CA,A1,CA 2999084 A1,017-151-775-577-725,2017-03-30,2017,CA 2999084 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The invention relates to a stereotactic frame for limbs, which guarantees a fixed and reproducible position for the limb, maintaining the same geometric conditions for the measurement or treatment devices in relation to the limb, or part thereof, during examination or therapy. The frame comprises a support for positioning and securing the limb and a measurement or treatment system, including a geometric location at which the measurement or treatment device is positioned, thereby ensuring that the position of the device relative to the region of the limb being examined or treated can be reproduced.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNANDEZ MONTEQUIN JOSE IGNACIO;;GUILLEN NIETO GERARDO ENRIQUE;;FLORES DIAZ LUIS MANUEL;;CABANAS RODRIGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GOMEZ RAIMUNDO,,https://lens.org/017-151-775-577-725,Patent Application,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B90/10;;A43D1/02;;A61B5/00;;A61B5/107,,0,0,,,,DISCONTINUED
263,MX,B,MX 367976 B,118-040-922-656-619,2019-08-09,2019,MX 2013004903 A,2013-04-30,MX 2013004903 A,2013-04-30,"FRACTIONED AGAVE FRUCTANES, PROCESS FOR OBTAINING AND USING THE SAME.","The invention refers to products obtained by fractionation of an aqueous extract of agave, consisting in branched fructanes of agave separated by size of molecular chain or degree of polymerization into two types: a) short-chain fructanes (fructo- oligosaccharides) with a degree of polymerization of about 3 to about 10 monomeric units, and b) long-chain fructanes with a degree of polymerization higher than 10. The process through which these products are obtained uses the cores of agave as raw material, which contain fructanes of different degrees of polymerization, and consists in washing the cores of agave, crushing and tearing the fiber thereof for being lixiviated with hot water and obtaining an aqueous extract containing the soluble solids of agave. The extract is clarified by coagulation, sedimentation and filtration for separating the insoluble solids present therein and for being purified by ion exchange and activated carbon. The purified extract is fractioned by tangential ul trafiltration. The obtained products have nutraceutical properties, thus they can be used as food supplements or functional ingredients in the manufacture of food products.",CENTRO DE INVESTIG Y ASISTENCIA EN TECNOLOGIA Y DISENO DEL ESTADO DE JALISCO A C,FRANCISCO JAVIER PEREZ MARTINEZ;;JOSE LUIS FLORES MONTAÑO;;JAVIER PLACIDO ARRIZON GAVIÑO;;JUAN CARLOS MATEOS DIAZ;;DIANA ALONSO SEGURA;;MARISELA GONZALEZ AVILA;;ROSA MARIA CAMACHO RUIZ;;ANA LAURA MARQUEZ AGUIRRE;;ANNE CHRISTINE GSCHAEDLERMATHIS;;ROGELIO PRADO RAMIREZ;;JORGE ALBERTO RODRIGUEZ GONZALEZ,,https://lens.org/118-040-922-656-619,Granted Patent,no,0,0,2,2,0,,C08B37/00;;A23L33/125;;A23L33/22,,0,0,,,,ACTIVE
264,MX,B,MX 363029 B,117-777-425-335-224,2019-02-07,2019,MX 2013004901 A,2013-04-30,MX 2013004901 A,2013-04-30,PROCESS FOR OBTAINING FRUCTANES FROM YOUNG AGAVE AND USE THEREOF AS FUNCTIONAL INGREDIENT.,"The invention refers to agave fructanes obtained from young agave, the process for obtaining and applying the same specifically as a functional ingredient with nutraceutical properties for reducing triglycerides in serum in normal, overweight and obese patients with dyslipidemia. The product has the characteristic of being constituted by a mixture of fructanes of different degree of polymerization DP, which are agaves with a degree of ripeness of about 3 years, in a ratio that varies from about 30/70 to about 50/50 referred to long-chain fructanes /short-chain fructanes. The process through which this product is obtained, using young agave, consists in washing the core, crush it and tear the fiber for being lixiviated with hot water and obtaining an aqueous extract that contains the soluble solids of the agave. The extract is clarified by coagulation, sedimentation and filtration for separating the insoluble solids present therein. The extract may be concentrated or dehydrated for obt aining a product in powder.",CENTRO DE INVESTIG Y ASISTENCIA EN TECNOLOGIA Y DISENO DEL ESTADO DE JALISCO A C,FRANCISCO JAVIER PEREZ MARTINEZ;;JOSE LUIS FLORES MONTAÑO;;JAVIER PLACIDO ARRIZON GAVIÑO;;JUAN CARLOS MATEOS DIAZ;;DIANA ALONSO SEGURA;;MARISELA GONZALEZ AVILA;;ROSA MARIA CAMACHO RUIZ;;ANA LAURA MARQUEZ AGUIRRE;;ROGELIO PRADO RAMIREZ;;JORGE ALBERTO RODRIGUEZ GONZALEZ;;ANNE CHRISTINE GSCHAEDLERMATHIS,,https://lens.org/117-777-425-335-224,Granted Patent,no,0,0,2,2,0,,A23L5/00;;A23L33/125;;A23L33/22,,0,0,,,,ACTIVE
265,MX,A,MX 2013004903 A,047-817-068-254-683,2014-10-31,2014,MX 2013004903 A,2013-04-30,MX 2013004903 A,2013-04-30,"FRACTIONED AGAVE FRUCTANES, PROCESS FOR OBTAINING AND USING THE SAME.","The invention refers to products obtained by fractionation of an aqueous extract of agave, consisting in branched fructanes of agave separated by size of molecular chain or degree of polymerization into two types: a) short-chain fructanes (fructo- oligosaccharides) with a degree of polymerization of about 3 to about 10 monomeric units, and b) long-chain fructanes with a degree of polymerization higher than 10. The process through which these products are obtained uses the cores of agave as raw material, which contain fructanes of different degrees of polymerization, and consists in washing the cores of agave, crushing and tearing the fiber thereof for being lixiviated with hot water and obtaining an aqueous extract containing the soluble solids of agave. The extract is clarified by coagulation, sedimentation and filtration for separating the insoluble solids present therein and for being purified by ion exchange and activated carbon. The purified extract is fractioned by tangential ul trafiltration. The obtained products have nutraceutical properties, thus they can be used as food supplements or functional ingredients in the manufacture of food products.",CT DE INVESTIGACION Y ASISTENCIA EN TECNOLOGIA Y DISEÑO DEL ESTADO DE JALISCO A C,MARTINEZ FRANCISCO JAVIER PEREZ;;MONTAÑO JOSE LUIS FLORES;;GAVIÑO JAVIER PLACIDO ARRIZON;;DIAZ JUAN CARLOS MATEOS;;SEGURA DIANA ALONSO;;AVILA MARISELA GONZALEZ;;RUIZ ROSA MARIA CAMACHO;;AGUIRRE ANA LAURA MARQUEZ;;GSCHAEDLERMATHIS ANNE CHRISTINE;;RAMIREZ ROGELIO PRADO;;GONZALEZ JORGE ALBERTO RODRIGUEZ,,https://lens.org/047-817-068-254-683,Patent Application,no,0,0,2,2,0,,A23L1/00;;C08B37/00,,0,0,,,,ACTIVE
266,KR,A,KR 20180056684 A,183-951-632-276-567,2018-05-29,2018,KR 20187010736 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,사지용 정위 고정 프레임,"본 발명은 사지 위치를 고정 및 재현 가능하도록 하여 조사 또는 치료 중에 사지 또는 그의 일부에 대한 측정 또는 치료 기기의 동일한 기하학적 조건을 유지하게 하는 사지용 정위 고정 프레임에 관한 것이다. 상기 프레임은 사지용 위치 조정 및 고정 홀더와, 측정 또는 치료 기기가 할당되어 있는 기하학적 궤적을 포함하는 측정 또는 치료 시스템을 포함하여 검사 또는 치료 중에 사지의 영역에 대한 상기 기기의 상대적 위치를 재현할 수 있게 한다.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZALEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNANDEZ MONTEQUIN JOSE IGNACIO;;GUILLEN NIETO GERARDO ENRIQUE;;FLORES DIAZ LUIS MANUEL;;CABANAS RODRIGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GOMEZ RAIMUNDO,,https://lens.org/183-951-632-276-567,Patent Application,no,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/00;;A61B5/107;;A61B90/10,,0,0,,,,PENDING
267,WO,A2,WO 2011/124742 A2,033-592-954-387-058,2011-10-13,2011,ES 2011070239 W,2011-04-08,ES 201030516 A,2010-04-09,METHOD FOR ESTIMATING THE PARAMETERS OF A CONTROL ELEMENT SUCH AS A TOKEN BUCKET,"The invention relates to a method and a program for estimating the parameters of a control element such as a token bucket for controlling or regulating data packet transmission ( QoS ) in communication networks. Said method enables the non-intrusive estimation of the parameters for each service controlled by a token-bucket regulator. Said method can also discriminate interferences with said service, and can be carried out in the presence of processes in systems that have shared resources. Said method enables the acquisition of the parameters of a control element such as a token-bucket in such a way that service level agreements (SLA) between a company and a telecommunications operator can be checked. The invention also relates to a computer program that can carry out said method.",UNIV MADRID AUTONOMA;;ARACIL RICO JAVIER;;RAMOS DE SANTIAGO JAVIER;;SANTIAGO DEL RIO PEDRO MARIA;;LOPEZ DE VERGARA MENDEZ JORGE;;DE PEDRO SANCHEZ LUIS;;LOPEZ BUEDO SERGIO;;GONZALEZ MARTINEZ IVAN;;GOMEZ ARRIBAS FRANCISCO JAVIER,ARACIL RICO JAVIER;;RAMOS DE SANTIAGO JAVIER;;SANTIAGO DEL RIO PEDRO MARIA;;LOPEZ DE VERGARA MENDEZ JORGE;;DE PEDRO SANCHEZ LUIS;;LOPEZ BUEDO SERGIO;;GONZALEZ MARTINEZ IVAN;;GOMEZ ARRIBAS FRANCISCO JAVIER,,https://lens.org/033-592-954-387-058,Patent Application,yes,0,3,4,4,0,H04L12/56;;H04L47/215;;H04L47/2425,,,0,0,,,,PENDING
268,WO,A3,WO 2011/124742 A3,131-016-648-375-072,2011-12-01,2011,ES 2011070239 W,2011-04-08,ES 201030516 A,2010-04-09,METHOD FOR ESTIMATING THE PARAMETERS OF A CONTROL ELEMENT SUCH AS A TOKEN BUCKET,"The invention relates to a method and a program for estimating the parameters of a control element such as a token bucket for controlling or regulating data packet transmission ( QoS ) in communication networks. Said method enables the non-intrusive estimation of the parameters for each service controlled by a token-bucket regulator. Said method can also discriminate interferences with said service, and can be carried out in the presence of processes in systems that have shared resources. Said method enables the acquisition of the parameters of a control element such as a token-bucket in such a way that service level agreements (SLA) between a company and a telecommunications operator can be checked. The invention also relates to a computer program that can carry out said method.",UNIV MADRID AUTONOMA;;ARACIL RICO JAVIER;;RAMOS DE SANTIAGO JAVIER;;SANTIAGO DEL RIO PEDRO MARIA;;LOPEZ DE VERGARA MENDEZ JORGE;;DE PEDRO SANCHEZ LUIS;;LOPEZ BUEDO SERGIO;;GONZALEZ MARTINEZ IVAN;;GOMEZ ARRIBAS FRANCISCO JAVIER,ARACIL RICO JAVIER;;RAMOS DE SANTIAGO JAVIER;;SANTIAGO DEL RIO PEDRO MARIA;;LOPEZ DE VERGARA MENDEZ JORGE;;DE PEDRO SANCHEZ LUIS;;LOPEZ BUEDO SERGIO;;GONZALEZ MARTINEZ IVAN;;GOMEZ ARRIBAS FRANCISCO JAVIER,,https://lens.org/131-016-648-375-072,Search Report,yes,1,0,4,4,0,H04L12/56;;H04L47/215;;H04L47/2425,H04L12/56,,0,0,,,,PENDING
269,ES,B1,ES 2372213 B1,137-053-568-822-662,2012-09-03,2012,ES 201030516 A,2010-04-09,ES 201030516 A,2010-04-09,METODO PARA ESTIMAR LOS PARAMETROS DE UN ELEMENTO DE CONTROL DEL TIPO TOKEN-BUCKET.,,UNIV MADRID AUTONOMA,ARACIL RICO JAVIER;;RAMOS DE SANTIAGO JAVIER;;SANTIAGO DEL RIO PEDRO MARIA;;LOPEZ DE VERGARA MENDEZ JORGE;;DE PEDRO SANCHEZ LUIS;;LOPEZ BUEDO SERGIO;;GONZALEZ MARTINEZ IVAN;;GOMEZ ARRIBAS FRANCISCO JAVIER,,https://lens.org/137-053-568-822-662,Granted Patent,no,0,0,4,4,0,H04L12/56;;H04L47/215;;H04L47/2425,H04L12/56,,0,0,,,,ACTIVE
270,ES,U,ES 1214704 U,075-869-386-516-001,2018-06-25,2018,ES 201830718 U,2018-05-18,ES 201830718 U,2018-05-18,"INTEGRATED TRAFFIC CONTROL SYSTEM. (Machine-translation by Google Translate, not legally binding)","Integrated traffic control system (100) characterized in that it comprises - a control center (110), - at least one ERU or Universal Remote Station (130), - at least one operator station (120), - a TCP/IP network (140) that allows communication between the control center, the at least one ERU and the at least one operator station, - at least one control and/or traffic management element directly connected (160) to said at least one ERU and/or - at least one control and/or traffic management element connected to said at least one ERU (170) through a communications bus (150), and where the management of the at least one control and/or management element (160, 170) is performed in an integrated manner from the control center (110) through the operator stations (120). (Machine-translation by Google Translate, not legally binding)",FCC IND E INFRAESTRUCTURAS ENERGETICAS S A U,ARRANZ BENITO JOSE ANGEL;;MALPARTIDA MARTINEZ-DARVE GONZALO;;CASTELLANOS TALAVERA MARIO;;MARTIN DE LA IGLESIA MARIA PILAR;;GONZALEZ MOLANO JOSE CARLOS;;RAMIREZ CASCAJERO MIGUEL ANGEL;;LORENZO LAJAS JORGE;;LOPEZ VAQUERO OLGA,,https://lens.org/075-869-386-516-001,Patent Application,no,0,0,2,2,0,,G08G1/00,,0,0,,,,ACTIVE
271,ES,Y,ES 1214704 Y,142-931-218-592-817,2018-09-14,2018,ES 201830718 U,2018-05-18,ES 201830718 U,2018-05-18,SISTEMA INTEGRADO DE CONTROL DE TRAFICO.,,FCC IND E INFRAESTRUCTURAS ENERGETICAS S A U,ARRANZ BENITO JOSE ANGEL;;MALPARTIDA MARTINEZ-DARVE GONZALO;;CASTELLANOS TALAVERA MARIO;;MARTIN DE LA IGLESIA MARIA PILAR;;GONZALEZ MOLANO JOSE CARLOS;;RAMIREZ CASCAJERO MIGUEL ANGEL;;LORENZO LAJAS JORGE;;LOPEZ VAQUERO OLGA,,https://lens.org/142-931-218-592-817,Limited Patent,no,0,0,2,2,0,,G08G1/00,,0,0,,,,ACTIVE
272,ES,U,ES 1216986 U,156-814-782-515-981,2018-09-06,2018,ES 201830861 U,2018-06-07,ES 201830861 U,2018-06-07,"INTEGRATED SYSTEM OF SUPERVISION AND INFRASTRUCTURE CONTROL. (Machine-translation by Google Translate, not legally binding)","Integrated infrastructure supervision and control system (100) characterized in that it comprises - at least one remote control server (110), wherein said server (110) has at least one access interface component (140) to one or more field devices (200), where said access interface component implements towards the external side of the system (100) the corresponding signal protocol of the field device (200) and implements towards the internal side of the system (100) a signal interface that unifies the internal way of handling the signal protocols of the device field (200), - at least one web application (120) accessible from any web browser (130) arranged to serve the user interface with the operations that can be performed on the system (100), and - a database (150) arranged to store the data required by the system (100) for its operation and the information that is received from the field devices (200) through the access interface component (140) for its subsequent treatment. (Machine-translation by Google Translate, not legally binding)",FCC IND E INFRAESTRUCTURAS ENERGETICAS S A U,ARRANZ BENITO JOSE ANGEL;;MALPARTIDA MARTINEZ-DARVE GONZALO;;CASTELLANOS TALAVERA MARIO;;MARTIN DE LA IGLESIA MARIA PILAR;;GONZALEZ MOLANO JOSE CARLOS;;RAMIREZ CASCAJERO MIGUEL ANGEL;;LORENZO LAJAS JORGE;;LOPEZ VAQUERO OLGA,,https://lens.org/156-814-782-515-981,Patent Application,no,0,0,2,2,0,,G08B25/10,,0,0,,,,ACTIVE
273,ES,A1,ES 2372213 A1,184-328-962-013-745,2012-01-17,2012,ES 201030516 A,2010-04-09,ES 201030516 A,2010-04-09,METHOD FOR ESTIMATING THE PARAMETERS OF A CONTROL ELEMENT SUCH AS A TOKEN BUCKET,"The invention relates to a method and a program for estimating the parameters of a control element such as a token bucket for controlling or regulating data packet transmission (QoS) in communication networks. Said method enables the non-intrusive estimation of the parameters for each service controlled by a token-bucket regulator. Said method can also discriminate interferences with said service, and can be carried out in the presence of processes in systems that have shared resources. Said method enables the acquisition of the parameters of a control element such as a token-bucket in such a way that service level agreements (SLA) between a company and a telecommunications operator can be checked. The invention also relates to a computer program that can carry out said method.",UNIV MADRID AUTONOMA,ARACIL RICO JAVIER;;RAMOS DE SANTIAGO JAVIER;;SANTIAGO DEL RIO PEDRO MARIA;;LOPEZ DE VERGARA MENDEZ JORGE;;DE PEDRO SANCHEZ LUIS;;LOPEZ BUEDO SERGIO;;GONZALEZ MARTINEZ IVAN;;GOMEZ ARRIBAS FRANCISCO JAVIER,,https://lens.org/184-328-962-013-745,Patent Application,no,1,0,4,4,0,H04L12/56;;H04L47/215;;H04L47/2425,H04L12/56,,0,0,,,,ACTIVE
274,ES,Y,ES 1216986 Y,024-881-447-625-511,2018-11-30,2018,ES 201830861 U,2018-06-07,ES 201830861 U,2018-06-07,SISTEMA INTEGRADO DE SUPERVISION Y CONTROL DE INFRAESTRUCTURAS.,,FCC IND E INFRAESTRUCTURAS ENERGETICAS S A U,ARRANZ BENITO JOSE ANGEL;;MALPARTIDA MARTINEZ-DARVE GONZALO;;CASTELLANOS TALAVERA MARIO;;MARTIN DE LA IGLESIA MARIA PILAR;;GONZALEZ MOLANO JOSE CARLOS;;RAMIREZ CASCAJERO MIGUEL ANGEL;;LORENZO LAJAS JORGE;;LOPEZ VAQUERO OLGA,,https://lens.org/024-881-447-625-511,Limited Patent,no,0,0,2,2,0,,G08B25/10,,0,0,,,,ACTIVE
275,WO,A2,WO 2005/029082 A2,161-448-310-750-688,2005-03-31,2005,EP 2004010841 W,2004-09-24,ES 200302213 A,2003-09-24,METHODS FOR THE IN VITRO DIAGNOSIS AND IN VITRO PROGNOSIS OF CANCER OF THE PANCREAS AND FOR THE DEVELOPMENT OF DRUGS AGAINST CANCER OF THE PANCREAS AND/OR PANCREATITIS,"The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma and/or pancreatitis in an individual, to determine the stage or severity of said conditions in an individual, or to monitor the effect of therapy administeied to an individual with either one or both of said conditions; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said conditions of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the DRM protein and/or the NBL1 protein, and/or the effects of said expression.",PROGENIKA BIOPHARMA SA;;DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,,https://lens.org/161-448-310-750-688,Patent Application,yes,0,6,4,4,32,C07K16/18;;G01N33/57438;;G01N33/68;;G01N33/57438;;G01N33/6893;;G01N2500/00;;G01N2800/067,C07K16/00;;C07K16/18;;G01N33/574;;G01N33/68,,0,0,,,,PENDING
276,WO,A3,WO 2005/029082 A3,178-083-086-983-214,2005-09-22,2005,EP 2004010841 W,2004-09-24,ES 200302213 A,2003-09-24,METHODS FOR THE IN VITRO DIAGNOSIS AND IN VITRO PROGNOSIS OF CANCER OF THE PANCREAS AND FOR THE DEVELOPMENT OF DRUGS AGAINST CANCER OF THE PANCREAS AND/OR PANCREATITIS,"The present invention refers to an in vitro method to detect pancreatic ductal adenocarcinoma and/or pancreatitis in an individual, to determine the stage or severity of said conditions in an individual, or to monitor the effect of therapy administeied to an individual with either one or both of said conditions; to screen for, identify, develop and evaluate the efficacy of compounds for the treatment of said conditions of the pancreas aimed at developing new medicinal products, as well as agents that inhibit the expression and/or activity of the DRM protein and/or the NBL1 protein, and/or the effects of said expression.",PROGENIKA BIOPHARMA SA;;DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,DEL AMO IRIBARREN JOKIN;;JUNQUERA SANCHEZ-VALLEJO CORIN;;OCHOA GARAY JORGE;;ESCUDERO GARCIA DE GALDEANO PE;;ARGUEELLES SANCHEZ MARIA ELADI;;DE LOS TOYOS GONZALEZ JUAN RAM;;SANTA CRUZ SIMON;;MARTINEZ MARTINEZ ANTONIO;;BARNEO SERRA LUIS;;ARIZ LOPEZ DE CASTRO USUE;;SIMON BUELA LAUREANO,,https://lens.org/178-083-086-983-214,Search Report,yes,4,0,4,4,0,C07K16/18;;G01N33/57438;;G01N33/68;;G01N33/57438;;G01N33/6893;;G01N2500/00;;G01N2800/067,C07K16/00;;C07K16/18;;G01N33/574;;G01N33/68,,3,3,090-433-846-511-962;;017-186-900-863-545;;002-880-498-827-946,12651607;;10.1016/s0002-9440(10)63911-9;;pmc1851213;;pmc232332;;10.1128/mcb.17.8.4801;;9234736;;10.1016/s1097-2765(00)80067-2;;9660951,"IACOBUZIO-DONAHUE ET AL: ""Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays"", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 162, no. 4, April 2003 (2003-04-01), pages 1151 - 1162, XP009027111, ISSN: 0002-9440;;TOPOL L Z ET AL: ""IDENTIFICATION OF DRM, A NOVEL GENE WHOSE EXPRESSION IS SUPPRESSED IN TRANSFORMED CELLS AND WHICH CAN INHIBIT GROWTH OF NORMAL BUT NOT TRANSFORMED CELLS IN CULTURE"", MOLECULAR AND CELLULAR BIOLOGY, WASHINGTON, DC, US, vol. 17, no. 8, August 1997 (1997-08-01), pages 4801 - 4810, XP002066577, ISSN: 0270-7306;;HSU D R ET AL: ""The Xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities"", MOLECULAR CELL, CAMBRIDGE, MA, US, vol. 1, April 1988 (1988-04-01), pages 673 - 683, XP002066230, ISSN: 1097-2765",PENDING
277,EP,B1,EP 0438200 B1,139-632-891-176-014,2002-07-17,2002,EP 91200074 A,1991-01-16,CU 1990007 A;;CU 1990104 A;;CU 1990132 A;;CU 1990142 A,1990-01-16,"Method for the expression of heterologous genes in the yeast Pichia pastoris, expression vectors and transformed microorganisms","The present invention provides a highly efficient method for the expression of heterologous genes, using as the host an auxotrophic his3 mutant of strain BKM-90 of Pichia pastoris and as recombinant DNA for the transformation thereof an integrative vector which contains a functional selection marker of Saccharomyces cerevisiae, the promotor of the alcohol oxidase gene (AOX1) of the yeast itself, as the transcription terminator that of glyceraldehyde 3-phosphate dehydrogenase (GAP) of S. cerevisiae, or that which is carried by the heterologous gene to be expressed, and another sequence homologous to the genome of Pichia pastoris which serves for the integration thereof. The expression vectors used further contain a heterologous gene bound to the signal peptide of the sucrose invertase gene (SUC2) of S. cerevisiae. This method guarantees that the polypeptide products are recoverable under controllable conditions and with high yields. The strains according to the present invention can be used for the large-scale production of pharmaceutical products or of enzymes of industrial interest.",CT INGENIERIA GENETICA BIOTECH,HERRERA MARTINEZ LUIS SATURNIN;;YONG GONZALEZ VLADIMIR;;MARGOLLEZ CLARK EMILIO;;DELGADO BOADA JULIO MARCOS;;MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARME;;SILVA RODRIGUEZ ALEJANDRO;;PAIFER REYES EDENIA;;FERBEYRE BINELFA GERARDO;;S OSA ESPINOSA ANGELA ESTELA;;MARTINEZ SANTANA VLADIMIR;;AGUIAR SANTIAGO JORGE AGUSTIN;;SERALENA MENENDEZ ALINA;;GONZALEZ LUPEZ TANIA;;MONTESINOS SEGUI RAQUEL;;CREMATA ALVAREZ JOSE ALBERTO;;VILLAREAL BARRIOS ADELAIDA;;GONZALEZ BADILLO BEATRIZ;;MENENDEZ ALARCUN ALFREDO,,https://lens.org/139-632-891-176-014,Granted Patent,yes,6,0,8,12,20,C07K14/485;;C07K2319/02;;C12N9/2417;;C12N9/6481;;C12N9/6483;;C12N15/815;;C12Y304/23004,C12N1/19;;C07K14/485;;C12N9/28;;C12N9/30;;C12N9/60;;C12N9/64;;C12N15/09;;C12N15/16;;C12N15/56;;C12N15/57;;C12N15/81;;C12P21/02;;C12R1/84,,3,0,,,"BIOTECHNOLOGY vol. 5, no. 12, December 1987, NEW YORK US pages 1305 - 1308; J.F.Tschopp et al.: ""High-level secretion of glycosylated invertase in the methylotrophic yeast, Pichia pastoris"";;GENE. vol. 23, no. 3, September 1983, AMSTERDAM NL pages 267 - 276; Ortlepp et al.: ""Molecular cloning in Bacillus subtilis of a Bacillus licheniformis gene encoding a thermostable alpha amylase"";;CHEMICAL ABSTRACTS, vol. 108, 1988 Columbus, Ohio, USA Yamashita Takashi et al.: ""Secretion of Mucor rennin, a fungal aspartic protease of Mucor & MGG, Mol. Gen. Genet. vol.210,1987,No.3,pp.462-7 ref. no. 217200Y",EXPIRED
278,DE,D1,DE 69133066 D1,152-277-481-349-442,2002-08-22,2002,DE 69133066 T,1991-01-16,CU 1990007 A;;CU 1990104 A;;CU 1990132 A;;CU 1990142 A,1990-01-16,"Verfahren zur Expression heterologischer Gene in der Hefe Pichia Pastoris, Expressionsvektoren und transformierte Mikroorganismen","The present invention provides a highly efficient method for the expression of heterologous genes, using as the host an auxotrophic his3 mutant of strain BKM-90 of Pichia pastoris and as recombinant DNA for the transformation thereof an integrative vector which contains a functional selection marker of Saccharomyces cerevisiae, the promotor of the alcohol oxidase gene (AOX1) of the yeast itself, as the transcription terminator that of glyceraldehyde 3-phosphate dehydrogenase (GAP) of S. cerevisiae, or that which is carried by the heterologous gene to be expressed, and another sequence homologous to the genome of Pichia pastoris which serves for the integration thereof. The expression vectors used further contain a heterologous gene bound to the signal peptide of the sucrose invertase gene (SUC2) of S. cerevisiae. This method guarantees that the polypeptide products are recoverable under controllable conditions and with high yields. The strains according to the present invention can be used for the large-scale production of pharmaceutical products or of enzymes of industrial interest.",CT INGENIERIA GENETICA BIOTECH,HERRERA MARTINEZ LUIS SATURNIN;;YONG GONZALEZ VLADIMIR;;MARGOLLEZ CLARK EMILIO;;DELGADO BOADA JULIO MARCOS;;MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARME;;SILVA RODRIGUEZ ALEJANDRO;;PAIFER REYES EDENIA;;FERBEYRE BINELFA GERARDO;;S OSA ESPINOSA ANGELA ESTELA;;MARTINEZ SANTANA VLADIMIR;;AGUIAR SANTIAGO JORGE AGUSTIN;;SERALENA MENENDEZ ALINA;;GONZALEZ L PEZ TANIA;;MONTESINOS SEGUI RAQUEL;;CREMATA ALVAREZ JOSE ALBERTO;;VILLAREAL BARRIOS ADELAIDA;;GONZALEZ BADILLO BEATRIZ;;MENENDEZ ALARC N ALFREDO,,https://lens.org/152-277-481-349-442,Granted Patent,no,0,0,8,12,0,C07K14/485;;C07K2319/02;;C12N9/2417;;C12N9/6481;;C12N9/6483;;C12N15/815;;C12Y304/23004,C12N1/19;;C07K14/485;;C12N9/28;;C12N9/30;;C12N9/60;;C12N9/64;;C12N15/09;;C12N15/16;;C12N15/56;;C12N15/57;;C12N15/81;;C12P21/02;;C12R1/84,,0,0,,,,EXPIRED
279,DE,T2,DE 69133066 T2,181-682-408-730-66X,2003-03-06,2003,DE 69133066 T,1991-01-16,CU 1990007 A;;CU 1990104 A;;CU 1990132 A;;CU 1990142 A,1990-01-16,"Verfahren zur Expression heterologischer Gene in der Hefe Pichia Pastoris, Expressionsverfahren und transformierte Mikroorganismen","The present invention provides a highly efficient method for the expression of heterologous genes, using as the host an auxotrophic his3 mutant of strain BKM-90 of Pichia pastoris and as recombinant DNA for the transformation thereof an integrative vector which contains a functional selection marker of Saccharomyces cerevisiae, the promotor of the alcohol oxidase gene (AOX1) of the yeast itself, as the transcription terminator that of glyceraldehyde 3-phosphate dehydrogenase (GAP) of S. cerevisiae, or that which is carried by the heterologous gene to be expressed, and another sequence homologous to the genome of Pichia pastoris which serves for the integration thereof. The expression vectors used further contain a heterologous gene bound to the signal peptide of the sucrose invertase gene (SUC2) of S. cerevisiae. This method guarantees that the polypeptide products are recoverable under controllable conditions and with high yields. The strains according to the present invention can be used for the large-scale production of pharmaceutical products or of enzymes of industrial interest.",CT INGENIERIA GENETICA BIOTECH,HERRERA MARTINEZ LUIS SATURNIN;;YONG GONZALEZ VLADIMIR;;MARGOLLEZ CLARK EMILIO;;DELGADO BOADA JULIO MARCOS;;MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARME;;SILVA RODRIGUEZ ALEJANDRO;;PAIFER REYES EDENIA;;FERBEYRE BINELFA GERARDO;;S OSA ESPINOSA ANGELA ESTELA;;MARTINEZ SANTANA VLADIMIR;;AGUIAR SANTIAGO JORGE AGUSTIN;;SERALENA MENENDEZ ALINA;;GONZALEZ L PEZ TANIA;;MONTESINOS SEGUI RAQUEL;;CREMATA ALVAREZ JOSE ALBERTO;;VILLAREAL BARRIOS ADELAIDA;;GONZALEZ BADILLO BEATRIZ;;MENENDEZ ALARC N ALFREDO,,https://lens.org/181-682-408-730-66X,Granted Patent,no,0,0,8,12,0,C07K14/485;;C07K2319/02;;C12N9/2417;;C12N9/6481;;C12N9/6483;;C12N15/815;;C12Y304/23004,C12N1/19;;C07K14/485;;C12N9/28;;C12N9/30;;C12N9/60;;C12N9/64;;C12N15/09;;C12N15/16;;C12N15/56;;C12N15/57;;C12N15/81;;C12P21/02;;C12R1/84,,0,0,,,,EXPIRED
280,SI,T1,SI 1787653 T1,105-950-703-308-439,2012-10-30,2012,SI 200531578 T,2005-07-05,CU 20040147 A;;CU 2005000003 W;;EP 05762122 A,2004-07-08,Antitumoral pharmaceutical composition containing polypeptide fragments of serralysins,,CT INGENIERIA GENETICA BIOTECH,ABRAHANTES PEREZ MARIA DEL CARMEN CALLE;;REYES GONZALEZ JESUS CALLE;;VELIZ RIOS GLORIA CALLE;;MARTINEZ DIAZ EDUARDO CALLE;;GASMURI GONZALEZ CARIDAD ANAIS;;GARCIA SUAREZ JOSE CALLE;;BEQUET ROMERO MONICA;;GONZALEZ LOPEZ LUIS JAVIER CALLE;;CASTELLANOS SERRA LILA ROSA KOHLY;;SELMAN-HOUSEIN SOSA MANUEL;;GOMEZ RIERA RAUL;;GAVILONDO COWLEY JORGE VICTOR CALLE G,,https://lens.org/105-950-703-308-439,Granted Patent,no,0,0,30,30,0,A61K38/16;;A61P29/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P37/04;;A61K38/16;;C07K14/265;;A61K38/16,A61K38/00;;A61P31/00;;A61P35/00;;C07K14/00,,0,0,,,,ACTIVE
281,US,B2,US 9302164 B2,192-520-305-554-170,2016-04-05,2016,US 201314071353 A,2013-11-04,US 201314071353 A,2013-11-04,Variably disposed multi-layer golf grip,"A golf grip for a golf club includes a cap, a body, a tip, and a grip surface. The body includes an under layer, a top layer, and a middle layer. The under layer includes a first color. The top layer includes a second color, different than the first color. The top layer is disposed on the under layer. The middle layer includes a third material. The middle layer is at least partially disposed between the under layer and the top layer. The tip is a portion of the under layer extending beyond the top layer and the middle layer. The grip surface extends between the cap and the tip. The grip surface is the radially outer surface of the body and includes the top layer, a plurality of exposed portions of the under layer, and a plurality of exposed portions of the middle layer.",LAMKIN CORP,LAMKIN ROBERT J;;PETTERSEN CARL;;CAMOU DENISSE;;MARQUEZ PATRICIA;;KERR ANDREW;;MARTINEZ CARLOS;;COLTON ADAM;;BROWN PETER;;KAUFFMAN KERRI;;RODRIGUEZ CARLOS;;MEDINA RAUL;;MEDINA RICARDO;;LAU TING;;TALLMAN STEVE;;GONZALEZ JORGE;;RAMIREZ MARY,LAMKIN CORPORATION (2013-10-28),https://lens.org/192-520-305-554-170,Granted Patent,yes,19,3,2,2,0,A63B60/14;;A63B60/14;;A63B53/14;;A63B60/00;;A63B60/00;;B29C43/146;;B29C43/146;;B29C43/18;;B29C43/18;;B29C43/24;;B29C43/24;;B29C43/305;;B29C43/305;;B29C69/02;;B29C69/02;;B29C2043/028;;B29C2043/028;;B29K2021/003;;B29K2021/003;;B29K2995/0021;;B29K2995/0021;;B29L2009/00;;B29L2009/00;;B29L2031/5227;;B29L2031/5227,A63B53/14;;A63B59/00;;B29C43/02;;B29C43/14;;B29C43/18;;B29C43/24;;B29C43/30;;B29C69/02;;B29K21/00;;B29L9/00;;B29L31/52,,0,0,,,,ACTIVE
282,US,A1,US 2015/0126299 A1,084-860-498-619-414,2015-05-07,2015,US 201314071353 A,2013-11-04,US 201314071353 A,2013-11-04,VARIABLY DISPOSED MULTI-LAYER GOLF GRIP,"A golf grip for a golf club includes a cap, a body, a tip, and a grip surface. The body includes an under layer, a top layer, and a middle layer. The under layer includes a first color. The top layer includes a second color, different than the first color. The top layer is disposed on the under layer. The middle layer includes a third material. The middle layer is at least partially disposed between the under layer and the top layer. The tip is a portion of the under layer extending beyond the top layer and the middle layer. The grip surface extends between the cap and the tip. The grip surface is the radially outer surface of the body and includes the top layer, a plurality of exposed portions of the under layer, and a plurality of exposed portions of the middle layer.",LAMKIN CORP,LAMKIN ROBERT J;;PETTERSEN CARL;;CAMOU DENISSE;;MARQUEZ PATRICIA;;KERR ANDREW;;MARTINEZ CARLOS;;COLTON ADAM;;BROWN PETER;;KAUFFMAN KERRI;;RODRIGUEZ CARLOS;;MEDINA RAUL;;MEDINA RICARDO;;LAU TING;;TALLMAN STEVE;;GONZALEZ JORGE;;RAMIREZ MARY,LAMKIN CORPORATION (2013-10-28),https://lens.org/084-860-498-619-414,Patent Application,yes,15,3,2,2,0,A63B60/14;;A63B60/14;;A63B53/14;;A63B60/00;;A63B60/00;;B29C43/146;;B29C43/146;;B29C43/18;;B29C43/18;;B29C43/24;;B29C43/24;;B29C43/305;;B29C43/305;;B29C69/02;;B29C69/02;;B29C2043/028;;B29C2043/028;;B29K2021/003;;B29K2021/003;;B29K2995/0021;;B29K2995/0021;;B29L2009/00;;B29L2009/00;;B29L2031/5227;;B29L2031/5227,A63B59/00;;A63B53/14;;B29C43/24;;B29C43/30,473/298;;264/139,0,0,,,,ACTIVE
283,EP,A1,EP 1520587 A1,188-778-319-397-114,2005-04-06,2005,EP 03724819 A,2003-05-08,CU 0300007 W;;CU 20020091 A,2002-05-08,"ALLERGY VACCINE COMPOSITION, PRODUCTION METHOD THEREOF AND USE OF SAME IN ALLERGY TREATMENT","The present invention rebates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic use using bacterial proteoliposomes, which transform the allergic response Th2 and IgE when being applied in allergic individuals, toward a protector response Th1; as well as it is able to prevent the appearance and the development of allergies in individuals non-allergic yet. The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided.",INST FINLAY CT DE INVESTIGACIO;;CT NAC BIOPREPARADOS,LASTRE GONZALEZ MIRIAM DE SAN;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;BIDOT MARTINEZ IGOR;;PEREZ LASTRE JORGE ERNESTO;;BRACHO GRANADA GUSTAVO RAFAEL;;DEL CAMPO ALONSO JUDITH MONICA;;PEREZ LASTRE DAINERYS ALEIDA;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;RODRIGUEZ MARTINEZ CLAUDIO;;SIERRA GONZELEZ VICTORIANO GUS,,https://lens.org/188-778-319-397-114,Patent Application,yes,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35,,0,0,,,,EXPIRED
284,AT,T1,AT E220721 T1,083-206-280-915-293,2002-08-15,2002,AT 91200074 T,1991-01-16,CU 1990007 A;;CU 1990104 A;;CU 1990132 A;;CU 1990142 A,1990-01-16,"VERFAHREN ZUR EXPRESSION HETEROLOGISCHER GENE IN DER HEFE PICHIA PASTORIS, EXPRESSIONSVEKTOREN UND TRANSFORMIERTE MIKROORGANISMEN","The present invention provides a highly efficient method for the expression of heterologous genes, using as the host an auxotrophic his3 mutant of strain BKM-90 of Pichia pastoris and as recombinant DNA for the transformation thereof an integrative vector which contains a functional selection marker of Saccharomyces cerevisiae, the promotor of the alcohol oxidase gene (AOX1) of the yeast itself, as the transcription terminator that of glyceraldehyde 3-phosphate dehydrogenase (GAP) of S. cerevisiae, or that which is carried by the heterologous gene to be expressed, and another sequence homologous to the genome of Pichia pastoris which serves for the integration thereof. The expression vectors used further contain a heterologous gene bound to the signal peptide of the sucrose invertase gene (SUC2) of S. cerevisiae. This method guarantees that the polypeptide products are recoverable under controllable conditions and with high yields. The strains according to the present invention can be used for the large-scale production of pharmaceutical products or of enzymes of industrial interest.",CT INGENIERIA GENETICA BIOTECH,MENENDEZ ALARCUN ALFREDO;;HERRERA MARTINEZ LUIS SATURNIN;;YONG GONZALEZ VLADIMIR;;MARGOLLEZ CLARK EMILIO;;DELGADO BOADA JULIO MARCOS;;MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARME;;SILVA RODRIGUEZ ALEJANDRO;;PAIFER REYES EDENA;;FERBEYRE BINELFA GERARDO;;S OSA ESPINOSA ANGELA ESTELA;;MARTINEZ SANTANA VLADIMIR;;AGUIAR SANTIAGO JORGE AGUSTIN;;SERALENA MENENDEZ ALINA;;GONZALEZ LUPEZ TANIA CALLE L-V;;MONTESINOS SEGUI RAQUEL;;CREMATA ALVAREZ JOSE ALBERTO;;VILLAREAL BARRIOS ADELAIDA;;GONZALEZ BADILLO BEATRIZ,,https://lens.org/083-206-280-915-293,Granted Patent,no,0,0,8,12,0,C07K14/485;;C07K2319/02;;C12N9/2417;;C12N9/6481;;C12N9/6483;;C12N15/815;;C12Y304/23004,C12N1/19;;C07K14/485;;C12N9/28;;C12N9/30;;C12N9/60;;C12N9/64;;C12N15/09;;C12N15/16;;C12N15/56;;C12N15/57;;C12N15/81;;C12P21/02;;C12R1/84,,0,0,,,,DISCONTINUED
285,EP,A1,EP 0438200 A1,154-387-222-010-671,1991-07-24,1991,EP 91200074 A,1991-01-16,CU 1990007 A;;CU 1990104 A;;CU 1990132 A;;CU 1990142 A,1990-01-16,"Method for the expression of heterologous genes in the yeast Pichia pastoris, expression vectors and transformed microorganisms.","The present invention provides a highly efficient method for the expression of heterologous genes, using as the host an auxotrophic his3 mutant of strain BKM-90 of  Pichia pastoris  and as recombinant DNA for the transformation thereof an integrative vector which contains a functional selection marker of  Saccharomyces cerevisiae , the promotor of the alcohol oxidase gene (AOX₁) of the yeast itself, as the transcription terminator that of glyceraldehyde 3-phosphate dehydrogenase (GAP) of  S .  cerevisiae , or that which is carried by the heterologous gene to be expressed, and another sequence homologous to the genome of  Pichia pastoris  which serves for the integration thereof. The expression vectors used further contain a heterologous gene bound to the signal peptide of the sucrose invertase gene (SUC2) of  S .  cerevisiae . This method guarantees that the polypeptide products are recoverable under controllable conditions and with high yields. The strains according to the present invention can be used for the large-scale production of pharmaceutical products or of enzymes of industrial interest.",CIGB,HERRERA MARTINEZ LUIS SATURNIN;;YONG GONZALEZ VLADIMIR;;MARGOLLEZ CLARK EMILIO;;DELGADO BOADA JULIO MARCOS;;MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARME;;SILVA RODRIGUEZ ALEJANDRO;;PAIFER REYES EDENA;;FERBEYRE BINELFA GERARDO;;S OSA ESPINOSA ANGELA ESTELA;;MARTINEZ SANTANA VLADIMIR;;AGUIAR SANTIAGO JORGE AGUSTIN;;SERALENA MENENDEZ ALINA;;GONZALEZ LUPEZ TANIA CALLE L-V;;MONTESINOS SEGUI RAQUEL;;CREMATA ALVAREZ JOSE ALBERTO;;VILLAREAL BARRIOS ADELAIDA;;GONZALEZ BADILLO BEATRIZ;;MENENDEZ ALARCUN ALFREDO,,https://lens.org/154-387-222-010-671,Patent Application,yes,6,33,8,12,20,C07K14/485;;C07K2319/02;;C12N9/2417;;C12N9/6481;;C12N9/6483;;C12N15/815;;C12Y304/23004,C12N1/19;;C07K14/485;;C12N9/28;;C12N9/30;;C12N9/60;;C12N9/64;;C12N15/09;;C12N15/16;;C12N15/56;;C12N15/57;;C12N15/81;;C12P21/02;;C12R1/84,,3,2,164-476-596-340-808;;030-517-214-467-862,10.1038/nbt1287-1305;;6313475;;10.1016/0378-1119(83)90017-3,"BIOTECHNOLOGY vol. 5, no. 12, December 1987, NEW YORK US pages 1305 - 1308; J.F.Tschopp et al.: ""High-level secretion of glycosylated invertase in the methylotrophic yeast, Pichia pastoris"";;GENE. vol. 23, no. 3, September 1983, AMSTERDAM NL pages 267 - 276; Ortlepp et al.: ""Molecular cloning in Bacillus subtilis of a Bacillus licheniformis gene encoding a thermostable alpha amylase"";;CHEMICAL ABSTRACTS, vol. 108, 1988 Columbus, Ohio, USA Yamashita Takashi et al.: ""Secretion of Mucor rennin, a fungal aspartic protease of Mucor & MGG, Mol. Gen. Genet. vol.210,1987,No.3,pp.462-7 ref. no. 217200Y",EXPIRED
286,ES,A1,ES 2431914 A1,098-423-019-476-659,2013-11-28,2013,ES 201200465 A,2012-04-27,ES 201200465 A,2012-04-27,HUMAN ANTI-HER2 MONOCLONAL ANTIBODY,The present invention relates to a human monoclonal antibody that recognizes the extracellular domain of human epidermal growth factor receptor 2 (HER2) and is produced in human embryonic retinal cells. The present invention also relates to the use of said antibody to measure the level of expression of HER2 and to prepare a drug for treating neoplastic disorders involving overexpression of HER2.,UNIV CADIZ;;CURAXYS S L,SANCHEZ DE MELO IVAN;;VILLEGAS MARTINEZ ENRIQUE;;BOLIVAR PEREZ JORGE;;HERNANDEZ RUIZ LAURA;;CASTRO GONZALEZ CARMEN;;GARCIA COZAR FRANCISCO JOSE;;PENDON MELENDEZ CARLOS;;CANTORAL FERNANDEZ JESUS MANUEL;;FERNANDEZ ACERO FRANCISCO JAVIER;;GARRIDO CRESPO CARLOS,,https://lens.org/098-423-019-476-659,Patent Application,no,0,0,3,3,0,A61P35/00;;C07K16/32;;C07K2317/14;;C07K2317/21;;C07K2317/41,C07K16/22;;A61K39/395;;A61P35/00,,0,0,,,,INACTIVE
287,PL,T3,PL 2075004 T3,109-980-040-594-317,2012-09-28,2012,PL 07817382 T,2007-10-01,CU 20060192 A;;EP 07817382 A;;CU 2007000018 W,2006-10-03,USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY,,CT INGENIERIA GENETICA BIOTECNOLOGIA,FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;GARCIA DEL BARCO HERRERA DIANA;;CIBRIAN VERA DANAY;;GUILLEN NIETO GERARDO ENRIQUE;;UBIETA GÓMEZ RAIMUNDO;;GONZALEZ BLANCO SONIA;;SÁEZ MARTÍNEZ VIVIAN MARÍA,,https://lens.org/109-980-040-594-317,Patent Application,no,0,0,32,32,0,Y10S930/12;;A61K38/1808;;A61P25/00;;A61P25/02;;A61P25/04;;A61P43/00;;A61K38/18;;A61K9/48;;C07K14/485;;A61K38/1808;;A61K9/16;;Y10S930/12,A61K38/18;;A61P25/00,,0,0,,,,PENDING
288,DK,T3,DK 0438200 T3,040-490-400-491-44X,2002-11-11,2002,DK 91200074 T,1991-01-16,CU 1990007 A;;CU 1990104 A;;CU 1990132 A;;CU 1990142 A,1990-01-16,"Fremgangsmåde til ekspression af heterologe gener i gæren Pichia pastoris, ekspressionsvektorer og transformerede mikroorganismer","The present invention provides a highly efficient method for the expression of heterologous genes, using as the host an auxotrophic his3 mutant of strain BKM-90 of Pichia pastoris and as recombinant DNA for the transformation thereof an integrative vector which contains a functional selection marker of Saccharomyces cerevisiae, the promotor of the alcohol oxidase gene (AOX1) of the yeast itself, as the transcription terminator that of glyceraldehyde 3-phosphate dehydrogenase (GAP) of S. cerevisiae, or that which is carried by the heterologous gene to be expressed, and another sequence homologous to the genome of Pichia pastoris which serves for the integration thereof. The expression vectors used further contain a heterologous gene bound to the signal peptide of the sucrose invertase gene (SUC2) of S. cerevisiae. This method guarantees that the polypeptide products are recoverable under controllable conditions and with high yields. The strains according to the present invention can be used for the large-scale production of pharmaceutical products or of enzymes of industrial interest.",CT INGENIERIA GENETICA BIOTECH,HERRERA MARTINEZ LUIS SATURNIN;;YONG GONZALEZ VLADIMIR;;MARGOLLEZ CLARK EMILIO;;MORALES GRILLO JUAN;;TORRENS MADRAZO ISIS DEL CARME;;FERBEYRE BINELFA GERARDO;;MARTINEZ SANTANA VLADIMIR;;AGUIAR SANTIAGO JORGE AGUSTIN;;DELGADO BOADA JULIO MARCOS;;SILVA RODRIGUEZ ALEJANDRO;;PAIFER REYES EDENIA;;S OSA ESPINOSA ANGELA ESTELA;;SERALENA MENENDEZ ALINA;;GONZALEZ LUPEZ TANIA CALLE L-V;;MONTESINOS SEGUI RAQUEL;;CREMATA ALVAREZ JOSE ALBERTO;;VILLAREAL BARRIOS ADELAIDA;;GONZALEZ BADILLO BEATRIZ;;MENENDEZ ALARCUN ALFREDO,,https://lens.org/040-490-400-491-44X,Granted Patent,no,0,0,8,12,0,C07K14/485;;C07K2319/02;;C12N9/2417;;C12N9/6481;;C12N9/6483;;C12N15/815;;C12Y304/23004,C12N1/19;;C07K14/485;;C12N9/28;;C12N9/30;;C12N9/60;;C12N9/64;;C12N15/09;;C12N15/16;;C12N15/56;;C12N15/57;;C12N15/81;;C12P21/02;;C12R1/84,,0,0,,,,EXPIRED
289,ES,A1,ES 2555005 A1,025-502-708-045-819,2015-12-28,2015,ES 201430951 A,2014-06-24,ES 201430951 A,2014-06-24,"Procedure for obtaining bituminous binder modified with sludge (Machine-translation by Google Translate, not legally binding)","The present invention relates to a process for obtaining bituminous binders modified with sludge from sewage treatment plants, by wet process, to the bituminous binder obtained by said process and to the use of the bituminous binder for paving. (Machine-translation by Google Translate, not legally binding)",UNIV HUELVA;;INGEVIERA INGENIERÍA Y GESTIÓN MED S L;;EMAPLICADA S C A,MARTINEZ GARCIA INMACULADA;;DELGADO CANTO MIGUEL ANGEL;;GALLEGOS MONTES CRÍSPULO;;PARTAL LOPEZ PEDRO;;MARTINEZ BOZA FRANCISCO JOSÉ;;NAVARRO DOMINGUEZ FRANCISCO JAVIER;;GARCIA MORALES MOISÉS;;JEREZ GOMEZ ABEL;;GOMEZ MARTINEZ DIANA;;WAMBA CHAARA FEDERICO;;BRAJONES RUIZ CANELA JUAN ANTONIO;;RIDAO BOULOUMIE JORGE GINÉS;;BERNABE GONZALEZ JOSÉ MANUEL;;AGUILA SANCHEZ ENCARNACIÓN;;FERNANDEZ CALIANI JUAN CARLOS;;GIRALDEZ DIAZ INMACULADA,UNIVERSIDAD DE HUELVA (2015-04-01),https://lens.org/025-502-708-045-819,Patent Application,no,6,0,2,2,0,C08L95/00;;E01C3/003;;Y10S106/07,C08L95/00;;E01C3/00,,0,0,,,,ACTIVE
290,CU,A1,CU 22983 A1,165-872-738-397-182,2004-09-09,2004,CU 20020091 A,2002-05-08,CU 20020091 A,2002-05-08,COMPOSICIÓN VACUNAL CONTRA LAS ALERGIAS Y MÉTODO PARA SU OBTENCIÓN Y EMPLEO EN EL TRATAMIENTO DE LAS MISMAS,"La presente invención se relaciona con el campo de la Inmunología, la Inmunoalergia y en particular con el empleo de adyuvantes o portadores para modular la respuesta inmunológica hacia los alérgenos. El objetivo técnico que se persigue es obtener una preparación farmacéutica de uso terapéutico o profiláctico utilizando proteoliposomas bacterianos, que al ser aplicada en individuos alérgicos transforma la respuesta alérgica Th2 e IgE dependiente, hacia una respuesta Th1 protectora; así como logre prevenir la aparición y el desarrollo de alergias en individuos aún no alérgicos. LA composición vacunal consiste en proteoliposomas de bacterias Gram-negativas acoplados a alérgenos y opcionalmente otros antígenos o adyuvantes. Se provee el método para su obtención y se incluye el esquema de 2 dosis para la inmunización con dicha composición vacunal.",INST FINLAY;;CT NAC BIOPREPARADOS,SIERRA GONZALES VICTORIANO GUSTAVO;;FACENDA RAMOS ELISA;;ZAYAS VIGNIER CARIDAD;;PEREZ LASTRE DAINERYS ALEIDA;;PEREZ LASTRE JORGE ERNESTO;;BIDOT MARTINEZ IGOR;;DEL CAMPO ALONSO JUDITH MONICA;;BRACHO GRANDOS GUSTAVO RAFAEL;;LASTRE GONZALEZ MIRIAM DE SAN JUAN BOSCO;;PEREZ MARTIN OLIVER GERMAN;;LABRADA ROSADO ALEXIS;;RODRIGUEZ MARTINEZ CLAUDIO,,https://lens.org/165-872-738-397-182,Limited Patent,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/35;;A61K39/39,,0,0,,,,EXPIRED
291,ES,B2,ES 2555005 B2,117-958-765-133-98X,2016-06-23,2016,ES 201430951 A,2014-06-24,ES 201430951 A,2014-06-24,Procedimiento para la obtención de ligante bituminoso modificado con lodos,,UNIV HUELVA;;INGEVIERA INGENIERÍA Y GESTIÓN MEDIOAMBIENTAL S L;;EMAPLICADA S C A,MARTINEZ GARCIA INMACULADA;;DELGADO CANTO MIGUEL ANGEL;;GALLEGOS MONTES CRÍSPULO;;PARTAL LOPEZ PEDRO;;MARTINEZ BOZA FRANCISCO JOSÉ;;NAVARRO DOMINGUEZ FRANCISCO JAVIER;;GARCIA MORALES MOISÉS;;JEREZ GOMEZ ABEL;;GOMEZ MARTINEZ DIANA;;WAMBA CHAARA FEDERICO;;BRAJONES RUIZ CANELA JUAN ANTONIO;;RIDAO BOULOUMIE JORGE GINÉS;;BERNABE GONZALEZ JOSÉ MANUEL;;AGUILA SANCHEZ ENCARNACIÓN;;FERNANDEZ CALIANI JUAN CARLOS;;GIRALDEZ DIAZ INMACULADA,UNIVERSIDAD DE HUELVA (2015-04-01),https://lens.org/117-958-765-133-98X,Granted Patent,no,0,0,2,2,0,C08L95/00;;E01C3/003;;Y10S106/07,C08L95/00;;E01C3/00,,0,0,,,,ACTIVE
292,BR,A,BR 0309901 A,162-276-847-146-243,2008-08-12,2008,BR 0309901 A,2003-05-08,CU 20020091 A;;CU 0300007 W,2002-05-08,"composição de vacina para alergia, método de produção e uso da mesma no tratamento de alergia","""COMPOSIçãO DE VACINA PARA ALERGIA, MéTODO DE PRODUçãO E USO DA MESMA NO TRATAMENTO DE ALERGIA"". Refere-se o presente invento ao campo da imunologia, especificamente ao ramo da imuno-alergia e em particular ao uso de compostos auxiliares ou de transporte, capazes de modular a resposta imune a alergenos. O objetivo técnico que é perseguido é o de obter um preparado farmacêutico de uso terapêutico ou profilático usando proteoliposomas bacteriais, que transforma a resposta alérgica Th2 e Ig2 e IgE quando aplicados em indivíduos alérgicos numa resposta Th1 protetora; bem como é capaz de evitar o surgimento e desenvolvimento de alergias em indivíduos ainda não alérgicos. A composição da vacina consiste de proteoliposomas redivados de bactérias Gram-negativa, acoplados a alergenos e opcionalmente contém outros auxiliares ou antígenos. Também são providos o método para a sua preparação e o esquema de imunização de duas doses.",INST FINLAY CT DE INVESTIGACIO;;CT NAC BIOPREPARADOS,DE SAN JUAN BOSCO LASTRE GONZALEZMIRIAM;;MARTIN OLIVER GERMAN PEREZ;;MARTINEZ IGOR BIDOT;;ROSADO ALEXIS LABRADA;;LASTRE JORGE ERNESTO PEREZ;;GRANADO GUSTAVO RAFAEL BRACHO;;ALONSO JUDITH MONICA DEL CAMPO;;LASTRE DAINERYS ALEIDA PEREZ;;RAMOS ELISA FACENDA;;VIGNIER CARIDAD ZAYAS;;MARTINEZ CLAUDIO RODRIGUEZ;;SIERRA GONZALEZ VICTORIANO GUSTAVO,,https://lens.org/162-276-847-146-243,Patent Application,no,0,0,20,20,0,A61K39/35;;A61K2039/55505;;A61K2039/55583;;A61K2039/55594;;A61K2039/57;;A61K2039/6018;;A61P37/00;;A61K39/39;;A61K38/16;;A61K9/127;;A61K39/395;;A61K39/35;;A61K2039/57;;A61K2039/55583;;A61K2039/55594;;A61K2039/55505;;A61K2039/6018,A61K39/39;;A61K39/35,,0,0,,,,DISCONTINUED
293,ES,B2,ES 2431914 B2,143-745-091-833-966,2014-07-24,2014,ES 201200465 A,2012-04-27,ES 201200465 A,2012-04-27,Anticuerpo monoclonal humano ANTI-HER2,,UNIV CADIZ;;CURAXYS S L,SANCHEZ DE MELO IVÁN;;VILLEGAS MARTINEZ ENRIQUE;;BOLIVAR PEREZ JORGE;;HERNANDEZ RUIZ LAURA;;CASTRO GONZALEZ CARMEN;;GARCIA COZAR FRANCISCO JOSÉ;;PENDON MELENDEZ CARLOS;;CANTORAL FERNANDEZ JES S MANUEL;;FERNANDEZ ACERO FRANCISCO JAVIER;;GARRIDO CRESPO CARLOS,,https://lens.org/143-745-091-833-966,Granted Patent,no,0,0,3,3,0,A61P35/00;;C07K16/32;;C07K2317/14;;C07K2317/21;;C07K2317/41,C07K16/22;;A61K39/395;;A61P35/00,,0,0,,,,INACTIVE
294,CU,A1,CU 23687 A1,026-964-647-665-688,2011-07-11,2011,CU 20090125 A,2009-07-15,CU 20090125 A,2009-07-15,MORTERO MONOCAPA EN PASTA PARA INTERIORES.,"La presente invención se relaciona con la rama de la química aplicada y la construcción y expone una nueva formulación de mortero monocapa en forma de pasta para el acabado constructivo de interiores de inmuebles con la siguiente formulación: carbonato de calcio micronizado (de granulometría entre 90 - 100 micrómetros) 60-70 %, resina poli Vinil acetato-estireno acrílico 3-5%, derivado celulósico hidroxi etil celulosa/hidroxi metil etil celulosa 0,3 - 0,4 %, derivado del éster del ácido ftálico dioctil ftalato/dibutil ftalato/ bis (2 etil hexil) ftalato 0,2-0,3%, biocida en solución acuosa de formaldehído 0,2 - 0,3% tensoactivo aniónico sodio lauril sulfato 0,2-0,3%, dióxido de silicio (silicagel G- Typ 60) 0,05 - 0,1% y agua 27 - 30%.",CT DE INVESTIGACION Y DESARROLLO TECNICO DEL MININT,DIAZ PITA LAZARA;;URALDES FERNANDEZ LOURDES;;PELAYO VALDIVIA MIRIAM;;MORA INNERARITY DAYAMI;;CABEZA MENDEZ ADIA;;LARA RIVADULLA MARTA;;RODRIGUEZ HIERREZUELO JORGE LUIS;;CORDERO GONZALEZ CORALIA;;ZABALA MARTINEZ YAMILET;;VILLAR MENDOZA REINALDO;;COLLAZO FRESNEDA ANA YBIS;;GONZALEZ CASTRO MAYELIN;;GALI NAVARRO ELVIRA MARIA;;ESTEVEZ SANCHEZ JUAN;;ILLOBRE PEREZ GRACIELA DEL CARMEN;;ACANDA GAZMURI SULAY;;GONZALEZ CASTILLO NORMA;;DE LA TORRE GONZALEZ ROBERTO;;GARCIA VILLA DEL REY GLORIA MARIA;;FERNANDEZ FREIXAS MARGARITA ANGELA,,https://lens.org/026-964-647-665-688,Limited Patent,no,0,0,1,1,0,,C04B28/18,,0,0,,,,EXPIRED
295,EP,B1,EP 0678516 B1,164-686-467-510-247,2002-11-27,2002,EP 95500056 A,1995-04-21,CU 1994048 A,1994-04-21,Preparation of 2-bromo-5-(2-bromo-2-nitrovinyl)-furan and its use as microcide,"An obtention and purification procedure of 1-(5-bromophur-2-il)-2-bromo-2-nitroethane is proposed, with a reaction from 1-(fure-2-il)-2-nitroethane with appropriate output and high purity, guaranteeing its use as active principle in the human and veterinary medical-pharmaceutical industry. The product demonstrates effectiveness in ""in vitro"" tests, in experimentation animals and in humans against negative gram, positive gram bacteria, superior bacteria, escotobacteria, monomorphic gemant fungi and monomorphic filamentose fungi. The microcide action of the product has been proven with numerous examples, as the active principle of several formulas being developed for human and veterinary use for the treatment of several ailments.",CT DE BIOACTIVOS QUIMICOS DE L,CASTANEDO CANCIO NILO RAMON;;GOIZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ GARCIA ORAIDA;;PEREZ DONATO JORGE ANTONIO;;GONZALEZ FEITOT JOSEFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;CUESTA MAZORRA MARIO;;MARTINEZ DEL PINO ANTONIO RAFA;;LUGO FARINAS ESTELA;;ESTRADA ROGER ERNESTO;;CARTA FUENTES ANA DEL CARMEN;;ZARRALUQUI OFELIA NAVIA;;DELGADO LASVAL MARIA SOLEDAD,,https://lens.org/164-686-467-510-247,Granted Patent,yes,0,0,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A61K31/04;;A01N43/08;;A61K31/00;;A61K31/34;;A61K31/341;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,2,0,,,"CHEMICAL ABSTRACTS, vol. 76, no. 23, 5 June 1972 Columbus, Ohio, US; abstract no. 139829q, GRUNTFEST ET AL 'Physicchemical properties and reactivity of furylnitroolefins.' page 390; column 2; & ZH.ORG.KHIM, vol. 8, no. 2, 1972 pages 404-411,;;CHEMICAL ABSTRACTS, vol. 78, no. 7, 19 February 1973 Columbus, Ohio, US; abstract no. 43166m, NAZAROVA ET AL 'Synthesis of some furylnitro olefins with potential biological activity' page 463; column 1; & KHIM.FARM.ZH., vol. 6, no. 10, 1972 pages 5-8,",EXPIRED
296,DE,D1,DE 69528922 D1,000-512-236-801-824,2003-01-09,2003,DE 69528922 T,1995-04-21,CU 1994048 A,1994-04-21,Herstellung von 2-Bromo-5-(2-bromo-2-nitro-vinyl)-furan und deren Verwendung als Microzide,"An obtention and purification procedure of 1-(5-bromophur-2-il)-2-bromo-2-nitroethane is proposed, with a reaction from 1-(fure-2-il)-2-nitroethane with appropriate output and high purity, guaranteeing its use as active principle in the human and veterinary medical-pharmaceutical industry. The product demonstrates effectiveness in ""in vitro"" tests, in experimentation animals and in humans against negative gram, positive gram bacteria, superior bacteria, escotobacteria, monomorphic gemant fungi and monomorphic filamentose fungi. The microcide action of the product has been proven with numerous examples, as the active principle of several formulas being developed for human and veterinary use for the treatment of several ailments.",CT DE BIOACTIVOS QUIMICOS DE L,CASTANEDO CANCIO NILO RAMON;;GOIZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ GARCIA ORAIDA;;PEREZ DONATO JORGE ANTONIO;;GONZALEZ FEITOT JOSEFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;CUESTA MAZORRA MARIO;;MARTINEZ DEL PINO ANTONIO RAFA;;LUGO FARINAS ESTELA;;ESTRADA ROGER ERNESTO;;CARTA FUENTES ANA DEL CARMEN;;ZARRALUQUI OFELIA NAVIA;;DELGADO LASVAL MARIA SOLEDAD,,https://lens.org/000-512-236-801-824,Granted Patent,no,0,0,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A61K31/04;;A01N43/08;;A61K31/00;;A61K31/34;;A61K31/341;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,0,0,,,,EXPIRED
297,JP,A,JP H11193278 A,112-511-800-317-491,1999-07-21,1999,JP 29985898 A,1998-10-21,CU 1994048 A,1994-04-21,PRODUCTION OF 1-(5-BROMOFUR-2-YL)-2-BROMO-2-NITROETHENE,"PROBLEM TO BE SOLVED: To provide a method for purifying 1-(5-bromofur-2-yl)-2-bromo-2- nitroethene in a high yield in a high purity and surely. SOLUTION: 1-(Fur-2-yl)-2-nitroethene is reacted with bromine in carbon disulfide or carbon tetrachloride as a solvent with stirring in the molar ratio of 1:1 to 1:2.6 to 1:2.6 at 20-60 deg.C for 1-6 hours and then successively the solvent is evaporated. The reaction mixture is simultaneously neutralized and dehydrobrominated by using preferably pyridine. Finally the formed product is extracted with a hot polar solvent and purified by using an adsorbent to give high-purity 1-(5-bromofur-2-yl)-2-bromo-2-nitroethene in a high yield. The compound has antimicrobial activity against gram-positive bacteria, gram-negative bacteria, higher bacteria, Scotobacteria, germinating single fungus and a filamentous single fungus.",UNIV LAS VILLAS,CASTANEDO CANCIO NILO RAMON;;GOIZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ GARCIA ORAIDA;;PEREZ DONATO JORGE ANTONIO;;GONZALEZ FEITOT JOSEFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;CUESTA MAZORRA MARIO;;MARTINEZ DEL PINO ANTONIO RAFA;;LUGO FARINAS ESTELA;;ESTRADA ROGER ERNESTO;;CARTA FUENTES ANA DEL CARMEN;;ZARRALUQUI OFELIA NAVIA;;DELGADO LASVAL MARIA SOLEDAD,,https://lens.org/112-511-800-317-491,Patent Application,no,0,1,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A01N43/08;;A61K31/00;;A61K31/34;;A61K31/04;;A61K31/341;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,0,0,,,,EXPIRED
298,DE,T2,DE 69528922 T2,050-498-129-232-158,2003-11-06,2003,DE 69528922 T,1995-04-21,CU 1994048 A,1994-04-21,Herstellung von 2-Bromo-5-(2-bromo-2-nitro-vinyl)-furan und deren Verwendung als Microzide,"An obtention and purification procedure of 1-(5-bromophur-2-il)-2-bromo-2-nitroethane is proposed, with a reaction from 1-(fure-2-il)-2-nitroethane with appropriate output and high purity, guaranteeing its use as active principle in the human and veterinary medical-pharmaceutical industry. The product demonstrates effectiveness in ""in vitro"" tests, in experimentation animals and in humans against negative gram, positive gram bacteria, superior bacteria, escotobacteria, monomorphic gemant fungi and monomorphic filamentose fungi. The microcide action of the product has been proven with numerous examples, as the active principle of several formulas being developed for human and veterinary use for the treatment of several ailments.",CT DE BIOACTIVOS QUIMICOS DE L,CASTANEDO CANCIO NILO RAMON;;GOIZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ GARCIA ORAIDA;;PEREZ DONATO JORGE ANTONIO;;GONZALEZ FEITOT JOSEFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;CUESTA MAZORRA MARIO;;MARTINEZ DEL PINO ANTONIO RAFA;;LUGO FARINAS ESTELA;;ESTRADA ROGER ERNESTO;;CARTA FUENTES ANA DEL CARMEN;;ZARRALUQUI OFELIA NAVIA;;DELGADO LASVAL MARIA SOLEDAD,,https://lens.org/050-498-129-232-158,Granted Patent,no,0,0,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A61K31/04;;A01N43/08;;A61K31/00;;A61K31/34;;A61K31/341;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,0,0,,,,EXPIRED
299,CU,A1,CU 22446 A1,102-987-749-863-163,2001-06-01,2001,CU 1994048 A,1994-04-21,CU 1994048 A,1994-04-21,PROCEDIMIENTO DE OBTENCIÓN DEL 1-(5-BROMOFUR-2-IL)-2-BROMO-2-NITROETENO Y SU ACCIÓN COMO MICROCIDA,"An obtention and purification procedure of 1-(5-bromophur-2-il)-2-bromo-2-nitroethane is proposed, with a reaction from 1-(fure-2-il)-2-nitroethane with appropriate output and high purity, guaranteeing its use as active principle in the human and veterinary medical-pharmaceutical industry. The product demonstrates effectiveness in ""in vitro"" tests, in experimentation animals and in humans against negative gram, positive gram bacteria, superior bacteria, escotobacteria, monomorphic gemant fungi and monomorphic filamentose fungi. The microcide action of the product has been proven with numerous examples, as the active principle of several formulas being developed for human and veterinary use for the treatment of several ailments.",CT DE BIOACTIVOS QUIMICOS,LUGO FARINAS ESTELA;;CUESTA MAZORRA MARIO;;CARTA FUENTES ANA DEL CARMEN;;NAVIA ZARRALUQUI OFELIA;;DELGADO LASVAL MARIA SOLEDAD;;GONZALEZ FEITOT JOSEFA;;ESTRADA ROGER ERNESTO;;PEREZ DONATO JORGE ANTONIO;;MARTINEZ DEL PINO ANTONIO RAFAEL;;SILVEIRA PRADO ENRIQUE ANTONIO;;GONZALEZ GARCIA ORAIDA;;GOIZUETA DOMINGUEZ RAMON DONATO;;CASTANEDO CANCIO NILO RAMON,,https://lens.org/102-987-749-863-163,Limited Patent,no,0,0,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A61K31/04;;A01N43/08;;A61K31/00;;A61K31/34;;A61K31/341;;A61K31/345;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,0,0,,,,EXPIRED
300,EP,A1,EP 0678516 A1,131-881-660-992-934,1995-10-25,1995,EP 95500056 A,1995-04-21,CU 1994048 A,1994-04-21,Preparation of 2-bromo-5-(2-bromo-2-nitrovinyl)-furan and its use as microcide.,"An obtention and purification procedure of 1-(5-bromophur-2-il)-2-bromo-2-nitroethane is proposed, with a reaction from 1-(fure-2-il)-2-nitroethane with appropriate output and high purity, guaranteeing its use as active principle in the human and veterinary medical-pharmaceutical industry. The product demonstrates effectiveness in ""in vitro"" tests, in experimentation animals and in humans against negative gram, positive gram bacteria, superior bacteria, escotobacteria, monomorphic gemant fungi and monomorphic filamentose fungi. The microcide action of the product has been proven with numerous examples, as the active principle of several formulas being developed for human and veterinary use for the treatment of several ailments.",UNIV LAS VILLAS,CASTANEDO CANCIO NILO RAMON;;GOIZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ GARCIA ORAIDA;;PEREZ DONATO JORGE ANTONIO;;GONZALEZ FEITOT JOSEFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;CUESTA MAZORRA MARIO;;MARTINEZ DEL PINO ANTONIO RAFA;;LUGO FARINAS ESTELA;;ESTRADA ROGER ERNESTO CALLE ES;;CARTA FUENTES ANA DEL CARMEN;;ZARRALUQUI OFELIA NAVIA;;DELGADO LASVAL MARIA SOLEDAD,,https://lens.org/131-881-660-992-934,Patent Application,yes,0,3,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A61K31/04;;A01N43/08;;A61K31/00;;A61K31/34;;A61K31/341;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,2,0,,,"CHEMICAL ABSTRACTS, vol. 76, no. 23, 5 June 1972, Columbus, Ohio, US; abstract no. 139829q, GRUNTFEST ET AL: ""Physicchemical properties and reactivity of furylnitroolefins."" page 390; column 2;;CHEMICAL ABSTRACTS, vol. 78, no. 7, 19 February 1973, Columbus, Ohio, US; abstract no. 43166m, NAZAROVA ET AL: ""Synthesis of some furylnitro olefins with potential biological activity"" page 463; column 1; XP002901702",EXPIRED
301,AT,T1,AT E228511 T1,131-747-816-903-014,2002-12-15,2002,AT 95500056 T,1995-04-21,CU 1994048 A,1994-04-21,HERSTELLUNG VON 2-BROMO-5-(2-BROMO-2-NITRO-VINYL)-FURAN UND DEREN VERWENDUNG ALS MICROZIDE,"An obtention and purification procedure of 1-(5-bromophur-2-il)-2-bromo-2-nitroethane is proposed, with a reaction from 1-(fure-2-il)-2-nitroethane with appropriate output and high purity, guaranteeing its use as active principle in the human and veterinary medical-pharmaceutical industry. The product demonstrates effectiveness in ""in vitro"" tests, in experimentation animals and in humans against negative gram, positive gram bacteria, superior bacteria, escotobacteria, monomorphic gemant fungi and monomorphic filamentose fungi. The microcide action of the product has been proven with numerous examples, as the active principle of several formulas being developed for human and veterinary use for the treatment of several ailments.",CT DE BIOACTIVOS QUIMICOS DE L,CASTANEDO CANCIO NILO RAMON;;GOIZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ GARCIA ORAIDA;;PEREZ DONATO JORGE ANTONIO;;GONZALEZ FEITOT JOSEFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;CUESTA MAZORRA MARIO;;MARTINEZ DEL PINO ANTONIO RAFA;;LUGO FARINAS ESTELA;;ESTRADA ROGER ERNESTO CALLE ES;;CARTA FUENTES ANA DEL CARMEN;;ZARRALUQUI OFELIA NAVIA;;DELGADO LASVAL MARIA SOLEDAD,,https://lens.org/131-747-816-903-014,Granted Patent,no,0,0,13,13,0,A01N43/08;;C07D307/56;;A61P17/00;;A61P31/00;;A61P31/04,A61K31/04;;A01N43/08;;A61K31/00;;A61K31/34;;A61K31/341;;A61P17/00;;A61P31/00;;A61P31/04;;C07C201/16;;C07C205/09;;C07D307/56,,0,0,,,,DISCONTINUED
302,CU,A1,CU 22267 A1,124-622-688-203-95X,2007-05-18,2007,CU 1989213 A,1989-11-15,CU 1989213 A,1989-11-15,"PROCEDIMIENTO DE OBTENCION, PURIFICACION Y ACCION MICROCIDA DEL PRINCIPIO ACTIVO 1(5 BROMO FUR 2 IL) 2 BROMO 2 NITROGENO","El producto 1-(5-bromofur-2-il)-2-bromo-2-nitroeteno presenta accion antibacteriana frente a bacterias Gran (+) y Gram (-) tales como: ESCHERICHIA coli, STAFNYLoCOCCU aureas, PSEUIDOMONASaeruginosa, pasteurella multocina, pasteurella hemolytica cirynebacterium pyogenes, salmonella choleraesuis, salmonella dublin, kledsilla pncumoniae, klebsiella aerogemes, proteus vulcaries, salmonella typhi, salmonella oxford, salmonella eteritidis, staphylococcus albus, sarcina lutea, streptococcus agalactiac, listeria monocytogenes, bacillus subtilis, bacillus alvei. alcanzando la concentracion inhibitoria mínima el rango de 1,56 hasta 25 meg/ml a las 24 horas y 48 horas de incubacion a 37 grados C. comprobAndose en efecto bactericida del producto a estas concentraciones.",UNIV LAS VILLAS,SERRANO PEREZ HECTOR ZOILO;;MARTIN TRIANA ESTHER LILIAM;;GOUZUETA DOMINGUEZ RAMON DONAT;;GONZALEZ FEITOT JUANA JOSEFA;;LUGO FARINAS ESTELA;;CUESTA MAZORRA MARIO;;CARTA FUENTES ANA DEL CARMEN;;NAVIA ZARRALUQUI OFELIA;;DELGADO LASVAL MARIA SOLEDAD;;SALAZAR YERA ELOISA;;DIAZ MARTINEZ GRISELL;;ESTRADA ROGER ERNESTO;;PEREZ DONATO JORGE ANTONIO;;MARTINEZ DEL PINO ANTONIO RAFA;;SILVEIRA PRADO ENRIQUE ANTONIO;;GONZALEZ GARCIA ORAIDA;;OLAZABAL MANSO ERVELIO ELISEO;;CASTANEDO CANCIO NILO RAMON,,https://lens.org/124-622-688-203-95X,Limited Patent,no,0,0,1,1,0,,A61K31/035,,0,0,,,,EXPIRED
303,US,A1,US 2018/0256112 A1,175-280-526-810-485,2018-09-13,2018,US 201615762479 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The present invention is related to a stereotaxic frame for extremities that ensures that the extremity position is fixed and reproducible; keeping the same geometric conditions of the measurement or treatment devices regards the extremity, or part thereof, during the study or therapy. The frame comprises a positioning and fixing holder for the extremity and a measuring or treatment system, that includes a geometric locus where the measurement or treatment device is allocated, ensuring that the relative position of said device regards the region of the extremity under examination or treatment is reproducible.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,CENTRO DE INGENIERÍA GENÉTICA Y BIOTECHNOLOGÍA (2018-05-16),https://lens.org/175-280-526-810-485,Patent Application,yes,0,1,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B5/00;;A61B5/01;;A61B5/107;;A61B90/14,,0,0,,,,DISCONTINUED
304,EP,A1,EP 3354224 A1,033-584-083-502-865,2018-08-01,2018,EP 16794498 A,2016-09-22,CU 20150132 A;;CU 2016050002 W,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The present invention is related to a stereotaxic frame for extremities that ensures that the extremity position is fixed and reproducible; keeping the same geometric conditions of the measurement or treatment devices regards the extremity, or part thereof, during the study or therapy. The frame comprises a positioning and fixing holder for the extremity and a measuring or treatment system, that includes a geometric locus where the measurement or treatment device is allocated, ensuring that the relative position of said device regards the region of the extremity under examination or treatment is reproducible.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,,https://lens.org/033-584-083-502-865,Patent Application,yes,0,0,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B90/10;;A43D1/02;;A61B5/00;;A61B5/107,,0,0,,,,DISCONTINUED
305,WO,A1,WO 2017/050302 A1,057-820-470-931-961,2017-03-30,2017,CU 2016050002 W,2016-09-22,CU 20150132 A,2015-09-24,STEREOTACTIC FRAME FOR LIMBS,"The invention relates to a stereotactic frame for limbs, which guarantees a fixed and reproducible position for the limb, maintaining the same geometric conditions for the measurement or treatment devices in relation to the limb, or part thereof, during examination or therapy. The frame comprises a support for positioning and securing the limb and a measurement or treatment system, including a geometric location at which the measurement or treatment device is positioned, thereby ensuring that the position of the device relative to the region of the limb being examined or treated can be reproduced.",CT INGENIERIA GENETICA BIOTECNOLOGIA,CABAL MIRABAL CARLOS ALBERTO;;GONZÁLEZ DALMAU EVELIO RAFAEL;;ORAMAS DIAZ LEONARDO;;HERRERA MARTINEZ LUIS SATURNINO;;BERLANGA ACOSTA JORGE AMADOR;;FERNÁNDEZ MONTEQUÍN JOSÉ IGNACIO;;GUILLÉN NIETO GERARDO ENRIQUE;;FLORES DÍAZ LUIS MANUEL;;CABAÑAS RODRÍGUEZ ORESTES LUCIO;;GONZALEZ BLANCO SONIA;;UBIETA GÓMEZ RAIMUNDO,,https://lens.org/057-820-470-931-961,Patent Application,yes,16,1,11,11,0,A61B5/6829;;A61B5/1074;;A61B90/10;;A61B5/70;;A61B90/10;;A61B5/0064;;A61B5/1074;;A61B5/1079;;A61B5/6829;;A61B5/70;;A61B5/6829;;A61B90/10;;A61B5/1074;;A61B5/70;;A61B90/14;;A61B5/01;;A61B5/107;;A61B5/1073,A61B90/10;;A43D1/02;;A61B5/00;;A61B5/107,,1,0,,,"WANG L ET AL., DIABETES SCI AND TECHNOL, 2015, pages 1 - 8",PENDING
306,ES,B2,ES 2919724 B2,114-779-545-864-323,2023-06-15,2023,ES 202130062 A,2021-01-26,ES 202130062 A,2021-01-26,RALTEGRAVIR PARA USO COMO INHIBIDOR DE LA FASCINA1 EN CANCER,,FUNDACION UNIV SAN ANTONIO;;FUNDACION PARA LA FORMACION E INVESTIG SANITARIAS FFIS;;UNIV GRANADA,CONESA ZAMORA PABLO;;ALBURQUERQUE GONZALEZ BEGONA;;PEREZ SANCHEZ HORACIO;;MONTORO GARCIA SILVIA;;GARCIA SOLANO JOSE;;BERNABE GARCIA ANGEL;;NICOLAS VILLAESCUSA FRANCISCO JOSE;;BERNABE GARCIA MANUEL;;CAYUELA FUENTES MARIA LUISA;;PENA GARCIA JORGE;;LUQUE FERNANDEZ IRENE;;RUIZ SANZ JAVIER;;MARTINEZ HERRERIAS JOSE CRISTOBAL,,https://lens.org/114-779-545-864-323,Granted Patent,no,0,0,2,2,0,A61K31/513;;C07D413/12;;A61P35/02;;A61P35/04,A61K31/513;;A61P35/02;;A61P35/04;;C07D413/12,,0,0,,,,ACTIVE
307,ES,A1,ES 2919724 A1,125-224-744-286-511,2022-07-27,2022,ES 202130062 A,2021-01-26,ES 202130062 A,2021-01-26,"Raltegravir for use as a fascin1 inhibitor in cancer (Machine-translation by Google Translate, not legally binding)","Raltegravir for use as a fascin1 inhibitor in cancer. The present invention refers to an inhibitor of the fascin1 for use in a method of treatment for cancer, in which patients suffering from cancer because cancer cells are positive for fascinate expression1, being said raltegravir inhibitor. It also refers to a pharmaceutical composition that includes this fascin inhibitor1. (Machine-translation by Google Translate, not legally binding)",FUNDACION UNIV SAN ANTONIO;;FUNDACION PARA LA FORMACION E INVESTIG SANITARIAS FFIS;;UNIV GRANADA,CONESA ZAMORA PABLO;;ALBURQUERQUE GONZALEZ BEGONA;;PEREZ SANCHEZ HORACIO;;MONTORO GARCIA SILVIA;;GARCIA SOLANO JOSE;;BERNABE GARCIA ANGEL;;NICOLAS VILLAESCUSA FRANCISCO JOSE;;BERNABE GARCIA MANUEL;;CAYUELA FUENTES MARIA LUISA;;PENA GARCIA JORGE;;LUQUE FERNANDEZ IRENE;;RUIZ SANZ JAVIER;;MARTINEZ HERRERIAS JOSE CRISTOBAL,,https://lens.org/125-224-744-286-511,Patent Application,no,2,0,2,2,0,A61K31/513;;C07D413/12;;A61P35/02;;A61P35/04,A61K31/513;;A61P35/02;;A61P35/04;;C07D413/12,,2,2,023-734-886-195-385;;027-100-479-199-718,10.1158/0008-5472.can-18-4080;;31358528;;10.1186/1741-7015-11-52;;pmc3635876;;23442983,"CHANG YU-CHAN ET AL. Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival. Cancer Research SEP 15 2019. , 15/09/2019, Vol. 79, Páginas 4754-4766 ISSN 0008-5472(print) ISSN 1538-7445(electronic), (DOI: doi:10.1158/0008-5472.CAN-18-4080) Ver resumen; resultados.;;VANESSA Y TAN ET AL. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC MEDICINE, 20130226 BIOMED CENTRAL LTD., LONDON, GB. , 26/02/2013, Vol. 11, Páginas 52 ISSN 1741-7015, (DOI: doi:10.1186/1741-7015-11-52) Ver resumen.",ACTIVE
308,US,A1,US 2013/0296200 A1,133-352-242-418-138,2013-11-07,2013,US 201113884925 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES,"The present invention relates to the application of geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts thereof as wettability modifiers of rocks such as limestone, dolomite, sand, quartz or heterogeneous lithologies, in the presence of brines with high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure in processes of enhanced oil recovery. Wettability modifier comprises a geminal zwitterionic liquid based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts, using as solvent distilled or brine with a high content of divalent ions such as calcium and magnesium or organic solvents compounds derived from alcohols like methanol, ethanol, isopropanol or mixtures thereof, or aromatic as isomers of xylene, toluene, or diesel, gasoline or mixtures thereof. Geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts are obtained by reacting an alkyl or alkenyl amine and an reactive polyether derivative of ethylene or propylene oxide or copolymer of these, which may contain in their structure mesyl or tosyl groups, and subsequently the reaction product is reacted with unsaturated acids such as acrylic acid or methacrylic acid and subsequently may or may not be neutralized with alkali metal bases such as the sodium or potassium hydroxide, carbonates or bicarbonates of potassium or sodium.",HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON;;MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,INSTITUTO MEXICANO DEL PETROLEO (2013-06-12),https://lens.org/133-352-242-418-138,Patent Application,yes,3,13,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C09K8/584,507/241;;507/244,0,0,,,,ACTIVE
309,MX,A,MX 2010012348 A,051-956-711-487-705,2012-05-15,2012,MX 2010012348 A,2010-11-12,MX 2010012348 A,2010-11-12,COMPOSITION BASED ON GERMINAL ZWITTERIONIC LIQUIDS AS WETTABILITY MODIFIERS IN PROCESSES FOR THE IMPROVED RECOVERY OF OIL.,"The present invention refers to the application of germinal zwitterionic liquids of the bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta iminoacid type or salts as rock wettability modifiers such as limestone, dolomite, grit, quartz or heterogeneous lithologies, in the presence of brine with a high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure, in improved processes of oil recovery. The wettability modifiers have zwitterionic liquids of the bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta iminoacid type, using distilled water or brine as a dissolvent with a high content of divalent ions such as calcium and magnesium or organic solvents derived from alcohols comprising methanol, ethanol, isopropanol or mixtures thereof, 6 aromatics such as isomers of xylem, toluene or diesel, gasoline or mixtures thereof. The zwitterionic liquids of the bis-N-alkyl polyether or b is-N-alkenyl polyether or bis-N-aryl polyether bis-beta iminoacid or the salts thereof are obtained upon reacting an aminealkyl or alkenyl or aromatic and a reactant polyether derived from the ethylene oxide or propylene or copolymer thereof, which may contain a tosyl or mesyl group structure; the reacting product is subsequently reacted with unsaturated acids such as acrylic acid or methacrylic acid and subsequently may or may not be neutralised with alkaline metal bases such as sodium or potassium hydroxide, potassium or sodium carbonates or bicarbonates.",MEXICANO INST PETROL,RIVERA LUIS SILVESTRE ZAMUDIO;;CONDE HIRAM ISAAC BELTRAN;;GONZALEZ EDUARDO BUENROSTRO;;CERVANTES VIOLETA YASMIN MENA;;ALTAMIRANO RAUL HERNANDEZ;;RAMIREZ SIMON LOPEZ;;VALENCIA CECILIA DE LOS ANGELES DURAN;;CRUZ JOSE LUIS MENDOZA DE LA;;MARTINEZ JORGE ALBERTO GARCIA;;ROJERO ERICK EMANUEL LUNA;;ALVAREZ DAVID AARON NIETO,,https://lens.org/051-956-711-487-705,Patent Application,no,0,7,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C02F1/04;;C07D211/98;;E21B43/22,,0,0,,,,ACTIVE
310,EP,A1,EP 2644685 A1,102-437-801-431-581,2013-10-02,2013,EP 11839690 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION COMPRISING ZWITTERIONIC GEMINAL LIQUIDS AS WETTABILITY MODIFIERS IN IMPROVED OIL RECOVERY PROCESSES,"The present invention relates to the application of geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts thereof as wettability modifiers of rocks such as limestone, dolomite, sand, quartz or heterogeneous lithologies, in the presence of brines with high content of divalent ions such as calcium, magnesium, barium and strontium, high temperature and pressure in processes of enhanced oil recovery. Wettability modifier comprises a geminal zwitterionic liquid based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts, using as solvent distilled or brine with a high content of divalent ions such as calcium and magnesium or organic solvents compounds derived from alcohols like methanol, ethanol, isopropanol or mixtures thereof, or aromatic as isomers of xylene, toluene, or diesel, gasoline or mixtures thereof. Geminals zwitterionics liquids based on bis-N-alkyl or bis-N-alkenyl or N-cycloalkyl or N-aryl bis-beta aminoacids or its salts are obtained by reacting an alkyl or alkenyl amine and an reactive polyether derivative of ethylene or propylene oxide or copolymer of these, which may contain in their structure mesyl or tosyl groups, and subsequently the reaction product is reacted with unsaturated acids such as acrylic acid or methacrylic acid and subsequently may or may not be neutralized with alkali metal bases such as the sodium or potassium hydroxide, carbonates or bicarbonates of potassium or sodium.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/102-437-801-431-581,Patent Application,yes,0,5,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C09K8/584;;C07C229/12;;C10G1/04;;C11D1/06,,0,0,,,,ACTIVE
311,WO,A1,WO 2012/064168 A1,000-291-401-880-321,2012-05-18,2012,MX 2011000134 W,2011-11-09,MX 2010012348 A,2010-11-12,COMPOSITION COMPRISING ZWITTERIONIC GEMINAL LIQUIDS AS WETTABILITY MODIFIERS IN IMPROVED OIL RECOVERY PROCESSES,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL;;HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/000-291-401-880-321,Patent Application,yes,9,1,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,5,2,049-361-453-092-270;;042-094-312-641-346,10.1007/s11743-009-1152-4;;10.1016/j.susc.2004.01.018,"Z. XIE ET AL.: ""Synthesis and properties of alkylbetaine zwitterionic gemini surfactants"", J. SURFACT. DETERG., vol. 13, 2010, pages 51 - 57, XP001551900;;DATABASE WPI Week 201048, Derwent World Patents Index; AN 2010-F55215, XP008170308;;DATABASE WPI Week 201062, Derwent World Patents Index; AN 2010-J98190, XP008170309;;H. CHEN ET AL.: ""The interfacial tension between oil and gemini surfactant solution"", SURFACE SCIENCE, vol. 552, 2004, pages L53 - L57, XP055120729;;See also references of EP 2644685A4",PENDING
312,CA,C,CA 2817681 C,027-242-048-312-655,2016-01-12,2016,CA 2817681 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/027-242-048-312-655,Granted Patent,no,0,0,14,14,0,C10G1/04;;C10G2300/4006;;C10G2300/44;;C07C229/12;;C09K8/584;;C11D1/06;;C10G1/04;;C10G2300/4006;;C10G2300/44;;C07C229/12;;C09K8/584,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,0,0,,,,ACTIVE
313,CO,A2,CO 6870041 A2,025-689-578-638-191,2014-02-20,2014,CO 13138762 A,2013-06-07,MX 2010012348 A,2010-11-12,Composiciones base líquidos zwitterionicos geminales como modificaciones de la mojabilidad en procesos de recuperación mejorada de petróleo,,MEXICANO INST PETROL,BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON;;LOPEZ RAMIREZ SIMON;;DURAN VALENCIA CECILIA DE LOS ANGELES;;MENA CERVANTES VIOLETA YASMIN;;ZAMUDIO RIVERA LUIS SILVESTRE;;HERNANDEZ ALTAMIRANO RAUL;;BELTRAN CONDE HIRAM ISAAC,,https://lens.org/025-689-578-638-191,Patent Application,no,0,0,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224,,0,0,,,,ACTIVE
314,CA,A1,CA 2817681 A1,017-505-292-767-335,2012-05-18,2012,CA 2817681 A,2011-11-09,MX 2010012348 A;;MX 2011000134 W,2010-11-12,COMPOSITION BASED ON GEMINALS ZWITTERIONICS LIQUIDS AS WETTABILITY MODIFIERS IN ENHANCED OIL RECOVERY PROCESSES.,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/017-505-292-767-335,Patent Application,no,0,0,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,0,0,,,,ACTIVE
315,CN,A,CN 103459567 A,095-061-764-912-276,2013-12-18,2013,CN 201180064989 A,2011-11-09,MX 2011000134 W;;MX 2010012348 A,2010-11-12,Composition comprising zwitterionic geminal liquids as wettability modifiers in improved oil recovery processes,"The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;BELTRAN CONDE HIRAM ISAAC;;DURAN VALENCIA CECILIA DE LOS ANGELES;;LOPEZ RAMIREZ SIMON;;BUENROSTRO GONZALEZ EDUARDO;;MENDOZA DE LA CRUZ JOSE LUIS;;GARCIA MARTINEZ JORGE ALBERTO;;LUNA ROJERO ERICK EMANUEL;;NIETO ALVAREZ DAVID AARON,,https://lens.org/095-061-764-912-276,Patent Application,no,6,6,14,14,0,C09K8/584;;C09K8/584;;C07C229/12;;C07C229/12;;C10G1/04;;C10G1/04;;C10G2300/4006;;C10G2300/4006;;C10G2300/44;;C10G2300/44;;C11D1/06,C10L1/224;;C07C227/18;;C07C229/26;;C09K8/584;;C10G75/02,,0,0,,,,ACTIVE
316,CA,A1,CA 2822806 A1,064-105-775-457-958,2012-06-28,2012,CA 2822806 A,2011-12-16,MX 2010014422 A;;IB 2011055721 W,2010-12-21,NEW AMPHOTERICIN ANALOGOUS COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"The present invention relates to polyene macrolide derivatives according to the formula (I): wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R is independently selected from an alkyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, arylalkyl, and heteroaryalkyl group; and i is an integer from 1 to 3, with the condition that it has a negative charge or the zwitterions character is restored; or a pharmaceutically acceptable salt thereof useful as antibiotics.",CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV AUTONOMA DEL ESTADO DE MORELOS;;UNIV MEXICO NACIONAL AUTONOMA,ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA;;FLORES ROMERO JOSE DAVID,,https://lens.org/064-105-775-457-958,Patent Application,no,0,0,9,9,0,A01N43/90;;A61K31/7048;;A61K45/06;;A61P31/10;;C07H17/08;;C07H17/08,C07H17/08,,0,0,,,,ACTIVE
317,WO,A2,WO 2012/085784 A2,165-905-035-175-506,2012-06-28,2012,IB 2011055721 W,2011-12-16,MX 2010014422 A,2010-12-21,NEW AMPHOTERICIN ANALOGOUS COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"The present invention relates to polyene macrolide derivatives according to the formula (I): wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R is independently selected from an alkyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, arylalkyl, and heteroaryalkyl group; and i is an integer from 1 to 3, with the condition that it has a negative charge or the zwitterions character is restored; or a pharmaceutically acceptable salt thereof useful as antibiotics.",CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV AUTONOMA DEL ESTADO DE MORELOS;;UNIV MEXICO NACIONAL AUTONOMA;;ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;FLORES MORENO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA,ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;FLORES MORENO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA,,https://lens.org/165-905-035-175-506,Patent Application,yes,2,3,9,9,0,A01N43/90;;A61K31/7048;;A61K45/06;;A61P31/10;;C07H17/08;;C07H17/08,,,79,61,057-031-739-627-339;;057-031-739-627-339;;063-369-238-078-023;;066-408-917-095-982;;047-537-075-495-403;;061-275-941-855-103;;035-738-683-851-868;;081-730-045-907-363;;022-893-197-199-374;;009-019-091-058-15X;;018-446-985-381-91X;;016-748-419-892-222;;019-592-745-181-064;;146-453-999-456-261;;037-579-403-921-639;;080-142-320-525-11X;;050-606-586-591-557;;048-734-213-381-033;;021-055-070-065-062;;053-519-822-849-219;;085-619-661-212-733;;157-263-071-160-131;;087-576-661-416-950;;105-911-352-969-427;;092-836-294-100-434;;070-602-446-074-248;;060-389-396-589-127;;023-108-259-934-97X;;006-616-960-101-882;;117-304-651-598-831;;001-476-196-916-221;;062-035-181-525-171;;058-171-592-788-63X;;071-006-899-006-614;;051-705-876-773-420;;068-119-554-427-993;;100-369-540-536-048;;020-442-376-272-148;;139-633-074-951-118;;060-657-878-190-934;;033-950-481-311-703;;039-108-506-426-691;;034-455-120-110-242;;105-911-352-969-427;;035-828-423-992-436;;012-964-279-790-697;;004-521-994-121-06X;;105-911-352-969-427;;087-970-578-851-826;;085-619-661-212-733;;058-000-460-585-121;;010-459-755-390-660;;091-578-159-447-587;;037-274-636-966-064;;085-619-661-212-733;;008-924-265-354-455;;010-171-991-509-712;;039-108-506-426-691;;004-521-994-121-06X;;001-904-414-108-31X;;007-855-144-305-064,10.1021/ja00747a037;;5131155;;10.1021/ja00747a037;;5131155;;10.1021/ja00222a030;;10.1007/978-3-0348-7102-0_3;;360289;;pmc181806;;7325646;;10.1128/aac.20.6.826;;12716221;;20088682;;10.3109/10408410903241444;;10.1007/s10096-009-0822-5;;19911208;;20019613;;10.1097/cco.0b013e328335a755;;20413018;;10.1016/j.emc.2010.01.001;;15815004;;pmc1081396;;10.1128/jcm.43.4.1829-1835.2005;;pmc522363;;15472288;;10.1128/jcm.42.10.4419-4431.2004;;10.1007/s10096-004-1103-y;;15029512;;12857779;;pmc164220;;10.1128/cmr.16.3.497-516.2003;;16243088;;10.1016/s0140-6736(05)67490-9;;17482982;;10.1016/s0140-6736(07)60605-9;;17806055;;10.1086/520980;;17568028;;10.1056/nejmoa066906;;pmc1303457;;10.1016/s0006-3495(03)74656-6;;14507696;;10.1128/jb.80.2.200-206.1960;;14413698;;pmc278841;;7076567;;10.7164/antibiotics.35.220;;10.1016/j.bbamem.2005.12.011;;16546117;;10.1021/ja051597r;;16045354;;10.1021/ol060353o.s001;;10.1021/ol060353o;;16623556;;4585230;;10.1007/bf01868444;;6094818;;10.1085/jgp.107.1.69;;8741731;;pmc2219249;;4703564;;10.1016/0006-291x(73)90022-3;;1643081;;10.1016/0005-2736(92)90113-z;;9767100;;10.1016/s0005-2736(98)00134-5;;10.1016/s0006-3495(02)75326-5;;pmc1302401;;12496093;;10.1021/ol0487276;;15469323;;10.1016/0005-2736(93)90246-v;;8399298;;10.1016/0005-2736(80)90074-7;;7397150;;10.1016/s1074-5521(04)00114-0;;10.1016/j.chembiol.2004.02.027;;15157878;;10.1097/01.inf.0000070843.65157.31;;10.1097/00006454-200306000-00013;;12799514;;10.1086/421961;;15546122;;10.1086/374850;;12746765;;10.1016/s0732-8893(02)00361-9;;12052624;;12821503;;pmc161841;;10.1128/aac.47.7.2373-2375.2003;;10.1097/00043426-200407000-00004;;15218415;;10.1016/0006-2952(88)90168-2;;3278711;;10.1016/s0304-4165(01)00166-0;;11514093;;10.1021/ol060353o.s001;;10.1021/ol060353o;;16623556;;10.1021/ja012026b;;11960425;;12049524;;10.1021/ol025982m;;16079135;;10.1074/jbc.m506689200;;10.1021/ol060353o.s001;;10.1021/ol060353o;;16623556;;10.1021/bc060205i;;17105224;;7076567;;10.7164/antibiotics.35.220;;11804288;;10.1016/s0142-9612(01)00251-4;;12757392;;10.1021/bc0256594;;10.1023/a:1008144208706;;11008890;;10.1021/jm800695k;;19055412;;7076567;;10.7164/antibiotics.35.220;;10.1099/jmm.0.010538-0;;19589904;;10.1007/978-1-60761-611-5_21;;20238277;;10.1016/0006-2952(88)90168-2;;3278711;;16079135;;10.1074/jbc.m506689200;;2735933;;10.1016/0006-2952(89)90409-7;;10.1089/jop.1996.12.35;;8925394,"GOLD ET AL., AM. CHEM SOC., vol. 93, 1971, pages 4560 - 4564;;GANIS ET AL., J. AM. CHEM. SOC., vol. 93, 1971, pages 4560 - 4564;;VANDEPUTTE ET AL., J. INFECT. DIS., vol. 154, 1986, pages 76 - 83;;NICOLAOU ET AL., J. AM. CHEM. SOC., vol. 110, 1988, pages 4696 - 4705;;D'ARCY, P.F.; SCOUT E. M., ANTIFUNGAL AGENTS, PROG DRUG RES, vol. 22, 1978, pages 93 - 147;;KESSLER ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 20, no. 6, 1981, pages 826 - 33;;QUINDOS, G., REVISTA IBEROAMERICANA DE MICOLOGIA, vol. 19, 2002, pages 1 - 4;;PFALLER ET AL., CRIT REV MICROBIOL., vol. 36, no. 1, 2010, pages 1 - 53;;HOF, EUR J CLIN MICROBIAL INFECT DIS., vol. 29, no. 1, 2010, pages 5 - 13;;MARR, CURR OPIN ONCOL., vol. 22, no. 2, 2010, pages 138 - 142;;KHAMBATY ET AL., EMERG MED CLIN NORTH AM., vol. 28, no. 2, 2010, pages 355 - 336;;ALMIRANTE ET AL., J. CLIN. MICROBIAL., vol. 43, 2005, pages 1829 - 1835;;PFALLER ET AL., J. CLIN. MICROBIAL., vol. 42, 2004, pages 4419 - 4431;;PFALLER ET AL., CLIN. INFECT. DIS., vol. 43, 2006, pages S3 - SL4;;BLOT ET AL., AM J MED, vol. 113, 2003, pages 480 - 485;;TORTORANO ET AL., EUR J CLIN MICROBIAL INFECT DIS, vol. 23, 2004, pages 317 - 322;;BONIFAZ, A.: ""Micologia Medica Básica"", 2002, pages: 498 - 500;;MURRIA ET AL.: ""Medical Microbiology"", 2002, MOSBY;;BENNET ET AL., CLINICAL MICROBIOLOGY REVIEW, vol. 16, 2003, pages 497 - 516;;KULLBERG ET AL., LANCET, vol. 366, 2005, pages 1435 - 1442;;KUSE ET AL., LANCET, vol. 369, 2007, pages 1519 - 1527;;TANGER ET AL., SAUDI MED J, vol. 29, no. 5, 2008, pages 728 - 733;;PAPPAS ET AL., CLIN INFECT DIS, vol. 45, 2007, pages 883 - 893;;REBOLI ET AL., NENGL JMED, vol. 356, 2007, pages 2472 - 2482;;VENEGAS ET AL., BIOPHYS J, vol. 85, 2003, pages 2323 - 2332;;LAMPEN ET AL., J. BACTERIAL., vol. 80, 1960, pages 200 - 206;;CHAPMAN ET AL., TRANS AM CLIN CLIM ASS, vol. 119, 2008, pages 197 - 216;;JARZEBSKI ET AL., J ANTIBIOTICS, vol. 35, 1982, pages 220 - 229;;IBAGRIMOVA ET AL., BIOCHEM BIOPHYS ACTA, vol. 1758, 2006, pages 29 - 37;;MATSUMORI ET AL., J. AM CHEM SOC., vol. 127, 2005, pages 10667 - 10675;;PAQUET ET AL., ORG LETT, vol. 8, 2006, pages 1807 - 1809;;PREOBRAZHENSKAYA ET AL., JMED CHEM, vol. 52, 2008, pages 189 - 196;;FINKELSTEIN ET AL., MEMBRANES, vol. 2, 1973, pages 377 - 408;;KLEINBERG ET AL., J. MEMBR BIOL, vol. 80, 1984, pages 257 - 269;;BRUTYAN ET AL., J GEN PHYSIO, vol. 1107, 1996, pages 69 - 78;;HSUCHEN ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 51, 1973, pages 972 - 978;;COHEN ET AL., BIOCHEM BIOPHYS ACTA, vol. 1108, 1992, pages 49 - 58;;COTERO ET AL., BIOCHIM BIOPHYS ACTA, vol. 1375, 1998, pages 43 - 51;;HUANG ET AL., BIOPHYS J, vol. 83, 2002, pages 3245 - 3255;;MILLHAUD ET AL., BIOCHIM BIOPHYS ACTA, vol. 1558, 2002, pages 95 - 108;;ZUMBUEHL ET AL., ORG LETT, vol. 6, 2004, pages 3683 - 3686;;LAMBING ET AL., BIOCHIM BIOPHYS ACTA, vol. 1152, 1993, pages 185 - 188;;BOLARD ET AL., BIOCHEM BIOPHYS ACTA, vol. 599, 1980, pages 280 - 293;;MATSUMORI ET AL., CHEM BIOL, vol. 11, 2004, pages 673 - 679;;JONSON ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 48, 2004, pages 693 - 715;;PATTERSON, TF, PEDIATR INFECT DIS J, vol. 22, 2003, pages 553 - 556;;SOBEL, JD, CLIN INFECT DIS, vol. 39, 2004, pages S224 - S227;;REX ET AL., CLIN INFECT DIS, vol. 36, 2003, pages 1221 - 1228;;ROLING ET AL., DIAGN MICROBIOL, vol. 43, 2002, pages 13 - 17;;GRAYBILL ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 47, 2003, pages 2373 - 2375;;DERAY, G., J ANTIMICROBIAL CHEMO, vol. 29, no. 1, 2002, pages 34 - 41;;GOLMAND ET AL., J PEDIATR HEMATOL ONCOL, vol. 26, no. 7, 2004, pages 421 - 426;;PONCIO-MENDEZ, REV INST MED TROP S PAULO, vol. 47, no. 14, 2005;;LEMKE ET AL., APPL MICROBIAL BIOTECHNOL, vol. 68, 2005, pages 151 - 161;;CHERON ET AL., BIOCHEM PHARMACOL, vol. 37, 1998, pages 827 - 836;;SZLINDER-RICHERT ET AL., BIOCHEM PHARMACOL, vol. 1528, 2001, pages 15 - 24;;PAQUET ET AL., ORG LETT, vol. 8, no. 9, 2006, pages 1807 - 1809;;MATSUMORI, N.; YAMAJI, N.; MATSUOKA, S.; OISHI, T.; MURATA, M.: ""Amphotericin B Covalent Dimers Forming Sterol-Dependent Ion-Permeable Membrane Channels"", J. AM. CHEM. SOC., vol. 124, 2002, pages 4180 - 4181, XP002439254, DOI: doi:10.1021/ja012026b;;YAMAJI, N.; MATSUMIRI, N.; MATSUOKA, S.; OISHI, T.; MURATA, M.: ""Amphotericin B Dimers with Bisamide Linkage Bearing Powerful Membrane-Permeabilizing Activity"", ORG. LETT., vol. 4, no. 12, 2002, pages 2087 - 2089;;CARMODY, M.; MURPHY, B.; BYME, B.; POWER, P.; RAI, D.; RAWLINGS, B.; CAFFREY, P.: ""Biosynthesis of Amphotericin Derivatives Lacking Exocyclic Carboxyl Groups"", J. BIOL. CHEM., vol. 280, no. 41, 2005, pages 34420 - 34426, XP055390733, DOI: doi:10.1074/jbc.M506689200;;PAQUET, V.; CARREIRA, E.M.: ""Significant Improvement of Antifungal Activity of Polyene Macrolides by Bisalkylation of the Mycosamine"", ORG. LETT., vol. 8, no. 9, 2006, pages 1807 - 1809, XP002503416, DOI: doi:10.1021/OL060353O;;PAQUET, V.; ZUMBUEHL, A; CARREIRA, E.: ""Biologically Active Amphotericin B-Calix[4]arene Conjugates"", BIOCONJUGATE CHEM., vol. 17, 2006, pages 1460 - 1463;;JARZEBSKI, A.; FALKOWSKI, L.; BOROWSKI, E.: ""Synthesis and structure-Activity Relationships for Amides of Amphotericin B"", J. ANTIBIOT., vol. 35, no. 2, 1982, pages 220 - 229, XP009005567;;OCAMPO MARTINEZ, L.: ""Evaluacion toxicologica comparativa de la anfotericina B y sus analogos sinteticos en modelos experimentales in vitro e in vivo"", TESIS DE LICENCIATURA. UNIVERSIDAD AUTONOMA DEL ESTADO DE MORELOS, 2007;;EHRENFREUND-KLEINMANA, T.; AZZAMA, T.; FALKB, R.; POLACHECKB, I.; GOLENSERC, J.; DOMB A. J.: ""Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates"", BIOMATERIALS, vol. 23, 2002, pages 1327 - 1335, XP004334096, DOI: doi:10.1016/S0142-9612(01)00251-4;;CONOVER, C.; ZHAO, H.; LONGLEY, C.; SHUM, K.; GREENWALD R.: ""Utility of Poly(ethylene glycol) Conjugation To Create Prodrugs of Amphotericin B"", BIOCONJUGATE CHEM., vol. 14, 2003, pages 661 - 666, XP008035191, DOI: doi:10.1021/bc0256594;;RESAT ET AL., J. OF COMPUTER-AIDED MOLECULAR DESIGN, vol. 14, 2000, pages 689 - 703;;HOLTZ ET AL., J. GEN. PHYSIOL, vol. 56, 1970, pages 125 - 145;;PREOBRAZHENSKAYA ET AL., J. MED. CHEM, vol. 52, 2009, pages 189 - 196;;JARZEBSKI ET AL., J. OF ANTIBIO, vol. 35, 1982, pages 220 - 229;;RUBINSON ET AL.: ""Contemporary Chemical Analysis"", 1998, PRENTICE HALL, pages: 352 - 403;;MOSMAN, INMUNOL METHODS, vol. 65, 2000, pages 55 - 63;;PINTO ET AL., J. MEDICAL MICROBIOLOGY, vol. 58, 2009, pages 1454 - 1462;;PINA-VAZ; RODRIGUEZ, METHODS MOL BIOL., vol. 638, 2010, pages 281 - 289;;CHERON ET AL., BIOCHEM. PHARMACOL., 1988, pages 827;;CARMODY M. ET AL., J. BIOL. CHEM., 2005, pages 34420;;CYBULSKA, B.; BOROWSKI, E.; GARY-BOBO, M.: ""Relationship between ionophoric and hemolytic activities of perimycin A and vacidin A, two polyene macrolide antifungal antibiotics"", BIOCHEM PHARMACOL., vol. 38, no. 11, 1989, pages 1755 - 1762, XP023736693, DOI: doi:10.1016/0006-2952(89)90409-7;;WANG, H.Z.; CHANG, C.H.; LIN, C.P.; TSAI, M.C: ""Using MTT viability assay to test the cytotoxicity of antibiotics and steroid to cultured porcine corneal endothelial cells"", J. OCUL. PHARMACOL. THER., vol. 12, 1996, pages 35 - 43, XP002567807, DOI: doi:10.1089/jop.1996.12.35;;LIPINSKI C.A. ET AL., ADVANCES IN DRUG DELIVERY REVIEWS, vol. 46, 2001, pages 3 - 26",PENDING
318,CA,C,CA 2822806 C,019-677-853-989-231,2019-09-24,2019,CA 2822806 A,2011-12-16,MX 2010014422 A;;IB 2011055721 W,2010-12-21,NEW AMPHOTERICIN ANALOGOUS COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"The present invention relates to polyene macrolide derivatives according to the formula (I): wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R is independently selected from an alkyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, arylalkyl, and heteroaryalkyl group; and i is an integer from 1 to 3, with the condition that it has a negative charge or the zwitterions character is restored; or a pharmaceutically acceptable salt thereof useful as antibiotics.",CENTRO DE INVESTIGACION Y DE ESTUDIOS AVANZADOS DEL INSTITUTO POLITECNICO NAC;;UNIV AUTONOMA DEL ESTADO DE MORELOS;;UNIV MEXICO NAC AUTONOMA,ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA;;FLORES ROMERO JOSE DAVID,,https://lens.org/019-677-853-989-231,Granted Patent,no,0,0,9,9,0,C07H17/08;;A61P31/10;;C07H17/08;;A01N43/90;;A61K31/7048;;A61K45/06,C07H17/08,,0,0,,,,ACTIVE
319,EP,A2,EP 2655391 A2,033-038-089-691-806,2013-10-30,2013,EP 11810890 A,2011-12-16,MX 2010014422 A;;IB 2011055721 W,2010-12-21,NEW AMPHOTERICIN ANALOGOUS COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,,CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV AUTONOMA DEL ESTADO DE MORELOS;;UNIV MEXICO NACIONAL AUTONOMA,ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;FLORES ROMERO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA,,https://lens.org/033-038-089-691-806,Patent Application,yes,0,0,9,9,0,A01N43/90;;A61K31/7048;;A61K45/06;;A61P31/10;;C07H17/08;;C07H17/08,C07H17/08,,1,0,,,See references of WO 2012085784A2,ACTIVE
320,MX,A,MX 2010014422 A,031-919-522-439-810,2012-06-21,2012,MX 2010014422 A,2010-12-21,MX 2010014422 A,2010-12-21,NEW AMPHOTERICIN ANALOGOUS COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.,"The present invention relates to polyene macrolide derivatives according to the formula (A) (See formula A) where: wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R is independently selected from an alkyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, arylalkyl, and heteroaryalkyl group; and i is an integer from 1 to 3, with the condition that it has a negative charge or the zwitterions character is restored; or a pharmaceutically acceptable salt thereof useful as antibiotics.",CT INVESTIG Y ESTUDIOS DEL IPN,DIAZ ARMANDO ANTILLON;;TRIPP MAURICIO CARRILLO;;ZERTUCHE MARIO FERNANDEZ;;ROMERO JOSE DAVID FLORES;;MONTEJO FABIOLA ELOISA JIMENEZ;;BUITIMEA ANGEL LEON;;MARTINEZ LILIA OCAMPO;;ESPARZA JORGE ALBERTO REYES;;FRAGOSO MARIA DE LOURDES RODRIGUEZ;;ANGELINO TANIA MINERVA SANTIAGO;;NAVA ROSMARBEL MORALES;;BLAKE IVAN ORTEGA;;GONZALEZ MARIA CRISTINA VARGAS,,https://lens.org/031-919-522-439-810,Patent Application,no,0,0,9,9,0,A01N43/90;;A61K31/7048;;A61K45/06;;A61P31/10;;C07H17/08;;C07H17/08,C07H17/08;;A61K31/7048;;A61P31/10,,0,0,,,,ACTIVE
321,WO,A3,WO 2012/085784 A3,176-567-469-317-639,2012-11-22,2012,IB 2011055721 W,2011-12-16,MX 2010014422 A,2010-12-21,NEW AMPHOTERICIN ANALOGOUS COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"The present invention relates to polyene macrolide derivatives according to the formula (I): wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R is independently selected from an alkyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, arylalkyl, and heteroaryalkyl group; and i is an integer from 1 to 3, with the condition that it has a negative charge or the zwitterions character is restored; or a pharmaceutically acceptable salt thereof useful as antibiotics.",CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV AUTONOMA DEL ESTADO DE MORELOS;;UNIV MEXICO NACIONAL AUTONOMA;;ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;FLORES ROMERO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA,ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICIO;;FERNANDEZ ZERTUCHE MARIO;;FLORES ROMERO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRAGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA,,https://lens.org/176-567-469-317-639,Search Report,yes,7,0,9,9,0,C07H17/08;;A61P31/10;;C07H17/08;;A01N43/90;;A61K31/7048;;A61K45/06,C07H17/08,,1,1,118-883-650-762-279,10.1016/s0223-5234(97)86175-2,"BRUZZESE T ET AL: ""Amide derivatives of partricin A with potent antifungal activity"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 31, no. 12, 1 January 1996 (1996-01-01), pages 965 - 972, XP004071791, ISSN: 0223-5234, DOI: 10.1016/S0223-5234(97)86175-2",PENDING
322,US,A1,US 2014/0256663 A1,115-704-569-574-363,2014-09-11,2014,US 201113996889 A,2011-12-16,MX 2010014422 A;;IB 2011055721 W,2010-12-21,Amphotericin Analogous Compounds and Pharmaceutical Compositions Containing Them,"The present invention relates to polyene macrolide derivatives according to the formula: wherein M is a macrocyclic lactone ring; N is a polyene sugar, substituted or unsubstituted; X is independently selected from O, S, N or NH; R is independently selected from an alkyl, cycloalkyl, heterocycloalkyl aryl, heteroaryl, arylalkyl, and heteroaryalkyl group; and i is an integer from 1 to 3, with the condition that it has a negative charge or the zwitterions character is restored; or a pharmaceutically acceptable salt thereof useful as antibiotics.",ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICO;;FERNANDEZ ZERTUCHE MARIO;;FLORES ROMERO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRANGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA;;CT INVESTIG Y ESTUDIOS DEL IPN;;UNIV MEXICO NACIONAL AUTONOMA;;UNIV AUTONOMA DEL ESTADO DEMORLOS,ANTILLON DIAZ ARMANDO;;CARRILLO TRIPP MAURICO;;FERNANDEZ ZERTUCHE MARIO;;FLORES ROMERO JOSE DAVID;;JIMENEZ MONTEJO FABIOLA ELOISA;;LEON BUITIMEA ANGEL;;MORALES NAVA ROSMARBEL;;OCAMPO MARTINEZ LILIA;;ORTEGA BLAKE IVAN;;REYES ESPARZA JORGE ALBERTO;;RODRIGUEZ FRANGOSO MARIA DE LOURDES;;SANTIAGO ANGELINO TANIA MINERVA;;VARGAS GONZALEZ MARIA CRISTINA,,https://lens.org/115-704-569-574-363,Patent Application,yes,4,7,9,9,0,A01N43/90;;A61K31/7048;;A61K45/06;;A61P31/10;;C07H17/08;;C07H17/08,C07H17/08;;A01N43/90;;A61K31/7048;;A61K45/06,514/31;;536/6.5,3,2,018-232-961-964-041;;037-274-636-966-064,15180569;;10.2174/0929867043365044;;10.1021/jm800695k;;19055412,"Aparicio, J. et al ""Polyene macrolide antibiotic biosynthesis"" Curr. Med. Chem. (2004) vol 11, pp 1643-1656.;;Preobrazhenskaya, M. et al ""Chemical modification and biological evalutation ..."" J. Med. Chem. (2009) vol 52, pp 189-196.;;Peacock, J. et al ""Amphotericin B therapy ..."" Infect. Dis. Clin. Pract. (1993) vol 2, pp 81-93.",DISCONTINUED
323,ES,B1,ES 2521940 B1,007-508-434-795-720,2015-09-09,2015,ES 201330678 A,2013-05-10,ES 201330678 A,2013-05-10,Variantes de beta-glucosidasa con actividad de transglicosilación reducida,,ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;GAVALDA MARTIN SANDRA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO;;MARTIN PEREZ LUCÍA,,https://lens.org/007-508-434-795-720,Granted Patent,no,0,0,3,3,0,C12N9/2445;;C12P19/02;;C12N9/2445;;C12P19/14;;C12Y302/01021;;C12Y302/01021;;Y02E50/10,C12N9/42;;C12P7/10;;C12P19/02,,0,0,,,,INACTIVE
324,ES,A1,ES 2527368 A1,085-100-898-526-879,2015-01-22,2015,ES 201331109 A,2013-07-22,ES 201331109 A,2013-07-22,MYCELIOPHTHORA THERMOPHILA HOST CELL EXPRESSING A HETEROLOGOUS ALPHA-XILOSIDASE ENZYME AND USE THEREOF IN A METHOD FOR THE DEGRADATION BIOMASS,"The present invention relates to a Myceliophthora thermophila host cell which expresses an alpha-xilosidase, preferably an AtaxI alpha-xilosidase of Aspergillus terreus, the use of said host cell for breaking down lignocellulosic biomass and a method for producing bioethanol which includes the use of said host cell.",ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;GAVALDA MARTIN SANDRA;;MARTIN PEREZ LUCÍA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO,,https://lens.org/085-100-898-526-879,Patent Application,no,1,0,3,3,0,C12N9/2434;;C12N9/248;;C12P7/06;;C12P19/14;;C12Y302/01037;;Y02E50/10,C12N1/15;;C12N9/24;;C12P7/10;;C12P19/14,,4,0,,,"VISSER, H. et al. ¿Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1¿. INDUSTRIAL BIOTECHNOLOGY. Junio 2011, Vol. 7, Nº 3, páginas 214-223, todo el documento.VISSER, H. et al. ¿Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1¿. INDUSTRIAL BIOTECHNOLOGY. Junio 2011, Vol. 7, Nº 3, páginas 214-223, todo el documento.;;HINZ, S.W.A. et al. ¿Hemicellulase production in Chrysosporium lucknowense C1¿. JOURNAL OF CEREAL SCIENCE¿. Noviembre 2009. Vol. 50, Nº 3, páginas 318-323, todo el documento.HINZ, S.W.A. et al. ¿Hemicellulase production in Chrysosporium lucknowense C1¿. JOURNAL OF CEREAL SCIENCE¿. Noviembre 2009. Vol. 50, Nº 3, páginas 318-323, todo el documento.;;BERKA, R.M. et al. ¿Comparative genomic analysis of the thermophilic biomass-degrading fungi Myceliophthora thermophila and Thielavia terrestres¿. NATURE BIOTECHNOLOGY. 02.10.2011. Vol. 29, Nº 10, páginas 922-927. Ver información adicional, Fig. 3. GH31.;;BIRREN, B.W. et al. ""Annotation of the Aspergillus terreus NIH2624 genome."". 17.10.2006. BASE DE DATOS UniProt [en línea], [recuperado el 03.12.2014], nº de acceso Q0CD44_ASPTN. http://www.genome.jp/dbget-bin/www_bget?uniprot:Q0CD44_ASPTN, Secuencia.",INACTIVE
325,US,B2,US 9834763 B2,020-309-995-298-774,2017-12-05,2017,US 201314891068 A,2013-05-20,ES 2013070318 W,2013-05-20,Expression of recombinant beta-xylosidase enzymes,"The present invention relates to a Myceliophthora thermophila host cell which expresses a recombinant enzymes from Fusarium oxysporum with beta-xylosidase activity. The invention also refers to an enzymatic composition comprising the host cell of the invention and/or the recombinant enzyme with beta-xylosidase activity expressed by the host cell of the invention. The invention further relates to the use of the host cell of the invention, the recombinant enzyme with beta-xylosidase activity expressed by the host cell of the invention or the composition of the invention for the degradation of biomass and to a method of producing bioproducts, preferably bioethanol, which comprises the use of the host cell of the invention, the recombinant enzyme with beta-xylosidase activity expressed by the host cell of the invention or the composition of the invention.",ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARIA;;PEREZ GOMEZ DOLORES;;MARTIN PEREZ LUCIA;;GAVALDA MARTIN SANDRA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACION;;BERMUDEZ ALCANTARA MARIA DE LOS ANGELES;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO,ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS S.A (2015-11-18),https://lens.org/020-309-995-298-774,Granted Patent,yes,7,0,9,9,8,C12P19/14;;C12N15/625;;C12P7/065;;C12P7/10;;C12Y302/01037;;C12N9/248;;Y02E50/10;;C12P19/14;;C12N15/625;;C12P7/065;;C12P7/10;;Y02E50/10;;C12N9/248;;C12P19/02;;C12P19/12;;C12Y302/01037,C12N1/20;;C12N9/24;;C12N9/42;;C12N15/62;;C12P7/06;;C12P7/10;;C12P19/02;;C12P19/12;;C12P19/14,,7,6,039-861-113-438-106;;004-409-251-635-22X;;006-843-468-845-687;;005-234-182-494-033;;046-916-230-353-231;;051-266-043-329-331,10.1007/bf01198746;;24425504;;10.1021/ie801542g;;10.1007/bf02920125;;10.1089/ind.2007.3.048;;10.1089/ind.2011.7.214;;10.1016/j.enzmictec.2012.04.008;;22664194,"K.B. Bastawde, “Xylan structure, microbial xylanases, and their mode of action”, World Journal of Microbiology and Biotechnology 8, 1998, pp. 353-368.;;National Renewable Energy Laboratory, Bioenergy, “Biomass Compositional Analysis Laboratory Procedures”, 7 pages, (http://www.nrel.gov/bioenergy/biomass-compositional-analysis.html), accessed Nov. 10, 2016.;;Parveen Kumar et al, “Methods of Pretreatment of Lignocellulosic Biomass for Efficient Hydrolysis and Biofuel Production”, Ind. Eng. Chem. Res 2009, 48, pp. 3713-3729.;;Q.A. Nguyen et al, “Dilute Acid Pretreatment of Softwoods”, Applied Biochemistry and Biotechnology, vol. 70-72, 1998, 11 pages.;;Jan C. Verdoes et al, “A dedicated vector for efficient library construction and high throughput screening in the hyphal fungus Chrysosporium lucknowense”, Industrial Biotechnology 3 (1), Spring 2007, pp. 47-58.;;Hans Visser et al, “Development of a mature fungal technology and production platform for industrial enzymes based on a Myceliophthora thermophila isolate, previously known as Chrysosporium lucknowense C1”, Industrial Biotechnology 7(3), Jun. 2011, pp. 214-223.;;Segato et al., High-yield secretion of multiple client proteins in Aspergillus, Enzyme and Microbial Technology, Jul. 5, 2012, pp. 100-106, vol. 51, Issue 2, Elsevier, Inc., https://doi.org/10.1016/j.enzmictec.2012.04.008.",INACTIVE
326,ES,A1,ES 2521940 A1,181-908-652-908-510,2014-11-13,2014,ES 201330678 A,2013-05-10,ES 201330678 A,2013-05-10,BETA-GLUCOSIDASE VARIANTS HAVING REDUCED TRANSGLYCOSYLATION ACTIVITY,"The invention relates to beta-glucosidase variants having reduced transglycosylation activity. The invention also relates to a gene construct, a host cell and an enzyme composition comprising said variants. The invention further relates to a method for producing said variants, a method for producing fermentable sugar and a method for producing a bioproduct, such as bioethanol, from cellulose material with the beta-glucosidase variants, the host cell or the enzyme composition comprising said variants.",ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;GAVALDA MARTIN SANDRA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO;;MARTIN PEREZ LUCÍA,,https://lens.org/181-908-652-908-510,Patent Application,no,2,0,3,3,0,C12N9/2445;;C12P19/02;;C12N9/2445;;C12P19/14;;C12Y302/01021;;C12Y302/01021;;Y02E50/10,C12N9/42;;C12P7/10;;C12P19/02,,2,1,161-339-339-286-927,10.1099/00221287-139-11-2825,"BHAT, K.M. et al. ""Purification and characterization of a n extracellular beta-glucosidase from the thermophilic fungus Sporotrichum thermophile and its influence on cellulase activity"". JOURNAL OF GENERAL MICROBIOLOGY. 01.11.1993. Vol. 139, N°. 11, páginas 2825 - 2832; todo el documento.;;KIM, T.J. et al. ""Role of the glutamate 332 residue in the transglycosilation activity of Thermus maltogenic amylase"". BIOCHEMISTRY. 13.06.2000. Vol. 39, N°. 23, páginas 6773 - 6780; resumen.",INACTIVE
327,ES,B1,ES 2527368 B1,136-972-701-444-48X,2015-10-27,2015,ES 201331109 A,2013-07-22,ES 201331109 A,2013-07-22,Célula hospedadora de Myceliophthora thermophila que expresa una enzima alfa-xilosidasa heteróloga y su uso en un procedimiento de degradación de biomasa,,ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;GAVALDA MARTIN SANDRA;;MARTIN PEREZ LUCÍA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO,,https://lens.org/136-972-701-444-48X,Granted Patent,no,0,0,3,3,0,C12N9/2434;;C12N9/248;;C12P7/06;;C12P19/14;;C12Y302/01037;;Y02E50/10,C12N1/15;;C12N9/24;;C12P7/10;;C12P19/14,,0,0,,,,INACTIVE
328,ES,T3,ES 2727390 T3,034-339-442-864-815,2019-10-15,2019,ES 13760069 T,2013-05-20,ES 2013070318 W,2013-05-20,Expresión de enzimas beta-xilosidasas recombinantes,"La presente invención se refiere a una célula hospedadora, preferiblemente una célula de Myceliophthora thermophila, que expresa enzimas recombinantes con actividad beta-xilosidasa, una composición enzimática que comprende dicha célula y/o la enzima recombinante con actividad beta-xilosidasa expresada por dicha célula, el uso de esta célula hospedadora, la enzima recombinante con actividad beta-xilosidasa expresada por dicha célula o la composición para la degradación de la biomasa y un procedimiento para producir bioproductos, preferiblemente bioetanol, que comprende el uso de dicha célula hospedadora, la enzima recombinante con actividad beta-xilosidasa expresada por dicha célula o dicha composición.",ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;MARTIN PEREZ LUCÍA;;GAVALDA MARTIN SANDRA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO,,https://lens.org/034-339-442-864-815,Granted Patent,no,0,0,9,9,0,C12P19/14;;C12N15/625;;C12P7/065;;C12P7/10;;C12Y302/01037;;C12N9/248;;Y02E50/10;;C12P19/14;;C12N15/625;;C12P7/065;;C12P7/10;;Y02E50/10;;C12N9/248;;C12P19/02;;C12P19/12;;C12Y302/01037,C12N9/24;;C12N15/62;;C12P7/06;;C12P7/10;;C12P19/14,,0,0,,,,ACTIVE
329,EP,A4,EP 2110799 A4,006-652-340-597-379,2013-08-07,2013,EP 07730323 A,2007-02-14,ES 2007000082 W,2007-02-14,SIMULATION SYSTEM FOR ARTHROSCOPIC SURGERY TRAINING,,SIMBIONIX LTD,ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESO CASIQUE MANLIO FAVIO;;ANANOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ MARTINEZ DE BARTOLOME ANGEL;;ESPADERO GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIA RABASCO PABLO;;SAN MARTIN LOPEZ JOSE JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO,SIMBIONIX LTD. (2012-08-08),https://lens.org/006-652-340-597-379,Search Report,no,2,0,7,7,0,G09B23/285;;G09B23/285,G09B23/28,,3,0,,,"""InsightMIST presentado en todo el mundo"", GMV NEWS,, no. 32, 1 December 2006 (2006-12-01), pages 25, XP008114614;;""Simulador avanzado de entrenamiento al servicio de la adquisicion de destrezas in tecnicas de cirugia minimamente invasivas. GMV Innovating Solutions"", 1 January 2005 (2005-01-01), pages 1 - 87, XP008137821, Retrieved from the Internet <URL:http://www.insightmist.com/img_eventos/presentacion-INVESCOT.pdf>;;See also references of WO 2008099028A1",ACTIVE
330,EP,A1,EP 2110799 A1,089-821-547-048-022,2009-10-21,2009,EP 07730323 A,2007-02-14,ES 2007000082 W,2007-02-14,SIMULATION SYSTEM FOR ARTHROSCOPIC SURGERY TRAINING,"The invention relates to a simulator for training in arthroscopic surgery on a joint of a simulated patient, comprising: a data processing unit (1); viewing means (2) for viewing the simulation exercise; a working platform (12); a human anatomy model (9) with arthroscopic portals (3) through which the user inserts the simulated arthroscopic instrument (10); two haptic devices (5a, 5b) arranged around the model (9) with a mobile member (6a, 6b), the end of which is provided with a guide (8a, 8b) for guiding the instrument that is inserted into the arthroscopic portals (3) during a simulated surgical procedure, each haptic device (5a, 5b) including means for synchronization with the control unit (1) and means for determining the position and orientation of the mobile members (6a, 6b); and a simulated arthroscopic camera (7). The data processing unit (1) is configured to send simulated images, as would be seen in a real operation, from the arthroscopic camera (7) to the viewing means (2) in real time.",GMV S A,ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESO CASIQUE MANLIO FAVIO;;ANANOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ MARTINEZ DE BARTOLOM;;ESPADERO GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIA RABASCO PABLO;;SAN MARTIN LOPEZ JOSE JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO,SIMBIONIX LTD. (2012-08-08),https://lens.org/089-821-547-048-022,Patent Application,yes,0,1,7,7,0,G09B23/285;;G09B23/285,G09B23/28,,0,0,,,,ACTIVE
331,ES,T3,ES 2597809 T3,007-397-606-645-894,2017-01-23,2017,ES 07730323 T,2007-02-14,ES 2007000082 W,2007-02-14,Sistema de simulación para adiestramiento en cirugía artroscópica,"Simulador para entrenamiento en cirugía artroscópica en una articulación de un paciente simulado, que comprende: una unidad de procesamiento de datos (1); medios de visualización (2) del ejercicio de simulación; una plataforma de trabajo (12); un modelo de anatomía humana (9) con portales artroscópicos (3) por donde el usuario introduce el instrumental artroscópico simulado (10); dos dispositivos hápticos (5a,5b) dispuestos alrededor del modelo (9) con un miembro móvil (6a,6b) en cuyo extremo dispone de una guía (8a,8b) del instrumental que se introduce en los portales artroscópicos (3) en la intervención quirúrgica simulada, disponiendo cadadispositivo háptico (5a,5b) de medios de sincronización con la unidad de control (1) y de medios de determinación de la posicióny orientación de sus miembros móviles (6a,6b); una cámara artroscópica simulada (7). La unidad de procesamiento de datos (1) estáconfigurada para enviar en tiempo real a los medios de visualización (2) imágenes simuladas desde la cámara artroscopica (7) tal como se visualizaría en una operación real.",SIMBIONIX LTD,ILLANA ALEJANDRO CARLOS;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESO CASIQUE MANLIO FAVIO;;ANANOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSÉ MANUEL;;TRIVINO BARROS GRACIÁN;;RODRIGUEZ MARTINEZ DE BARTOLOME ANGEL;;ESPADERO GUILLERMO JOSÉ MIGUEL;;BAYONA BERISO SOFÍA;;GARCIA LORENZO MARCOS JOSÉ;;TOHARIA RABASCO PABLO;;SAN MARTIN LOPEZ JOSÉ JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CÉSAR AUGUSTO,,https://lens.org/007-397-606-645-894,Granted Patent,no,0,0,7,7,0,G09B23/285;;G09B23/285,G09B23/28,,0,0,,,,ACTIVE
332,WO,A1,WO 2008/099028 A1,131-562-171-592-640,2008-08-21,2008,ES 2007000082 W,2007-02-14,ES 2007000082 W,2007-02-14,SIMULATION SYSTEM FOR ARTHROSCOPIC SURGERY TRAINING,"The invention relates to a simulator for training in arthroscopic surgery on a joint of a simulated patient, comprising: a data processing unit (1); means (2) for viewing the simulation exercise; a working platform (12); a human anatomy model (9) with arthroscopic portals (3) through which the user inserts the simulated arthroscopic instrument (10); two haptic devices (5a, 5b) disposed around the model (9) with a mobile member (6a, 6b), the end of which is provided with a guide (8a, 8b) for guiding the instrument that is inserted into the arthroscopic portals (3) during a simulated surgical procedure, each haptic device (5a, 5b) including means for synchronisation with the control unit (1) and means for determining the position and orientation of the mobile members (6a, 6b); and a simulated arthroscopic camera (7). The data processing unit (1) is configured to send simulated images, as would be seen in a real operation, from the arthroscopic camera (7) to the viewing means (2) in real time.",GMV S A;;ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESO CASIQUE MANLIO FAVI;;ANANOS HINOJOSA FRANCISCO JAVI;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ MARTINEZ DE BARTOLOM;;ESPADERO GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIA RABASCO PABLO;;SAN MARTIN LOPEZ JOSE JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO,ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESO CASIQUE MANLIO FAVI;;ANANOS HINOJOSA FRANCISCO JAVI;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ MARTINEZ DE BARTOLOM;;ESPADERO GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIA RABASCO PABLO;;SAN MARTIN LOPEZ JOSE JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO,,https://lens.org/131-562-171-592-640,Patent Application,yes,2,6,7,7,0,G09B23/285;;G09B23/285,G09B23/28,,5,0,,,"""Simulador avanzado de entrenamiento al servicio de la adquisicion de destrezas in tecnicas de cirugia minimamente invasivas. GMV Innovating Solutions"", INVESCOT V, CONGRESO NACIONAL, SALAMANCA, January 2005 (2005-01-01), XP008137821, Retrieved from the Internet <URL:http://www.insightmist.com/img_eventos/presentacion_INVESCOT.pdf>;;""insightMIST presentado in the whole the mundo"", GMV NEWS NO. 32, TECNOLOGIA DE GMV CLAVE IN METOP, GMV INNOVATION SOLUTIONS, December 2006 (2006-12-01), pages 25, XP008114614, Retrieved from the Internet <URL:http://www.gmv-sgi.eu/imagenes_comunicacion/boletin_corporativo/revista25.pdf>;;""Phantom Omni Technical Specification"", SENSABLE TECHNOLOGIES, August 2006 (2006-08-01), XP008114609, Retrieved from the Internet <URL:http://www.web.archive.org.web/20060830070030/www.sensable.com/products/phantom_ghost/phantom-omni.asp>;;""Virtual Laparoscopic Interface"", IMMERSION, XP002509910, Retrieved from the Internet <URL:http://www.web.archive.org/web/20061016081307/www.immersion.com/medical/products/laparoscopy>;;See also references of EP 2110799A4",PENDING
333,CN,A,CN 103849366 A,018-989-021-653-117,2014-06-11,2014,CN 201310645983 A,2013-12-04,MX 2012014187 A,2012-12-05,FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY,"The present invention relates to obtaining and using foaming compositions with wettability-modifying and corrosion inhibitory properties that control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions; by means of the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are characterized for being tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and for the fact that for their application in the reservoir, seawater and/or congenital water characteristic of the reservoir may be used as means of transportation.",MEXICANO INST PETROL,RAUL HERNANDEZ ALTAMIRANO;;LUIS SILVESTRE ZAMUDIO RIVERA;;VIOLETA YASMIN MENA CERVANTES;;LUNA ROJERO ERICK EMANUEL;;ENRIQUE SERRANO SALDANA;;MARTINEZ MAGADAN JOSE MANUEL;;RAUL OVIEDO ROA;;DAVID AARON NIETO ALVAREZ;;EDUARDO BUENROSTRO GONZALEZ;;RODOLFO CISNEROS DEVORA;;MARIA DEL PILAR ARZOLA GARCIA;;MIRNA PONS JIMENEZ;;AMERICA ELIZABETH MENDOZA AGUILAR;;SUNG JAE KO KIM;;JORGE FRANCISCO RAMIREZ PEREZ;;TOMAS EDUARDO CHAVEZ MIYAUCHI,,https://lens.org/018-989-021-653-117,Patent Application,no,7,11,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K8/584;;C09K23/02;;C07C303/32;;C07C309/14;;C09K8/54;;C09K8/594;;C09K23/00;;C09K23/04;;C09K23/18;;C09K23/24;;E21B41/02;;E21B43/22,,0,0,,,,ACTIVE
334,PH,B1,PH 12013000298 B1,054-710-542-746-17X,2015-04-20,2015,PH 12013000298 A,2013-10-02,MX 2012014187 A,2012-12-05,FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY,"The present invention relates to obtaining and using foaming compositions with wettability-modifying and corrosion inhibitory properties that control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions; by means of the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are characterized for being tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and for the fact that for their application in the reservoir, seawater and/or congenital water characteristic of the reservoir may be used as m eans of transportation.",MEXICANO INST PETROL,RAUL HERNANDEZ ALTAMIRANO;;LUIS SILVESTRE ZAMUDIO RIVERA;;VIOLETA YASMIN MENA CERVANTES;;ERICK EMANUEL LUNA ROJERO;;ENRIQUE SERRANO SALDANA;;JOSE MANUEL MARTINEZ MAGADAN;;RAUL OVIEDO ROA;;DAVID AARON NIETO ALVAREZ;;EDUARDO BUENROSTRO GONZALEZ;;RODOLFO CISNEROS DEVORA;;MARIA DEL PILAR ARZOLA GARCIA;;MIRNA PONS JIMENEZ;;AMERICA ELIZABETH MENDOZA AGUILAR;;SUNG JAE KO KIM;;JORGE FRANCISCO RAMIREZ PEREZ;;TOMAS EDUARDO CHAVEZ MIYAUCHI,,https://lens.org/054-710-542-746-17X,Granted Patent,no,0,0,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K23/02;;C09K8/584;;C09K8/594;;C09K23/00;;C09K23/04;;C09K23/18;;C09K23/24;;E21B43/16,,0,0,,,,ACTIVE
335,CA,A1,CA 2828519 A1,095-676-019-391-600,2014-06-05,2014,CA 2828519 A,2013-09-27,MX 2012014187 A,2012-12-05,FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY,"The present invention relates to obtaining and using foaming compositions with wettability-modifying and corrosion inhibitory properties that control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions; by means of the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are characterized for being tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and for the fact that for their application in the reservoir, seawater and/or congenital water characteristic of the reservoir may be used as means of transportation. (see above formula)",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;LUNA ROJERO ERICK EMANUEL;;SERRANO SALDANA ENRIQUE;;MARTINEZ MAGADAN JOSE MANUEL;;OVIEDO ROA RAUL;;NIETO ALVAREZ DAVID AARON;;BUENROSTRO GONZALEZ EDUARDO;;CISNEROS DEVORA RODOLFO;;ARZOLA GARCIA MARIA DEL PILAR;;PONS JIMENEZ MIRNA;;MENDOZA AGUILAR AMERICA ELIZABETH;;KIM SUNG JAE KO;;RAMIREZ PEREZ JORGE FRANCISCO;;CHAVEZ MIYAUCHI TOMAS EDUARDO,,https://lens.org/095-676-019-391-600,Patent Application,no,0,2,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K23/02;;C09K8/54;;C09K8/584;;C09K23/00;;C09K23/04;;C09K23/18;;C09K23/24;;E21B43/16,,0,0,,,,ACTIVE
336,US,A1,US 2014/0151041 A1,091-168-879-787-334,2014-06-05,2014,US 201314089280 A,2013-11-25,MX 2012014187 A,2012-12-05,FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY,"The present invention relates to a method of obtaining and using foaming compositions with wettability-modifying and corrosion inhibitory properties that control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions by the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates having the formula (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and are suitable for use in the reservoir, seawater and/or congenital water characteristic of the reservoir for transporting the crude oil from the reservoir.",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;LUNA ROJERO ERICK EMANUEL;;SERRANO SALDANA ENRIQUE;;MARTINEZ MAGADAN JOSE MANUEL;;OVIEDO ROA RAUL;;NIETO ALVAREZ DAVID AARON;;BUENROSTRO GONZALEZ EDUARDO;;CISNEROS DEVORA RODOLFO;;ARZOLA GARCIA MARIA DEL PILAR;;PONS JIMENEZ MIRNA;;MENDOZA AGUILAR AMERICA ELIZABETH;;KIM SUNG JAE KO;;RAMIREZ PEREZ JORGE FRANCISCO;;CHAVEZ MIYAUCHI TOMAS EDUARDO,INSTITUTO MEXICANO DEL PETROLEO (2012-11-04),https://lens.org/091-168-879-787-334,Patent Application,yes,2,11,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K23/00;;C09K8/584;;C09K23/04;;C09K23/02;;C09K23/18;;C09K23/24;;E21B43/16,166/271;;507/240;;166/308.6,0,0,,,,ACTIVE
337,PH,A1,PH 12013000298 A1,075-663-693-326-140,2015-04-20,2015,PH 12013000298 A,2013-10-02,MX 2012014187 A,2012-12-05,FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY,"The present invention relates to obtaining and using foaming compositions with wettability-modifying and corrosion inhibitory properties that control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions; by means of the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are characterized for being tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and for the fact that for their application in the reservoir, seawater and/or congenital water characteristic of the reservoir may be used as m eans of transportation.",MEXICANO INST PETROL,ALTAMIRANO RAUL HERNANDEZ;;RIVERA LUIS SILVESTRE ZAMUDIO;;CERVANTES VIOLETA YASMIN MENA;;ROJERO ERICK EMANUEL LUNA;;SALDANA ENRIQUE SERRANO;;MAGADAN JOSE MANUEL MARTINEZ;;ROA RAUL OVIEDO;;ALVAREZ DAVID AARON NIETO;;GONZALEZ EDUARDO BUENROSTRO;;DEVORA RODOLFO CISNEROS;;GARCIA MARIA DEL PILAR ARZOLA;;JIMENEZ MIRNA PONS;;AGUILAR AMERICA ELIZABETH MENDOZA;;KIM SUNG JAE KO;;PEREZ JORGE FRANCISCO RAMIREZ;;MIYAUCHI TOMAS EDUARDO CHAVEZ,,https://lens.org/075-663-693-326-140,Patent Application,no,0,0,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K8/584;;C09K23/02;;C09K8/594;;C09K23/00;;C09K23/04;;C09K23/18;;C09K23/24;;E21B43/16,,0,0,,,,ACTIVE
338,ES,A1,ES 2542621 A1,036-027-321-377-746,2015-08-07,2015,ES 201430155 A,2014-02-07,ES 201430155 A,2014-02-07,"Polypeptides with polysaccharide monooxygenase activity and their use for the production of fermentable sugars (Machine-translation by Google Translate, not legally binding)","Polypeptides with polysaccharide monooxygenase activity and their use for the production of fermentable sugars. The invention relates to polypeptides with polysaccharide monooxygenase activity, to a host cell expressing them, preferably a myceliophthora thermophila cell, to an enzymatic composition comprising at least one of said polypeptides, preferably together with other cellulolytic enzymes, to the use of this host cell, of at least one of the polypeptides with polysaccharide monooxygenase activity or of the enzymatic composition for the degradation of cellulosic biomass and to a process for producing bioproducts, preferably bioethanol, comprising the use of said host cell, of at least one of the polypeptides of the invention or of the enzymatic composition of the invention. (Machine-translation by Google Translate, not legally binding)",ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;REYES SOSA FRANCISCO MANUEL;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;GAVALDA MARTIN SANDRA;;MARTIN PEREZ LUCÍA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;LEDESMA GARCIA LAURA;;PLATERO GOMEZ ANA ISABEL;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO,,https://lens.org/036-027-321-377-746,Patent Application,no,3,1,3,3,0,C12P7/10;;C12P19/14;;C12N9/0083;;C12P7/10;;C12P19/14;;C12P2203/00;;C12Y302/01004;;Y02E50/10,C12N1/15;;C12P7/10;;C12P19/14,,2,0,,,"BASE DE DATOS UNIPROT (EN LINEA). JB389821. 01-OCT-2013. Secuencia 30 de la patente WO2013028701. ""GH61 GLYCOSIDE HYDROLASE PROTEIN VARIANTS AND COFACTORS THAT ENHANCE GH61 ACTIVITY"" [recuperado de EBI] NUMERO DE ACCESO JB389821. Muestra una identidad del 99,7% sobre la SEQ. ID Nº 44.;;BASE DE DATOS UNIPROT (EN LINEA). JB389890. 01-OCT-2013. Secuencia  99 de la patente WO2013028701. ""GH61 GLYCOSIDE HYDROLASE PROTEIN VARIANTS AND COFACTORS THAT ENHANCE GH61 ACTIVITY"". [Recuperado de EBI] NUMERO DE ACCESO JB389890. Muestra una identidad del 100% sobre la SEQ.ID. Nº 43.",INACTIVE
339,US,B2,US 9469804 B2,191-533-149-709-287,2016-10-18,2016,US 201314089280 A,2013-11-25,MX 2012014187 A,2012-12-05,Foaming composition with wettability modifying and corrosion inhibitory properties for high temperature and ultra-high salinity,"A foaming composition with wettability-modifying and corrosion inhibitory properties is used to control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions by the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates having the formula (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and are suitable for use in the reservoir, seawater and/or congenital water characteristic of the reservoir for transporting the crude oil from the reservoir.",MEXICANO INST PETROL;;INST MEXICO DEL PETROLEO,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;LUNA ROJERO ERICK EMANUEL;;SERRANO SALDANA ENRIQUE;;MARTINEZ MAGADAN JOSE MANUEL;;OVIEDO ROA RAUL;;NIETO ALVAREZ DAVID AARON;;BUENROSTRO GONZALEZ EDUARDO;;CISNEROS DEVORA RODOLFO;;ARZOLA GARCIA MARIA DEL PILAR;;PONS JIMENEZ MIRNA;;MENDOZA AGUILAR AMERICA ELIZABETH;;KIM SUNG JAE KO;;RAMIREZ PEREZ JORGE FRANCISCO;;CHAVEZ MIYAUCHI TOMAS EDUARDO;;RUIZ MORALES YOSADARA,INSTITUTO MEXICANO DEL PETROLEO (2012-11-04),https://lens.org/191-533-149-709-287,Granted Patent,yes,32,6,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K23/02;;C09K8/54;;E21B43/16;;C09K8/584;;C09K8/594;;C09K23/00;;C09K23/04;;C09K23/18;;C09K23/24;;E21B41/02;;E21B43/22,,0,0,,,,ACTIVE
340,ES,B1,ES 2542621 B1,004-704-649-698-695,2016-08-16,2016,ES 201430155 A,2014-02-07,ES 201430155 A,2014-02-07,Polipéptidos con actividad polisacárido monooxigenasa y su uso para la producción de azúcares fermentables,,ABENGOA BIOENERGIA NUEVAS TECNOLOGIAS SA,DIEZ GARCIA BRUNO;;GOMEZ RODRIGUEZ ANA;;GIL MARTINEZ JORGE;;VALBUENA CRESPO NOELIA;;REYES SOSA FRANCISCO MANUEL;;MORENO PEREZ ANTONIO JAVIER;;DUENAS SANCHEZ RAFAEL;;MUNOZ GONZALEZ ANA MARÍA;;PEREZ GOMEZ DOLORES;;GAVALDA MARTIN SANDRA;;MARTIN PEREZ LUCÍA;;SANCHEZ ZAMORANO LAURA;;ALVAREZ NUNEZ CONSOLACIÓN;;BERMUDEZ ALCANTARA MARÍA DE LOS ANGELES;;LEDESMA GARCIA LAURA;;PLATERO GOMEZ ANA ISABEL;;GUTIERREZ GOMEZ PABLO;;ARJONA ANTOLIN RICARDO,,https://lens.org/004-704-649-698-695,Granted Patent,no,0,0,3,3,0,C12P7/10;;C12P19/14;;C12N9/0083;;C12P7/10;;C12P19/14;;C12P2203/00;;C12Y302/01004;;Y02E50/10,C12N1/15;;C12P7/10;;C12P19/14,,0,0,,,,INACTIVE
341,CA,C,CA 2828519 C,116-167-019-850-98X,2016-10-18,2016,CA 2828519 A,2013-09-27,MX 2012014187 A,2012-12-05,FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY,"The present invention relates to obtaining and using foaming compositions with wettability-modifying and corrosion inhibitory properties that control the channeling of fluids in naturally fractured carbonate reservoirs, favorably alter the rock wettability in crude oil enhanced recovery processes and control uniform corrosion problems occurring in production rigs under high temperature and ultra-high salinity conditions; by means of the synergistic effect resulting from the supramolecular interaction of alkyl amido propyl hydroxysultaines or alkyl hydroxysultaines with sodium alkyl hydroxysulfonates and sodium alkenyl sulfonates (1). The foaming compositions with wettability-modifying and corrosion inhibitory properties are characterized for being tolerant to high concentrations of divalent ions such as calcium, magnesium, strontium and barium and for the fact that for their application in the reservoir, seawater and/or congenital water characteristic of the reservoir may be used as means of transportation. (see above formula)",MEXICANO INST PETROL,HERNANDEZ ALTAMIRANO RAUL;;ZAMUDIO RIVERA LUIS SILVESTRE;;MENA CERVANTES VIOLETA YASMIN;;LUNA ROJERO ERICK EMANUEL;;SERRANO SALDANA ENRIQUE;;MARTINEZ MAGADAN JOSE MANUEL;;OVIEDO ROA RAUL;;NIETO ALVAREZ DAVID AARON;;BUENROSTRO GONZALEZ EDUARDO;;CISNEROS DEVORA RODOLFO;;ARZOLA GARCIA MARIA DEL PILAR;;PONS JIMENEZ MIRNA;;MENDOZA AGUILAR AMERICA ELIZABETH;;KIM SUNG JAE KO;;RAMIREZ PEREZ JORGE FRANCISCO;;CHAVEZ MIYAUCHI TOMAS EDUARDO;;RUIZ MORALES YOSADARA,,https://lens.org/116-167-019-850-98X,Granted Patent,no,0,0,14,14,0,C09K8/54;;C09K8/584;;C09K8/594;;E21B41/02;;C09K8/594;;C09K8/584;;C09K8/584;;E21B43/16;;C09K8/594,C09K23/02;;C09K8/54;;C09K8/584;;C09K23/00;;C09K23/04;;C09K23/18;;C09K23/24;;E21B43/16,,0,0,,,,ACTIVE
342,WO,A1,WO 2020/071897 A1,027-428-872-993-028,2020-04-09,2020,MX 2019050021 W,2019-10-02,MX 2018012036 A,2018-10-02,"DEVICE FOR EXCHANGING ROTORS, PROPELLERS OR ENGINES FOR AIRCRAFT AND WATERCRAFT","The present invention relates to the aeronautical, maritime and drone industry, comprising the use of a system for exchanging and replacing rotors, propellers or engines, based on a combination of part-securing mechanisms, lift and push mechanisms, closing and opening mechanisms, relative movement mechanisms, and folding rotors or propellers, said system being applied directly to the design of aircraft and watercraft, of the transport, drone, toy, robot and research type, specifically to propulsion systems, since the invention can be used to equip same with a means for the manual, semi-automatic or automatic replacement of rotors and propellers in the event of severe damage or breakage, and even of engines on small or custom design aircraft. The present invention relates to a device for exchanging rotors and propellers for aircraft and watercraft, providing a system for replacing rotors or propellers in the event of full or partial breakage, using: a rotor-securing mechanism, a system for supplying new rotors, a closure system for locking or releasing the propeller-securing device, folding propellers or rotors, and a relative movement mechanism allowing interaction between the moving and stationary parts, with the possible embodiments of the invention being shown. Although the system of the invention increases the flight load, it is also useful in preventing situations whereby the loss of a rotor, propeller or engine results in the complete loss of an aircraft or watercraft.",MENDOZA MENDOZA JULIO ALBERTO;;SOCCONINI ALVARADO HAZUR SAHIB;;BUTRON CASTANEDA MARCO ANTONIO,MENDOZA MENDOZA JULIO ALBERTO;;SOCCONINI ALVARADO HAZUR SAHIB;;GONZALEZ VILLELA VICTOR JAVIER;;GARCIA SANCHEZ IGNACIO;;AGUILAR IBAÑEZ CARLOS FERNANDO;;FONSECA RUIZ LEONARDO;;MENDEZ MARTINEZ MAURICIO;;ENCINAS PÓRCEL JORGE RODRIGO;;JIMENEZ LIZARRAGA MANUEL ALEJANDRO;;SAMANO HERNANDEZ MANUEL ALEJANDRO;;CARRETO ARELLANO CHADWICK;;SUAREZ CASTAÑÓN MIGUEL SANTIAGO;;SOSSA AZUELA JUAN HUMBERTO;;AQUINO ROBLES JOSE ANTONIO;;RODRIGUEZ RODRIGUEZ MANUEL JESUS;;FLORES CAMPOS JUAN ALEJANDRO;;SEPULVEDA CERVANTES GABRIEL;;GARCIA PEREZ ORLANDO,,https://lens.org/027-428-872-993-028,Patent Application,yes,3,1,2,2,0,B64C11/00;;B64C11/04,B64C11/00;;B64C11/04,,0,0,,,,PENDING
343,WO,A4,WO 2020/071897 A4,140-688-097-470-740,2020-05-28,2020,MX 2019050021 W,2019-10-02,MX 2018012036 A,2018-10-02,"DEVICE FOR EXCHANGING ROTORS, PROPELLERS OR ENGINES FOR AIRCRAFT AND WATERCRAFT","The present invention relates to the aeronautical, maritime and drone industry, comprising the use of a system for exchanging and replacing rotors, propellers or engines, based on a combination of part-securing mechanisms, lift and push mechanisms, closing and opening mechanisms, relative movement mechanisms, and folding rotors or propellers, said system being applied directly to the design of aircraft and watercraft, of the transport, drone, toy, robot and research type, specifically to propulsion systems, since the invention can be used to equip same with a means for the manual, semi-automatic or automatic replacement of rotors and propellers in the event of severe damage or breakage, and even of engines on small or custom design aircraft. The present invention relates to a device for exchanging rotors and propellers for aircraft and watercraft, providing a system for replacing rotors or propellers in the event of full or partial breakage, using: a rotor-securing mechanism, a system for supplying new rotors, a closure system for locking or releasing the propeller-securing device, folding propellers or rotors, and a relative movement mechanism allowing interaction between the moving and stationary parts, with the possible embodiments of the invention being shown. Although the system of the invention increases the flight load, it is also useful in preventing situations whereby the loss of a rotor, propeller or engine results in the complete loss of an aircraft or watercraft.",MENDOZA MENDOZA JULIO ALBERTO;;SOCCONINI ALVARADO HAZUR SAHIB;;BUTRON CASTANEDA MARCO ANTONIO,MENDOZA MENDOZA JULIO ALBERTO;;SOCCONINI ALVARADO HAZUR SAHIB;;GONZALEZ VILLELA VICTOR JAVIER;;GARCIA SANCHEZ IGNACIO;;AGUILAR IBAÑEZ CARLOS FERNANDO;;FONSECA RUIZ LEONARDO;;MENDEZ MARTINEZ MAURICIO;;ENCINAS PÓRCEL JORGE RODRIGO;;JIMENEZ LIZARRAGA MANUEL ALEJANDRO;;SAMANO HERNANDEZ MANUEL ALEJANDRO;;CARRETO ARELLANO CHADWICK;;SUAREZ CASTAÑÓN MIGUEL SANTIAGO;;SOSSA AZUELA JUAN HUMBERTO;;AQUINO ROBLES JOSE ANTONIO;;RODRIGUEZ RODRIGUEZ MANUEL JESUS;;FLORES CAMPOS JUAN ALEJANDRO;;SEPULVEDA CERVANTES GABRIEL;;GARCIA PEREZ ORLANDO,,https://lens.org/140-688-097-470-740,Patent Application,yes,0,0,2,2,0,B64C11/00;;B64C11/04,B64C11/00;;B64C11/04,,0,0,,,,PENDING
344,US,A1,US 2010/0086905 A1,057-611-332-132-669,2010-04-08,2010,US 52710907 A,2007-02-14,ES 2007000082 W,2007-02-14,SIMULATION SYSTEM FOR ARTHROSCOPIC SURGERY TRAINING,"The invention relates to a simulator for training in arthroscopic surgery on a joint of a simulated patient, comprising: a data processing unit ( 1 ); viewing means ( 2 ) for viewing the simulation exercise; a working platform ( 12 ); a human anatomy model ( 9 ) with arthroscopic portals ( 3 ) through which the user inserts the simulated arthroscopic instrument ( 10 ); two haptic devices ( 5 a, 5 b ) arranged around the model ( 9 ) with a mobile member ( 6 a, 6 b ), the end of which is provided with a guide ( 8 a, 8 b ) for guiding the instrument that is inserted into the arthroscopic portals ( 3 ) during a simulated surgical procedure, each haptic device ( 5 a, 5 b ) including means for synchronization with the control unit ( 1 ) and means for determining the position and orientation of the mobile members ( 6 a, 6 b ); and a simulated arthroscopic camera ( 7 ). The data processing unit ( 1 ) is configured to send simulated images, as would be seen in a real operation, from the arthroscopic camera ( 7 ) to the viewing means ( 2 ) in real time.",GMV S A,ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESCO CASIQUE MANLIO FAVIO;;ANANOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ BARTOLOME ANGEL;;GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIO RABASCO PABLO;;SAN MARTIN LOPEZ JOSE;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO,SIMBIONIX LTD (2014-12-15);;3D SYSTEMS INC (2014-11-19);;GMV AEROSPACE AND DEFENCE S.A (2009-11-17),https://lens.org/057-611-332-132-669,Patent Application,yes,3,28,7,7,0,G09B23/285;;G09B23/285,G09B23/28,434/262,0,0,,,,ACTIVE
345,US,B2,US 8550821 B2,116-627-667-137-079,2013-10-08,2013,US 52710907 A,2007-02-14,ES 2007000082 W,2007-02-14,Simulation system for arthroscopic surgery training,"The invention relates to a simulator for training in arthroscopic surgery on a joint of a simulated patient, comprising: a data processing unit ( 1 ); viewing means ( 2 ) for viewing the simulation exercise; a working platform ( 12 ); a human anatomy model ( 9 ) with arthroscopic portals ( 3 ) through which the user inserts the simulated arthroscopic instrument ( 10 ); two haptic devices ( 5 a, 5 b ) arranged around the model ( 9 ) with a mobile member ( 6 a, 6 b ), the end of which is provided with a guide ( 8 a, 8 b ) for guiding the instrument that is inserted into the arthroscopic portals ( 3 ) during a simulated surgical procedure, each haptic device ( 5 a, 5 b ) including means for synchronization with the control unit ( 1 ) and means for determining the position and orientation of the mobile members ( 6 a, 6 b ); and a simulated arthroscopic camera ( 7 ). The data processing unit ( 1 ) is configured to send simulated images, as would be seen in a real operation, from the arthroscopic camera ( 7 ) to the viewing means ( 2 ) in real time.",ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESCO CASIQUE MANLIO FAVIO;;ANANOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ BARTOLOME ANGEL;;GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIO RABASCO PABLO;;SAN MARTIN LOPEZ JOSE JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO;;SIMBIONIX LTD,ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESCO CASIQUE MANLIO FAVIO;;ANANOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PEREZ LUIS;;FERNANDEZ-ARROYO JOSE MANUEL;;TRIVINO BARROS GRACIAN;;RODRIGUEZ BARTOLOME ANGEL;;GUILLERMO JOSE MIGUEL;;BAYONA BERISO SOFIA;;GARCIA LORENZO MARCOS JOSE;;TOHARIO RABASCO PABLO;;SAN MARTIN LOPEZ JOSE JAVIER;;ROBLES SANCHEZ OSCAR DAVID;;MENDOZA SERRANO CESAR AUGUSTO,SIMBIONIX LTD (2014-12-15);;3D SYSTEMS INC (2014-11-19);;GMV AEROSPACE AND DEFENCE S.A (2009-11-17),https://lens.org/116-627-667-137-079,Granted Patent,yes,9,3,7,7,0,G09B23/285;;G09B23/285,G09B23/28,434/267;;434/262;;434/274,9,2,048-606-543-431-551;;116-869-541-130-121,16394733;;10.1097/01.blo.0000194678.10130.ff;;16394738;;10.1007/bfb0029258,"http://web.archive.org/web/20060830070030/www.sensable.com/products/phantom-g Oct. 26, 2007.;;http://web.archive.org/web/20061016081307/www.immersion.com/medical/products Oct. 26, 2007.;;International Search Report for PCT application PCT/ES2007/00008 dated Oct. 31, 2007.;;Written Opinion of the International Search Authority for PCT application PCT/ES2007/00008 dated Oct. 31, 2007.;;Response to Written Opinion of the International Search Authority for PCT application PCT/ES2007/00008 dated Dec. 9, 2008.;;A McCarthy et al ""Passive Haptics in a Knee Arthroscopy Simulator, Is it Valid for Core Skills Training? "" Clinical Orthopedics and Related Search, 442:13-20 (2006).;;I.P. Logal et al. ""Virtual Environment Knee Arthroscopy Training System"", Simulation for Emergency Management. Proceedings of the 1996 Simulation Multiconference, pp. 11-16 1996).;;S. Gibson et al. ""Simulating Arthroscopy Knee Surgery Using Volumetric Object Representations , Real-Time Volume Rendering and Haptic Feed back"", CVR Med-MRCAS '97 First Joint Conference, Computer Vision, Virtual Reality and Robotics in Medicine and Medical Robotics and Computer-Assisted Surgery Proceedings, pp. 369-378 (1997).;;""Virtual Reality Arthroscopy Trainer. Technological Innovation for Minimally Invasive Surgery Training"", GMV Innovating Solutions, (2008).",ACTIVE
346,EP,B1,EP 2110799 B1,166-999-669-344-013,2016-07-20,2016,EP 07730323 A,2007-02-14,ES 2007000082 W,2007-02-14,SIMULATION SYSTEM FOR ARTHROSCOPIC SURGERY TRAINING,,SIMBIONIX LTD,ILLANA ALEJANDRO CARLOS G;;SIERRA PICON BERNARDO;;VERCHER MARTINEZ JUAN;;RODRIGUEZ BESCOS SAMUEL;;VALDIVIESO CASIQUE MANLIO FAVIO;;AÑAÑOS HINOJOSA FRANCISCO JAVIER;;POTTI CUERVO JORGE;;SANCHEZ GONZALEZ ALMUDENA;;PASTOR PÉREZ LUIS;;FERNANDEZ-ARROYO JOSÉ MANUEL;;TRIVIÑO BARROS GRACIÁN;;RODRÍGUEZ MARTÍNEZ DE BARTOLOMÉ ÁNGEL;;ESPADERO GUILLERMO JOSÉ MIGUEL;;BAYONA BERISO SOFÍA;;GARCÍA LORENZO MARCOS JOSÉ;;TOHARIA RABASCO PABLO;;SAN MARTIN LÓPEZ JOSÉ JAVIER;;ROBLES SÁNCHEZ OSCAR DAVID;;MENDOZA SERRANO CÉSAR AUGUSTO,SIMBIONIX LTD. (2012-08-08),https://lens.org/166-999-669-344-013,Granted Patent,yes,4,0,7,7,0,G09B23/285;;G09B23/285,G09B23/28,,6,0,,,"""InsightMIST presentado en todo el mundo"", GMV NEWS,, no. 32, 1 December 2006 (2006-12-01), page 25, XP008114614,;;""Simulador avanzado de entrenamiento al servicio de la adquisicion de destrezas in tecnicas de cirugia minimamente invasivas. GMV Innovating Solutions"", INVESCOT V, CONGRESO NACIONAL, SALAMANCA, , 1 January 2005 (2005-01-01), pages 1-87, XP008137821, Retrieved from the Internet: URL:http://www.insightmist.com/img_eventos /presentacion-INVESCOT.pdf;;'Simulador avanzado de entrenamiento al servicio de la adquisicion de destrezas in tecnicas de cirugia minimamente invasivas. GMV Innovating Solutions' INVESCOT V, CONGRESO NACIONAL, SALAMANCA, [Online] January 2005, XP008137821 Retrieved from the Internet: <URL:http://www.insightmist.com/img_eventos /presentacion_INVESCOT.pdf>;;'insightMIST presentado in the whole the mundo' GMV NEWS NO. 32, TECNOLOGIA DE GMV CLAVE IN METOP, GMV INNOVATION SOLUTIONS, [Online] December 2006, page 25, XP008114614 Retrieved from the Internet: <URL:http://www.gmv-sgi.eu/imagenes_comunic acion/boletin_corporativo/revista25.pdf>;;'Phantom Omni Technical Specification' SENSABLE TECHNOLOGIES, [Online] August 2006, XP008114609 Retrieved from the Internet: <URL:http://www.web.archive.org.web/2006083 0070030/www.sensable.com/products/phantom_g host/phantom-omni.asp>;;'Virtual Laparoscopic Interface' IMMERSION, [Online] XP002509910 Retrieved from the Internet: <URL:http://www.web.archive.org/web/2006101 6081307/www.immersion.com/medical/products/ laparoscopy>",ACTIVE
